Phenotypic and Genotypic Analysis of \u3ci\u3eIn Vitro\u3c/i\u3e Selected Artemisinin Resistant \u3ci\u3ePlasmodium falciparum\u3c/i\u3e by Tucker, Matthew Scott
University of South Florida
Scholar Commons
Graduate Theses and Dissertations Graduate School
10-19-2010
Phenotypic and Genotypic Analysis of In Vitro
Selected Artemisinin Resistant Plasmodium
falciparum
Matthew Scott Tucker
University of South Florida
Follow this and additional works at: http://scholarcommons.usf.edu/etd
Part of the American Studies Commons, Public Health Commons, and the Public Policy
Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in
Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
scholarcommons@usf.edu.
Scholar Commons Citation
Tucker, Matthew Scott, "Phenotypic and Genotypic Analysis of In Vitro Selected Artemisinin Resistant Plasmodium falciparum"
(2010). Graduate Theses and Dissertations.
http://scholarcommons.usf.edu/etd/3495
 
 
 
 
 
Phenotypic and Genotypic Analysis of In Vitro Selected Artemisinin Resistant 
 
Plasmodium falciparum 
 
 
 
by 
 
 
 
Matthew Scott Tucker 
 
 
 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
Department of Global Health 
College of Public Health 
University of South Florida 
 
 
 
Major Professor: Dennis E. Kyle, Ph.D. 
Azliyati Azizan, Ph.D. 
Jacqueline Cattani, Ph.D. 
John Dame, Ph.D. 
Boo Kwa, Ph.D. 
 
 
Date of Approval: 
October 19, 2010 
 
 
 
Keywords: Malaria, Drug, Resistance, Molecular, Mechanism 
 
Copyright © 2010, Matthew Scott Tucker 
 
 
 
 
 
Acknowledgments 
This study represents a substantial amount of work that could not have been 
completed without the help of many people.  I thank my advisor, Dr. Dennis Kyle, for 
helping me polish skills that will help me become an excellent research scientist in the 
future.  Dr. Kyle has been a great source of knowledge and advice during my time in his 
laboratory.  He is also a wonderful teacher and person who has helped me not only 
succeed in the laboratory, but he has helped me with various administrative issues while 
at USF.  I consider myself lucky to have found him as a research mentor.  I would also 
thank my other committee members: Dr. Azliyati Azizan, Dr. Jacqueline Cattani, Dr. 
John Dame, and Dr. Boo Kwa for adding expertise to my dissertation research and taking 
the time to peruse my thesis in a time period that is relatively short considering the length 
of the document.  My mother and brother have been a constant source of support during 
my academic career.  My mother has instilled in me an excellent work ethic and 
determination, and she has always encouraged me to succeed at every endeavor.  My 
father has helped me succeed as a student, by showing me the importance of knowledge 
and education.  I wish to thank my wife Kim, for her constant support while I have been 
in graduate school.  She has helped me become a better person and I thank her dearly for 
putting up with me during the grind of my graduate career.  Finally, I would like to 
recognize my co-workers Alexis LaCrue, Tina Mutka, Kansas Sparks, and Janus Patel for 
assisting me in different experiments that contributed to my research.
i 
 
 
 
 
 
 
 
Table of Contents 
 
 
 
List of Tables ..................................................................................................................... vi 
 
List of Figures .................................................................................................................. viii 
 
Abstract .............................................................................................................................. xi 
 
Chapter One: Introduction ...................................................................................................1 
 Malaria: Background ...............................................................................................1 
 Plasmodium spp. Life Cycle ....................................................................................5 
  Mosquito (Definitive Host) ..........................................................................5 
  Human (Intermediate Host) .........................................................................6 
  Malaria: Life Cycle in Relation to Cell Cycle ...........................................10 
Malaria: Clinical Manifestations and Diagnosis ....................................................12 
  Uncomplicated Malaria ..............................................................................12 
  Severe Malaria ...........................................................................................13 
 Global Impact of Malaria .......................................................................................15 
 Malaria Public Health Control and Eradication Efforts .........................................18 
  Malaria in the United States .......................................................................20 
 Current Malaria Control Programs ........................................................................21 
 Vaccines .................................................................................................................27 
  Pre-erythrocytic Stage ................................................................................27 
  Erythrocytic Stage ......................................................................................30 
  Transmission Blocking Vaccines ...............................................................32 
 Antimalarial Drugs for Treatment .........................................................................35 
  Quinolines ..................................................................................................36 
   Quinine ...........................................................................................37 
   Chloroquine....................................................................................38 
   Mefloquine, Other Aminoalcohols, and Primaquine .....................39 
   Amodiaquine and Piperaquine .......................................................41 
  Antifolates ..................................................................................................42 
  Atovaquone ................................................................................................43 
  Antibiotics ..................................................................................................44 
  Artemisinins ...............................................................................................45 
 Antimalarial Drug Recommendations ...................................................................50 
  Prophylaxis ................................................................................................50 
  Curative Treatment ....................................................................................50 
ii 
 
 Antimalarial Drug Resistance ................................................................................52 
  In Vivo Measures of Drug Resistance ........................................................54 
  Quinolines .......................................................................................................... 56 
   Chloroquine....................................................................................56 
   Amodiaquine and Piperaquine .......................................................62 
  Arylaminoalcohols .....................................................................................63 
   Quinine ...........................................................................................63 
   Mefloquine and Other Arylaminoalcohols ....................................64 
  Antifolates ..................................................................................................69 
  Atovaquone ................................................................................................71 
  Artemisinins ...............................................................................................72 
 Preliminary Studies from the Kyle Laboratory ......................................................80 
  Dormancy ...................................................................................................80 
  Studies Relevant to This Work ..................................................................91 
  Molecular Characterization of Artemisinin Resistance .............................93 
  Dormancy, Recrudescence, and Artemisinin Resistance ...........................97 
 Focus of Study .......................................................................................................98 
 
Chapter Two: Induction of High Level Artemisinin Resistance and Phenotypic 
Characterization (Specific Aim 1) .............................................................................112 
  Rationale for Study ..............................................................................................112 
 Materials and Methods .........................................................................................115 
  Parasites and In Vitro Culture ..................................................................115 
  Development of Resistant Parasite Lines In Vitro ...................................115 
  Quantitative Recrudescence Assays ........................................................117 
   W2 Recovery Assay .....................................................................117 
   Initial D6 Recovery Assay ...........................................................118 
   Adapting D6 Parasites Beyond Clinically Relevant 
Concentrations .......................................................................119 
  Growth Assay...........................................................................................120 
  In vitro Drug Susceptibility Testing ........................................................121 
   Antimalarial Drugs.......................................................................121 
   In Vitro SYBR Green Drug Susceptibility Assay ........................121 
  Ring Stage Viability in Parental and Resistant Lines ..............................123 
   In Vitro Drug Testing Using a Radioisotope Microdilution 
Technique ...............................................................................123 
  DNA Sequencing .....................................................................................124 
   Genomic DNA Extraction............................................................124 
  Sequencing for Single Nucleotide Polymorphisms in Candidate 
Resistance Genes Identified by Preliminary Microarrays .................125 
  Real-time Quantitative Polymerase Chain Reaction ................................126 
   Optimization of Oligonucleotide Sets for Real-Time 
Quantitative Polymerase Chain Reaction ..............................126 
   Determination of Gene Copy Number by Real-Time QPCR ......127 
 Results ..................................................................................................................129 
iii 
 
  Discontinuous Drug Pressure Generated P. falciparum Lines 
Resistant to Increased Levels of Artelinic Acid and Artemisinin 
In Vitro ...............................................................................................129 
  Resistant Progeny of D6 and W2 Recover Faster than Parent 
Strains After Exposure to Clinically Relevant Concentrations 
of Artemisinin ....................................................................................131 
  Analysis of Growth Rates and Merozoite Number Reveals 
Differences Between Parental and Resistant Parasites ......................135 
  Resistant Parasites Exhibit Reduced Susceptibility to Artemisinins 
and Mefloquine, but Increased Susceptibility to Chloroquine...........137 
  Ring-stage Viability Assay Reveals that Resistant Parasites 
Withstand Greater Levels of Drug Compared to Parental 
Parasites .............................................................................................138 
  Sequencing and Real-Time QPCR of Genes Implicated in Prior 
Molecular Studies ..............................................................................141 
 Discussion ............................................................................................................144 
  Induction of Resistance ............................................................................144 
  Recovery Assays ......................................................................................145 
  In Vitro Susceptibility Testing .................................................................148 
   SYBR Green Assays ....................................................................148 
   Ring Stage Viability Assays ........................................................150 
  Growth Rates and Merozoite Number .....................................................155 
  Importance of Artemisinin Resistance and Dormancy to Patient 
Studies ................................................................................................157 
  Studies Based on Previous Microarray Data ...........................................161 
  Artemisinin Resistance Phenotype ..........................................................166 
 
Chapter Three: Proteomic, Whole Genome, and Transcriptional Approaches for 
Dissecting Artemisinin Resistance (Specific Aim 2).................................................210 
 Rationale for Study ..............................................................................................210 
 Materials and Methods .........................................................................................212 
  Parasites and In Vitro Culture ..................................................................212 
  Proteomics................................................................................................213 
   Parasites .......................................................................................213 
   Two Dimensional Fluorescence Difference Gel 
Electrophoresis .......................................................................214 
   Isoelectric Focusing and Sodium Dodecyl Sulfate 
Polyacrylamide Gel Electrophoresis ......................................215 
   Image Scan and Data Analysis ....................................................215 
   Protein Identification by Mass Spectrometry ..............................215 
   Database Search ...........................................................................216 
  Whole Genome Sequencing .....................................................................217 
   Parasites and DNA isolation ........................................................217 
   Paired End Library Preparation ...................................................217 
   Downstream Analysis ..................................................................218 
iv 
 
  Sequencing for Verifying Single Nucleotide Polymorphisms from 
Whole Genome Sequence Data .........................................................219 
  Real-time QPCR for Copy Number Assessment of Chromosome 
10 Genes.............................................................................................220 
   Optimization of Oligonucleotide Sets  .........................................220 
   Determination of Gene Copy Number by Real-Time QPCR ......220 
  Measurement of the Rate of Recovery from Dormancy for D6 
Parasites .............................................................................................221 
  Microarrays ..............................................................................................222 
   Culture for Microarray Experiments ............................................222 
   Microscopy and Smear Counts ....................................................223 
   RNA Extraction and Amplification .............................................224 
   Cy Dye Labeling and Microarray Hybridization .........................224 
   Array Analysis .............................................................................225 
 Results ..................................................................................................................226 
  Proteomics Identified Differentially Expressed Proteins in 
Artemisinin Resistant vs. Parent Parasites .........................................226 
  Whole Genome Sequencing Identified Single Nucleotide 
Polymorphisms and Copy Number Amplifications in 
Artemisinin Resistant Parasites ..........................................................227 
   Single Nucleotide Polymorphisms Identified in Resistant 
D6 Strains...............................................................................228 
    Single Nucleotide Polymorphisms Verified in 
Resistant D6 Strains ...................................................230 
   Amplifications Identified in Chromosome 10 in 
Artemisinin Resistant D6 and W2 lines .................................231 
    Copy Number Amplification was Verified in D6 
and W2 Artemisinin Resistant Strains by QPCR .......233 
  Dihydroartemisinin Treatment is Associated with the Appearance 
of Dormant Forms Prior to Recrudescence ........................................235 
  Transcriptional Analysis of Dihydroartemisinin-Treated Parental 
and Resistant Parasites Reveals Transcriptional Arrest and 
Differences in Gene Expression .........................................................236 
   Dihydroartemisinin Induces Transcriptional Arrest at Ring 
Stage in W2 Parasites.............................................................236 
   Dihydroartemisinin Induces Arrest With a Ring-Like 
Transcriptome in Artemisinin Sensitive and Resistant 
D6 Parasites ...........................................................................237 
   Recovery Following Exposure to Dihydroartemisinin: 
Artemisinin Resistant Parasites Exit Dormancy Earlier 
than Parental Parasites ...........................................................239 
   Asynchronous Cultures Exposed to Dihydroartemisinin 
Become Dominated by a Ring-Like Transcriptome ..............242 
   Dihydroartemisinin-Induced Dormancy is Characterized by 
Unique Gene Expression in Parental and Resistant 
Strains ....................................................................................244 
v 
 
   Dihydroartemisinin Induces Differential Expression of 
Genes in Artemisinin Resistant and Sensitive Parasites ........245 
   Constitutive Transcription Differences were Identified 
Between Artemisinin Resistant and Sensitive Strains ...........246 
 Discussion ............................................................................................................247 
  Proteomics................................................................................................248 
  Whole Genome Sequencing .....................................................................254 
   Single Nucleotide Polymorphisms ...............................................254 
   Chromosome 10 Amplification....................................................258 
  Recrudescence Assays with D6 vs. D6.QHS2400x5 ...............................266 
  Transcriptional Analyses of D6 and D6.QHS2400x5..............................267 
   Differentially Expressed Genes in Parental/Resistant 
Strains During Dormancy ......................................................270 
   Dihydroartemisinin Induces Differential Expression of 
Genes in Artemisinin Resistant and Sensitive Parasites ........277 
   Constitutive Transcription Differences Were Identified 
Between Resistant and Sensitive Strains ...............................279 
 
Chapter Four: Summary ...................................................................................................328 
 Current Reports of Artemisinin Resistance .........................................................329 
 Artemisinin Resistance in This Work ..................................................................332 
 Dormancy and Resistance ....................................................................................334 
 Utility of Molecular Markers for Field Studies ...................................................339 
 
Chapter Five: List of References .....................................................................................343 
 
Appendices .......................................................................................................................389 
 Appendix A: Extra Tables ...................................................................................390 
 
About the Author ................................................................................................... End Page 
  
vi 
 
 
 
 
 
 
 
List of Tables 
 
 
 
Table 2.1. Oligonucleotides Used in Analyses of PFE1050w, PF11_0466, pfmdr2, 
and pfmdr1 .......................................................................................................202 
 
Table 2.2. Stepwise Induction of Artemisinin Resistance in D6 .....................................204 
 
Table 2.3. Stepwise Induction of Artelinic Acid Resistance in TM91c235 ....................206 
 
Table 2.4. In Vitro Susceptibility Testing of Parental and Resistant Lines: 
Artemisinin Drugs ...........................................................................................207 
 
Table 2.5. In Vitro Susceptibility Testing of Parental and Resistant Lines: 
Common Antimalarial Drugs ..........................................................................208 
 
Table 2.6. Ring Stage Viability Assay Utilizing D6 and W2 Parental and Resistant 
Strains at 24 and 48 Hours Post-Drug Exposure .............................................209 
 
Table 3.1. Oligonucleotides Used for Sequencing and Real-time QPCR........................308 
 
Table 3.2. Spots Identified in Proteomic Analyses in D6 and W2 Strains With 
Indicated Differential Expression ....................................................................310 
 
Table 3.3. Differentially Expressed Proteins in D6.QHS2400x3/D6 and 
W2.QHS200/W2 .............................................................................................311 
 
Table 3.4. Whole Genome Sequencing Produced a Preliminary Set of Single 
Nucleotide Polymorphisms in D6 and D6.QHS2400x2 ..................................312 
 
Table 3.5. Reduced List of Single Nucleotide Polymorphisms in D6 vs. 
D6.QHS2400x2 ...............................................................................................314 
 
Table 3.6. Confirmation of Single Nucleotide Polymorphisms for D6 vs. D6 
QHS-Resistant Progeny and 3D7/D6 vs.D6 QHS-Resistant Progeny ............315 
 
Table 3.7. List of Genes That are Either Up-Regulated or Down-Regulated in 
Both D6 and D6.QHS2400x5 During Dormancy ...........................................316 
 
vii 
 
Table 3.8. List of Genes That are Differentially Expressed in D6 vs. 
D6.QHS2400x5 During Dihydroartemisinin Treatment .................................320 
 
Table 3.9. List of Genes That are Differentially Expressed Before D6 and 
D6.QHS2400x5 Were Exposed to Dihydroartemisinin ..................................322 
 
Table A-1. Summary of Merozoite Characterization for Parental and Resistant 
Strains ............................................................................................................390 
 
Table A-2. Real Time QPCR Copy Number Results for PFE1050w, PF11_0466, 
pfmdr2, and pfmdr1 ........................................................................................391 
 
Table A-3. Real Time QPCR Copy Number Results for Chromosome 10 Genes ..........393 
  
viii 
 
 
 
 
 
 
 
List of Figures 
 
 
 
Figure 1.1. Malaria Life Cycle .........................................................................................100 
 
Figure 1.2. Current Global Malaria Situation as of 2009 ................................................102 
 
Figure 1.3. Countries in Phases of Malaria Control, Pre-elimination, Elimination, 
and Prevention of Re-introduction .................................................................103 
 
Figure 1.4. Global Map of Antimalarial Drug Resistance as of 2005 .............................104 
 
Figure 1.5. Origin and Spread of Global P. falciparum Chloroquine Resistance ...........105 
 
Figure 1.6. Synchronous P. falciparum Ring Stage Parasites Exposed to 
Artesunate, but not Quinine, are Arrested at Ring Stage ...............................106 
 
Figure 1.7. Treatment of Synchronized Ring Cultures of P. falciparum With 
Dihydroartemisinin Produced Dormant Parasites That Recrudesced In 
Vitro ...............................................................................................................108 
 
Figure 1.8. Localization of Early Transcribed Membrane Protein-2 and Green 
Fluorescent Protein in Dihydroartemisinin-Treated Ring Stage P. 
falciparum Parasites .......................................................................................109 
 
Figure 1.9. Different Fates of Artemisinin-Treated Stages of P. falciparum ..................110 
 
Figure 1.10. Induction of Resistance to Artelinic Acid and Artemisinin in P. 
falciparum ...................................................................................................111 
 
Figure 2.1. 96 Well Plate Setup for a Typical Hypoxanthine Assay ...............................169 
 
Figure 2.2. 96 Well Plate Setup for a Typical QPCR Assay for Assessment of 
Copy Number .................................................................................................171 
 
Figure 2.3. Amplification Plots of Standards and Unknowns in a Typical QPCR 
Assay ..............................................................................................................172 
 
ix 
 
Figure 2.4. Individual Amplification Plots of an Unknown Gene and Normalizer 
ldh. .................................................................................................................173 
 
Figure 2.5. Standard Curve Generation for a QPCR Assay .............................................174 
 
Figure 2.6. Treatment of D6.QHS80 With Increments of Artemisinin Produced 
Parasites That Tolerated 2400 ng/ml Artemisinin .........................................175 
 
Figure 2.7. Treatment of TM91c235.AL80 With Increments of Artelinic Acid 
Produced Parasites That Tolerated 280 ng/ml Artelinic Acid .......................176 
 
Figure 2.8. Recrudescence Assay With W2 and W2.QHS200 Clones Found the 
Resistant Parasite Recrudesced Before the Parent Strain After 
Dihydroartemisinin Treatment .......................................................................177 
 
Figure 2.9. Recovery Assays With D6 Parent and Resistant Lines Show Resistant 
Parasites Recrudesce Before the Parent Strain After Artemisinin 
Treatment .......................................................................................................179 
 
Figure 2.10. Decreased Growth and Merozoite Number is Associated With D6 
Resistant Progeny but not All Resistant Strains .........................................182 
 
Figure 2.11. Ring Stage Viability Assay Determined That Resistant Parasites 
Tolerate More Drug Than Parental Strains .................................................186 
 
Figure 2.12. Alignment of pfmdr2 Nucleotide Sequences in W2 Lines did not 
Identify Dissimilarities................................................................................188 
 
Figure 2.13. Alignment of PFE1050w Nucleotide Sequences in W2 Lines did not 
Identify Dissimilarities................................................................................194 
 
Figure 2.14. Real-Time QPCR Assays for Copy Number Found PFE1050w, 
PF11_0466, and pfmdr2 Were not Amplified in Resistant Parasites, 
but pfmdr1 was Amplified in W2 and TM91c235 Lines ............................197 
 
Figure 3.1. 2-D DIGE of D6.QHS2400x3/D6 and W2.QHS200/W2 Identified 
Potential Spots Representing Differentially Expressed Proteins ...................288 
 
Figure 3.2. Artemisinin Microarray Experimental Design ..............................................289 
 
Figure 3.3. Analysis of Spots From 2D-DIGE Reveals Differentially Regulated 
Proteins for D6.QHS2400x3 vs. D6 ..............................................................290 
 
Figure 3.4. Analysis of Spots From 2D-DIGE Reveals Differentially Regulated 
Proteins for W2.QHS200 vs. W2 ...................................................................291 
 
x 
 
Figure 3.5. Chromosome 10 Genes are Amplified in Artemisinin-Selected D6 and 
W2 Strains ......................................................................................................292 
 
Figure 3.6. D6.QHS2400x5 Recrudesces Before D6 After Exposure to 200 ng/ml 
Dihydroartemisinin ........................................................................................297 
 
Figure 3.7. Pilot Microarray Experiment With W2 Strains Shows 
Dihydroartemisinin Arrests Ring Stage Parasites ..........................................300 
 
Figure 3.8. Dihydroartemisinin Arrests Ring Stages in D6 Parental and Resistant 
Parasites and D6.QHS2400x5 Exits Dormancy Before D6 ...........................301 
 
Figure 3.9. During Transcriptome Analysis, D6.QHS2400x5 Recrudesced Before 
D6 and a Greater Percentage of Normal Parasites Were Present After 
Dormancy .......................................................................................................303 
 
Figure 3.10. Dihydroartemisinin Causes a Convergence on a Ring-Like 
Transcriptome in Asynchronous D6 Strains ...............................................306 
  
xi 
 
 
 
 
Abstract 
Artemisinin and its derivatives provide faster clearance of parasitemia than any 
other antimalarial drugs and these drugs are part of frontline combination therapies in 
areas where drug-resistant Plasmodium falciparum exists.  Clinical resistance to 
artemisinins is emerging on the Thailand-Cambodia border, making it imperative to 
investigate mechanisms of artemisinin resistance.  Previous work in our laboratory 
showed ring-stage parasites enter a dormant state after exposure to artemisinin.  We 
hypothesize that this period of dormancy is directly related to recrudescence and 
prolonged parasite clearance times in patients, and possibly resistance.  The target of 
artemisinin is currently unknown, and potential resistance mechanisms are not well 
described.  Our laboratory previously selected artemisinin resistance in P. falciparum 
clones D6 (Africa), W2 (southeast Asia), and a patient isolate from Thailand, TM91c235.  
Studies were attempted in order to characterize artemisinin resistant phenotypes and 
molecular mechanisms of resistance in these lines.  W2 lines resistant to 40 ng/ml 
artemisinin (W2.QHS40) and 80 ng/ml artelinic acid (W2.AL80) were exposed to AL 
and transcriptionally profiled.  Analysis of results found genes that were significantly 
differentially expressed (such as pfmdr1, pfmdr2, PF11_0466, PFE1050w) in resistant vs. 
parental lines.  It was hypothesized that the differential expression of genes may be due to 
novel single nucleotide polymorphisms (SNPs).  Further studies found that the P. 
falciparum multidrug resistance transporter-1 gene (pfmdr1) is involved in resistance in 
xii 
 
W2 and TM91, but not D6.  Resistant parasites also exhibited resistance to other 
artemisinin drugs than those used to originally select resistance in these strains.  We 
expanded on earlier selection of D6, W2, and TM91 artemisinin selection to produce high 
level resistance to concentrations of artemisinin and artelinic acid that are considered 
clinically relevant.  Parental and resistant parasites were characterized for differences in 
recovery after drug, growth rates, and in vitro susceptibility to antimalarial drugs.  During 
the generation of D6 resistant lines, it was determined that parental D6 could tolerate up 
to 1500 ng/ml QHS, but D6.QHS340x3 tolerated 2400 ng/ml of artemisinin.  Resistant 
D6 parasites recrudesced before parental strains in these assays.  Recovery assays also 
found D6 and W2 resistant lines treated with 200 ng/ml dihydroartemisinin recrudesced 
before parent strains after drug treatment.  In vitro susceptibility testing with various 
antimalarial drugs found that resistant D6, W2, and TM91c235 parasites all exhibited 
reduced susceptibility to artemisinin drugs compared to parental parasites, with marked 
resistance to QHS and AL.  A novel hypoxanthine incorporation assay showed that 
resistant progeny and parental lines of D6 and W2 both entered dormancy following 
treatment with various artemisinin drugs, but resistant parasites tolerated higher drug 
concentrations.  These results have clinical relevance with artemisinin resistance that may 
be occurring in patients.  Analysis of merozoite number in resistant parasites found D6 
and TM91c235 resistant progeny had significantly less merozoites than parent strains, 
whereas W2 resistant progeny had significantly more.  However, this only coincided with 
a slower growth rate in the D6 resistant parasite, marked by a decrease in progression 
from ring to trophozoite.  Through these methods of characterization, we defined a 
phenotype for artemisinin resistance and have made strides toward the relationship of 
xiii 
 
dormancy, resistance, and recrudescence.  We investigated potential molecular markers 
of artemisinin resistance using a variety of drug selected lines.  Next generation 
approaches that included proteomics, whole genome sequencing, and microarrays 
allowed us to identify putative resistance mechanisms in the highest artemisinin-selected 
D6 and W2 lines.  SNPs in D6.QHS2400x5 vs. D6 were identified and an amplification 
event on chromosome 10 in QHS-resistant D6 and W2 were identified.  Microarray 
analyses found ring stage parasites of D6 and D6.QHS2400x5 were transcriptionally 
arrested at ring stage, but the resistant parasite exited the transcriptional arrest before the 
parent parasite.  We also identified genes that were differentially expressed in both parent 
and resistant parasites during dormancy, along with genes that were constitutively 
expressed in resistant vs. parent strains before drug was added.  Genes identified in the 
amplification of chromosome 10 in D6.QHS2400x5 were up-regulated in the resistant 
parasite before drug was added.  Future studies will focus on validating transcriptional 
data by real-time PCR and analyzing early selected parasites to determine when markers 
of resistance accumulated.  Our molecular analyses have identified high-probability 
markers of artemisinin resistance in strains from different locations in the world which 
may be useful in surveillance of artemisinin resistance.   
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Chapter One: 
Introduction 
Malaria: Background 
Malaria is the most important parasitic disease of man, causing considerable 
mortality on four continents, and it is also a significant source of morbidity in endemic 
areas.  This disease is caused by one or more species of intracellular parasitic protozoans 
of the Plasmodium genus (Superphylum Alveolata, Phylum Apicomplexa, Class 
Aconoidasida, Order Haemosporida, Family Plasmodiidae).  The Phylum Apicomplexa 
encompasses other important intracellular pathogens of humans including Babesia spp. 
(B. microti) and the Coccidians Toxoplasma spp. (T. gondii), Cyclospora cayetanensis, 
and Cryptosporidium spp. (C. parvum).  Apicomplexan organisms are defined by the 
presence of the apicoplast, an apical polar ring (microtubule-organizing center), and a 
specialized set of secretory organelles, termed micronemes and rhoptries, all of which 
define the apical complex 
1
.  The apicoplast is a non-photosynthetic plastid that functions 
in fatty acid, isoprenoid and heme synthesis, and it is essential for survival.  It is 
theorized that plastids originated through a series of phagocytic events whereby 
prokaryotes (e.g. cyanobacteria) entered primary and secondary endosymbiosis 
2
.   
Laboratory research with human malaria has taken place relatively recently, if one 
considers how long the disease has existed.  Attempts at growing human malaria parasites 
in vitro were first recorded in 1912, but it was not until some 60 years later that the 
2 
 
procedure was perfected 
3
.  Two groups of scientists independently published methods 
for the continuous culture of human malaria in 1976, but the method of Trager and Jensen 
4
 is considered the seminal procedure for cultivation of malaria.  These scientists 
revolutionized malaria research, making it possible to study various processes of malaria 
parasites, and most importantly, unlock aspects of the most pathogenic species, P. 
falciparum.  
The genetic aspects of Plasmodium spp. have only recently been elucidated, and 
more mysteries of the parasite continue to be uncovered.  Research over the last decades 
has determined that Plasmodium spp. have a total of three genomes (nuclear, 
mitochondrial, and apicoplast).  The nuclear genome of P. falciparum strain 3D7 (cloned 
from isolate NF54, which was derived from a case of airport malaria in the Netherlands 
presumed to be acquired from the bite of an infected African mosquito 
5
) was published 
in 2002 and it was found to encode over 5000 genes 
6
.  It is composed of approximately 
23 mega bases (Mb) distributed among 14 chromosomes that range in size from 
approximately 0.643 to 3.29Mb.  The entire nuclear genome is unique in that it is 
approximately 80% adenine+thymine and 20% guanine+cytosine, making it the most 
A+T rich genome sequenced to date.  The apicoplast contains a 35 kilobase (Kb) genome 
that encodes only 30 proteins 
6
, but its proteome is supplemented by proteins encoded in 
the nuclear genome that are targeted back to the apicoplast.  The mitochondrial genome is 
made up of tandem repeats of a 6 Kb element 
7
, making it the smallest reported 
mitochondrial genome.  It contains three open reading frames with homology to 
components of the mitochondrial electron transport system. 
3 
 
The history of malaria is fascinating and many have worked through the years to 
dissect the etiology of the disease.  Malaria has been known since antiquity, as ancient 
civilizations documented symptoms such as fever and splenomegaly that we now 
recognize as classic signs of malaria.  The name “malaria” stems from the medieval 
Italian name for the disease, “mal‟aria”, which means “bad air”.  This name was used to 
describe the association of intermittent fevers and exposure to vapors from marsh areas.  
The malaria parasite was discovered by the French physician Alphonse Laveran in 1880, 
and he named it Oscillaria malariae.  While working in North Africa, he found crescent-
shaped bodies containing pigmented granules inside red blood cells (RBCs) of soldiers 
suffering from fevers.  He subsequently found that these bodies were alive after he 
observed filaments radiating from these microscopic bodies 
8
.  Although his findings 
were first met with criticism, Laveran was awarded the Nobel Prize in 1907 for 
determining the role of protozoa in causing disease (he made considerable advancements 
not only for malaria, but in trypanosome research as well).  In 1897, Ronald Ross 
conclusively showed that mosquitoes transmit malaria when he found parasites in the 
stomach of mosquitoes after feeding them blood from a malaria patient.  For this 
momentous discovery, he was awarded the Nobel Prize in 1902.  
Ronald Ross‟ discovery was vital for solving the mosquito part of the life cycle, 
but he had not observed human malaria parasites completely develop in mosquitoes (he 
did do this with avian malaria).  The Italian neurophysiologist Camillo Golgi recognized 
in 1885 that there were different forms of the disease, where fevers either occurred every 
other day (tertian) or every third day (quartan) (see below).  However, he did not realize 
that more than one species of the malaria parasite was responsible for human disease.  He 
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also found that the characteristic fever of malaria coincided with rupture of erythrocytes 
and the liberation of parasites (merozoites).  In 1890, the Italian researchers Giovanni 
Grassi and Raimondo Filetti differentiated the malaria parasite into two species based on 
Laveran‟s work, naming them Plasmodium vivax (tertian) and Plasmodium malariae 
(quartan) 
9
.  Later, the third human malaria species (Plasmodium falciparum) was named 
by the American, William Welch (1897), and the fourth (P. ovale) named by John 
Watson (1922).  Plasmodium falciparum is the most lethal malaria parasite infecting 
humans, responsible for most the mortality due to malaria each year.  Grassi, Amico 
Bignami, and other Italian researchers fed mosquitoes on malaria parasites, and by 1897, 
this group described the development of P. falciparum, P. vivax, and P. malariae in 
anopheline mosquitoes.  The tissue stage of human malaria was not completely explained 
until 1948, when H.E. Shortt, P.C. Garnahm, and others found malaria parasite 
developing in livers of rhesus monkeys infected with P. cynomolgi.  They later described 
the complete life cycles of P. vivax and P. falciparum.  A final, vital part about 
Plasmodium spp. in humans concerns relapsing malaria, or the reappearance of 
parasitemia in a sporozoite-induced infection following antimalarial therapy.  This type 
of malaria is due to stages of parasites called hypnozoites that lie dormant in hepatocytes 
10
, and it only occurs with P. ovale and P. vivax.  Research in this area of malaria biology 
is limited, but should not be discounted, since these stages represent a serious obstacle for 
vaccines against P. vivax.  At present, an estimated 156 species of Plasmodium are 
reported to infect a variety of animals 
11
 including rodents, birds, reptiles, and humans.  
We now know there are four species of Plasmodium that exclusively infect man, which 
include P. falciparum, P. vivax, P. ovale, and P. malariae.  Plasmodium knowlesi has 
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recently emerged as a human pathogen, with reports of infections in Malaysia and other 
countries in southeast Asia 
12,13
.  This parasite, which was once confused with P. 
malariae, naturally infects long-tailed macaques.  It has not been shown to be transferred 
from human to human via a mosquito, so it is classified as a zoonotic disease.   
Plasmodium spp. Life Cycle 
The life cycle of human malaria is pictured in Figure 1.1 
11
.  The life cycle of P. 
falciparum involves distinct stages, including exo-erythrocytic schizogony (asexual 
reproduction) in human hepatocytes, a 48 hour cycle in human erythrocytes (erythrocytic 
schizogony), and a cycle of development in female Anopheles spp. mosquitoes that 
involved sexual reproduction (sporogonic cycle).  The sporgonic cycle in mosquitoes, 
consisting of maturation of ingested gametocytes to infective sporozoites, may range 
from 10-18 days (extrinsic incubation period) depending on the species and relative 
temperature 
14
.   
Mosquito (definitive host).  There exists over 400 species of Anopheles 
worldwide, with 60 species capable of transmitting malaria, and approximately 30 
species that are of major importance 
15
.  The most efficient species of Anopheles for P. 
falciparum transmission are A. gambiae complex and A. funestus.  The normal life span 
of an adult Anopheles female mosquito in nature is 1-2 weeks.  Therefore, they must exist 
longer than the extrinsic incubation period in order to transmit malaria to humans.  
Considering that a small percentage of mosquitoes survive long enough for parasites to 
become infective for humans, it is impressive that so many cases of malaria exist in the 
world each year.   
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Female Anopheles mosquitoes feed on infected humans and ingest gametocytes 
with the blood meal.  A gametocyte can be either male (microgametocyte) or female 
(macrogametocyte), and in P. falciparum, they are in the characteristic shape of a 
crescent or banana (the species name is from the Latin falcis= sickle).  Male gametocytes 
exflagellate and fertilize the female macrogametocyte, forming a zygote.  The zygotes 
become motile and elongated (ookinetes), and they invade the midgut wall of the 
mosquito.  Here, ookinetes transform into oocysts.  Mature, segmenting oocysts divide 
asexually (sporogony) into numerous sporozoites, which reach the salivary gland of the 
mosquito.  
Human (intermediate host).  Humans become infected when a mosquito takes a 
blood meal and injects sporozoites into the skin.  Sporozoites are approximately 10μm in 
length and are sickle-shaped.  They are capable of invading multiple cells and they use 
gliding motility for traversing various tissues 
16
.  It has been estimated that a mosquito 
carrying P. falciparum can inject 5-20 sporozoites upon taking a blood meal 
17
.  For years, 
it was thought that sporozoites travel to the liver and invade hepatocytes, with the process 
occurring within minutes.  However, a series of recent studies using rodent malaria 
parasites have suggested that sporozoites may not leave the injection site immediately, 
either remaining in the dermis, or invading blood or lymphatic vessels 
18,19
.  It was found 
that P. berghei and P. yoelii sporozoites inoculated by mosquitoes are released from skin 
into blood circulation in a slow manner extending for 1-3 hours after a mosquito bite 
19,20
.  
It appears that a proportion of sporozoites randomly find their way into the bloodstream, 
although it is not known why some sporozoites exit the dermis, while others stay near the 
site of inoculation 
21
.  Once in the bloodstream, sporozoites must penetrate hepatocytes to 
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continue development.  The method in which this is accomplished is controversial, but it 
is hypothesized that sporozoites pass through sinusoidal layer cells to access liver 
parenchyma.  It was recently shown in P. yoelii that sporozoites must pass through 
Kupffer cells (resident macrophages in liver) before they reach hepatocytes 
22
.  
Plasmodium sporozoites contain the circumsporozoite protein (CSP), which is essential 
for attachment to liver cells 
23
.  Once in hepatocytes, sporozoites divide and multiply, 
becoming merozoites.  Sporozoites of P. vivax and P. ovale may go through schizogony 
like other Plasmodium spp., or become hypnozoites.  These stages persist in hepatocytes 
for years, and they are responsible for relapsing malaria.  It has been estimated that 
20,000-30,000 merozoites can be formed from one sporozoite 
17
.  Merozoites are 1.5-
2.5μm in length 24, and possess the necessary machinery for penetrating and invading 
erythrocytes.  It was recently found that P. berghei merozoites leave hepatocytes in 
merosomes, or large membrane-bound vesicles in liver sinusoids, and the merosomes 
help the release of merozoites into circulation 
25
.  Regarding activities of Plasmodium spp. 
while in the intraerythrocytic stage of development, perhaps the most is known about P. 
falciparum.  Therefore, some of what is described here is generalized to this species, but 
these events may also occur in other Plasmodium species. 
Merozoites enter the bloodstream and invade erythrocytes in a complicated and 
organized process that involves a variety of interactions between the merozoite and 
erythrocyte surface 
26,27
.  Merozoites first bind to the erythrocyte surface receptors via 
ligands such as merozoite surface proteins 1 (MSP-1 to 9), apical membrane antigen-1 
(AMA-1), and erythrocyte binding antigen-175 (EBA-175), then they re-orientate 
themselves to their apical pole.  There is formation of a tight junction between host and 
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parasite apical surface allowing the merozoite to invade, forming a parasitophorous 
vacuole (PV).  While P. falciparum uses various receptors to invade human erythrocytes 
(above), erythrocyte invasion by P. vivax and P. knowlesi depend on the interaction with 
Duffy blood group antigen displayed on young erythrocytes (reticulocytes) 
28
.  Humans 
lacking this antigen are not susceptible to infection, explaining why this parasite is not 
present in West Africa, where the Duffy negative blood group is prevalent 
29
.  After 
invasion, the parasite develops in a PV through young (ring-stage) trophozoite (0–24 
hours), mature trophozoite (24–36 hours) and schizont stages (40–48 hours) 30.  The time 
for completion of the life cycle may be strain-dependent, ranging from 44-48 hours 
31
.  
Ring-stage trophozoites (named this way because of the appearance of thickened 
cytoplasm and position of nucleus) begin feeding on contents of the RBC.  Parasites 
ingest hemoglobin via an endocytic feeding mechanism into a lysosomal compartment, 
the digestive vacuole (DV).  Here, hemoglobin is broken down into the moiety 
ferriprotoporphyrin IX (free heme) 
32,33
.  This molecule is toxic to the parasite, so it is 
converted into non-toxic hematin and inert brownish-yellow crystals termed hemazoin 
(also known as malaria pigment) 
34
.  The trophozoite stage can be differentiated from the 
ring stage based on size and shape of the developing parasite and the presence of darker 
hemazoin granules. 
Mature erythrocytic stages of P. falciparum (>24 h after development) display 
knob-like structures on the erythrocyte membrane.  The parasite is able to transport these 
proteins (PfEMP1 [Plasmodium falciparum Erythrocytic Membrane Protein 1] and others) 
to the surface of the erythrocyte through a tubovesicular membrane network (TVM) and 
associated protein trafficking/sorting structures called Maurer‟s clefts 35.  The 
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development of a protein trafficking network and subsequent changes to the erythrocyte 
surface parallel the increased selective adhesiveness of the parasitized erythrocyte 
membrane, responsible for the sequestration of trophozoites and schizonts in deep 
visceral blood vessels, and severe pathogenesis marked by obstruction of placental and 
cerebral vasculature 
32
.  The persistence of P. falciparum during blood stage proliferation 
in its host depends on the variant expression of PfEMP1, which is a type of antigenic 
variation used by the parasite.  This variation is mediated by the differential control of 
PFEMP1 encoded by approximately 60 var genes 
36
, and it allows the parasite to escape 
the immune system.  Early studies showed that sera from infected children and adults did 
not recognize a common epitope (now thought to be PfEMP1) found on all infected 
RBCs, but epitopes that are strain specific 
37,38
.  Therefore, there is a lack of cross-
reactive epitopes and the presence of immunodominant variant epitopes on PfEMP1 may 
explain how the immune response to PfEMP1 is kept variant-specific despite repeated 
exposure to the pathogen. 
The ligands displayed on erythrocytes by P. falciparum allow these cells to 
adhere to venular endothelium (cytoadherence) 
39
.  The ability to express different 
PfEMP1 allows the parasite to sequester in deep blood vessels and avoid antibodies and 
spleen-mediated clearance, thereby allowing transmissibility.  Because of this 
cytoadherence property, the only stages usually found in patient peripheral circulation are 
ring-stage trophozoites and gametocytes, because infected red blood cells (IRBCs) 
harboring these stages do not have these proteins on the cell surface.  Schizonts are the 
most mature forms in the asexual intraerythrocytic part of the life cycle, which are 
characterized by nuclear division.  In these stages, hemazoin continues to appear in the 
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DV, and export of proteins from the parasite to the erythrocyte cytosol and beyond 
continues as well 
32
.  Interestingly, synthesis of proteins and other factors needed for 
DNA replication and partitioning into merozoites is completed during the late trophozoite 
phase 
31
.  The final step is the liberation of merozoites from segmenting schizonts, and 
these merozoites go on to infect other erythrocytes.  A segmenting schizont of P. 
falciparum may release 16–32 daughter merozoites 30.  The number of merozoites is 
typically greater in P. falciparum compared to other Plasmodium species (below).  Some 
merozoites do not develop through the normal intraerythrocytic cycle, but mature into 
gametocytes.  Mature gametocytes will be ingested by a mosquito upon taking a blood 
meal, to complete the cycle.   
Malaria: life cycle in relation to cell cycle.  The development of erythrocytic 
forms of Plasmodium spp. involves critical changes in gene expression, antigen 
presentation, and processes that are important for research aimed at vaccination, drug 
discovery, and cell biology.  Because of the different stages of parasites in the life cycle 
of malaria, it is difficult to make comparisons to the cell cycle of other cells (or 
organisms) that exist in a normal format of G0-G1-S-G2-M.  However, the part of the life 
cycle of human malaria parasites that may best approximate this format is the 
erythrocytic stage in humans.  Studies on synchronized RBC stages have helped to 
dissect the possible cell cycle of P. falciparum, the most important malaria parasite.  
Based on microscopic studies and nuclear staining with flow cytometry, Arnot and Gull 
(1998) 
31
 described a model of the relationship between asexual parasite development and 
the cell-cycle.  A merozoite, both free and in late segmenting schizonts, is essentially in a 
G0-like state (resting phase), with condensed chromatin.  After the haploid merozoite 
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invades an erythrocyte, ring stage trophozoites develop into early trophozoites, which 
represent pre-nuclear division stages where cell growth and preparation for DNA 
replication occurs (probably analogous to G1 of cell cycle).  Before DNA synthesis, 
trophozoites accumulate high levels of RNA, a step in the preparation for proteins needed 
for DNA synthesis.  It appears that DNA synthesis starts about 28-31 hours after 
merozoite invasion after the appearance of pigmented trophozoites (early-mid 
trophozoites) and DNA content then increases for approximately 8-10 hours in late 
trophozoites.  This corresponds to S phase of the cell cycle, where DNA replication 
begins.  As trophozoites mature, subdivision of nuclear material (signaling onset of 
schizogony) proceeds.  DNA synthesis may continue in schizonts (defined as having 
more than one nucleus) but it has not been established whether G2 (checkpoint between 
DNA synthesis and mitosis) and then M (mitotic) phases occur during progression from 
the haploid DNA content (1 merozoite) to the final genome complement of the mature 
segmenter (which can reach a maximum of 32 merozoites).  Merozoites are formed after 
S phase, so if mitotic genome segregations occur, they must be very rapid, allowing 
complete packaging and DNA segregation before the completion of the life cycle.  
Unfortunately, transitions from one stage of the life cycle to the next are not clearly 
separable biochemically or morphologically, so the relationship of schizogony to both the 
DNA-synthetic cycle and the cell-cycle is poorly defined.  Researchers have taken 
advantage of similarities between the cell cycle and Plasmodium stages to exploit 
potential drug targets and further understand gene expression. 
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Malaria: Clinical Manifestations and Diagnosis 
Uncomplicated malaria.  All human malaria species can cause mild 
(uncomplicated) malaria, with similar symptoms.  However, the incubation period (time 
between initial infection and appearance of symptoms) and pre-patent period (period 
between sporozoite inoculation and detectable stages) varies.  The incubation period may 
range from 7-30 days 
40
, but it is usually shorter in the case of P. falciparum (9-14 days).  
The incubation period of P. vivax and P. ovale (12-18 days) is almost similar to P. 
falciparum, but that of P. malariae is significantly longer (18-40 days) 
41
.  The minimum 
pre-patent periods of P. falciparum (9-10 days), P. vivax (11-13 days), and P. ovale (10-
14 days) have similar ranges as well 
42
, but that of P. malariae can be much longer (16-
59 days) 
43
.  
Uncomplicated malaria is defined as symptomatic malaria without signs of 
severity or evidence (clinical or laboratory) of vital organ dysfunction 
44
.  The first 
symptoms of classical, uncomplicated malaria after the pre-patent period (period between 
sporozoite inoculation and detectable stages) can be described as the primary attack, or 
prodrome (symptom, or set of symptoms).  It is usually atypical and may resemble any 
febrile illness (marked by fever), but common symptoms are headache, myalgia, general 
malaise nausea, and loss of appetite 
40
.  The asexual intra-erythrocytic stages of 
Plasmodium spp. cause all pathophysiological processes in humans.  In uncomplicated 
malaria, the hallmark of disease is episodes of chills (cold stage) and fever (hot stage).  
The cold stage may last for 1 hour duration, followed by profuse sweating as the body 
temperature decreases.  A fever stage rapidly follows for 6-12 hours where patients 
commonly experience nausea and vomiting.  These episodes are caused by rupture of 
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schizont-infected erythrocytes, where the massive release of hemazoin, toxins and RBC 
components induce macrophages to secrete pro-inflammatory cytokines such as Tumor 
Necrosis Factor-alpha (TNF-α) and Interleukin-1 (IL-1), common mediators of the 
immune system (see below) induced by Plasmodium spp. 
39,45
.   
The pattern of intermittent chills/fever is directly dependent on the synchronized 
development of the infecting species of Plasmodium in the bloodstream.  The appearance 
of symptoms can be 48 or 72 hours depending on the species.  This recurrence of 
symptoms was noted by ancient Romans and they named the disease by measuring the 
elapsed time from the beginning of the first episode to the end of the second episode 
46
.  
When fevers recurred every third day, it was called tertian malaria, although only forty-
eight hours separated the two attacks.  A fever appearing every fourth day was called 
quartan.  Plasmodium vivax and P. ovale cause benign tertian malaria and P. falciparum 
causes malignant tertian malaria.  These parasites have 48 hour life cycles.  Plasmodium 
malariae causes benign quartan malaria (72 hour life cycle).  Plasmodium knowlesi, a 
fifth human malaria parasite has a 24-hour life cycle.  If the disease is not treated 
effectively, severe malaria can result in a few hours (mostly P. falciparum).  There is 
variability in the epidemiology and clinical manifestation of malaria due to factors such 
as the species of parasite occurring in a given area, parasite susceptibility to antimalarial 
drugs, environmental conditions, and the behavior and immune status of the host 
47
.   
Severe malaria.  Severe malaria occurs when P. falciparum infections are 
complicated by serious organ failures or abnormalities in the patient's blood or 
metabolism 
40
.  This may occur in non-immune individuals, people who delayed 
treatment, or those who were given sub-optimal antimalarial or ineffective antimalarial 
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drugs.  Severe malaria is life-threatening and it requires hospitalization, intravenous 
antimalarial therapy (below), and management of various complications.  The mortality 
associated with severe malaria remains high, ranging from 10-50%, depending on the 
setting 
48
.  However, if left untreated, severe malaria is fatal in the majority of cases.  
Severe malaria usually manifests with one or more of the following: coma (cerebral 
malaria), metabolic acidosis, severe anemia, hypoglycemia, acute renal failure, acute 
pulmonary edema, blackwater fever, acute respiratory distress syndrome (ARDS), among 
others 
44
.  The WHO defined criteria for severe malaria that includes one or more of a 
clinical (prostration, impaired consciousness, respiratory distress, abnormal bleeding, 
jaundice, hemoglobinuria, among others) or laboratory feature (severe anemia, acidosis, 
renal impairment, hypoglycemia, hyperparasitemia) 
49
.   
Cerebral malaria is the most common complication and cause of death in severe P. 
falciparum infection (10% of all hospital admissions and 80% of deaths [falciparum 
malaria] are due to Central Nervous System [CNS] involvement) 
50
.  The disease is 
typified by a sudden onset of headache, convulsions, body temperature reaching 106-108º 
F, and rapid progression to death (24-72 hours Cerebral malaria is the result of 
parasitized erythrocytes adhering to the cerebral microvasculature (a form of 
sequestration) and parasite-induced inflammatory response.  There is blockage of the 
blood's pathway, leading to a shortage of oxygen (hypoxia) and nutrients to those areas of 
the brain.  A mentioned above, mature parasites induce the formation of knobs (formed 
by PfEMP1 in association with KAHRP [knob-associated histidine-rich protein]) on the 
surface of the erythrocyte 
51
.  The cells expressing knobs will bind to host molecules such 
as CD36, Intracellular Adhesion Molecule-1 (ICAM-1), E-selectin, and Vascular Cell 
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Adhesion Molecule-l on vascular endothelium and uninfected erythrocytes 
39
.  IRBCs 
containing mature parasites can adhere to many uninfected RBCs, forming rosettes.  This 
is thought to be mediated by knobs such as PfEMP1, but also by various other parasite-
derived ligands such as rosettins and rifins 
52
.  Like cytoadherence, rosettes have the 
potential to block blood flow and contribute to cerebral malaria.  Cerebral malaria must 
be treated immediately, or death can result in a period of hours.  Treatments for cerebral 
malaria include quinine, quinidine gluconate, and artesunate (below).  Because of 
cardiotoxicity and advantages over quinine, intravenous artesunate may be the best option.  
Blackwater fever is an acute, massive lysis of erythrocytes, marked by high levels of free 
hemoglobin in the blood and urine.  Hemoglobin and its products in the urine give it a 
dark color, lending the name to the disease.   
Global Impact of Malaria 
Malaria affects almost half of the global population, which is represented by the 
poorest countries in the world.  There are at least 190 million cases of malaria per year 
and the disease accounts for nearly one million deaths per year 
53
, covering four 
continents of the world.  A large percentage of malaria fatalities occur in Africa, but 
malaria is endemic through most of Southeast Asia, sub-continental India, the South 
Pacific, and parts of South America (Figs. 1.2, 1.3).  Plasmodium falciparum causes the 
majority of cases and deaths in Africa, where the most mortality and morbidity due to 
malaria occurs in the world.  A large portion of deaths due to malaria in Africa are in 
children under five years old 
53
.  It has been estimated that 85% of malaria deaths in the 
world can be attributed to children under 5 years of age 
54
.  A 2007 study found that 2.37 
billion people (about 35% of the world's population) live in areas where there is some 
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risk of P. falciparum transmission, and that 1 billion of these people live where there is a 
low, but evident risk of malaria transmission 
55
.  The study found that on a global scale, 
nearly all the regions where prevalence of P. falciparum is more than 50% are in Africa, 
although there are some African regions where few people are infected with P. 
falciparum.  Outside of Africa, the prevalence of P. falciparum is less than 5% 
55
.  
Although P. falciparum is the most lethal and is concentrated in Africa, P. vivax is 
actually more widely distributed in the world.  It has been estimated that 70-80 million 
cases of P. vivax occur each year, and greater than 50% of malaria cases (outside of 
Africa) are caused by P. vivax 
56
.  A more recent estimate of P. vivax risk by Guerra et al. 
(2010) 
57
 estimated that 2.85 billion people were at risk for transmission in 2009, with 
57.1% of them (1.63 billion) living in areas of unstable transmission.  The vast majority 
(2.59 billion, 91.0%) were located in central and southeast Asia, with the remainder 
located in the Americas (0.16 billion, 5.5%) and Africa/Yemen/Saudi Arabia (0.10 billion, 
3.5%).  In all, a total of 95 P. vivax endemic countries and territories listed in 
international travel and health guidelines were identified.   
A variety of estimates as to the number of people affected by malaria and also the 
number killed each year have been proposed in the literature.  Breman (2001) 
15
 listed 
annual malaria mortality estimates and stated that they range from 0.7-2.7 million.  This 
number is significantly higher than most report as it accounts for insufficient reporting 
and clinical diagnosis.  In 2006, the World Health Organization (WHO) estimated that 
3.3 billion people are at risk for contracting malaria worldwide 
54
.  The most recent 
World Malaria Report 
53
 reported data for 2008 in 108 malaria-endemic countries, when 
there was an estimated 243 million cases of malaria (5th-95th percentiles: 190–311 
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million).  The cases were predominantly in Africa (85%), followed by South-East Asia 
(10%) and Eastern Mediterranean Regions (4%).  For 2008, malaria was responsible for 
an estimated 863,000 deaths (5th-95th percentiles: 708–1003 thousand), of which 89% 
were in the African Region, followed by the Eastern Mediterranean (6%) and the South-
East Asia Regions (5%).  Hay et al. (2010) 
58
 recently estimated that 451 million (95% 
credible interval 349–552 million) clinical cases of P. falciparum malaria existed in 2007 
in 87 endemic countries.  There were 271 (241–301) million cases estimated to have 
occurred in Africa/Yemen/Saudi Arabia, 177 (89–270) million in central/south east Asia, 
and 3 (1–7) million in the Americas.  More than half of the world's estimated P. 
falciparum clinical cases came from India, Nigeria, DRC, and Myanmar (Burma).  
African populations suffered the largest proportion (60%) of the 451 million clinical 
cases of P. falciparum.  The reasons for discrepancies in disease burden between WHO 
and other studies may stem from features of P. falciparum infection that confound 
traditional measures of disease burden and disability 
58
.  These may include the fact that 
not all infections result in progression to disease, notably in areas of stable transmission, 
where populations have acquired clinical immunity.  Also, since symptoms of malaria 
(principally fever) may overlap with other locally prevalent diseases in an area of stable 
transmission, the routine reporting of malaria can overestimate disease rates by assuming 
that most fevers are due to malaria.  Many infected people elect to self-medicate after 
experiencing a malaria-like syndrome, and they will not seek care from a health care 
center that reports malaria cases.  Finally, inaccurate diagnoses might be used to report 
disease rates, and these errors may be compounded through inadequate and incomplete 
national reporting systems. 
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Malaria Public Health Control and Eradication Efforts 
Malaria eradication seemed possible in the 1950s after the discovery of effective 
antimalarials such as chloroquine and Paul Müller‟s finding that 
dichlorodiphenyltrichloroethane (DDT) had insecticidal use.  In 1955, the WHO 
established the Global Malaria Eradication Program, with efforts focused on house-
spraying with DDT, antimalarial drug treatment (mainly chloroquine), and surveillance.  
The program was designed to be carried out in 4 successive steps: preparation, attack, 
consolidation, and maintenance 
59
.  The program took place in many countries, regardless 
of geography and epidemiology.  A notable part of this program was the exclusion of 
sub-Saharan Africa from this strategy 
60
.  This approach failed to interrupt transmission 
completely in many countries and malaria resurged to previous or even higher levels as 
eradication programs crumbled and the strategy was abandoned.  Successes included 
eradication in nations with temperate climates and seasonal malaria transmission.  Some 
countries such as India and Sri Lanka had sharp reductions in the number of cases, 
followed by increases to substantial levels after efforts ceased.  The emergence of drug 
resistance, widespread resistance to available insecticides, wars and massive population 
movements, difficulties in obtaining sustained funding from donor countries, and lack of 
community participation made the long-term maintenance of the effort unattainable
59
.  By 
1969, WHO admitted the failure of this campaign and the global eradication policy was 
abandoned in favor of control programs.  Malaria mortality and morbidity began to 
increase again in the 1980s due to a combination of factors such as the increase in 
parasite and vector resistance to available antimalarial drugs and insecticides, the 
weakening of traditional malaria control programs, rapid decentralization and 
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deteriorating primary health services, and the development of humanitarian crisis 
situations in many malaria-endemic areas 
61
.  This dramatic increase led to the adoption 
of the Global Strategy for Malaria Control (GSMC) in 1992.  GSMC was founded on 
four technical elements, including early diagnosis and prompt treatment of malaria, 
planning and implementation of selective/sustainable preventive measures (ex. vector 
control), early detection/containment/prevention of epidemics, and strengthening of local 
capacities in basic and applied research 
62
.  A few years later, the Roll Back Malaria 
Partnership (RBM) was created (1998) to coordinate global efforts in combating malaria. 
The goal of most current national malaria prevention and control programs in 
endemic countries is to reduce the number of malaria-related cases and deaths.  RBM is a 
global framework for coordinated action against malaria.  RBM was launched by WHO, 
the United Nations Children‟s Fund (UNICEF), United Nations Development Program 
(UNDP), and the World Bank in an effort to provide a coordinated global response to the 
disease
 63
.  In 2009, the RBM Partnership comprised more than 500 partners, including 
malaria endemic countries, developmental partners, the private sector, non-governmental 
and community-based organizations, and research and academic institutions.  Through 
RBM partnership mechanisms, players in malaria control coordinate their activities at 
global, regional and country level, while striving to achieve optimal use of resources.  
RBM‟s overall strategy aims to reduce malaria morbidity and mortality by reaching 
universal coverage and strengthening health systems.  In 2008, key actors in malaria 
control endorsed an ambitious plan to put an end to malaria as a global health problem.  
The Global Malaria Action Plan (GMAP) consolidates the input of 30 endemic countries 
and regions, 65 international institutions and hundreds of experts from a wide range of 
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fields.  The GMAP is supported by RBM and it aims for a substantial and sustained 
reduction of malaria.  The GMAP departs from other solutions that desire rapid results by 
using strategies adapted to the specific ecology and epidemiology of malaria in a country 
or region.  Major goals of the GMAP include universal coverage of at-risk populations, 
reducing global malaria cases from 2000 levels by 75% in 2015, and reducing global 
malaria deaths to near zero in 2015 
64
.  Malaria eradication is now being brought back to 
the forefront as well.  In 2008, the Bill and Melinda Gates Foundation called for malaria 
eradication 
65
.  They cited encouraging research into vaccines, vector control, and 
antimalarial drugs as major factors that could lead to eradication.  Also, a number of 
collaborators have contributed significant energy and resources to the global effort to 
control malaria, amounting in almost $4 billion for malaria control that will reach more 
than 70 countries.  Also, the GMAP lists eradication as an eventual goal where the global 
incidence is reduced to zero through progressive elimination in countries.  The GMAP 
aims to eliminate malaria in 8-10 countries by 2015 and afterwards in all countries in the 
pre-elimination phase today 
64
.   
Malaria in the United States.  Malaria was previously endemic in the United 
States.  The disease was a significant problem in the southeastern U.S., and Malaria 
Control in War Areas (MCWA) was developed to prevent malaria on military bases and 
prevent the spread to the general public from infected soldiers returning from endemic 
areas 
59
.  The MCWA became the Communicable Disease Center (now Centers for 
Disease Control [CDC] and Prevention house in Atlanta) in 1946 and much of the CDC‟s 
early work focused on malaria.  The National Malaria Eradication Program commenced 
operations in1947.  The program consisted primarily of DDT application to the interior 
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surfaces of rural homes or entire premises in counties where malaria was reported to have 
been prevalent in recent years. By the end of 1949, over 4,650,000 house spray 
applications had been made.  By 1951, CDC gradually withdrew from active participation 
in the operational phases of the program and shifted to its interest to surveillance.  By 
1951, malaria was considered eradicated from the U.S.  Today, the majority of cases 
diagnosed in the U.S. are acquired in endemic areas, although transmission via blood 
transfusion has been reported 
66
.  In addition, local mosquito-borne transmission 
(autochthonous) has been implicated in outbreaks of P. vivax malaria in several states, 
most recently Virginia (2002) and Florida (2003) 
67
.  In 2006, CDC received 1,564 
reports of cases of malaria occurring among persons in the U.S. and its territories.  Of 
these cases, the infecting Plasmodium species was identified in only 63.4%, and P. 
falciparum and P. vivax made up the majority of infections (61.8% and 27.7%, 
respectively) 
68
.   
Current Malaria Control Programs 
Control of malaria requires an integrated approach that targets vectors, allows 
distribution of proper drugs, and access to prompt medical care.  Since no antimalarial 
drug is 100% protective, drug use should be combined with the use of personal protective 
measures (i.e., insect repellent, long sleeves/pants, use of bed nets).  Progress to control 
malaria has been slow because of drug resistance, insecticide resistance, differences in 
mosquito biology/ecology (breeding preferences/sites, flight/resting behavior) that 
hamper universal vector control, and the cost of malaria control programs exceeds public 
health resources in poor countries.  The choice of interventions depends on the malaria 
transmission level in the area (e.g. Intermittent Preventive Treatment in Pregnancy [IPTp] 
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for pregnant women in areas of low transmission).  The main components of malaria 
control are case management (diagnosis and treatment) of patients with malaria and 
prevention (Insecticide-Treated Nets [ITNs], IPTp in pregnant women [above], Indoor 
Residual Spraying [IRS]) 
69
.  In most malaria-endemic countries, these interventions are 
packaged into public health programs.  Other control measures include environmental 
strategies to control mosquitoes and mass drug administration (this is not recommended 
in order to discourage drug resistance).  The current malaria control strategy calls for the 
selection of those control measures which are most appropriate to local circumstances 
and capabilities and malaria risk (Fig. 1.3).   
Case-management of malaria involves accurate diagnosis and the use of proper 
antimalarial drugs.  Malaria infections can be diagnosed clinically and confirmed by 
parasitological diagnosis with either microscopy or with rapid diagnostic tests (RDTs).  
Importantly, RDTs are useful for diagnosis of malaria outside of health facilities where 
equipment and diagnostic expertise may not be available.  However, microscopic 
diagnosis should be used to enhance case management of the patient.  ACTs are the drug 
of choice against uncomplicated P. falciparum malaria, but chloroquine and sulfadoxine-
pyrimethamine (now ineffective in many countries) are still the treatment of choice in 
some areas for other Plasmodium spp. (more below).  Thorough case management takes 
into account the infecting Plasmodium species for correct antimalarial drug prescription, 
patient tolerability of drug, and form of administration of drug.  Some patients fail 
antimalarial treatment and they must be handled carefully to ascertain if recrudescence of 
infection or re-infection occurred 
44
.  Most malaria patients in epidemics and emergencies 
are non-immune, partially immune, or otherwise vulnerable to severe disease.  Therefore, 
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the WHO recommends an active search should be made for febrile patients to ensure that 
as many patients as possible receive adequate treatment, rather than relying on patients to 
come to a fixed clinic 
44
. Home-based management of malaria (HMM) is one of the 
strategies recommended by WHO to improve access to prompt and effective treatment of 
malaria episodes through trained community members living as close as possible to 
where the patients live.  HMM allows for coverage of the health services for malaria to 
extend beyond the reach of health facilities.  It requires that effective and appropriate 
treatment with first-line ACTs, as well as guidance on referral criteria are provided at the 
community level through trained community-based providers, such as community health 
workers, mother coordinators and private vendors.  Management of severe malaria is very 
important, as death can occur rapidly after patients are admitted to a hospital or clinic.  
The recommended steps to be taken for the management of severe malaria are clinical 
assessment of the patient, specific antimalarial treatment (artesunate or quinine), 
adjunctive therapy, and supportive care 
44
. 
Vector control measures directed towards adult mosquitoes such as IRS and ITNs 
are geographically broad and applicable compared to more ecology specific measures 
directed towards larvae.  Many important vectors of malaria bite indoors at night, and 
may rest on indoor surfaces after biting, whereas larval habitats vary markedly among 
anopheline species.  IRS with an effective insecticide was a staple of early malaria 
eradication programs, but the deterioration of IRS programs in some countries led to the 
resurgence of malaria and the abandonment of the global campaign for eradication.  IRS 
is still used today, particularly in areas of seasonal transmission, including epidemic-
prone areas, and increasingly in more malaria-endemic areas.  DDT was used primarily in 
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early malaria eradication for IRS, but it was abandoned after reports of insecticide 
resistance, and accumulation of DDT in the food chain, which can lead to long-term 
toxicity in animals and humans.  The production and use of DDT is restricted by the 
Stockholm Convention on Persistent Organic Pollutants 
70
.  There are currently 12 
insecticides recommended for IRS, and DDT is one of them.  The WHO recommends 
DDT only for IRS in high transmission area, stressing that it is still useful for vector 
control because there is no alternative of both equivalent efficacy and operational 
feasibility 
70
.  IRS is dependent on logistics such as adequate surfaces in the housing 
structures that can be sprayed, the targeted mosquito must rest indoors before or after a 
blood meal, and the mosquito must be susceptible to the insecticide.  Because of the 
problems with DDT, alternative insecticides classified as carbamates, organophosphates, 
and pyrethroids were developed for vector control.  Of these, pyrethroids are probably the 
best since they have great utility in long lasting insecticidal nets (LLINs) reflected by 
their low toxicity, ability to mosquitoes effectively, and affordance of personal protection 
71
. 
The development of pyrethroids with long residual action and very low 
mammalian toxicity suggested that sub-optimal mechanical protection afforded by 
mosquito netting could be paired with an insecticidal effect for greater protection.  
Mosquitoes are positively attracted to individuals sleeping inside an ITN, making the ITN 
work like a baited trap.  Currently, there are two types of bed nets used for malaria 
control, and only pyrethroids are allowed as treatment.  Standard ITNs are cost-effective 
but  require re-treatment with insecticide every 6-12 months, which presents a barrier for 
widespread use in endemic countries 
72
.  LLINs are ITNs that maintain insecticide levels 
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for up to 3 years.  LLINs have been associated with sharp decreases in malaria in 
countries where malaria programs have achieved high LLIN coverage.  Mobilizing 
resources to procure these nets remains a major challenge.  After much debate, WHO 
now recommends that LLINs be provided free, establishing universal coverage in 
malarious areas.  Donors and programs such as the Global Fund Against HIV/AIDs, 
Tuberculosis, and the President‟s Malaria Initiative support the purchase of LLINs for 
many countries.  Making LLINs free to people has greatly increased bed net ownership 
and encouraged their usage in endemic areas 
73,74
.  A recent analysis estimated that 
between 2008 and 2012, 327 million LLINs would be needed to achieve full coverage of 
women and children in malaria-endemic countries of Africa, while 545 million LLINs 
would be needed to achieve universal coverage in that same region 
72
.   
ITNs are a form of malaria control that offers protection not only for the 
individual, but for the community as well.  There is much evidence that community-wide 
use of ITNs leads to large-scale killing of mosquitoes and personal protection, indicated 
by reduction of severe disease and mortality due to malaria in endemic regions 
75-79
.  The 
community-wide use of ITNs reduces the vector population and shortens the mean 
mosquito lifespan, leading to a reduction of malaria 
80
.  Apart from their killing effect, 
ITNs also inhibit mosquito feeding, hence reducing the reproductive potential of vectors 
and decreasing the number of potential mosquito bites in a community.  A troubling fact 
is that the mass use of ITNs or LLINs impregnated with pyrethroids may lead to 
resistance, rendering this class of insecticides ineffective.  Resistance (knock-down 
resistance [kdr]) can be due either to detoxification of insecticide by enzymes or by 
mutation on its target site: sodium channels for DDT and pyrethroids 
81
, and acetyl-
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cholinesterase for organophosphates and carbamates 
82
.  Mutations in kdr genes were first 
detected in A. gambiae from Africa in 1998, and mutations have been detected in other 
African countries as well.  However, reports have shown that mortality of wild 
mosquitoes entering experimental huts areas of resistance remains high, and personal 
protection from biting is still effective 
80
.  
Vector control strategies have a proven track record of successfully reducing or 
interrupting disease transmission when coverage is sufficiently high.  However, vector 
control also has proven weaknesses (insecticide resistance) that relate to technical and 
managerial deficiencies and obstacles.  Also, there may be differences in environmental 
and societal determinants in parts of endemic areas, making one single vector control 
approach unreasonable.  Therefore, Integrated Vector Management (IVM) has emerged 
as an adaptive and flexible approach of controlling mosquitoes in malarious areas that 
uses a range of interventions.  The approach encourages collaborations within health 
sectors and communities, and seeks to improve the efficacy, cost-effectiveness, 
ecological soundness, and sustainability of disease-vector control 
83
.  The Round Four 
Global Funds to fight Aids, Tuberculosis and Malaria submitted by Zambia in 2004 
established key objectives and service areas pertinent to IVM that included scaling up 
coverage for IRS, expanding environmental management and larviciding, and improving 
the capacity for monitoring and evaluation 
62
.  IVM selects proven vector control 
methods based on knowledge of local vector biology and ecology, disease transmission 
and morbidity.  The application of IVM principles to vector control will contribute to the 
judicious use of insecticides and extend their useful life, discouraging resistance 
84
.  An 
IVM approach takes into account the available health infrastructure and resources and 
27 
 
integrates all available and effective measures, whether chemical, biological, or 
environmental 
83
.   
Vaccines 
Pre-erythrocytic stage.  Currently, vaccines that target pre-erythrocytic stages 
focus on subunits of sporozoites, whole organism, or DNA-based approaches.  Although 
subunit vaccines (e.g. RTS,S below) show the most promise of malaria vaccines, they 
actually have achieved lower efficacy than whole-parasite vaccines in phase IIa clinical 
trials 
85
.  The use of live, attenuated sporozoites for a whole parasite vaccine was 
originally reported in the 1960s and subsequent work found that irradiated sporozoites 
produce sterile and long-lasting protection in mice and humans 
85
.  It appears that 
immunity is mediated by specific antibody to the irradiated sporozoites (Radiation 
Attenuated Sporozoites, RAS), but CD8+ T-cells are also necessary for the elimination of 
infected hepatocytes.  Although this method of vaccination seemed promising, the 
vaccine must be totally protective against sporozoites since even one sporozoite can 
initiate malaria infection.  Also, a large number of sporozoites must be injected from the 
bite of an irradiated mosquito (>1,000), which can cause logistical problems 
86
.  In 2003, 
scientists from Sanaria revisited the potential for a metabolically active and attenuated 
whole parasite P. falciparum sporozoite (PfSPZ) vaccine.  A preliminary study was 
conducted in the U.S. in order to provide proof of safety, immunogenicity and protective 
efficacy studies 
87
.  A phase II/IIa clinical trial in non-immune healthy adults is being 
conducted as a collaborative effort between Sanaria, PATH MVI, and the U.S. Military 
Malaria Vaccine Program), and the Center for Vaccine Development at the University of 
Maryland at Baltimore.   
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The most effective malaria vaccine currently in clinical trials is the RTS,S vaccine 
developed by Glaxo Smith Kline (GSK) in collaboration with the Walter Reed Army 
Institute of Research (WRAIR).  Clinical development of the RTS,S candidate vaccine 
has continued in partnership with the Program for Appropriate Technology in Health and 
the Malaria Vaccine Initiative (PATH MVI).  The vaccine consists of a portion of CSP 
(C-terminus amino acids 207-395) from P. falciparum fused to hepatitis B surface 
antigen and mixed with free hepatitis B surface antigen.  It also contains a GSK 
proprietary adjuvant (ex. AS02) and the vaccine is expressed in the form of virus like 
particles in Saccharomyces cerevisiae 
88,89
.  Clinical evaluation of RTS,S began in adults 
in the U.S. in 1992, and in Africa in 1998.  A phase IIb trial with RTS,S/AS02A was 
initiated in 2003 and it was conducted with more than 2,000 children aged 1-4 years in 
southern Mozambique.  There was confirmed vaccine efficacy (VE) during an initial 6-
month follow-up (30% against clinical malaria, 45% against infection, and 58% against 
severe malaria), as well as sustained protection up to 21 months (35% clinical malaria, 49% 
severe malaria) and 45 months (VE against clinical and severe malaria over entire follow 
up= 31% and 38%, respectively; VE against all clinical episodes=26%) 
90-92
.  A phase 
II/IIb clinical trial in Mozambican infants found RTS,S/AS02D had VE of 66% over a 
three-month follow-up period 
93
.  Importantly, it displayed a promising safety and 
tolerability profile and the trial was the first to show efficacy in infants of any malaria 
vaccine candidate.  The results of a RTS,S/AS02D phase IIb study in Tanzanian infants 
found that VE against first infection of P. falciparum 6 months after last dose was 65.2% 
94,95
.  A study of children aged 5-17 months in Tanzania showed that RTS,S/AS01E 
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reduced the risk of clinical episodes of malaria by 53% over an eight-month follow-up 
period 
95
.   
Based on these promising results, RTS,S is the first malaria vaccine candidate to 
reach large-scale phase III clinical testing, the last stage of development before regulatory 
file submission.  A large-scale phase III multi-center efficacy trial in both infants and in 
young children was launched in May, 2009.  It is imperative to show effectiveness and 
safety in these groups because they represent populations that are most vulnerable and 
who would benefit most from an effective malaria vaccine.  The multi-center trial is 
underway in 11 sites in seven African countries (Gabon, Mozambique, Tanzania, Ghana, 
Kenya, Malawi, and Burkina Faso).  This trial, which will enroll up to 16,000 infants and 
children, is expected to become the largest malaria vaccine trial to date 
96
.  Pending 
sufficient safety and immunogenetic profiles, general implementation of RTS,S for 
infants 6-12 weeks of age may be possible within five years.  The vaccine could be 
available for specific use among young children 5-17 months old as early as 2013 
96
.   
Other pre-erythrocytic vaccines that show efficacy in animal models are based on 
genetically attenuated sporozoites (GAS) 
97-100
.  DNA vaccine approaches for malaria 
prevention have recently been described where different degrees of protection are 
produced 
88,89
.  There are a wide range of candidates being studied, some of which are in 
clinical trials.  A majority of these are plasmid DNA vaccines and live recombinant 
vaccines that use differently prepared viruses (modified vaccinia Ankara (MVA) strain, 
fowlpoxvirus (FPV), Adenovirus, Sindbis virus, yellow fever virus or a cold-adapted 
attenuated influenza virus strain) as a vector.   
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Erythrocytic stage.  Vaccines against sporozoites such as RTS,S have been 
designed to prevent infection, which theoretically should prevent disease.  In contrast, 
vaccines against the pathogenic asexual blood stages aim to prevent disease, but not 
infection.  Because merozoite attachment to RBCs is specific and essential for 
progression of the erythrocytic cycle, antigens on the merozoite surface have been 
targeted for vaccine development 
85
.  Spf66, regarded as the first malaria vaccine, was the 
first asexual blood-stage malaria vaccine developed.  This vaccine is essentially a 
synthetic protein consisting of amino acid sequences of three merozoite peptides linked 
by repeat sequences of CSP from P. falciparum 
101,102
.  The vaccine initially showed great 
efficacy and promise 
103,104
, but testing in several phase III field trials involving 
thousands of volunteers found that its efficacy was too low to warrant a role for malaria 
control 
89
.  Currently, the most promising asexual blood-stage vaccines are based on 
immunogenicity to merozoite surface proteins such as MSP-1, MSP-2, MSP-3, AMA-1, 
and GLURP (glutamate rich protein).  Of the different merozoite proteins, MSP-1 has 
been characterized the most.  MSP-1 is present in all Plasmodium spp. and it has a 
molecular mass of ~200 kDa 
105
.  MSPs are not variant antigens, so they represent 
suitable targets for antibody response.  However, there is considerable polymorphism 
within MSPs, and some are considered dimorphic with two major, conserved forms.  
Although MSPs exhibit polymorphisms, each parasite clone expresses only one allele of 
each MSP, indicating that a single clone cannot escape immune surveillance by switching 
expression to a different variant form (as with VSAs) 
106
.  A vaccine using a combination 
of MSP 1/2 and ring stage infected erythrocyte surface antigen (RESA), called 
Combination B vaccine, is the blood stage vaccine that has been characterized the most.  
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This vaccine was used in a phase I/IIb clinical trial in 5–9 year old children in Papua New 
Guinea and it provided 62% reduction in parasite density in vaccinees 
107
.  However, the 
vaccine preparation contained only the 3D7 allelic form of MSP-2 and subsequent 
research found that vaccination with this formation led to a significant increase in 
parasites with the FC27 allele genotype, the opposite dimorphic form of MSP-2 
108
.  
Therefore, a new version of the vaccine is necessary that includes both variants of MSP-2 
in order to target both genotypes.  A vaccine using the MSP-1 42 kDa fragment in the 
GSK AS02 adjuvant (used in RTS,S) was found to be safe and very immunogenic in 
rhesus monkeys and humans in Kenya 
109,110
. 
AMA-1 is a merozoite protein found in the micronemes and on the merozoite 
surface, and it displays a high level of polymorphism 
111
.  The vaccine potential of AMA-
1, like MSP-1, is also supported by the fact that antibodies inhibit invasion of RBCs in 
vitro and that AMA-1 protein can induce species-specific protection against malaria in 
rodent and non-human primate models 
111-113
.  The level of polymorphism in AMA-1 has 
been a variable in some studies, complicating the ability to design an effective vaccine.  
However, AMA-1 vaccines have recently been reported to have efficacious results in 
humans 
114-116
.  There are also other antigens that are being investigated as vaccine 
candidates.  The merozoite proteins MSP-3 
89,117-119
, MSP-4 
89
, MSP-5 
89
, MSP-8 and 
MSP-9 
89
, GLURP 
89,120-122
, and serine repeat antigen (SERA) 
89,123-126
 have shown 
promise in animal and/or human models examples.  EBA-175, which binds glycophorin 
A on RBCs was shown to be antiparasitic in Aotus monkeys 
127
.  A recent clinical trial 
testing the safety and immunogenicity of EBA-175 RII-NG has just been completed in 
the U.S. 
128
.   
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Transmission blocking vaccines.  Unlike the other classes of malaria vaccines, 
the goal of transmission-blocking vaccines (TBVs) is not to prevent infection or 
associated disease in the human host, but rather to prevent transmission of the parasite 
once inside a mosquito.  An effective transmission-blocking vaccine would not confer 
protection from disease upon the individuals, but it would help to reduce disease 
prevalence in the community.  These vaccines intend to induce antibodies to sexual stage 
antigens to prevent further fertilization and development of the parasite in the mosquito 
host 
129
.  Studies have shown they have been successful at preventing parasite 
transmission in experimental animals and they are being investigated for stopping 
transmission of P. falciparum and P. vivax 
85
.  The targets of transmission blocking 
antibodies include pre-fertilization antigens (Pfs230 and Pfs48/45) expressed in the 
circulating gametocytes and post-fertilization antigens (Pfs25 and Pfs28) expressed 
during mosquito stage ookinete development 
130
.  Antibodies produced to pre-fertilization 
antigens would have the added benefit of boosting immunity to blood stage infection as 
well.  A phase I clinical trial investigating Pfs25 and Pvs25 (P. vivax homolog of Pfs25) 
found that significant levels of antibody were produced to Pfs25, which correlated with 
transmission blocking activity.  However, significant adverse skin reactions were 
experienced by volunteers 
131
.  Chowdhury et al. (2009) 
130
 showed that blocking 
antibodies to Pfs48/45 could be produced in non-human primates and mice.  Recently, 
Dinglasan et al. (unpublished) found an Anopheles midgut protein (midgut alanyl 
aminopeptidase [AnAPN1] that causes humans to produce antibodies, and this could be a 
feasible TBV 
132
.  Although TBVs have the potential to reduce malaria transmission and 
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maybe contribute greatly to eradication, long-term studies must be conducted in order to 
determine if malaria prevalence can be reduced over time. 
Decades of research effort to develop malaria vaccines have seen many 
candidates undergo preclinical trials, with a subset of these undergoing clinical trials.  
Currently, only one vaccine has entered phase III clinical trials (RTS,S) and there are a 
few in phase IIb trials.  This reflects the difficulty and complexity of the malaria parasite 
life cycle and vaccine development challenges.  A major problem is that although 
vaccines are efficacious, immunogenic, and safe, they do not provide complete protection 
from infection (e.g. RTS,S).  The Malaria Vaccine Technology Roadmap (2006) 
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established a landmark goal to develop and license a first-generation vaccine by 2015 that 
has 50% protective efficacy against severe disease and death, with protection lasting at 
least one year.  Also, a strategic goal for 2025 was established: developing and licensing 
a malaria vaccine that has a protective efficacy of more than 80% against clinical disease 
and lasts longer than four years.  The RTS,S vaccine is close to meeting the 2015 goal, 
but it remains to be seen how the RTS,S vaccine performs outside of Africa where 
different transmission dynamics and drug resistance profiles exist.  It may be more 
prudent for endemic countries to focus on sound and comprehensive malaria control 
programs, as a fully efficacious vaccine may not be released for decades.  Also, 
improving the vaccine with different adjuvants or other components may be necessary in 
order to achieve increased levels of efficacy.   
A fundamental problem in regard to lack of complete efficacy lies in the fact that 
even in endemic populations, natural immunity is slow to develop after repeated parasite 
exposures.  In fact, rapid immunity is never produced and it is only after several years, 
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that a degree of „clinical‟ immunity develops.  Partial immunity is manifested as reduced 
morbidity, due to reduced parasitemia and possibly the development of an anti-toxic 
response 
111
.  Therefore, immunological memory is a problem that most malaria vaccines 
meet with.  The protective immune status acquired through repeated natural exposures 
over years can be lost if continuous antigenic stimulation ceases.  This suggests that low-
level antigenic persistence will be required for immunity to malaria, and, therefore, 
vaccines will need to simulate such a persistence to induce long-lasting protection 
134
.  
Perhaps the use of prime-boost vaccination can circumvent this problem, but long-term 
studies are required to ascertain this. 
Despite the relative ineffectiveness of natural immunity, vaccine strategies aim to 
induce the same type and specificity of immune responses as those that are induced by 
natural exposure.  Vaccines try to improve on host immune response by using highly 
immunogenic antigens to produce antibodies and a CMI response.  However, some of the 
subunits (as discussed above) are polymorphic, in addition to containing a small number 
of T-cell recognition sites.  Furthermore, there are the complex relationships between the 
parasite and immune system to deal with.  Induction of immunity by vaccines can be 
compromised by existing infection or the passage of maternal antibodies to infants.  
Parasitized RBCs have been shown to suppress maturation of dendritic cells (DCs) and 
also lead to apoptosis of parasite-specific T cells, memory B cells, and plasma cells 
111
.  
Vaccine-induced immunity can be affected by the passage of maternal antibodies to 
infants (occurs in measles).  A study of P. yoelii showed that exposure of mother mice to 
a malaria infection or a MSP-1 vaccine led to a diminished antibody response of her pups 
to MSP-1.  Passively acquired P. yoelii-specific antibodies most likely inhibited the 
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development of an antibody response by blocking access to critical B cell epitopes 
135
.  
Parasite biology is another problem as well.  Erythrocytic vaccines using merozoite 
antigens (MSP-1, AMA-1) do not confer high protection.  Unlike P. vivax, P. falciparum 
uses multiple redundant pathways to invade erythrocytes, complicating the effort to 
develop anti-invasion vaccines 
85
.  As mentioned before, P. falciparum encodes many 
VSAs that make clearance of secondary malaria infections caused by different parasite 
clones difficult.  Clearance of a specific parasite clone appears to follow the development 
of a VSA-specific antibody response.  The new clone may have a slightly different 
phenotype in terms of tissue adhesion, resulting in different pathology 
106
.  Therefore, a 
vaccine targeting PfEMP1 would need to incorporate a variety of antigens, perhaps to 
common strains in a certain location, in order to elicit effective immunity.  Finally, some 
vaccine studies primarily use animal models and these may not be appropriate to 
ascertain human immune responses and immunogenicity.  Laboratory models cannot 
replicate the intricacies of host-parasite interactions in nature.  Therefore, vaccination 
studies in animal models must be carefully designed to assure any beneficial effects can 
correctly be related to human infection. 
Antimalarial Drugs for Treatment 
The complexities of the malaria parasite have made the malaria vaccine 
development process arduous and a completely successful vaccine currently does not 
exist.  However, malaria is a curable disease if promptly diagnosed and treated correctly.  
Antimalarial drugs are the most important global malaria intervention, responsible for 
saving lives in many malaria-endemic countries.  In general, there are only a few classes 
of antimalarial medications, and most of the drugs currently available have been in use 
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for decades.  Those that are easily affordable for many malaria-endemic countries are 
restricted to chloroquine, sulfadoxine/pyrimethamine, quinine and amodiaquine 
136
.  
Their use is now severely limited by the emergence and spread of drug resistance, 
primarily in P. falciparum, which exhibits resistance to almost every class of antimalarial 
drug.  Therefore, many endemic countries now face a situation in which there are no 
affordable, effective antimalarial drugs available.  The progress of drug discovery is not 
keeping pace with the emergence of drug resistance, and there are problems such as 
distribution, accessibility, and correct usage that have compounded the situation.  Also, in 
many malarious areas, a majority of the population may not receive reliable and 
consistent information about malaria treatment and prevention, and drugs that are 
available may be counterfeit or contain insufficient dosages to be completely effective 
against local parasite strains 
137
.  Drug resistance is a major problem where malaria is 
endemic, described not only in P. falciparum, but for P. vivax as well 
47
.  Drug resistant 
parasites have appeared in areas almost as soon as new medications have been introduced, 
making it important to understand the molecular mechanisms involved and to develop 
strategies subverting the parasite‟s ability to survive in the presence of drug pressure.  In 
order to understand the mechanisms of resistance, it is important to first review the 
history of antimalarial drugs and development, and to recognize the mechanisms of drug 
activity. 
Quinolines.  Quinolines are aromatic nitrogen compounds characterized by a 
central solid-ring structure, essentially benzene fused to pyridine at two adjacent carbon 
atoms.  However, there can be various functional groups on the main quinoline molecule 
that add to solubility and specificity of drug activity.  The main quinolines that are used 
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as antimalarial drugs can be divided into groups based on chemical attributes.  Type-1 
quinolines (the 4-aminoquinolines chloroquine, amodiaquine, pyronaridine) are weak 
bases, deprotonated, and hydrophilic at pH 7.0.  Type-2 quinolines (the aryl-
aminoalcohols quinine, mefloquine, halofantrine, lumefantrine) are weaker bases and 
lipid soluble at neutral pH 
138
.  Additional quinolines include the bis-quinoline 
piperaquine and the 8-aminoquinoline, primaquine. 
Quinine.  The alkaloid quinine (QN) occurs naturally in the bark of the Cinchona 
tree, which is native to South America.  There is evidence that South American indians 
used the bark as medicine, but not necessarily for the treatment of malaria 
139
.  In the 
1600s, the drug was brought to Europe by missionaries serving in Peru.  It was not until 
1820 that QN was isolated from the bark of the Cinchona tree by the French scientists 
Joseph Pelletier and Jean Biename Caventou 
140
.  Today, QN can be used for 
uncomplicated malaria treatment, but it is not recommended for prophylaxis or routine 
treatment because of toxicity (especially in children and pregnant women) and a 
syndrome called cinchonism (dizziness, impaired hearing, nausea, vertigo) 
49
.  Quinine 
may be a useful first-line treatment in areas with multidrug-resistant malaria where P. 
falciparum does not respond to chloroquine, sulfa drug-pyrimethamine combinations, and 
mefloquine.  It is usually combined with an antibiotic (doxycycline or tetracycline) 
especially where some degree of quinine resistance may be present, such as in southeast 
Asia 
49
.  Quinine is a reasonable option for treatment in travelers returning to non-
endemic areas who develop malaria, since the drug-resistance pattern of the parasite may 
not be known and a fully efficacious drug is needed in non-immunes to prevent 
progression of uncomplicated malaria to severe disease 
137
.  Quinine is used to treat 
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severe malaria because it can be administered intravenously (IV) and it is highly effective.  
However, QN has been replaced by IV artemisinin drugs for the treatment of severe 
malaria 
44
.   
Quinine is principally active on mature trophozoites 
141
.  It does not prevent 
sequestration or further development of circulating rings, nor is it active against pre-
erythrocytic stages of P. falciparum 
49
.  Like other structurally similar antimalarials, QN 
also kills sexual stages of P. vivax, P. malariae, and P. ovale, but not mature gametocytes 
of P. falciparum.  The exact mechanism of QN action is unknown, but it is postulated 
that it may interfere with heme detoxification as with chloroquine 
142-144
 or nucleic acid 
synthesis 
145
 in the malaria parasite.  In some strains of P. falciparum, a decreased 
amount of QN in the DV was associated with increased sensitivity to the drug, indicating 
that it may target areas of the parasite other than the DV 
146
. 
Chloroquine.  In the 1920s, a German effort was conducted to find alternative 
antimalarial drugs to quinine, which produced pamaquine and mepacrine 
147
.  In the 
1930s, synthetic drugs for malaria were introduced, as mepacrine was made widely 
available for treatment.  It replaced QN in routine treatment of non-severe malaria, as it 
was a cheaper and less toxic alternative 
148
.  Further German research produced 
chloroquine (CQ) in 1934 
149
, and U.S./British scientists recognized CQ as an effective 
and safe antimalarial in 1946 
9
.  CQ replaced mepacrine in the late 1940s because it was 
easier to use and the cost (total cost of treatment was less than 10 cents) enabled poorer 
nations to treat more cases of malaria.  Chloroquine, which has utility for treatment and 
prophylaxis, has become the most widely used antimalarial drug in the world.  
Historically, it has been the first-line drug of choice for treatment of uncomplicated 
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malaria and chemoprophylaxis, but extensive resistance to the drug has made it quite 
ineffective.  CQ is a weak base that accumulates in the parasite‟s acidic DV.  The 
sequence of events related to heme degradation and CQ interference is complex, but 
essentially CQ becomes deprotonated in the acidic DV (a membrane-impermeable form) 
and trapped inside the DV 
138
.  CQ acts to directly inhibit the polymerization of toxic 
heme molecules (produced from hemoglobin degradation) into hemazoin, and monomeric 
heme accumulates to levels in the DV that kill the parasite.  CQ affects stages of the 
erythroctyic cycle primarily, but there is some debate as to the specific stages it affects 
150-152
.  It is known that CQ is not active against pre-erythrocytic stages and it has low 
activity against young gametocytes 
44,147
.  Although CQ is ineffective in most areas of the 
world where P. falciparum exists, it remains effective against P. falciparum in areas of 
the Caribbean, Central America, and the Middle East 
142
.  In most of the world, CQ is still 
the first line of treatment for P. vivax malaria 
153
.  Against P. vivax, CQ is well-tolerated 
and affordable, and its long half-life provides protection from early relapses following 
treatment.  However, P. vivax is resistant to CQ in some parts of the world, most notably 
areas of Papua, Indonesia; sporadic cases are reported from South America, Vietnam, and 
Turkey 
153
. 
Mefloquine, other aminoalcohols, and primaquine.  Mefloquine (MQ) is also 
effective against CQ or multi-drug resistant strains of P. falciparum.  The U.S. Army 
Antimalarial Drug Development Program (initiated in the 1960s), has screened over 
200,000 compounds over 40 years for antimalarial activity.  MQ was one of two licensed 
drugs developed as a result of this effort 
154
.  MQ was first synthesized in 1969 primarily 
for the purpose of chemoprophylaxis in the military following the then recently 
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discovered threat of CQ-resistant P. falciparum.  It was first introduced for general use in 
1977 (trade name Lariam) 
155
.  It has been reported that MQ targets growing trophozoites, 
but it also has activity against sexual stages 
154,156
.  MQ is recommended for prophylaxis 
when traveling in malarious areas were CQ resistance is prevalent, but there are areas of 
the world (Thailand, Cambodia) where the drug is ineffective due to resistance 
147,154
.  
MQ has a long half-life in the body, allowing it to be used in combination therapies.  MQ 
is known to cause neuropsychiatric episodes 
49
.  The other important aminoalcohols are 
halofantrine and lumefantrine.  Halofantrine (HAL) is effective against CQ-resistant P. 
falciparum.  Because it is associated with cardiotoxicity, it has been taken off-market by 
several countries 
157
.  Lumefantrine (LUM) is active on blood stages 
156
 and it is only 
available as a co-formulation with artemether (Coartem) 
49
.  LUM has a shorter half-life 
than MQ 
147
, but Coartem is still a useful ACT, with high activity against drug-resistant P. 
falciparum.  The mechanism of action of LUM is thought to be linked to heme 
detoxification 
158
. 
Primaquine was part of the search for antimalarial drugs that predated the 
discovery of CQ 
159
.  It was first deployed to prevent relapsing P. vivax malaria in U.S. 
soldiers returning from World War II and the Korean War 
156
.  Primaquine is the only 8-
aminoquinoline available for use currently, and it is effective against all stages of 
parasites (except sporozoites) 
156
.  It is used to provide radical cure of P. vivax and P. 
ovale malaria, (elimination of relapse) in combination with a blood schizontocide for the 
erythrocytic parasites 
49
.  Primaquine (PQ) also kills P. falciparum gametocytes and it has 
significant blood stage activity against P. vivax (and some against asexual stages of P. 
falciparum).  Primaquine is contraindicated in people that have severe glucose 6-
41 
 
phosphate dehydrogenase deficiency because of the risk of hemolytic anemia 
49
.  The 
drug also displays marked toxicity, preventing it from being a widely used antimalarial 
drug.  Tafenoquine is a new 8-aminoquinoline under development, and it has higher 
antiparasitic activity than PQ 
157
.  It is also tolerated better than PQ, but the risk of 
anemia in glucose-6-phosphate people still remains.  The exact mechanism of MQ and 
PQ is unknown but it has been thought that these drugs inhibit membrane trafficking 
events involved in uptake of metabolites in RBCs 
33
 or that they are involved in 
hemoglobin degradation similar to the mechanism of CQ 
160
. 
Amodiaquine and piperaquine.  Amodiaquine (AQ) was discovered to have 
antimalarial properties around the same time as CQ 
147
.  AQ is metabolized to the primary 
metabolite monodesethylamodiaquine, and it has a similar mode of action as CQ 
49
.  AQ 
is effective against some low-level CQ-resistant strains of P. falciparum, although there 
is cross-resistance between the two drugs 
44,157
.  AQ is used as monotherapy because it is 
inexpensive in the developing world, but it is most commonly used in combination with 
artesunate (as an artemisinin combination therapy, [ACT]) or in combination with 
sulfadoxine-pyrimethamine (where efficacy of both is high) 
49
.  Piperaquine (PIP) was 
originally synthesized in the 1960s and it is approved for use in combination therapy with 
dihydroartemisinin 
44,157
.  It is thought to act on mature trophozoites and target heme 
detoxification 
161
.  PIP is a bisquinoline antimalarial drug that was first synthesized in the 
1960s, and used extensively in China and Indochina as prophylaxis and treatment during 
the next 20 years 
162
.  This widespread use of PIP contributed to high levels of resistance.  
However, during the next decade, PIP was rediscovered by Chinese scientists as one of a 
number of compounds suitable for combination with an artemisinin derivative.  The 
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rationale for such artemisinin combination therapies (ACTs) was to provide an 
inexpensive, short-course treatment regimen with a high cure rate and good tolerability 
that would reduce transmission and protect against the development of parasite resistance.  
It was used extensively in China after its development, and resistance to the drug 
emerged.  However, CQ-resistant isolates in Africa are susceptible to PIP, giving promise 
to PIP+DHA in African countries 
157
. 
Antifolates.  Antifolates were developed as part of antimalarial research 
programs during World War II.  Most of the antifolates used for antimalarial treatment 
today were developed in the 1940s and 1950s 
163
.  These drugs result in decreased 
pyrimidine synthesis, leading to reduced DNA, serine, and methionine formation.  Type I 
antifolates (sulfonamides, sulfones) compete for the active site of dihydropteroate 
synthase (DHPS), preventing the formation of dihydropteroate.  Type II antifolates 
(pyrimethamine, biguanides) inhibit parasite dihydrofolate reductase (DHFR), preventing 
H4 folate (necessary for biosynthesis of thymidylate, purines, amino acids) from being 
formed 
138
.  Because DHFR and DHPS inhibitors target DNA synthesis, they exert high 
activity when DNA synthesis peaks (late trophozoites) in parasites 
163
.  Resistance 
developed to the drugs when used alone, but when used in combination (commonly 
sulfadoxine+pyrimethamine [SP, Fansidar]), a synergy is observed which makes the pair 
very effective in treating all types of malaria.  Pyrimethamine is reported to be active 
against all parasite stages (not sporozoites), whereas sulfadoxine displays blood stage 
activity and activity against sexual stages 
156
.  SP replaced CQ as first line therapy in 
areas of CQ-resistance.  SP is inexpensive and provides protection from new infections 
for a prolonged period due to its long half-life 
142
.  Resistance to SP emerged almost as 
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soon as it was introduced in the 1950s, and it is no longer effective for P. falciparum in 
areas of Asia, Africa, and South American, and for P. vivax in many areas 
49
.  SP is now 
used in combination with artesunate as an effective ACT where SP resistance is low.  
However, this is ineffective for P. vivax in some areas.  Proguanil is a biguanide 
compound that is metabolized to cycloguanil, which targets DHFR.  The parent 
compound, proguanil, has a separate target than cycloguanil and makes the drug dually 
effective against parasites 
164
.  Proguanil has slow schizontocidal action compared with 
QN or mepacrine, and when it was used in the late 1940s as prophylaxis for plantation 
workers in Southeast Asia and elsewhere, it provided an opportunity for widespread drug 
selection pressure on the parasite and the subsequent development of resistance to this 
drug 
163
.  Proguanil is used in combination with atovaquone (below) as an effective 
combination drug.  Proguanil is reported to have activity against all parasite stages 
(except sporozoites) 
156
.  Chlorproguanil is a biguanide that has actions and properties 
similar to those of proguanil.  It is available only in combination with a sulfone such as 
dapsone (co-formulated as Lapdap) 
49
.  Studies indicate that Lapdap remains active 
against the dhfr and dhps genotypes in Africa that cause SP failure, and there is 
increasing discussion of replacing SP with Lapdap due to the latter combination‟s shorter 
half-life of 12 h (thought to discourage selection of resistance) 
163
.   
Atovaquone.  Atovaquone (ATOV) is a naphthoquinone that was first introduced 
for treatment in 1996 
155
.  ATOV displays activity against all Plasmodium spp., and it 
exerts its effects by collapsing mitochondrial membrane potential and inhibiting the 
electron transport chain 
49,165
.  ATOV can inhibit pre-erythrocytic development in the 
liver, oocyst development in the mosquito, and it has blood stage activity 
156
.  ATOV is 
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not very effective when used alone, as resistance to the drug develops quickly.  However, 
there is a synergistic effect when ATOV is paired with proguanil (forming Malarone
®
) or 
cycloguanil.  Interestingly, the action of proguanil in Malarone
®
 is not to inhibit DHFR 
(as when used by itself), but it lowers the effective dose needed to cause mitochondrial 
membrane potential collapse by ATOV 
166
.  The double activity of proguanil reported by 
Fidock et al. (1998) 
164
 gives triple-action to Malarone
®
.  A short course of Malarone
®
 is 
very effective at curing multi-drug resistant malaria infections.  However, ATOV is 
expensive to manufacture, so the use of Malarone
®
 is not practical for malaria-endemic 
countries 
147
.  Malarone
®
 is a useful alternative to MQ for travelers from non-endemic 
countries going to malarious areas. 
Antibiotics.  The apicomplexan plastid (apicoplast) arose by endosymbiosis of a 
cyanobacterial-like prokaryotic cell 
2
.  Antibiotics have antimalarial activity because they 
can inhibit the prokaryote-like processes in Plasmodium spp., such as protein synthesis 
and DNA/RNA replication.  Interestingly, antibiotics do not immediately kill malaria 
parasites, but they cause delayed death in the second erythrocytic cycle 
157
.  The delay of 
parasite killing equates to longer parasite clearance times and prolonged symptoms.  
Therefore, antibiotics are used in combination (e.g. quinine) for non-immunes 
experiencing acute malaria.  Doxycycline (DOX), clindamycin (CLIN), and tetracycline 
(TET) inhibit protein synthesis, and they are prescribed for malaria treatment.  It is 
reported that these drugs affect liver and blood stage parasites 
156
.  Doxycycline has a 
long elimination time, making it useable for prophylaxis when traveling to areas where 
MQ is ineffective, or where multi-drug P. falciparum exists.  However, it is 
contraindicated in young children and pregnant women.  CLIN is a safer alternative, but 
45 
 
it has a short elimination time (unsuited for prophylaxis) and should be paired with a 
faster acting antimalarial 
157
.   
Artemisinins.  The history of antimalarial drugs can be traced back thousands of 
years with the use of the herb qinghao (Artemisia annua, sweet wormwood) for treatment 
of fevers in traditional Chinese medicine.  In 1967, the Government of the People‟s 
Republic of China began a program to systematically identify remedies from plants in 
response to Ho Chi Min‟s request for antimalarial drugs for Vietnamese troops 141,167.  In 
1971, Chinese scientists found that extracts of A. annua killed Plasmodium berghei in 
mice and a year later, they identified the active ingredient.  The Chinese called it 
“qinghaosu”, but it is now known as artemisinin.  In 1985, artemisinin (QHS) was 
extracted at WRAIR in the U.S. 
167
.  Today, artemisinin is still obtained by extraction 
from A. annua, but there is a growing demand for high yields of the drug.  Therefore, 
methods are being developed for microbial and synthetic production of artemisinin 
precursors and similar peroxides 
168
.  Artemisinins are currently the most important class 
of antimalarials, used in combination therapies for routine treatment, and also for 
treatment of severe malaria.   
Artemisinin is a sesquiterpene trioxane lactone (empirical formula C15H22O5) that 
contains an endoperoxide ring that is critical for antimalarial activity 
169
.  After QHS was 
identified, it was determined that it was not soluble in oil or water and must be given 
orally 
170
, so chemical modifications were introduced to improve solubility.  The common 
derivatives of artemisinin are dihydroartemisinin (DHA), oil-soluble artemether (AM) 
and arteether (AE), and water-soluble artesunate (AS) and artilenate (artelinic acid, AL) 
171,172
.  The many derivatives of artemisinin also offer different routes of administration, 
46 
 
which is beneficial for treating a variety of patients.  The most clinically useful 
artemisinins are metabolized to DHA after being absorbed, and then to inactive 
metabolites via hepatic cytochrome P-450 and other enzyme systems 
170
.  Artemisinin 
itself is not converted to DHA, but to inactive metabolites. 
The artemisinin class of compounds represents the most rapidly acting and 
effective antimalarial drugs.  The parent drug QHS and its derivatives all possess 
remarkable activity against P. falciparum isolates, even those strains that are multiply 
resistant to other antimalarial drugs.  As a class the artemisinin drugs are active at low 
nanomolar concentrations, with the primary human metabolite DHA being the most 
active (50% Inhibitory Concentration [IC50] range 2.2-3.9 nM) (Kyle, Personal 
Communication).  In vivo artemisinin drugs produce faster parasite and fever clearance 
times than any other antimalarial drug  and reduce gametocyte carriage 
141,173
, thereby 
effectively reducing transmission of malaria.  Artemisinin‟s broad stage specificity 
against blood stages 
141,156
 has important therapeutic consequences.  It is believed that the 
ability of artemisinins to kill young ring stages results in more rapid reduction in 
parasitemia compared with other antimalarials 
141
 and reduces the number of parasites 
that could mature and sequester in capillaries 
174
.  Importantly, the rapid reduction of 
parasites by artemisinins is a critical factor in treating severe malaria, as preventing 
sequestration can prevent cerebral malaria.  Artemisinin is better than QN for treating 
severe malaria in this regard, as QN does not prevent sequestration.  DHA has a half-life 
of approximately 45 minutes, whereas AS is rapidly hydrolyzed (~10 minutes) to DHA 
and its antimalarial activity is largely mediated by DHA 
175
.  Artemether and arteether are 
converted to DHA more slowly.  Artemisinins have been linked to neurotoxicity and 
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embryo death in animal models, and they have not been evaluated in the first trimester of 
human pregnancy.  Therefore, they are not recommended in first trimester patients with 
uncomplicated malaria 
49
. 
Perhaps the greatest benefit of artemisinin drugs is that they are effective in 
treating severe malaria that is resistant to CQ and they can be incorporated with other less 
effective drugs in combination therapies for high cure rates.  ACTs take advantage of 
pairing artemisinins, which have a short elimination time, with a longer eliminated drug.  
The rapid action of the artemisinin component reduces the number of parasites for the 
partner drug to remove and discourages parasites resistant to the partner drug from 
emerging (protection) 
174
.  In successfully treated patients, the partner drug also protects 
the artemisinin component by removing all residual parasites originally exposed to the 
drug; thus, there is low chance for the selection of artemisinin resistance.  The 
combination of AS+MQ exhibits these properties and it is very effective, even in areas of 
MQ resistance.  Because artemisinins have relatively short half-lives for elimination, the 
selection for drug-resistant parasites is less likely.  However, the relatively short half-
lives of artemisinin drugs may be responsible for the frequent recrudescence (~10%) 
observed in patients after treatment with a single artemisinin drug 
176
.  Also, a study 
showed that over 90% of DHA is bound to plasma proteins is malaria patients and in 
healthy volunteers 
177
.  It is remarkable that these drugs are so active against parasites 
although a majority of drug does not participate in killing.   
Given the global adoption of ACTs, considerable research has been devoted to the 
artemisinins and their effects on Plasmodium spp.  However, the mechanism of action of 
artemisinin and its derivatives on Plasmodium spp. remains unclear.  The absolute 
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requirement of the trioxane subunit of artemisinin for activity has led researchers to focus 
on this for mode of action studies.  It has been proposed that artemisinins can exert their 
effect via the generation of reactive oxygen species, which can be enhanced in the 
presence of free iron (heme) (Fe
+2
) that is found in parasites after hemoglobin digestion.  
The Fe
+2
-catalysed reductive cleavage of the endoperoxide may give rise to O-centered, 
or alkoxyl, radicals and then C-centered radicals and neutral products becoming activated 
by free ferrous or heme iron.  It is possible that these radicals may exert effects by 
overwhelming parasite oxidative stress mechanisms 
175
.  The peroxide pharmacophore 
could also undergo ring-opening via protonation (H+), or formation of a complex with a 
metal ion to generate an open hydroperoxide or metal peroxide.  This may lead to 
conversion into a peroxy radical, or the transfer of oxygen to oxidizable substrates, which 
can have detrimental effects on biomolecules 
178
.  Other studies found that artemisinin 
can interfere with heme detoxification 
179
 in the DV or artemisinin derivatives localize to 
neutral lipid bodies in the DV where they damage parasite membranes after oxidation 
reactions 
180
.  There may be a link between development of parasites and artemisinin 
activity.  Since more hemoglobin is metabolized by older trophozoites, one might think 
that more mature stages is the main target of artemisinins due to the abundance of iron 
that would be available in the DV and used in the above mechanisms.  Indeed, this 
appears to be how CQ works on older trophozoites where large amounts of ferrous heme 
are produced and not detoxified due to the presence of CQ.  The Kyle lab found that 
trophozoites and schizonts are easily killed by artemisinins (Kyle et al., unpublished).  
However, ring stages are also known to be susceptible to artemisinins 
141
, (Kyle et al., 
unpublished data), although we know ring stages enter dormancy and may recrudesce 
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later to cause re-infection (below).  Artemisinin and MQ can inhibit endocytosis in P. 
falciparum, possibly indicating a role for these drugs in blocking intracellular 
development 
181
.  Artemisinins have also been found to target mitochondrial function in 
Plasmodium spp. by interfering with the electron transport chain and by inducing reactive 
oxygen species that cause mitochondrial membrane potential loss and disrupt the normal 
function of mitochondria 
182,183
.   
The most recent hypothesis for artemisinin mode of action is the inhibition of a 
calcium-dependent ATPase that exhibits similarity to mammalian Sarco/endoplasmic 
reticulum Ca
+2
 ATPase (SERCA), also known as PfATP6 
184
.  The SERCA ortholog of P. 
falciparum was expressed in Xenopus laevis oocytes and it was found that artemisinin 
inhibited the protein with similar potency as thapsigargin (another sesquiterpene lactone 
with high inhibition of Ca
+2-
transporting ATPases).  Thapsigargin also competed with 
artemisinin in terms of anti-parasitic activity and imaging of parasites with labeled 
thapsigargin and artemisinin showed localization to the cytoplasm, and not the digestive 
vacuole.  Furthermore, after chelation of iron by desferrioxamine, the antiparasitic 
activity was reduced.  Taken together, the evidence suggests that artemisinins inhibit 
PfATP6 outside the digestive vacuole after iron-activation.  Molecular evidence also 
suggests that mutations within pfatp6 are responsible for artemisinin resistance in P. 
falciparum 
185,186
.  All these studies point toward plausible, although somewhat 
controversial, artemisinin action mechanisms, but none is generally accepted.  The 
question of the true mechanism of action has become more pressing and more 
controversial as reports of emerging resistance to artemisinins have been published. 
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Antimalarial Drug Recommendations 
Prophylaxis.  Recommendations for drugs to prevent malaria differ by country of 
travel and a good source is the CDC‟s country-specific tables of the Yellow Book 
(http://www.cdc.gov/malaria/travelers/country_table/a.html) 
187
.  It is imperative to 
establish a clear potential for encountering drug resistance parasites in order to receive 
the current antimalarial drug regimen.  For all medicines, the possibility of interactions 
with other medicines that the person is taking should be considered, as well as other 
medical contraindications.  For travelers leaving the U.S. to malarious areas, the CDC 
recommends Malarone
®
, CQ (not where CQ- or MQ-resistance exists), DOX (not in 
pregnant women and children <8 years old), MQ (not for MQ-resistant areas), and 
Primaquine (where there is >90% P. vivax prevalence) 
188
.  Because several different 
drugs may be recommended for an area, it is critical to examine factors such as potential 
side-effects, ease of use, contraindications, protection time, and time for activity. 
Curative treatment.  Treatment of malaria depends on many factors including 
disease severity, the species of malaria parasite causing the infection, and the part of the 
world in which the infection was acquired.  It is crucial to determine the probability that 
the organism is resistant to certain antimalarial drugs.  Additional factors such as age, 
weight, and pregnancy status may limit the available options for malaria treatment, as 
well.  Currently, the WHO recommends ACTs as front-line therapy for uncomplicated P. 
falciparum malaria worldwide 
44
.  Since 2001, at least 56 countries have adopted a WHO-
recommended ACT, mostly as first-line treatment 
189
.  The following ACTs are 
recommended: AE+LUM, AS+AQ, AS+MQ, AS+SP, and DHA+PIP.  The choice of 
ACT in a country or region will be based on the level of resistance of the partner 
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medicine in the combination.  In areas of multi-drug resistance (east Asia and Africa), 
AS+MQ, AS+AQ, AE+LUM, or DHA+PIP are currently recommended and being used 
161
.  In Africa where there is multidrug resistance, any of the ACTs including those 
containing AQ or SP may still be effective.  It is imperative that artemisinin and its 
derivatives are not used as monotherapy, in order to discourage the emergence of 
resistance.  Any ACT should include a 3 day course of the artemisinin component in 
order to eliminate at least 90% of the parasitemia.  This allows cover up to three post-
treatment asexual cycles of the parasite.  This ensures that only about 10% of the 
parasitemia is present for clearance by the partner medicine, thus reducing the potential 
for development of resistance.  Shorter courses (1–2 days) of the artemisinin component 
would lead to a larger proportion of parasitemia for clearance by the partner medicine.  
This is undesired because the artemisinin drug would be less efficacious (except when the 
partner drug is highly effective), less effective on gametocyte carriage, and less protective 
of the slowly eliminated partner antimalarial.  For second-line therapies, an alternative 
ACT known to be effective in a region, AS+TET/DOX/CLIN, or 
QN+AS+TET/DOX/CLIN can be used.  Any of these combinations should be given for 7 
days.  Pregnant women represent an exception for to these recommendations, as they 
should take QN+CLIN for 7 days (AS+CLIN if treatment fails) during the first trimester 
of pregnancy.  During the second and third trimesters, an ACT known to be effective in 
the country/region, AS+CLIN, or QN+CLIN can be given.  Non-immune travelers 
returning from endemic areas are recommended to be treated with Malarone
®
, AE+LUM, 
DHA+PIP, or QN+DOX/CLIN (all drugs for 7 days).   
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Severe malaria requires full doses of parenteral antimalarial treatment should be 
started without delay with any effective antimalarial first available 
44
.  For adults, IV or 
intramuscular (IM) artesunate should be given on admission, then at 12 h, 24 h, then once 
a day.  Quinine is an acceptable alternative (IV or IM) if parenteral AS is not available, 
but it has to be carefully administered (IV) in a rate-controlled fashion to avoid lethal 
hypotension.  For children, (especially in the malaria endemic areas of Africa), AS and 
quinine are recommended as for adults, and IM artemether is available as an alternative.  
Following initial parenteral treatment for 24 hours, once the patient can tolerate oral 
therapy, it is essential to administer a full course of an effective ACT (any of five above).  
In 2007, the U.S. Food and Drug Administration approved an investigational new drug 
protocol for the use of IV Artesunate in the U.S. 
190
. This should replace quinidine 
gluconate (cardiotoxicity) as the drug of choice for treating severe malaria in the U.S.  
This protocol makes artemisinins available for malaria treatment in the U.S. for the first 
time. 
Antimalarial Drug Resistance 
Drug resistance in relation to the malaria parasite was defined by the WHO in 
1965 as the “ability of a parasite strain to survive and/or multiply despite the 
administration and absorption of a drug given in doses equal to, or higher than, those 
usually recommended but within the limits of tolerance of the subject” 149.  The definition 
was slightly changed decades later to reflect the fact that the drug must actually reach the 
parasite or erythrocyte and act for the duration it takes for normal drug action.  Drug 
resistance has been attributed to the practice of constantly taking sub-curative doses of an 
antimalarial drug, which only serves to eliminate the most sensitive parasites in the blood, 
53 
 
allowing resistant parasites to propagate.  Longer half-life drugs such as CQ have an 
extended elimination period from the body, during which time malarial parasites are 
exposed to sub-therapeutic levels of the drug in the blood.  The problem of taking sub-
curative doses is compounded by the availability of cheap drugs in many countries, which 
can be problematic for adherence to regimens (side-effects) and the emergence of drug 
resistance.  There will always be a small number of parasites not eliminated by 
medications, but host immunity can usually clear the infection.  However, factors 
decreasing the effectiveness of the immune system can increase the survivorship of 
parasites, lending towards resistance.  In certain malarious areas (Southeast Asia), 
parasites will repeatedly cycle through non-immune populations, causing significant 
morbidity and intensifying resistance.  In addition, it has been reported that a synergistic 
effect exists between P. falciparum and certain Anopheles spp., which can produce a 
biological advantage favoring resistant parasites 
47
.  The genetic events that lead to 
resistance to an antimalarial drug are usually spontaneous mutations or changes in copy 
number of genes relating to the drug target of the parasite 
191
.  These events confer 
reduced sensitivity to a particular drug, or a whole drug class.  Over time, resistance 
becomes stable in the population and it can persist even after drug pressure is removed. 
Among the species causing human malaria, drug resistance has been reported and 
characterized the most in P. falciparum, although resistance to antimalarials has been 
documented for P. malariae and P. vivax, as well.  In P. falciparum, resistance has been 
observed in all currently used antimalarials (including artemisinin derivatives). The 
geographical distributions and rates of spread have varied considerably (Fig. 1.4).  P. 
vivax has developed resistance rapidly to SP in many areas, while resistance to CQ is 
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confined largely to Indonesia, Papua New Guinea, Timor-Leste and other parts of 
Oceania.  There are also reports of CQ resistance from Brazil, Peru, India, and Africa 
(Fig. 1.4).  However, P. vivax remains sensitive to CQ in most of South-East Asia, the 
Indian subcontinent, the Korean peninsula, the Middle East, north-east Africa, and most 
of South and Central America 
44
.   
In vivo measures of drug resistance.  Susceptibility of P falciparum to 
antimalarial drugs is commonly assessed by therapeutic response (in vivo testing).  The 
WHO developed a scheme for estimating the degree of antimalarial drug resistance, 
which involves studying patient parasitemia over 28 days.  The in vivo response to drugs 
was originally defined by WHO in terms of parasite clearance (sensitive [S] and three 
degrees of resistance [RI, RII, RIII]) 
137,155
.  Blood smears were taken on days 2, 7 and 28 
after initiation of antimalarial treatment to grade the resistance as RI-RIII.  Sensitivity 
was classified as reduction of initial parasitemia by ≥75% on day 2 with smears negative 
for malaria parasites from day 7 to 28 (end of follow up, but could be longer if drugs with 
longer half lives are used [mefloquine]).  RI response was classified as initial clearance of 
parasitemia with negative smear on day 7, but recrudescence 8 or more days after 
treatment started.  RII response was classified as an initial clearance or substantial 
reduction of parasitemia (<25% of the initial count on day 2) but with persistence or 
recrudescence of parasitemia during days 4–7 after treatment.  RIII was classified as  no 
significant reduction of parasitemia at 28 days after treatment.  This scheme of 
classification still remains valid for areas with low or no malaria transmission, but it is 
difficult to apply to areas with intensive transmission, because of the chance that new 
infection can be mistaken for recrudescences (which can also happen after 28 days).  
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Other drawbacks of this method included the fact that RII was too broad of a category, 
practical difficulties in following a patient for 28 days, and the intermittent nature of 
parasitemia in the blood of infected patients.  Therefore, WHO introduced a modified 
protocol in 1996 based on clinical outcome targeted at a practical assessment of 
therapeutic responses in areas with intense transmission, where parasitemia in the 
absence of clinical signs or symptoms is common 
137,155
. The modified classification 
established categories of Early treatment failure (ETF) (aggravation/persistence of 
clinical symptoms in the presence of parasitemia during the first 3 days of follow-up), 
Late treatment failure (LTF) (reappearance of symptoms in the presence of parasitemia 
during days 4–14 of follow-up), and Adequate clinical response (ACR) (Absence of 
parasitemia on day 14 irrespective of fever, or absence of clinical symptoms irrespective 
of parasitemia, in patients not meeting ETF or LTF criteria).  The WHO has continued to 
update therapeutic efficacy protocols for high transmission areas and validate the 
therapeutic efficacy protocol for low-to-moderate transmission areas on the basis of 
feedback from countries and scientific recommendations.  Recently, the WHO modified 
the existing protocol to include applications of the same definitions of treatment 
responses at all levels of malaria transmission, with slight adjustment of patient inclusion 
criteria; administration of rescue treatment to patients with parasitological treatment 
failure at all levels of malaria transmission; requirement for 28 or 42 days of follow-up as 
a standard, depending on the medicine tested; and requirement for genotyping by PCR to 
distinguish between recrudescence and re-infection.  The 28-day follow-up is 
recommended as the minimum standard to allow national malaria control programs to 
capture most failures with most medicines, except mefloquine and piperaquine, for which 
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the minimum follow-up should be 42 days 
192
.  There are now set definitions of treatment 
response that are used in all areas of malaria transmission.  The ETF definition has been 
modified to the following: danger signs or severe malaria on day 1, 2 or 3, in the presence 
of parasitemia; parasitemia on day 2 higher than on day 0, irrespective of axillary 
temperature; parasitemia on day 3 with axillary temperature ≥ 37.5 °C; and parasitemia 
on day 3 ≥ 25% of count on day 0.  Late clinical failure (LCF) is defined as: severe 
malaria in the presence of parasitemia on any day between day 4 and day 28 (day 42) in 
patients who did not previously meet any of the criteria of ETF; and presence of 
parasitemia on any day between day 4 and day 28 (day 42) with axillary temperature ≥ 
37.5 °C in patients who did not previously meet any of the criteria of early treatment 
failure. Late parasitological failure (LPF) is defined as the presence of parasitemia on any 
day between day 7 and day 28 (day 42) with axillary temperature < 37.5 °C in patients 
who did not previously meet any of the criteria of early treatment failure or late clinical 
failure.  Adequate clinical and parasitological response (ACPR) is defined as an absence 
of parasitemia on day 28 (day 42), irrespective of axillary temperature, in patients who 
did not previously meet any of the criteria of early treatment failure, late clinical failure 
or late parasitological failure.  
Quinolines. 
Chloroquine.  Resistance to CQ is a major problem because it remains the most 
affordable and widely used antimalarial globally.  Resistance was reported only a decade 
after it was introduced and now widespread resistance has rendered it virtually useless 
against P. falciparum infections in most parts of the world, although it still maintains 
considerable efficacy for the treatment of P. vivax, P. ovale and P. malariae infections 
44
.  
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It is theorized that P. falciparum resistance to CQ emerged in the epicenters of the 
Thailand/Cambodia border in 1957 and in two foci in South America in 1960 (Columbia, 
South America) 
149,193
 (Fig. 1.5).  Resistance on the Thailand-Cambodia border can be 
traced to the border town, Pailin.  Malaria was hyperendemic at the time, and the most 
prevalent species was P. falciparum (80%), transmitted by A. dirus and A. balabacensis.  
In the late 1940s/early 1950s, many people migrated to the area for the business of 
sapphire and ruby mining.  Most of these migrants had not been previously exposed to 
the parasite and consequently the low-immune population led to a cycle of epidemics.  
Migrants would be repeatedly bitten by mosquitoes that bred in the damp mining pits 
when gems were harvested.  Chloroquine resistance was propagated by the practice of 
taking medication until symptoms of malaria began to lessen.  Resistance in Columbia 
followed a similar pattern as in Pailin but P. falciparum was transmitted by A. 
nuneztovari.  In this case, emerald mining was implicated as encouraging drug resistance.  
The spread of CQ resistance in the world is quite remarkable.  From 1960-1970, 
resistance was occurring more in South American countries than Southeast Asia.  By 
1970, it spread to Panama south of the Panama Canal, and by 1989, the drug resistance 
distribution in South America, had become almost identical with the distribution of P. 
falciparum.  From the original focus of high-level CQ resistance first found in Thailand 
in 1962, P. falciparum CQ-resistance spread gradually and contiguously throughout 
Southeast Asia 
163
.  Decreased susceptibility in Africa was noted in 1978, as cases were 
reported in Kenya and Tanzania 
149
.  As of 1985, resistance had spread from East Africa 
throughout sub-equatorial Africa 
148
.  It is theorized that resistance spread from Southeast 
Asia to the African coast, then inland, as a result of population movements.  White and 
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Pongtavornpinyo (2003) 
194
 proposed that the genetic events conferring resistance to CQ 
are so rare, that it is possible that resistance occurred in few foci globally, then spread as 
a result of human or vector movements.  This hypothesis was supported by Mehlotra et al. 
(2001) 
195
, who conducted a population genetic survey showing similarity of parasites of 
African and Asian origin.   
Chloroquine-resistant parasites have the ability to limit the accumulation of the 
drug in the digestive vacuole, but the mechanism leading to low drug concentration was 
unknown for years.  One approach to elucidating CQ resistance assumed an ATP 
membrane transporter may be involved in changing the flux of CQ into the parasite 
digestive vacuole 
193
.  Pfmdr1 is the P. falciparum ortholog of mammalian P-
glycoproteins that assist in multidrug resistance in cancer cells 
196
.  Pfmdr1 (P. 
falciparum multidrug resistance transporter-1) is encoded on chromosome 5, and is 
located on the surface of the DV in mature parasites 
197
.  Since this protein showed high 
homology to mammalian P-glycoproteins known to be involved in drug efflux, it was 
hypothesized that Pfmdr1 somehow modulated intracellular CQ concentrations 
193,198
.  
Altered susceptibility to CQ was thought to be linked to point mutations in Pfmdr1, such 
as the Asp-Tyr change at position 86 (N86Y) and to other mutations (Y184F, S1034C, 
N1042D, and D1246Y) 
155,193,199-203
.  However, some in vitro and in vivo studies showed 
that there is not a significant relationship between pfmdr1 and CQ resistance 
193,204-208
.  
Therefore, it appeared that CQ-resistance cannot be conferred by pfmdr1 alone and it 
requires the presence of other genotypic changes. 
In the late 1980s, two approaches were used to elucidate the genetic basis of CQ 
resistance: genetic crosses and the observation of transporter homologs in mammalian 
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tumor cells exhibiting a multi-drug resistance (mdr) phenotype 
193
.  The identification of 
the critical molecular determinant of CQ resistance was the result of a genetic cross 
between CQ-resistant Dd2 (southeast Asia) and CQ-sensitive HB3 (Honduras) P. 
falciparum clones, where it was found that a single genetic locus, localized to a 36 kb 
segment on chromosome 7, segregated with inheritance of CQ resistance 
208
.  Another 
important finding of this study was that the CQ resistance phenotype was not attributed to 
pfmdr1 (thought to be responsible for CQ resistance at the time).  Subsequent studies 
found a gene on the 36 kb segment coding for a 48.6 kDa protein with 10 predicted 
membrane domains, and it was named PfCRT 
209
.  Immunofluorescence and 
immunoelectron studies 
209,210
 showed that the PfCRT protein is part of the digestive 
vacuole, further implicating PfCRT in CQ resistance.  Mutations in the pfcrt gene have 
been linked to CQ resistance in isolates from around the world, and it is possible to map 
certain mutations to specific countries.  There is a specific mutation in resistant isolates at 
amino acid (AA) position 76 (K76T) that has been found as critical for the resistance 
phenotype 
155,199,209,210
.  These in vitro results are largely consistent with in vivo findings 
that document a strong association between the PfCRT K76T mutation and failure of CQ 
treatment, leading to its widespread use as a molecular marker of CQ-resistance 
196,211
.  
Interestingly, isolates from different countries that carry similar pfcrt mutant alleles 
exhibit a wide range of CQ susceptibility, indicating the participation of additional genes 
in modulating the level of response to CQ 
201
.  It is possible that co-selection of pfcrt 
amino acid T76 and pfmdr1 Y86 may occur as a result of CQ treatment, as has been 
already reported 
199,212
, suggesting either that the two genes may work in concert in 
determining CQ resistance levels or that the mutation at pfmdr1Y86 may compensate 
60 
 
deleterious pfcrt mutations.  Other studies have found that other genes, such as P. 
falciparum multi-drug resistance-associated proteins 1 and 2 (pfmrp1, pfmrp2) 
201,213,214
 
and a host of transporters 
201
 are associated with CQ resistance. 
The pfcrt gene is polymorphic, reported to have mutations that can potentially 
lead to 10 different amino acid changes 
207
.  The K76T mutation is in a block of 5 amino 
acids (normally CVMNK, #72-76) on the first transmembrane segment of PfCRT that are 
strongly associated with geographic region-restricted evolution of P. falciparum 
resistance to CQ 
207,209
.  As mentioned above, CQ resistance is thought to have emerged 
in Asia and South America separately.  It appears that at least three foci were involved in 
spreading CQ resistance worldwide.  There was the focus at the Thai/Cambodia border, 
two foci in South America, and a possible focus in Papua New Guinea, where CQ-
resistance was reported in 1976 
149
.  Therefore, the spread of CQ-resistant parasites 
worldwide can be thought to have occurred from Asia to Africa, through South America 
from a different origin, and through the Pacific islands from a different origin. This has 
been verified by studies showing that nearly all resistant parasites in Southeast Asia and 
Africa are of the CVIET type of PfCRT.  Still, studies such as that by Chen et al. (2003) 
215
 in the Philippines make a case for more independent origins of CQ resistance in Asia.  
Other PfCRT types have been described in Africa (SVMNT, commonly distributed in 
South America and the Pacific; SVIET described in isolates from West Papua) 
207
.  
Genotyping of pfcrt from isolates of the Pacific islands suggests a common lineage of CQ 
resistance, as all CQ-resistant parasites harbored the SVMNT type in Papua New Guinea.  
Another lineage of CQ resistance has been observed in the Philippines, where CQ 
resistance was first described in the 1970s.  In addition to the migration of the Papuan 
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lineage (SVMNT), an indigenous lineage harboring a CVMNT type has also been 
prevalent.  The indigenous CVMNT type appears to have evolved into the SVMNT type.  
In pfcrt, two distinct genotypes were initially identified in South America, the SVMNT 
type and the CVMET type 
207,209,216
, consistent with the hypothesis based on 
epidemiology that CQ resistance was generated from two foci.  The most widely 
distributed pfcrt genotype in South America is the SVMNT type, suggesting that the 
SVMNT type (Venezuela origin), has been responsible for the emergence of CQ-resistant 
isolates in South America 
207
.  Another lineage, the CVMET type, has been observed 
only in Colombia where CQ resistance was first reported 
209,216
.  Other pfcrt genotypes 
observed with less frequency in Brazil, Peru, and Ecuador are thought to have evolved 
from the SVMNT type 
207
.  Interestingly, the withdrawal of CQ in Malawi (1993) and in 
China (1979) has correlated with a loss of both K76T in pfcrt and CQ resistance 
217-220
.  
This may indicate that CQ has regained efficacy in these areas, and that CQ susceptible 
parasites that dominate represent a re-expansion of the susceptible parasites that survived 
in the population despite widespread drug pressure.  This may also indicate that the Asian 
and African CQ resistance alleles seem to confer a fitness cost, since CQ-resistant 
populations did not flourish after the removal of drug pressure 
196
. 
The association between mutations in PfCRT and reduced amount of CQ 
accumulated by the parasite is somewhat controversial.  It is now known that the majority 
of intraparasitic CQ is concentrated within the DV, and since PfCRT is located in the DV 
membrane, it seems plausible that mutations in PfCRT cause CQ resistance by reducing 
the CQ concentration in the DV 
196,221
.  Saliba et al. (1998) 
222
 showed that CQ-resistant 
parasites had reduced CQ in the DV.  Other studies found that CQ-resistant parasites 
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initially accumulate CQ, but transport it out more efficiently than CQ-susceptible 
parasites 
223,224
.  This supports the idea that CQ resistance in P. falciparum is the result of 
an inability of CQ-resistant parasites to accumulate CQ to toxic levels.   
Amodiaquine and piperaquine.  AQ is effective against some CQ-resistant 
strains of P. falciparum in Africa, but it is more commonly used in combination with SP 
or AS (as an ACT).  In addition, it is used as monotherapy with effectiveness against P. 
vivax 
49
.  However, the drug exhibits poor efficacy against P. falciparum in regions of 
India, Southeast Asia, the Philippines, South America, and Papua New Guinea 
225
.  
Studies have found mutations (K76T and others) in pfcrt that are associated with AQ 
resistance 
211,226,227
, and this corresponds to areas where CQ resistance has been reported 
228,229
.  However, other studies suggest AQ is still effective against CQ-resistant parasites 
161
.  AS+AQ is effective in Africa 
230-234
.  A recent alarming study in Uganda found 
resistance mediating alleles in pfcrt and pfmdr1 after AE+AQ therapy, indicating that 
treatment selected for AQ resistance
235
.  PIP was used for the treatment of CQ-resistant P. 
falciparum since the 1960s, but its effectiveness declined in the 1980s due to resistance 
162
.  Recent studies showed introduction of mutant pfcrt had effects on sensitivity to PIP 
in different strains 
236
 and disruption of pfmrp1 was associated with PIP susceptibility 
214
.  
PIP is now packaged with DHA as an ACT recommended by the WHO.  A study in 
Cameroon found that PIP is highly active against CQ-sensitive and CQ-resistant P. 
falciparum 
237
.  Studies of DHA+PIP found it is a highly effective ACT in Africa and 
Asia 
233,238-242
.  One study found that DHA+PIP was more effective and better tolerated 
than AS+AQ against multidrug-resistant P. falciparum and P. vivax infections in Papua 
243
.  Another study found that DHA+PIP and AE+LUM were both effective for treating P. 
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vivax and P. falciparum in Papua, with low recrudescence of P. falciparum.  However, 
there was a significant level of P. vivax relapse and gametocyte carriage with AE+LUM 
treatment compared to DHA+PIP 
244
.  A recent report from Burkina Faso indicated that 
patients infected with P. falciparum failed DHA+PIP therapy, and parasites that were 
genotyped may have a different resistance mechanism as that mediating CQ resistance 
245
.  
Also, DHA+PIP is reported to be less effective compared to AS+MQ for the elimination 
of gametocytes, which is a tremendous drawback for controlling transmission 
246
. 
Arylaminoalcohols. 
Quinine.  The earliest resistance to an antimalarial drug was reported for quinine 
in 1910 (Brazil) and in 1938 (German railroad workers returning from Brazil/Bolivia 
border) 
163
.  It was not until the 1960s that successive observations of quinine resistance 
were observed (Thai-Cambodia border) 
155
.  Today, resistance exists globally, but the 
highest levels of drug resistance are in Southeast Asia.  This may be the result of 
widespread use of QN in Thailand in the early 1980s as an interim therapy in the face of 
declining SP efficacy 
155
.  Resistance to quinine is not a serious problem and it still 
remains an effective treatment (above) for multi-drug resistant strains.  
The fact that QN resistance has been slow to evolve and disseminate in P. 
falciparum indicates that there may be a multifactorial basis of resistance.  The 
mechanism of drug resistance is not clear, but certain genes have been implicated in 
reduced susceptibility to quinine 
247
.  These studies have indicated that there may be 
overlap in mechanisms of resistance between QN and CQ/MQ.  Early studies of field 
isolates in Africa found an association between CQ and QN resistance 
248,249
.  One gene 
implicated is a P. falciparum Na(+)/H(+) exchanger (pfhne), as studies found increases in 
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QN resistance as a result of pfhne-mediated pH perturbations, microsatellite 
polymorphisms, or decreased expression 
247,250-254
.  Studies found that mutations in the 
Plasmodium falciparum CQ resistance transporter gene (pfcrt) were associated with 
changes of QN sensitivity, but this may be dependent on the particular mutant allele as 
well as the genetic background of the host strain 
201,211,236,254-256
.  Research also found that 
mutations 
201-203,205,251,257-259
 in Plasmodium falciparum multi-drug resistance transporter 
(pfmdr1) or increase in its copy number 
260-263
 are linked to QN resistance.  Other studies 
implicated pfmrp1 in QN resistance 
201,214
.  A recent study showed that QN may actually 
inhibit pfmdr1, possibly establishing this as a parasite killing mechanism 
264
. 
Mefloquine and other aryl-amino alcohols.  Resistance to other antimalarial 
aryl-amino alcohols been exhibited in areas where quinine is no longer effective (some 
areas of Southeast Asia).  Patients maintain sub-therapeutic levels of MQ for an extended 
period following treatment because of its long half-life, which may promote the selection 
of resistance in areas where persons are likely to be re-infected with malaria 
154
.  An 
alarming fact is that resistance to MQ was reported at the Thai-Cambodia border in 1982, 
5 years after its introduction 
149
.  Today, resistance is widespread in southeast Asia.  As 
stated above, early studies with pfmdr1 showed polymorphisms in pfmdr1 were linked to 
CQ resistance.  However, pfmdr1 was also been implicated in resistance to MQ and HAL.  
Reed et al. (2000) 
202
 found that amino acid changes in pfmdr1 (S1034C, N1042D, and 
D1246Y) in a CQ-sensitive strain doubled resistance for QN (with no effect on CQ 
sensitivity).  Interestingly, the opposite effect was found for MQ, HAL, and artemisinins 
as sensitivity to these drugs was increased.  However, changing AAs in a MQ, HAL-
resistant strain to C1034S, D1042N, and Y1246D conferred resistance to MQ, HAL, and 
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artemisinin.  Notably, the single Y1246D mutation had a larger effect resistance for 
MQ/HAL, suggesting that this amino-acid position is directly involved in MQ 
accumulation.  Resistance to MQ often correlates with CQ susceptibility, and vice-versa 
248,261,265
.  Other studies showed that point mutations in pfmdr1 either increased 
susceptibility to MQ (HAL, LUM as well 
259
) 
203,257-259,262,266
 or decreased susceptibility 
205
 to MQ.  These data emphasize that the pattern of mutations in any given field sample 
may reflect a complex interplay of selection pressures arising from differing degrees of 
exposure to the various quinoline-type drugs and differences in their precise mode of 
interaction with the parasites 
193
.  Lumefantrine is now paired with AE in the ACT 
Coartem, and success at treating P. falciparum has reported in Asia and Africa 
267
.  Some 
recent studies have reported on the presence of AA residues in pfmdr1 (such as N86, 
184F, 1246D) that may be associated with susceptibility/resistance to Coartem in Africa 
268-271
. The selection of these mutations could be indicative of LUM resistance in the field.  
Interestingly, the wild-type K76 pfcrt position was associated with LUM susceptibility in 
some of those studies in Africa 
245,272
.  Also, a recent study found that short term failure 
of Coartem in Asia was associated with pfmdr1 amplification 
273
. 
As well as polymorphisms arising from point mutations, variation in copy number 
of the pfmdr1 gene has been associated with MQ resistance (and cross resistance to HAL, 
QN, or LUM 
206,261,263
) in a number of studies, either in samples isolated from the field 
205,260,262,266,274,275
, or arising through deliberate selection of highly resistant progeny of 
laboratory strains 
261,263,276-278
.  The presence (or lack) of copy number changes and/or 
point mutations which influence levels of resistance to these inhibitors indicates that there 
are several possible contributory factors and mechanisms involved in the acquisition of 
66 
 
resistance to these drugs.  Still, these data have direct applicability to public health as a 
predictor of resistance in clinical samples and can assist in assigning alternative treatment 
regimens in MQ resistant areas.  Another study reported that pfmrp2 expression was 
associated with MQ treatment, implicating another transporter in possible MQ resistance 
213
.  A more recent study found that MQ is able to induce expression of pfmdr1, pfcrt, 
pfmrp1 and pfmrp2, which may further indicate that additional transporter genes may be 
involved in MQ resistance 
279
.  
Mefloquine resistance in southeast Asia prompted the introduction of the ACT 
AS+MQ in 1995 in Thailand and in Cambodia (2000) 
280
.  Although MQ resistance is 
widespread in southeast Asia, the addition of AS to MQ provides protection that allows 
MQ to effectively eliminate parasites.  The list of studies reporting on this ACT is 
exhaustive.  A group of studies in the early 1990s found that treating patients in Thailand 
with MQ after an initial AS treatment produced high cure rates (even with a half dose) 
and cured recrudescent infections 
281-284
.  With the introduction of AS+MQ, malaria cure 
rates increased in southeast Asia and the combination has been efficacious in general 
285-
292
.  However, there are reports of resistance to MQ after the introduction of this ACT 
262,286
.  AS+MQ has not been used at high levels beyond Asia, but some studies have 
found it is highly efficacious and it should be recommended for treatment in Africa and 
South America 
293-295
. 
Although ACTs display high activity against multi-drug resistant parasites, they 
are often used in an area where resistance already exists to the longer lasting component 
of the ACT.  Therefore, there is a risk that pre-existing resistance to these older partner 
drugs could lead to drug failure.  The case for this is becoming clear on the Thailand-
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Cambodia border 
280
.  Wongsrichanalai and Meshnick (2008) 
280
 summarized three 
studies that discussed the emergence of AS+MQ resistance based on the border of 
Thailand/Cambodia or Thailand/Burma.  Two of these were by Denis et al. (2006) 
296
 
which focused on a group of 14 Cambodian efficacy studies from 2001-2004.  In Pailin 
(2002), AS+MQ response was 86% at day 28 follow-up, whereas a repeat study in Pailin 
(2004), which used the same drug combination but more precise dosing and follow-up at 
42 days, found efficacy to be 79%.  Vijaykadga et al. (2006) 
297
 aimed to monitor the 
efficacy of anti-malarial treatments in Thailand.  This study took place in nine provinces 
that bordered Cambodia and Burma.  One group included the provinces Mae Hong Son 
(NW border with Burma), Chiang Mai (NW border with Burma), Ratchaburi (W border 
with Burma) and Ubon Ratchathani (E border with Cambodia).  A second group included 
patients from Kanchanaburi (W border with Burma).  The third group had patients from 
provinces with high-level mefloquine resistance (Tak [NW border with Burma], Ranong 
[on border with S tip of Burma], Chanthaburi and Trat [both SE border with Cambodia]).  
The percentage of adequate clinical and parasitological response to MQ was 62% in Mae 
Hong Son, 75% in Chiang Mai, 94.0% in Ratchaburi and 90% in Ubon Ratchathani.  In 
Kanchanaburi, the percentage of adequate clinical and parasitological response to 
AS+MQ was 94%. In the third group, this response exceeded 90%, except in Trat, where 
it was only 79%.   
Thus, evidence indicates that AS+MQ failures are occurring in different locations 
in Thailand, but the ACT remains effective in others.  Based on these data, it was 
suggested that MQ monotherapy be replaced in Mae Hong Son and Chiang Mai.  The 
markedly reduced efficacy of the AS+MQ used in Trat raises questions about the future 
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of this therapy on the SE border of Thailand with Cambodia.  These studies as a whole 
bring the prospect of widespread AS+MQ resistance to the forefront.  In terms of 
molecular mechanisms of resistance in AS+MQ therapy, it appears that treatment failures 
most likely result from MQ resistance rather than artemisinin resistance because 
increased pfmdr1 copy number has been linked with MQ resistance (or AS+MQ 
resistance) 
205,260,262,298,299
.  Indeed, recrudescence in the 2004 Pailin study above was 
linked to amplification of pfmdr1 
298
 and pfmdr1 amplification was associated with 
recrudescence after AS+MQ in NW Thailand in another study 
274
.  Also, mutations 
thought to be associated with artemisinin resistance (pfatp6) (below)  have not been 
detected in Cambodia, and no isolates resistant to artesunate in vitro have been found 
280
.  
However, reports that link increased copy number of pfmdr1 to artemisinin and recent 
reports of emerging artemisinin resistance in southeast Asia allude to the possibility of 
artemisinin resistance as part of the resistance phenotype for ACTs (below).   
The reason for emerging AS+MQ resistance is multifactorial.  It may be that MQ 
resistance in western Cambodia had already reached a level too extreme for the drug to 
be further protected by AS.  This is similar to what occurred when MQ+SP was 
introduced in areas where there was already pre-existing SP resistance 
154
.  The improper 
use of antimalarial drugs may be a result of a number of reasons (i.e. misdiagnosis, lack 
of adherence, taking substandard drugs, taking drugs for prophylaxis).  A very recent 
study found that a new fixed dose AS+MQ treatment was well-tolerated and effective, 
making it a suitable replacement of AS+MQ non-fixed regimens 
300
.  Perhaps finding 
better ways to utilize existing components of ACTs can help maintain effectiveness of 
drugs and protect the emergence of resistance.  Another, more important, reason concerns 
69 
 
pharmacokinetics of the drugs.  The short half-life of the artemisinin component means 
that if any parasites remained after an initial AS+MQ treatment, they may be selected for.  
When patients become re-infected, tolerance to MQ may develop.  Finally, malaria 
parasites in southeast Asia are known to develop resistance to antimalarial drugs very 
quickly 
155,191
, and one study found that parasites from this region are capable of 
assuming an accelerated resistance to multiple drugs (AMRD) phenotype 
301
.  
Resistance in southeast Asia to ACTs may not be limited to the Thai-Cambodia 
region.  Reduced efficacy of AS+MQ was reported in Kampot, a province in southern 
Cambodia that borders Vietnam 
280
.  Therefore, resistant parasites may be spreading and 
an alternative ACT may be needed soon to replace AS+MQ.  A disturbing possibility is 
that emergence and spread of ACT resistance could occur in Africa, where the parasite 
density is much greater, the transmission dynamics would ameliorate the spread of drug 
resistance, drug use is inappropriate or uninformed, and the public health infrastructure is 
weak 
302
.  Although AS+MQ is not typically used in Africa, AE+LUM is a recommended 
ACT that is used there.  LUM is chemically related to MQ, which brings up the potential 
for a situation that is like the one occurring in southeast Asia.  The WHO is now 
recommending ACTs to be first-line therapies in areas of falciparum malaria, and 
because of this, presumptive treatment with ACTs may soon be commonplace in sub-
Saharan Africa.  This drug-use practice can only serve to promote the evolution of 
resistance.   
Antifolates.  Resistance to the antifolate drugs first appeared in the 1950s with 
the report of curative failures involved in the use of proguanil.  Treatment failures were 
observed with the once-effective pyrimethamine (PYR) shortly after it was introduced, 
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rekindling interest in sulfonamides as antimalarials.  The pairing of PYR with 
sulfadoxine (SP) represented a first line drug for use in multi-drug resistant infections, 
but the combination was found to exhibit adverse reactions and resistance emerged 
shortly after it was introduced in Thailand and in Africa 
155
.  High-level SP resistance is 
found in many parts of South-East Asia, southern China and the Amazon basin, and 
lower levels of resistance are seen on the coast of South America and in southern Asia 
and Oceania.  In eastern Africa, SP resistance has progressed westwards across Africa 
over the last decade 
49
.  Resistance to the antifolate antimalarials is well-established, and 
it can be assigned to point mutations within DHFR (Pyrimethamine target) and DHPS 
(Sulfadoxine target).  Resistance to SP is attributable to parasites carrying mutations at 
A16V, R50A, N51I, C59R, S108N, and I164L of the dhfr gene, and resistance is 
augmented by point mutations at codons S436A, A437G, S436P, A581G, coupled with 
A613T or A613S, and K540Q of the dhps gene 
149,193,207,303
.  When mutations are found 
together in an isolate, there is sometimes a synergistic effect on resistance.  For example, 
S108N is essential for in vitro PYR resistance.  Additional mutation(s) in other 
polymorphic sites synergistically increase the levels of resistance.  Triple mutants 
(N51I+C59R+S108N and C59R+S108N+I164R) show greater PYR resistance compared 
to dhfr double mutants, and the quadruple mutant (N51I+C59R+S108N+I164R) shows 
the highest resistance to PYR so far 
207
.  The A437G mutation in dhps confers a 5-fold 
increase in SULF resistance over wild-type parasites.  Triple dhps mutants confer even 
greater increases in sulfadoxine resistance: S436A+A437G+K540E (9.8-fold increase 
over wildtype) and S436A+A437G+A613S (24-fold increase over wild-type) 
207
.  The 
effect of these point mutations is probably to alter the active binding site cavity where the 
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drugs interact with the particular enzyme, thereby blocking drug action.  As with CQ 
resistance, it is possible to associate mutations in dhfr with geographical location of PYR-
resistant parasites.  It appears that a resistant lineage having a double mutation in dhfr 
(AA positions 59 and 108) was probably generated near the Thai-Cambodia border in the 
1960s, and evolved to triple (positions 51, 59, 108; 59, 108, 64) and quartet (positions 51, 
59, 108, 164) mutant types and spread to other regions in Asia and to Africa.  In the 
Pacific region, an indigenous lineage and a lineage that migrated from Southeast Asia 
emerged.  In South America, two distinct lineages of PYR resistance have been detected 
in Venezuela (positions 50, 51, 108) and Peru (positions 51, 108, 164). These triple 
mutant lineages sequentially evolved from different lineages of the same dhfr double 
mutant (positions 51, 108) 
207
.  Although SP may still retain some efficacy in areas of CQ 
and MQ resistance, its repeated use will only serve to lower its efficacy due to the 
accumulation of mutations in parasites, and this may compromise the efficacy of newer 
antifolates even before they are brought into use. Because of this, SP is paired with AS 
for ACT use.  AS+SP has been effective in South America and Africa for treating P. 
falciparum 
304-306
.  AS+SP was reported to be very efficacious for P. vivax 
307,308
, but dhfr 
mutations were detected in Papua after treatment 
308
.  The WHO states that AS+SP is 
ineffective at treating P. vivax in many locations in the world 
44
.   
Atovaquone.  ATOV is a relatively new drug that was developed in the 1980s, 
but it was originally synthesized in the 1940s 
309
.  When used as a single agent against 
malaria, ATOV leads to high rates of recrudescence 
310,311
, and evidence suggests that 
patients taking ATOV only may quickly develop resistance to the drug 
311
.  ATOV 
inhibits the cytochrome bc1 complex of the electron transport chain of malaria parasites, 
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inhibiting electron transport and collapsing mitochondrial potential 
165,309,312
.  Studies of 
laboratory-generated ATOV resistant mutants and field isolates showed that mutations in 
the cytochrome bc1 complex are linked to ATOV resistance 
309,313-315
.  When ATOV is 
combined with proguanil, cure rates are usually high 
311,315
.  The effectiveness of this 
combination then led to the inclusion of proguanil as a synergistic agent with ATOV 
therapy.  The recently introduced drug Malarone
®
 (ATOV+proguanil) is used for 
treatment and prophylaxis.  Although Malarone
®
 is a powerful combination, there is 
potential for the emergence of drug resistance.  There are reports of in vivo Malarone
®
 
resistance in patients 
315-319
.  These studies found that mutations at codon 268 in the 
cytochrome b gene (within the region encoding the putative ATOV-binding domain) are 
associated with Malarone
®
 resistance.  Currently, this appears to be the only genetic 
change that is associated with Malarone
®
 treatment failure in vivo.  Therefore, these 
mutations are considered useful tools for the surveillance of resistance to Malarone
®
. 
Artemisinins.  The potential emergence of artemisinin resistance is a major 
concern given the fact that artemisinin is widely used as a monotherapy and it is part of 
combination therapies utilized in areas where drug-resistant malaria is already prevalent.  
The mechanism(s) of action of artemisinin drugs is controversial and not well-known, but 
even less is known about potential resistance mechanisms to the drugs.  Until recently, 
resistance to artemisinin drugs had not been documented in the field.  Several clinical 
studies based in southeast Asia have classified artemisinin resistance as delayed parasite 
clearance along with reduction of in vitro susceptibility to artemisinin drugs 
320-322
.  
Although these authors acknowledge the potential of artemisinin resistance, they also 
note that it is not a widespread phenomenon.  Because artemisinin drugs are part of 
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current recommended combination treatments for P. falciparum, it is critical to 
investigate possible mechanisms of resistance to these drugs in Plasmodium spp.  
Currently, there are a group of genes that have tentative associations with the site of 
action or reduced susceptibility (or cross-resistance) to artemisinins.   
As stated above, pfatp6 is reported to be the best candidate for the link to 
artemisinin activity, and a recent report thoroughly discussed the reasoning behind this 
and potential artemisinin resistance 
323
.  However, there is a dearth of studies that have 
reported on the involvement of this gene and artemisinin resistance.  Uhlemann et al. 
(2005) 
186
 reported that introducing a L263E mutation in transmembrane segment 3 in 
pfatp6 abolished artemisinin activity, and it was theorized that this mutation existed in the 
binding pocket for artemisinin.  However, a study by Valderramos et al. (2010) 
324
 found 
that parasites expressing engineered L263E variant PfATP6 did not have a significant 
change in 50% inhibitory concentrations (IC50s)
 
for QHS, DHA, or AS.  In a study using 
patient isolates from Cambodia, French Guiana, and Senegal, the S769N mutation was 
found exclusively in French Guiana isolates (the double mutation A623E E431K was also 
found in low prevalence), which correlated with resistance to AE 
185
.  Further studies by 
this group 
325
 of 100 isolates from sites in Africa, Asia, and South America found large 
diversity in pfatp6 coding sequence including 32 SNPs (average of one SNP/115 bp), of 
which 19 were novel mutations.  The PfSERCA functional domains were very well 
conserved, with non synonymous mutations located outside the functional domains, 
except for the S769N mutation associated in French Guiana with elevated IC50 for AE.  
The S769N mutation is located close to the hinge of the headpiece, which in other species 
modulates calcium affinity and in consequence efficacy of inhibitors, possibly linking 
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calcium homeostasis to drug resistance.  Another study reported on pfatp6 diversity from 
~400 samples from 17 countries (mainly Zanzibar and Tanzania).  This resulted in the 
identification of 33 SNPs, of which 29 had not been described previously.  Three 
mutations were found in high frequency in Zanzibar and Tanzania (E431K, N569K and 
A630S).  Interestingly, no variation was found in position 263 or in position 769 
326
.  
Another study examined SNPs of pfatp6 in 87 P. falciparum samples from Niger and 
found SNPs at positions 537, 561, 569, 630, 639, and 716.  All the mutations found were 
rare, except N569K, which was found in 17.2% of samples 
327
.  A recent study with 
Vietnam isolates reported mutations (N460N, N463S, N465S, C1031C) and one double 
deletion (463-464) in pfatp6 that had not been reported before
328
.  Others did not find 
mutations within pfatp6 in Asia or Africa 
276,320,321,329-331
 or its homolog in P. chabaudi 
332
.  
Price et al. (2004) 
262
 detected the I89T mutation in two isolates from NW Thailand that 
had elevated IC50 to AS.  A survey of a larger number of parasites did not associate this 
mutation with an IC50 change, however.  Toovey et al., 2008 
333
 reported that DHA, MQ, 
and LUM inhibited mammalian SERCA at peri-physiological concentrations, further 
implicating this gene type in artemisinin activity.  Importantly, the prevalence of pfatp6 
mutations may correspond to regions of ACT use 
323,326,327
.  However, studies that 
identified the SNPs did not attempt to associate mutations with altered susceptibility with 
artemisinin drugs (except 
262,324
), indicating that a causal association between resistance 
and mutations cannot be made at this time. 
Studies have also found that artemisinin susceptibility can be influenced by 
genetic changes in loci encoding pfmdr1and pfcrt.  As discussed above, point mutations 
and amplification of pfmdr1 can alter parasite susceptibility to different antimalarial 
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drugs, leading to cross resistance to antimalarials in some cases.  The study by Reed et al. 
(2000) 
202
 found that amino acid changes in pfmdr1 (S1034C, N1042D, and D1246Y) 
correlated with increase in MQ, HAL, and QHS sensitivity (the converse was true when 
the residues were removed).  Therefore, it appeared that there is cross resistance for these 
drugs, possibly mediated by a common mechanism of resistance.  Reports have justified 
this assertion in different studies in Africa and Asia showing cross resistance between 
QHS and QN/MQ/HAL 
334
, QHS and MQ/HAL 
249
, AS and MQ/QN 
335
, and 
AS/DHA/MQ 
336
.  It was recently found that genetic disruption of pfmdr1 led to 
enhanced susceptibility of QHS/HAL/MQ 
259
 and decreased pfmdr1 copy number was 
associated with susceptibility to QHS/MQ/LUM/HAL/QN 
263
.  Increased copy number of 
pfmdr1 in patient isolates or in vitro artemisinin- selected lines correlates with 
recrudescence after AS+MQ treatment 
298
 and decreased susceptibility to QHS/MQ/HAL 
206
, AS/MQ/HAL/CQ 
266
, AS/MQ 
262,286
, QHS/MQ/QN (but increased CQ) 
205
, 
QHS/MQ/LUM/QN 
260
, and AL/QN/MQ/DHA/QHS (but increased CQ) 
276
.  However, 
other studies have reported a disassociation with pfmdr1 (or its homolog in murine 
malaria) and artemisinin resistance 
202,257-259,276,320,321,329,332,337
.  This may indicate that 
depending on location in the world and the presence of other genetic alterations, drug 
susceptibility profiles change.   
PfCRT is usually not implicated in artemisinin resistance, but again, there are not 
many studies attempted at making the association.  Ngo et al. (2003) 
258
 reported on 
isolates from Vietnam that were taken from patients before and after QHS therapy.  
These isolates exhibited MQ resistance and CQ susceptibility (with concomitant SNPs in 
pfcrt and pfmdr1), with no change in QHS sensitivity.  This may indicate that AS+MQ 
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treatment in the area selected for MQ resistance.  Sidhu et al. (2002) 
211
 found that mutant 
pfcrt haplotypes from Asia, Africa, and South America correlated with CQ-resistance, but 
QHS susceptibility.  The use of AE+LUM in Africa has been reported with susceptibility 
to AE+LUM and wild-type K76 in pfcrt 
245,272
.  It is unclear from these studies if the 
presence of K76 is associated with any artemisinin activity.  Very recently, Valderramos 
et al., (2010) 
236
 placed CQ-resistance alleles from strain 7G8 (Brazil) into strains 3D7, 
D10 (Papua New Guinea), and GC03 (Dd2xHB3cross).  They found that QHS and LUM 
susceptibility increased, but QN susceptibility was unchanged.  In this study, the authors 
also conducted susceptibility testing on isolates from French Guiana (originally reported 
on in Jambou et al, (2005) 
185
 in study of pfatp6).  They found that isolate H209 exhibited 
elevated IC50 to QHS, AS, AE, LM, and QN.  H209 carried a novel PfCRT mutation 
(C350R) and this parasite was highly sensitive to CQ, yet demonstrated delayed 
recrudescence.  It remains to be seen if transfecting the C350R mutation into other 
parasite lines will cause reduced artemisinin sensitivity in other strains.  Chavchich et al. 
(2010) 
276
 recently reported on the induction of artemisinin resistance in P. falciparum, 
which did not associate with changes in pfcrt.  Overall, it appears that pfcrt does not 
correlate well with artemisinin resistance.  However, the potential of a novel mutation for 
artemisinin resistance is disturbing.  Importantly, the strain carrying this mutation is from 
French Guiana, an area where AE+LUM is actively used, and the presence of an 
artemisinin-resistance mutation would be devastating.  On the positive side, this could be 
a potential marker for artemisinin resistance in the field.   
Research on artemisinin resistance has intersected with several other genes 
including pfmrp1, P. falciparum transitionally controlled tumor protein (pftctp), and 
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murine homologs of P. falciparum ubiquitin protein 1 (pfubp-1) and pfmdr1.  As 
discussed above, pfmrp1 was previously found to be associated with QN and CQ 
resistance.  Disrupting this gene appeared to increase sensitivity to these drugs, and also 
to QHS 
214
.  PfTCTP was identified as a potential alkylated protein that may be acted on 
by artemisinin activity 
338
.  TCTP was found to be located in the DV and cytoplasm 
339
 
and it was found to interact with QHS and bind hemin 
338
.  Therefore, it is possible that 
its position in the DV could provide a link to heme metabolism and artemisinin activity.   
Studies in murine models of malaria have shed light on many facets of malaria, 
including drug resistance, because these models are amenable to in vivo studies.  An 
artemisinin-resistant line of P. yoelii was described by Ferrer-Rodriguez et al. 2004 
340
 
that had increased copy number of pymdr1.  However, resistance was not stable, 
preventing an association from being established between pymdr1 and artemisinin 
resistance.  Afonso et al. (2006) 
332
 reported on the induction of in vivo QHS and AS 
stable resistance in P. chabaudi, which may be the first published work on the selection 
of stable artemisinin-resistant malaria parasites.  The QHS and AS-resistant parasites 
were derived from CQ-resistant clones that were exposed to subcurative doses of QHS 
and AS.  Parasites that were resistant to artemisinins in this study had 6-15 fold increase 
in the minimum curative dose.  The parasites derived in this study have served for future 
studies on artemisinin resistance in P. chabaudi.  In this study, orthologs of pfatp6, pfcrt, 
pfmdr1, and pftctp were analyzed in resistant and parental lines, and it was determined 
that nucleotide sequences were similar and copy numbers were not elevated.  
Interestingly, artemisinin resistance could not be induced in CQ-sensitive parasites.  The 
authors attributed the acquisition of artemisinin resistance in CQ-resistant parasites as a 
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result of the parasites' ability to generate mutations in response to drug treatment (called 
the ARMD phenotype) 
301
, which might have occurred during the generation of the CQ-
resistant lines, or that the artemisinin resistance phenotype is expressed only in CQ-
resistant clones.  Although this would tend to suggest that there is some functional 
interaction between the pathways underlying CQ and artemisinin resistance, studies have 
shown that a CQ-resistance phenotype is associated with increased artemisinin 
susceptibility in Asia and Africa 
210,211,249
.  We and Chavchich et al. 2010 
276
 found that 
artemisinin resistance can be induced in CQ-sensitive D6, and CQ susceptibility 
decreased in D6 resistant lines.  Clearly, the link between CQ and QHS resistance 
warrants more attention in the future.   
A study by Hunt et al. (2007) 
341
 employed the QHS-resistant version of P. 
chabaudi from 
332
 and crossed it with a QHS-sensitive strain.  This experiment identified 
a locus on chromosome 2 that conferred in vivo ART resistance and revealed two point 
mutations in a gene (pcubp-1) encoding a de-ubiquitin carboxyl-terminal hydrolase.  One 
of the mutations came as a result of crossing with the QHS strain (V739F), but the other 
was in the CQ-resistant parent of the ART resistant strain to begin with (V770F).  The P. 
chabaudi ortholog of pfatp6 (pcatp6) also existed on chromosome 2, but no mutations 
were detected in the gene.  During this study, QHS resistance was also selected in P. 
falciparum lines NF54 and 7G8, although it did not prove to be stable.  However, in the 
resistant parasite, pfcrt, pfmdr1, and the P. falciparum ortholog of pcubp-1 (pfubp-1) all 
did not display mutations relative to the parental parasite.  A subsequent study 
342
 
implicated the V770F mutation as the sole indicator of shifting artemisinin response in 
CQ and artemisinin resistant P. chabaudi parasites.  Imwong et al., 2010 
329
 reported that 
79 
 
P. falciparum isolates from Western Cambodia (where artemisinin resistance is reported 
to be emerging) did not have putative mutations in pfubp-1 (those reported by Hunt et al. 
2007 
341
).  It remains to be seen how ubiquitin hydrolases relate to artemisinin resistance.  
Because of the importance that pfmdr1 plays in drug resistance, researchers investigated 
the relation of the P. chabaudi ortholog (pcmdr1).  Cravo et al. (2003) 
343
 reported on the 
induction of in vivo MQ resistance in P. chabaudi, and found that the sequence of both 
copies of pcmdr1 in the genome of the resistant parasite were identical to that of the 
parent sensitive clone.  A cross between the MQ clone and a MQ-sensitive clone revealed 
that duplication and over-expression of the pcmdr1 gene was an important determinant of 
resistance. However, not all mefloquine-resistant progeny contained the duplicated gene, 
showing that at least one other gene was involved in resistance.  Rodrigues et al. (2010) 
335
 aimed to dissect factors influencing ACT resistance and its acquisition.  Using the 
QHS-resistant P. chabaudi described by 
332
, in vivo resistance to AS+MQ was achieved, 
through prolonged exposure of parasites to both drugs over many generations.  A stably 
resistant parasite showed increased resistance to AS+MQ treatment and to AS or MQ 
administered separately.  Examination of putative artemisinin-resistance genes found a 
duplication of pcmdr1 with concomitant increased levels of pcmdr1 transcripts and 
protein.  No point mutations were found in pcatp6 or pcubp1.  This is the first report to 
show selected resistance to a surrogate ACT, showing that resistance to ACTs may 
evolve even when the two drugs within the combination are taken simultaneously and 
amplification of an mdr1 gene may contribute to this phenotype.  Walker et al (2000) 
344
 
attempted to characterize QHS accumulation and the role of TCTP in a QHS-resistant P. 
yoelii strain from Peters and Robinson (1999) 
345
.  This study found that QHS-resistant 
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parasites accumulated significantly less radiolabeled DHA compared to sensitive 
parasites.  Radiolabeled DHA bound to proteins in both parasites, but TCTP was 
expressed about 2.5 times more as the sensitive strain.  Based on these results, it appeared 
QHS resistance is multifactorial in P. yoelii.  However, these mechanisms of resistance in 
murine malaria species may not be exhibited in human malaria species.  A study by 
Chavchich et al. (2010) 
276
 did not find sequence differences in pftctp, pfubp-1 or 
expression of pftctp in in vitro selected artemisinin-resistant P. falciparum. 
The above studies on artemisinin resistance have scratched the surface of what 
may be a potentially emerging problem.  Artemisinins were thought to be the one class of 
drugs that were reliable as a last resort.  However, studies from the field are now raising 
fears that these drugs are no longer effective.  What is concerning is that these drugs are 
used in combination with other drugs that often have long half-lives and maybe sub-
optimal themselves at treating malaria.  Therefore, it may be possible to select for 
resistance to either part of the ACT.  The biological basis of artemisinin activity is still 
controversial, and molecular mechanisms of resistance cannot be causally associated with 
patient treatment failure.  As described above, it is only in the last few years that 
researchers have attempted to examine these mechanisms, which may be imperative to 
stopping spread of artemisinin resistance.  Our laboratory has focused on dissecting 
artemisinin-induced dormancy and molecular mechanisms of artemisinin resistance.  
Preliminary Studies from the Kyle Laboratory 
Dormancy.  Artemisinin drugs and their derivatives are very effective for treating 
malaria, but they are rapidly eliminated (approximately 1 hour, 
346
), which may be 
responsible for the high number of patients that experience recrudescence following 
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monotherapy treatment lasting less than 7 days 
347
.  The recrudescent parasites remain 
susceptible to artemisinin in vitro 
282,284,288,348-351
 (Kyle et al., 2010 unpublished), 
suggesting that the high frequency of treatment failure is not due to conventional 
resistance mechanisms.   
Previous in vitro studies provide compelling evidence that the artemisinin drugs 
are not completely cidal, but may produce a static effect on parasite growth.  Studies 
showed that after treatment with some antimalarials, parasites enter a survival state 
before they recrudesce in culture.  Reports of P. falciparum entering a dormant state have 
been described after PYR and MQ treatment 
352-354
.  It has been suggested that 
recrudescence after artemisinin treatment is attributable to parasites surviving in a hidden, 
protected state 
355-358
.  The persistent suppression of parasite growth following short 
exposures to artemisinins is similar to the postantibiotic effect (PAE) observed for 
antimicrobial drugs 
359
.  Although these studies observed effects on parasites after 
antimalarial drugs, a causal association could not be made between drug activity and a 
mechanism allowing parasites to survive and cause re-infection.  
The apparently conflicting observations on the cidal mechanism of action for 
artemisinin drugs and the frequency of recrudescence following treatment led our group 
to investigate the stage specific activity of artemisinin drugs.  Parasites were treated with 
1 and 10 ng/ml of AS and 1 and 10 μg/ml QN for 6 hours.  Development of the parasites 
at 0, 4, 24, 28, and 44 hr was followed by using flow cytometry (Fig. 1.6).  After 
exposure to either 1 or 10 ng/ml of AS, the development of 8-12 hr old ring stage 
parasites was abruptly halted, whereas QN-treated parasites continued to develop to 
trophozoites.  By 28 hours, there was a clear difference in the intensity of the observed 
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fluorescence in the controls and the quinine treated parasites versus the AS groups.  This 
was indicative of parasite maturation to early schizonts in the control and quinine groups. 
In contrast, the development of parasites was completely arrested in the presence of 10 
ng/ml AS and very few parasites developed in the 1 ng/ml group.  By 44 hours, the 
control parasites had completely developed through schizogony and had initiated a new 
cycle.  In contrast, the AS-treated parasites still had not developed past the ring stage nor 
had they synthesized DNA.  Throughout the 44 hour experiment, the profiles observed 
for the AS-treated samples remained similar to the control parasites at the beginning of 
the experiment.  Throughout the experiment, profiles observed for the AS-treated 
samples remained similar to the control parasites at the beginning of the experiment.  
Further experiments showed that treatment of ring stage parasites with DHA had a 
significant effect on the subsequent development of the parasite to mature stages.  
Treatment with 2 and 20 ng/ml DHA for 24 hours significantly delayed the growth of 
parasites to trophozoites and schizonts, as parasites were arrested at ring-stage (Fig. 1.7).  
This DHA-induced arrest was both dose and duration of exposure dependent.  Although a 
prolonged delay in growth was observed, in all cases the parasites eventually resumed 
normal growth at a rate similar to that observed for untreated parasites.  Microscopic 
examination of blood smears revealed that the development of parasites was arrested at 
ring stage during the “non-growth” period.  Morphology of ring stage parasites exposed 
to 2.0 ng/ml DHA for 6 hours revealed that for the first 48 hours, most parasites had 
pyknotic nuclei and reduced cytoplasmic mass.  By 72 hours, predominant forms seen 
were parasites with densely stained nuclei with little or no cytoplasm.  From 48-72 hours, 
some parasites were more severely affected with the shape of the nuclei becoming less 
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rounded and with clumps of more densely stained chromatin.  There was no evidence that 
parasites were developing to mature stages at either the 2 or 20 ng/ml doses by 72 hours.  
In the 2 and 20 ng/ml groups normal ring stage parasites were seen at 72 hours and by 
120 hours, morphologically normal mature stages were prevalent.  Although the exact 
proportions were not determined, there were many DHA-affected parasites still observed 
at 144 hours, especially in the 20 ng/ml DHA group.  Parallel experiments with QN also 
produced a significant delay in development, but the effect upon the morphology of the 
parasite was very different compared to parasites treated with DHA.  Only DHA 
produced the arrested development of ring stages.  Subsequent experiments with 
synchronous trophozoites and schizonts aimed to investigate stage-specific effects of 
artemisinins.  These results showed that trophozoites were severely affected by DHA, 
with no formation of schizonts.  The majority of parasites were shrunken, dead, and/or 
extracellular.  In contrast, schizonts exposed to DHA ruptured and produced merozoites 
that were seen in newly invaded erythrocytes.  The morphology of most young ring 
stages observed in the DHA-treated group appeared normal.  Some schizonts also 
remained at 18 hour post-exposure to DHA, suggesting a delay in maturation of the 
treated parasites.  These parasites continued to develop normally.  These data indicated 
that schizonts were affected much less by equivalent DHA concentrations than other 
erythrocytic stages of the parasites.  Following the rupture of schizonts exposed to DHA, 
morphologically normal rings and some forms that were similar to the ring stage 
dormants were observed.  The experiment could not be continued past 96 hours (due to 
rapid growth of most parasites in the culture), but dormant ring stages were observed in 
all slides from 24-96 hr.  These results suggest the possibility that progeny of schizonts 
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exposed to DHA may become dormant following invasion of a new erythrocyte.  
Additional studies are required to determine the proportion of progeny from DHA-
exposed schizonts that continue to grow normally versus the proportion that may become 
dormant. 
These data that demonstrate recrudescence in vitro are similar in part to previous 
observations by Witkowski et al. (2010) 
360
 and Nakazawa et al. 
352,354
.  The study by 
Witkowski et al. (2010) 
360
 detailed induction of artemisinin resistance in a P. falciparum 
isolate from Tanzania.  They noted that following QHS treatment, parasites were arrested 
at ring-stage.  However, they only noted this in the parental line (not resistant progeny), 
and only reported on epifluorescence without thorough microscopic observations of the 
arrested parasites.  The studies by Nakazawa et al. reported on exposure of asynchronous 
P. falciparum cultures to PYR or MQ in vitro, where recrudescence occurred up to 10 
days after the end of treatment.  Unfortunately, these excellent studies did not include any 
observations on the morphological changes associated with drug treatment, stage specific 
activity of PYR was not investigated, nor did the authors propose the mechanism that 
allowed the parasites to recrudesce. Therefore, our lab compared the ability of other 
commonly used antimalarial drugs to arrest ring stage development.  Ring stages of 
TM93c1546 (Thai isolate of P. falciparum) were exposed to CQ (500 nM), MQ (100 nM), 
QN (1 M), HAL (100 nM), PYR (1 M), or DHA (100 nM) for 6 hours.  Of the 
antimalarial drugs tested, only DHA induced ring stage arrest and dormancy in >90% of 
the parasites observed at 48 hr post-exposure.  In contrast, the other drugs allowed a 
significant proportion of the parasites to develop to more mature asexual stages, which is 
consistent with reports that these drugs are most active against trophozoites. Although 
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morphological abnormalities were observed in some ring stage parasites after treatment 
with MQ and HAL, they were much different to that produced by DHA.  These results 
indicated that artemisinin drugs uniquely induce dormancy in ring stages, yet these data 
do not exclude the possibility that other antimalarial drugs may induce dormancy in a 
subsequent generation of the parasite.  Previous studies suggest that some antimalarial 
drugs have a significant effect upon the 2
nd
 asexual generation following exposure to the 
drug 
361
.  Our data on the effect of DHA on schizonts are consistent with that hypothesis 
and may help explain the data on recrudescence from PYR and MQ exposure in vitro 
352,354
.  
The preliminary data generated by our lab led to the intriguing hypothesis that 
dormant ring stage parasites may be the forms that survive treatment with artemisinin 
drugs and recover to initiate a recrudescent infection.  To fully explore the hypothesis, 
dormant forms were characterized at the cellular and molecular level.  Our initial efforts 
assessed if dormant ring stage parasites express proteins normally found in early ring 
stages.  We focused our attention on genes that would allow differentiation of rings from 
other stages.  One type of gene family is the early transcribed membrane proteins 
(ETRAMPs), which are located on the parasitophorous vacuole membrane.  ETRAMP2 
is expressed only in ring stages, whereas ETRAMP4 is found only in trophozoites.  
Exposure of synchronous ring stages of K1 and S99 (isolate from the Solomon Islands) to 
10 or 400 nM DHA for 4-12 hours found that ETRAMP2 labeled ring stage parasites in 
untreated control preparations, with fluorescence localized to the periphery of the parasite 
(Fig. 1.8-A-C).  ETRAMP2 antisera labeled dormant parasites with a fluorescence pattern 
identical to normal early rings.  In addition, many parasite nuclei were found without any 
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associated staining by ETRAMP2 antisera (Fig. 1.8-D).  In Giemsa-stained smears from 
these same preparations, approximately 25% of the dormant parasites had intact nuclei 
with evidence of cytoplasm. The rest of the dormant parasites had little or no cytoplasm 
and many of the nuclei were irregularly shaped with uneven staining of the chromatin.  
Interestingly, no signal was seen with the trophozoite-specific ETRAMP4 sera in either 
the low or high dose DHA-induced dormant parasites.  Parasites transformed with GFP 
were also used to assess the effect of artemisinin-induced dormancy on protein 
expression.  Parasites exposed to DHA (100 nM) for 6 hours continued to fluoresce even 
in the arrested ring stages (Fig. 1.8-E).  GFP fluorescence was observed associated with 
parasite nuclei during drug-induced dormancy and progeny from these cultures remained 
fluorescent after they recovered from the drug effects.  Similar to the data for ETRAMP2, 
by 72 hr following drug exposure, many nuclei were found without any evidence of GFP 
fluorescence.  These data suggest that dormant parasites continue to express proteins 
observed during normal ring stage development, but do not express trophozoite specific 
proteins during artemisinin-induced dormancy.  The intriguing finding of parasite nuclei 
without corresponding protein expression > 72 hr post treatment may be indicative of 
parasite viability, drug induced suppression of newly transcribed proteins, or both.  
Continuation of these studies has enhanced our understanding of the physiological effect 
of short-term drug exposures and lead to identification of markers that could be used to 
enhance the detection of dormant parasites on blood smears (LaCrue et al., unpublished 
data).   
Our in vitro data demonstrate that in the early stages of dormancy the parasites 
could easily be confused microscopically with tiny rings or newly invaded merozoites. 
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Within 48-72 hr after dormancy is induced in vitro, many nuclei are found with little to 
no blue-stained cytoplasm in giemsa stained smears.  These forms could be easily missed 
in thick or thin blood films since most experienced microscopists will not count a form as 
a malaria parasite without evidence of typical purple-red nuclear and blue cytoplasmic 
staining.  With these limitations in mind, thick and thin blood smears were 
retrospectively examined from two animal experiments with AL, an artemisinin 
derivative that also induces dormancy.  Retrospective examination of blood smears from 
mouse studies with P. berghei and monkeys infected with P. falciparum provided 
evidence that artemisinin-drug induced dormancy occurs in vivo.  The search for dormant 
parasites required prolonged examination of the smears and it was difficult to distinguish 
between newly invaded merozoites and possibly dormant parasites.  Interestingly, the 
technician that reads the smears for routine antimalarial drug testing studies reported the 
smears as negative.  Clearly, there is a need to develop better tools or methods to 
adequately examine the role of dormancy in in vivo recrudescence (and for in vitro 
studies).  Perhaps probing with sera to ETRAMP2 may lead to a better estimation of 
some dormant forms, but the method may not be sensitive enough to identify parasite 
nuclei (i.e., no cytoplasm).  We have expanded on our immunofluorescence studies with 
ETRAMPs, by assessing in situ hybridization methods to enhance the detection of 
dormant parasites in vivo (LaCrue et al., unpublished data). 
Our data on DHA-induced dormancy allowed us to draw some conclusions about 
the relevance of this phenomenon to the clinic and also to propose experiments that 
specifically address the most relevant questions.  We hypothesized that ring stage 
parasites exposed to artemisinins in vivo could have three fates: become dormant, 
88 
 
continue to grow at a slower rate, or be cleared by specific and non-specific immune 
mechanisms (above).  The drugs kill trophozoites efficiently, whereas cytoadherent 
schizonts can either continue to produce viable progeny, or enter dormancy after 
infecting a new erythrocyte (Fig. 1.9).  If dormant parasites recover and resume growth 
during the treatment period when the plasma drug level is above the MIC, they may enter 
another cycle of dormancy or be killed.  A recrudescence of infection will occur when 
dormant parasites recover and resume growth when drug levels decline below the MIC. 
Interestingly, our dormancy hypothesis is consistent with clinical observations of 
recrudescence, yet remains at odds with proposals for artemisinin activity, focusing on  
heme or iron-mediated mechanism of toxicity to parasites 
175,178
. 
In contrast to a completely cidal mechanism of action, in vivo efficacy studies and 
our in vitro dormancy data are more consistent with a specific protein target for the drug 
class.  As discussed above, several targets have been implicated.  Perhaps the most 
important implication of our data is that P. falciparum may survive exposure to 
artemisinin drugs to a unique mechanism of drug resistance.  As discussed above, 
resistance to other antimalarial drugs is due to reduced binding affinity (antifolates and 
ATOV), reduced accumulation of drug at the active site (CQ), or increased expression of 
drug resistance associated proteins (MQ).  Similar to these accepted mechanisms of 
resistance, artemisinin induced dormancy possibly allows parasites to evade the action of 
drugs and survive in the host long enough to reproduce.  In previous studies we observed 
that parasites from recrudescent infections were equally susceptible to AS and DHA as 
the parasite collected prior to treatment 
282,284,288,348-351
.  Since artemisinin drugs have 
short effective half-lives (~2 hr), dormant parasites would not be under pressure to 
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develop the more classical mechanism(s) of resistance to DHA as they may remain 
dormant during the brief period these drugs persist in blood.  It is important to determine 
if the inherent susceptibility to artemisinin is reduced after multiple dormancy episodes or 
if the recovery rate increases or duration of dormancy decreases. Either of these outcomes 
would confirm a unique parasite survival mechanism to the most important class of 
antimalarial drugs.  
The use of artemisinin drugs is increasing worldwide and there is an ongoing 
international effort to determine the most effective partner drug to prevent recrudescent 
infections.  One proposal suggests that ACTs utilizing AS should be used with all new 
and existing drugs to prevent or slow the emergence of resistant malaria.  The formation 
of dormant parasites during treatment with AS could be an important factor in selecting 
the best companion drug, especially since the second drug may be ineffective against a 
dormant, metabolically quiescent parasite.  Since AS+MQ is an ACT under heavy use in 
Asia, we tested this theory by exposing ring stage K1 and FC27 parasites to 10 nM DHA 
for 6 hours followed by mefloquine (50 nM) for an additional 18 hours.  The FC27 rings 
exposed to DHA alone produced dormant forms that did not begin to recover and grow.  
Normal ring and trophozoites were first observed 172 hr after the experiment was begun. 
Interestingly, rings exposed sequentially to DHA and then to MQ also recovered by 172 
hours.  In similar experiments with K1, there was a delay of 24 hours in the recovery of 
the DHA+MQ treated group versus those only exposed to DHA.  These results could 
have significant implications for the use of artemisinin combinations. These data suggest 
that a successful companion drug must have activity against dormant forms or have a 
90 
 
long enough half-life to remain active in the blood when dormant forms revive to produce 
recrudescent infections. 
Based on the preliminary studies our laboratory has conducted, we hypothesize 
that DHA and AS arrest the development of ring stages and induce a metabolically 
quiescent or dormant parasite.  These parasites can remain dormant and survive for a 
minimum of 3 days after exposure to 10-100 fold concentrations above the MIC.  These 
data are consistent with previous observations in vitro and in vivo and for the first time, 
provided evidence that the dormant ring stage parasites are the forms that survive to 
produce recrudescent infections.  The persistent suppression of parasite growth following 
short exposures to DHA was similar to the PAE described above.   
Another study from our group examined rates of recovery from dormancy, which 
may be an important facet for uncovering why patients experience delayed clearance 
times and recrudescence after treatment with a single artemisinin drug.  Teuscher et al. 
(2010) 
362
 exposed ring-stage parasites of several Plasmodium falciparum lines to 
different doses of DHA alone or in combination with MQ.  For each drug treatment series, 
the proportion of recovering parasites was determined daily for 20 days with and without 
the use of a magnetic column that would take out parasites unaffected by DHA. Parasite 
development was abruptly arrested after a single exposure to DHA, with some parasites 
remaining dormant for up to 20 days. Approximately 50% of dormant parasites recovered 
to resume growth within the first 9 days. The overall proportion of parasites recovering 
was dose dependent, with recovery rates ranging from 0.001% to 1.313%. Repeated 
treatment with DHA or with DHA in combination with MQ led to a delay in recovery and 
a ∼10-fold reduction in total recovery. Strains with different genetic backgrounds 
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appeared to vary in their capacity to recover. These results imply that artemisinin-induced 
arrest of growth occurs readily in laboratory-treated parasites and may be a key factor in 
P. falciparum malaria treatment failure. 
Studies relevant to this work.  Investigators have attempted to establish 
resistance models to artemisinin drugs, including P. falciparum and T. gondii in vitro and 
rodent malaria in vivo 
332,335,340,341,345,363-368
 .  Although all of these studied proved 
artemisinin resistance can be induced in different models, some noted associated 
problems with selection of resistance (unstable resistance, reversion to a sensitive 
phenotype, parasites exhibiting a range of artemisinin sensitivity compared to the 
sensitive strain, or lack of data on stability of resistance).  However, some of these studies 
have provided significant contributions toward dissecting putative molecular mechanisms 
of artemisinin resistance. 
Previous studies from our group found that multiple rounds of parasite exposure 
to an artemisinin drug, followed by dormancy, recovery, and growth, selects for parasites 
with reduced susceptibility to this class of antimalarial drugs.  Studies have reported on 
detailed selection of P. falciparum resistance to artelinic acid (AL) and QHS in vitro and 
molecular changes occurring during the selection 
276,337
 (Gerena and Kyle, unpublished 
data).  Resistance was first induced to AL in P. falciparum strains in vitro by adopting the 
methods Oduola et al. (1988) 
369
 used for MQ (W2Mef).  Clones of W2 (Indochina) and 
D6 (Sierra Leone) and a patient isolate from Thailand (TM91c235) were cultured under 
increasing drug pressure in step-wise increments over 28 months 
276
 (Fig. 1.10).  The 
increments of AL used were 0.5, 1, 2, 4, 10, 20, 30, 40, 50, and 80 ng/ml, with each stage 
of exposure lasting between 11-93 days.  It is important to note that AL pressure was not 
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applied continuously, even as parasites adapted to growth at higher AL concentrations.  A 
routine drug exposure cycle began with adding AL to asynchronous cultures at 4-8% 
parasitemia.  Drug pressure was removed when parasite morphology degraded so that 
most of the parasites were abnormal or drug-affected (usually 2-3 days).  AL pressure 
was resumed when parasite growth and morphology became normal.  A parasite was 
considered adapted when the recovery phase occurred in 2-4 days.  After W2 and D6 
were adapted to 80 ng/ml AL, they were exposed to stepwise increments of 
concentrations of QHS, starting from 20 ng/ml and extending up to a maximum of 200 
ng/ml (W2 only).  Overall, this procedure produced W2 progeny resistant up to 200 
ng/ml AL and 200 ng/ml QHS, TM91c235 progeny resistant up to 80 ng/ml AL, and D6 
progeny resistant up to 80 ng/ml AL and 80 ng/ml QHS 
276
.   
Parasite susceptibility to the drugs was assayed by measuring the inhibition of [
3
H] 
hypoxanthine uptake 
276
.  Interestingly, parasite susceptibility to AL and other 
antimalarial drugs shifted significantly in response to the increased drug pressure.  In 
general, as AL drug pressure increased, drug susceptibility decreased to other artemisinin 
drugs (DHA, QHS), and MQ, whereas parasites under AL pressure became more 
susceptible to CQ.  In the W2 clone, a significant reduction in sensitivity to AL, QHS, 
and MQ was observed when parasites became adapted to 40 ng/ml AL drug pressure and 
this trend continued through the 80 ng/ml AL level.  For D6, a significant reduction in 
sensitivity to AL, MQ, and DHA was observed when parasites were adapted to 30 ng/ml, 
but only AL resistance continued to increase as parasites were adapted to 80 ng/ml AL.  
Interestingly, sensitivity to QHS was significantly decreased when D6 was adapted to 40 
ng/ml AL and this trend continued to 80 ng/ml AL.  For TM91c235, susceptibility to AL 
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and QHS in TM91C235 decreased immediately and after exposure to 10 ng/ml AL, and 
after 30 ng/ml AL, there was no noticeable change at higher levels.  Susceptibility to 
DHA significantly decreased as parasites tolerated 40 ng/ml AL, and this trend increased 
up to 80 ng/ml AL.  Parasites became noticeably less susceptible to MQ at 30 ng/ml AL, 
but then parasites became more sensitive to MQ as AL tolerance increased. 
Although long-term stability studies at these high levels of drug exposure have 
not been completed, several important conclusions can be made from these observations. 
Firstly, resistance to artemisinin derivatives (as indicated by the ability to survive 
increasing concentrations of the drug) can be induced in P. falciparum in vitro.  Secondly, 
there is a significant degree of cross-resistance induced between various artemisinin 
derivatives and to MQ.  Finally, these artemisinin resistant parasites represent a unique 
resource for the study of artemisinin resistance mechanism(s), mechanism of action 
studies, and for determining the role of drug-induced dormancy as a mechanism of 
recrudescence.  
Molecular characterization of artemisinin resistance.  It was previously 
maintained that clinical resistance to artemisinins had not been observed 
347,358
.  
Interestingly, data to support these claims ignore the frequent recrudescence of infection 
following treatment with less than 7 days of an artemisinin derivative, with or without a 
companion drug 
347,370
.  It is important to note that confirmation of clinical resistance to 
artemisinin will be difficult to discern from normal recrudescence infections. The 
difficulty is amplified by the short half-life of the drug, which complicates therapeutic 
drug monitoring confirmation of patient compliance with the proper regimen.  Due to 
these technical issues, it is likely that artemisinin resistance could emerge and spread 
94 
 
rapidly before its occurrence is detected. Identification and development of molecular 
markers, or other methods of identifying and tracking artemisinin resistant parasites, is 
critically important.  Recent reports of artemisinin resistance have emerged recently 
320-
322
, but it remains to be seen if this will become a widespread phenomenon. 
As discussed above, there is a paucity of data on possible mechanism(s) of 
artemisinin resistance in P. falciparum, therefore our lab initially chose to characterize in 
vitro selected artemisinin resistant parasites for global gene expression and analysis of 
candidate resistance genes.  Microarrays were conducted with early trophozoites of W2 
vs. W2.AL80 and W2.QHS40, where transcriptional differences were measured after 
treatment with DHA (unpublished data).  Three-way ANOVA identified sets of genes 
that were differentially expressed in the parent and resistant progeny or in response to 
drug treatment.  Overall, the most pronounced expression changes were observed for 
pfmdr1 (PFE1150w), where there was a 4-fold increase in expression for W2.AL80 and 
~2 fold increase in W2.QHS40 when compared to W2.  A subset of putative ABC 
transporters was under-expressed in the W2-resistant progeny (ex. pfmdr2).  Genome-
wide screening of genes associated with drug resistant found 215 probesets whose values 
of genotype effects were significant at P<0.01 level, and 40 probesets were significant at 
P<0.001 level.  Of these non-transporter genes, PFE1050w (S-adenosyl homocysteine 
hydrolase, up-regulated) was the most significant.  Targeted analysis of transporter genes 
found that six were significant at P<0.05 level.  Among 42 transporter genes, the most 
significant gene to be differentially expressed was PF11_0466 (down-regulated).  We 
wondered if SNPs may occur within one or more of the 11 independent probe sets for a 
particular gene that may contribute to a reduced signal due to reduced binding affinity.  
95 
 
These results led us to hypothesize that differential expression of a subset of genes may 
be associated with increased AL and QHS resistance.   
More recent studies from our lab focused on three genes that have tentative 
associations with the site of action or reduced susceptibility to this class of drugs (pftctp, 
pfatp6, pfmdr1).  Gene copy number, genotype, and expression of tctp, pfatp6, and 
pfmdr1 were analyzed in parent/resistant progeny that survive pressure up to 80 ng/ml 
AL (W2.AL80, D6.AL80, TM91c235.AL80), 200 ng/ml AL (W2.AL200) or up to 200 
ng/ml QHS (W2.QHS200) 
276
.  No differences in copy number, sequence, and 
transcription profile between the parent lines and the resistant lines were observed for 
tctp or pfatp6.  Only one copy of tctp and pfatp6 was found in all lines tested and the 
complete sequence of these genes confirmed they were similar to wild type.  In addition, 
there was no difference in stage specific expression of tctp or pfatp6 in resistant or parent 
lines in the absence of drug pressure.  Therefore, these data suggested that tctp or pfatp6 
are not associated with AL or QHS resistance in P. falciparum.  Although these genes are 
not implicated in artemisinin resistance, there was an observed increase in pfmdr1 copy 
number in W2 from a single copy in the parent clone to 3 copies in the W2.AL80 line.  
The copy number was stable at three copies even up to 200 ng/ml AL in W2.  Once the 
W2.AL80 parasite was switched to pressure with a different artemisinin drug, QHS at 20 
and then 40 ng/ml, the pfmdr1 copy number dropped to two.  The copy number remained 
stable at two, as this parasite was adapted up to 200 ng/ml QHS.  In addition, expression 
of pfmdr1 was increased ~ 2-fold in the resistant progeny; these data are consistent with 
gene copy number increase. Consistent with pfmdr1 amplification in the W2 AL resistant 
progeny was a concomitant increase in resistance to MQ and other artemisinin drugs, but 
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not to CQ. These data are consistent with other reports showing that pfmdr1 amplification 
is linked to MQ resistance and that MQ-resistant parasites exhibit a degree of cross-
resistance to artemisinin drugs (above).  TM91c235 also had increase pfmdr1 copy 
number (2 copies at 10ng/ml AL, up to 3 copies at 80 ng/ml AL).  Again, this 
corresponded to resistance to AL, QHS, MQ, and susceptibility to CQ.  Conversely, the 
same studies carried out for a parasite with a different genetic background (D6) and its 
AL resistant progeny found no amplification of pfmdr1 or significant changes in 
expression of pfmdr1 between the parent clone and the AL resistant line. The D6 lines at 
all drug pressure levels only had one copy of pfmdr1. These data suggest that pfmdr1 
amplification can be associated with stable resistance to AL and QHS in vitro, but clearly 
pfmdr1 amplification is not the only mechanism involved in conferring artemisinin 
resistance. The interesting de-amplification of pfmdr1 in W2 following a switch in 
pressure from AL to QHS may indicate drug-specific mechanism(s) the parasite can 
adopt to become resistant to different artemisinin derivatives.   
Further studies on pfmdr1 from our lab have focused on examining the stability 
and fitness of parasites having multiple copies of pfmdr1.  The importance of these 
factors on the artemisinin resistance phenotype in W2.AL80 (and clones originating from 
W2AL80) was examined by Chen et al. (2010) 
337
.  A rapid reduction in pfmdr1 copy 
number was observed in the non-cloned W2.AL80 line (63% of this population reverted 
to less than three copies of pfmdr1) when grown without drug pressure.  Deamplification 
of the pfmdr1 amplicon was then determined in three clones, each initially containing 
three copies of pfmdr1.  Interestingly, two outcomes were observed during three months 
without drug pressure.  In one clone, parasites rapidly emerged with fewer than 3 copies 
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of the pfmdr1.  In 2 other clones, the reversion was significantly delayed. In all sub-
clones the reduction in pfmdr1 CN involved the de-amplification of the entire amplicon 
(19 genes). Importantly, deamplification of the pfmdr1 amplicon resulted in partial 
reversal of resistance to AL and  increased susceptibility to MQ  These results 
demonstrate that multiple copies of the pfmdr1-containing amplicon in AL resistant 
parasites are unstable when drug pressure is withdrawn, having practical implications for 
the maintenance and spread of parasites resistant to artemisinin derivatives. 
Dormancy, recrudescence, and artemisinin resistance.  The preliminary data 
from our lab suggested that artemisinin drugs induce dormancy in ring stage parasites and 
that the effect is unique to this class of antimalarial drugs.  Furthermore, it was 
determined that there are stage specific effects of the artemisinin drugs and hypothesize 
that the artemisinin-induced dormant rings are the form likely to survive to initiate 
recrudescence in vivo.  Parasites with different genetic backgrounds respond similarly, 
which suggests that drug induced dormancy of rings is a universal phenomenon and that 
it is not linked to any prior exposure or conventional mechanism of resistance to the 
drugs. 
The selection of resistance to AL and QHS in vitro allows a detailed study of 
possible mechanism(s) of artemisinin resistance in P. falciparum and its association with 
artemisinin-induced dormancy.  These studies will define the relationship between 
resistance and changes in the recovery rates or duration of dormancy.  In addition, these 
mechanism(s) can be examined directly with other possible mechanism(s) of resistance, 
such as amplification of pfmdr1, mutations or amplification of other transporters (as with 
CQ and QN resistance 
201
).  Clearly, more studies are required to identify the 
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mechanism(s) by which resistance to artemisinin emerges and to find molecular markers 
that can be used for epidemiological studies to track the possible emergence of 
artemisinin resistance. 
Based on observations of dormancy and in vitro selection of artemisinin 
resistance, it may be possible to implicate dormancy as an artemisinin-resistance 
mechanism.  We believe that multiple rounds of exposure to artemisinin drugs and 
recovery from dormancy select for parasites with reduced susceptibility to artemisinin 
drugs.  It is possible that induction and selection of artemisinin resistant parasites could 
enhance recrudescence rates (i.e., treatment failure) and explain a resistance mechanism 
where an increased the proportion of parasites recover from dormancy following the 
removal of drug pressure, by decreasing the duration of dormancy, or both.  It is also 
possible that this mechanism of dormancy and re-emergence is responsible for extended 
parasite clearance times in patients where artemisinin resistance is reported to occur.  
Focus of Study 
In the present study, higher levels of artemisinin resistance in P. falciparum 
strains was induced in order to further dissect artemisinin-induced dormancy and 
mechanisms of artemisinin resistance.  Because it was previously determined that various 
strains of P. falciparum enter dormancy and recrudesce after artemisinin treatment, we 
hypothesized that parasites could be treated with higher amounts of drug over a shorter 
period.  This process was continued in a stepwise manner in order to increase artemisinin 
tolerance.  However, during the induction of resistance procedure above, different 
parasites were not characterized in terms of dormancy rates, rates of recovery, growth 
rates, etc.  Also, in regard to these methods of characterization, comparisons of parent vs. 
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resistant parasites were not conducted.  Strains W2 and TM91c235 (from Asia) have an 
associated increase of pfmdr1 copy number with reduced susceptibility to artemisinin 
drugs.  However, D6 lines do not have amplification of pfmdr1, yet are still able to enter 
dormancy and survive drug pressure.  Since artemisinin resistance is most likely 
multifactorial, we were interested in defining a phenotype for artemisinin resistance 
based on different characteristics of resistant vs. parental strains.  Furthermore, we 
expanded on our previous molecular methods in order to identify potential new 
mechanisms and markers of artemisinin resistance.  We have generated a large amount of 
data that can be used for future research on determinants of artemisinin resistance.  
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Figure 1.1.  Malaria Life Cycle 
11
.  The malaria parasite life cycle involves an 
intermediate host (man, where asexual stages of parasites develop) and a definitive host 
(mosquito, where sexual stages of parasites develop).  During a blood meal, a malaria-
infected female Anopheles mosquito inoculates sporozoites (infective stage [i]) into the 
human host (1).  Sporozoites infect liver cells (2) and mature into schizonts (3), which 
rupture and release merozoites (4) (in P. vivax and P. ovale, a dormant stage [hypnozoites] 
can persist in the liver and cause relapses by invading the bloodstream weeks, or even 
years later).  After this initial replication in the liver (exo-erythrocytic schizogony, [A]), 
the parasites undergo asexual multiplication in the erythrocytes (erythrocytic schizogony, 
[B]).  Merozoites invade RBCs to initiate the erythrocytic cycle (5).  Merozoites develop 
into ring stage trophozoites and mature into trophozoites and segmenting schizonts, 
which rupture releasing merozoites (6).  Some invading merozoites differentiate into 
sexual erythrocytic stages (gametocytes), which are the diagnostic stage (7).  These blood 
stage parasites represent diagnostic stages (d).  In P. falciparum, only rings and 
characteristic crescent-shaped gametocytes are found in peripheral blood (see text), 
whereas all forms can be found in other species.  The blood forms of Plasmodium spp. 
are responsible for the clinical manifestations of the disease. The gametocytes, male 
(microgametocytes) and female (macrogametocytes), are ingested by an Anopheles 
female mosquito during a blood meal (8).  The parasites‟ multiplication in the mosquito 
is known as the sporogonic cycle (C).  While in the mosquito's stomach, the 
microgametes penetrate the macrogametes generating zygotes (9).  The zygotes, in turn, 
become motile and elongated (ookinetes [10]) which invade the midgut wall of the 
mosquito where they develop into oocysts (11).  The oocysts grow, rupture, and release 
sporozoites (12), which make their way to the mosquito's salivary glands.  Inoculation of 
the sporozoites into a new human host perpetuates the malaria life cycle. 
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Figure 1.2.  Current Global Malaria Situation as of 2009 
371
.  The map shows countries 
where malaria transmission occurs (dark green) and where there is a limited risk of 
transmission (light green).  Areas where transmission does not occur are not colored. 
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Figure 1.3.  Countries in Phases of Malaria Control, Pre-elimination, Elimination, and 
Prevention of Re-introduction 
53
.  The map shows the global malaria situation as of 2008, 
showing countries currently in different phases of elimination and control.  White 
indicates countries certified malaria-free and/or no ongoing transmission over a decade; 
gray indicates countries in stages of prevention of re-introduction; light blue indicates 
countries in phase of elimination; sky-blue indicates countries in phases of pre-
elimination, dark blue indicates countries in control phase. 
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Figure 1.4. Global Map of Antimalarial Drug Resistance as of 2005. 
372
.  The map shows 
areas where malaria transmission occurs (dark gray/light gray=high/low transmission), as 
well as P. falciparum chloroquine (CQ) resistance (triangles), sulfadoxine-pyrimethamine 
(SP) resistance (circles), and mefloquine (MQ) resistance (stars).  Areas of P. vivax CQ-
resistance are also showed (rectangles).  Malaria free areas are not colored. 
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Figure 1.5.  Origin and Spread of Global P. falciparum Chloroquine Resistance 
373
.  
Pockets of resistance were first noted within years of each other on Thailand/Cambodia 
border and in Columbia, South America in the late 1950s.  Resistance spread from 
Southeast Asia to Africa, where CQ resistance was first noted in 1978.  Since then, CQ-
resistance has spread through virtually the whole African continent.  Resistance spread 
from foci in South America through much of the continent, as well (see text).  The color 
scheme (decreasing in shade intensity from magenta to light pink) indicates progression 
of spread of CQ resistance from foci to other locations. 
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Figure 1.6.  Synchronous P. falciparum Ring Stage Parasites Exposed to Artesunate, but 
not Quinine, are Arrested at Ring Stage.  Parasites were treated with 1 and 10 ng/ml of 
AS and 1 and 10 μg/ml QN for 6 hours.  Development of the parasites at 0, 4, 24, 28, and 
44 hr was followed by using flow cytometry.  The top panel represents the flow 
cytometric data for ring stage SHAM controls and parasites exposed to AS (left, 1 or 10 
ng/ml) or QN (right, 1 or 10 μg/ml) 28 hours after the beginning of a 6 hr exposure to 
drug. In the lower panel, the same groups are shown at 44 hr.  Graphs are 3-dimensional 
plots of P. falciparum infected erythrocytes stained with propidium iodide in which the 
Y-axis represents cell number, the X-axis is the DNA content (or distribution), and the Z-
axis represents the side scatter.  AS arrested the development of ring stage parasites (8-12 
hours post-invasion), whereas QN did not (parasites continued to develop to trophozoites).  
Parasites continued to mature to early schizonts in the control and QN groups. In contrast, 
the development of parasites was completely arrested in the presence of 10 ng/ml 
artesunate and very few parasites developed in the 1 ng/ml group. By 44 hr the control 
parasites had completely developed through schizogony and had initiated a new cycle. In 
contrast, the artesunate treated parasites still had not developed past the ring stage nor 
had they synthesized DNA.  
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Figure 1.7.  Treatment of Synchronized Ring Cultures of P. falciparum With 
Dihydroartemisinin Produced Dormant Parasites That Recrudesced In Vitro.  This figure 
shows the duration of antimalarial activity following a 24 hour exposure of young rings 
to Dihydroartemisinin (here, abbreviated DAR).  Treatment with 0.2 ng/ml DAR 
appeared to have no effect on parasite growth, but exposure to 2.0 and 20.0 ng/ml 
induced a period of non-growth, or dormancy.  After 72 hours, parasites exposed to 2.0 
ng/ml DAR began to recrudesce and surpassed the starting parasitemia by 96 hours.  
Treatment with 20.0 ng/ml produced a steady reduction of parasitemia up to 120 hours, 
when parasites began to recrudesce.  Parasites grew well beyond the starting parasitemia 
at 192 hours post-drug.  Microscopic examination of blood smears revealed that the 
development of parasites was arrested at ring stage during the period of non-growth. 
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Figure 1.8.  Localization of Early Transcribed Membrane Protein-2 and Green 
Fluorescent Protein in Dihydroartemisinin-Treated Ring Stage P. falciparum Parasites.  
Images A-C show Early Transcribed Membrane Protein-2 (ETRAMP2) (red) is localized 
around the periphery of the nuclei (blue) of dormant ring stages (S99 following a 12 hour 
exposure to 10 nM dihydroartemisinin [DHA]).  In contrast, ETRAMP2 staining was less 
uniform and some parasite nuclei had little to no ETRAMP2 staining evident (*) 96 hours 
after exposure to 400 nM DHA (D).  Panel E shows a parasite expressing Green 
Fluorescent Protein (GFP) (green) associated with the nucleus (orange) at 72 hours post-
exposure to DHA. 
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Figure 1.9.  Different Fates of Artemisinin-Treated Stages of P. falciparum.  We have 
shown that ring stage parasites can enter dormancy and recrudesce in vitro (this may lead 
to recrudescence in patients).  Trophozoites are most likely killed by artemisinins.  
Schizonts may be unaffected and  merozoites may enter dormancy or resist effects of 
artemisinins, thereby allowing re-invasion of RBCs, and later recrudescence.   
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Figure 1.10.  Induction of Resistance to Artelinic Acid and Artemisinin in P. falciparum.  
Two clones (W2 and D6) were included from the beginning of the study, whereas a 
chloroquine (CQ) and mefloquine (MQ)-resistant isolate from Thailand (TM91c235) was 
introduced at the 10 ng/ml artelinic acid (AL) level (left arrow). Parasites that were 
adapted to grow in 80 ng/ml of AL (W2.AL80) were then transferred to pressure with a 
different artemisinin derivative to examine the degree of cross-resistance induced.  The 
dashed line shows the point at which drug pressure was switched from 80 ng/ml AL to 20 
ng/ml QHS (right arrow). 
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Chapter Two: 
Induction of High Level Artemisinin Resistance and 
Phenotypic Characterization (Specific Aim 1) 
Rationale for Study 
There is a short history of induction of resistance to artemisinin in apicomplexan 
parasites that has included in vivo and in vitro selection methods mechanisms of 
resistance.  However, these attempts to select stable resistance with increasing drug 
pressure have led to various results, and only a few studies have reported on stable 
artemisinin resistance induced in vitro for P. falciparum.  Our laboratory has succeeded 
in producing strains of P. falciparum that are stably resistant to levels of artemisinin 
drugs that may be found in patients undergoing artemisinin treatment for malaria.  Our 
group reported detailed selection of P. falciparum resistance to artelinic acid (AL) and 
artemisinin (QHS) in vitro, changes in antimalarial drug susceptibility, and molecular 
changes occurring during the selection (Chapter One).  Three families of parasites were 
used and the highest levels reached were W2.QHS200 (also W2.AL80), TM91.AL80, 
D6.QHS80 (also D6.AL80) 
276
.  The induction of resistance methods described by 
Oduola et al., (1988) 
369
 and Chavchich et al. (2010) 
276
 were cumbersome and lengthy, 
so we hypothesized that it would be possible to use a selection procedure that induced a 
higher degree of artemisinin resistance more rapidly.  These parasites would be pressured 
in a stepwise manner as before, but by using shorter pulses of drug exposure and larger 
increments of drug at each treatment.  Parasites would enter dormancy, recrudesce, and 
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tolerate successive, increasing doses of QHS or AL in the procedure.  We took parasites 
that already tolerated 80 ng/ml of artemisinin (D6.QHS80 and TM91c235.AL80) and 
attempted to adapt these parasites to increasingly higher levels of the respective drug they 
were already resistant to.  The most resistant W2 parasite on hand was W2.QHS200, but 
we did not adapt this parasite to higher levels of resistance.  Here, we report the induction 
of a higher degree of QHS resistance in D6 and AL resistance in TM91c235.  Parasites 
were generated that tolerated concentrations of QHS that are beyond levels found in the 
plasma of patients undergoing treatment for malaria.  We hypothesized that by using a 
variety of characterization methods, we could definitively show a difference in the 
phenotypes of parental and artemisinin resistant lines. During the induction of resistance 
procedure, we designed assays to quantitatively define differences between recovery rates 
after drug exposure between resistant vs. parental strains.  These drug recovery assays 
also included analyses of the number of dormant parasites present in each strain.  We 
characterized resistant parasites in relation to parental strains by employing SYBR Green 
antimalarial drug susceptibility testing for different artemisinin drugs and a few other 
commonly used antimalarial drugs.  While conducting these assays, we designed a novel 
hypoxanthine incorporation assay to further determine viability of resistant vs. parental 
parasites in a short window of time.  This assay greatly helped to separate effects of drugs 
on parent vs. resistant strains.  Finally, we were also were interested in determining 
growth rates of parent vs. resistant lines and concomitant merozoite development in order 
to see the stepwise procedure of artemisinin resistance impaired the resistant parasites in 
any way.  Through these methods of characterization, we defined an artemisinin resistant 
phenotype which will be useful for future resistance studies.   
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The first attempts at molecular characterization of artemisinin resistance from our 
group focused on transcriptional analysis of low level AL and QHS selected W2 strain 
(W2.AL80, W2.QHS40) (see Chapter One).  From these results, it was thought that 
differential expression of a subset of genes may be associated with increased AL and 
QHS resistance.  We hypothesized that gene expression changes between resistant W2 
parasites vs. W2 were an effect of actual transcriptional changes in parasites due to 
artemisinin treatment.  Alternatively, we hypothesized that SNPs in genes may also have 
caused a change in oligo binding affinity, thereby leading to the appearance of 
differential regulation.  Although the microarrays were performed with lower-level QHS-
resistant W2 parasites, we aimed to test our hypotheses in the most resistant W2 parasite 
on hand (W2.QHS200) in relation to the parental W2 parasite.  We planned to sequence 
pfmdr1, pfmdr2, and several of the most significant differentially expressed transporters 
and non-transporters most from the microarrays (including PFE1050w and PF11_0466) 
in order to determine if SNPs were involved in the array results.  In tandem, we 
conducted real-time PCR assays to examine copy number of these genes in parent and 
resistant parasites to find any links between resistance and gene amplification.  Our 
laboratory previously found that in W2 and TM91c235 resistant lines, exposure to 
increasing doses of AL or QHS resulted in the proportionate increase in the pfmdr1 copy 
number as well as in its mRNA and protein expression 
276
.  Therefore, we planned copy 
number analyses for pfmdr1 to investigate if amplification changes might change from 
what was previously found.  We also planned on examining early artemisinin resistant 
parasites and well as intermediate pressure levels to identify where amplification in genes 
or SNPs may have occurred. 
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Materials and Methods 
Parasites and in vitro culture.  Asexual stages of P. falciparum were maintained 
in culture by using previously described methods 
4
.  Parasites were cultured in complete 
media which consisted of RPMI 1640 medium (Invitrogen, Carlsbad, CA.) supplemented 
with 10% heat-inactivated A+ human plasma in anticoagulant/preservative Citrate 
Phosphate Dextrose Adenine (CPDA-1) (Interstate Blood Bank, Memphis, TN), a final 
concentration of 25 mM HEPES (Invitrogen), and 0.24% v/v sodium bicarbonate 
(Invitrogen).  Routine cultures were maintained in a total volume of 5-60 ml in 25 cm
2
, 
75 cm
2
, or 150 cm
2 
sealed culture flasks.  An inoculum of stock culture of each parasite 
was cultured in a 4% suspension of type A+ human erythrocytes in CPDA-1 (Interstate 
Blood Bank) (hematocrit changed for drug and hypoxanthine assays, below) at 1-15% 
parasitemia.  Cultures were synchronized using 5% (w/v) D-sorbitol (Sigma-Aldrich 
Corp. St. Louis, MO.), following the method of Lambros and Vanderberg (1979) 
374
.  
Synchronization of cultures was repeated 1-2 times before parasites were used for an 
experiment.  Media was changed every 48 hours or daily, depending on parasitemia.  
Cultures were incubated at 37°C under a gas mixture of 5% O2, 5%CO2, and 90% N2.  
For molecular analyses, pelleted cultures were saved for later genomic DNA extraction.   
Development of resistant parasite lines in vitro.  P. falciparum laboratory 
clones W2 (Indochina), D6 (Sierra Leone) and a laboratory adapted field isolate 
TM91c235 (Thailand) were previously selected for resistance to QHS or AL 
276
 (see 
Chapter One) using a method developed by Oduola et al. (1988) 
369
.  Discontinuous 
exposure to AL produced W2, D6, and TM91c235 parasites that tolerated 80 ng/ml [191 
nM] (W2.AL80, D6.AL80, TM91c235.AL80).  W2.AL80 was subsequently cloned by 
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limiting dilution and one clone was subjected to increasing pressure with QHS up to a 
concentration of 200 ng/ml (709 nM).  W2.AL80 was also pressured up to 200 ng/ml AL 
(478 nM).  D6.AL80 was subjected to QHS treatment up to 80 ng/ml (D6.QHS80) 
(Gerena and Kyle, unpublished data).   
In this work, the above method was modified to produce parasites resistant to 
higher levels of QHS and AL.  D6.QHS80 and TM91c235.AL80 were used as starter 
parasites.  Asynchronous cultures grown at 1.4-3.9% parasitemia were exposed to 
particular drug levels as follows.  D6.QHS80 was first exposed to 80 ng/ml QHS, and 
then it was treated at increasing levels, each at 20 (70.8 nM) or 40 ng/ml (142 nM) QHS.  
TM91c235.AL80 did not tolerate 80 ng/ml of AL after thawing from cryopreservation, so 
40 ng/ml AL (95.6 nM) was applied to start.  The level of increasing AL was applied in a 
similar manner as for D6 (20-40 ng/ml increments).  At 48 hours post-drug addition, 
cultures were washed three times with stock RPMI to remove drug.  After parasites 
recrudesced to a point when parasite growth (≥1% parasitemia) and morphology became 
normal, cultures were treated again at the current drug level (e.g. 80 ng/ml, recrudesce, 
treat with 80 ng/ml again).  Cultures were treated 2-4 more rounds at the current drug 
level before being moved up in concentration as described above.  Parasites were not 
cloned at each level of resistance during the stepwise procedure.  The last level of QHS 
treatment using this method with D6 was 340 ng/ml and the last level of AL treatment for 
TM91c235 was 280 ng/ml (669 nM).  W2 resistant to 200 ng/ml QHS (W2.QHS200) was 
treated with 200 ng/ml QHS once (similar manner) to maintain this resistance level.  
After this parasite grew back to >3% parasitemia, it was cloned by limiting dilution.  
These clones were then subjected to an additional round of 200 ng/ml QHS.  One of these 
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clones was picked for further analyses (C5), referred as W2.QHS200x2 in this work.  
During this time, standard laboratory D6 and W2 parental lines were re-cloned and one 
clone of each was chosen for further analyses (D6 clone C11, W2 clone D7).  A clone of 
TM91c235 (#23) (referred as TM91c235 in this work) (Gerena and Kyle, unpublished 
data) was used as the parental strain in all experiments that involved comparisons with 
TM91c235 parasites resistant to AL.  Parasites were cryopreserved at each level of 
resistance during the stepwise procedure (D6, TM91c235) and parasite pellets were saved 
for later genomic DNA extraction. 
Quantitative recrudescence assays. 
W2 recovery assay.  W2 (clone D7) and W2.QHS200x2 were synchronized to 
ring-stage and split to 2% parasitemia in 5 ml volumes in 25 cm
2
 flasks.  DHA (1 mg/ml) 
was diluted 1:40 in complete media and added to each flask at a final concentration of 
200 ng/ml (703 nM).  DMSO was diluted 1:40 in complete media and a volume equal to 
the 200 ng/ml drug amount was added to control flasks.  At 6 hours post-drug addition, 
parasites were washed three times with stock RPMI, resuspended in the original volume 
of media, and transferred to new flasks.  Thick and thin smears were made before drug 
treatment and at every 24 hours after DHA was added.  Culture media was changed every 
day and parasite cultures were monitored until parasitemia of morphologically normal 
parasites exceeded 2.5% (about 170 hours post-drug).  For each time point, parasitemia 
was determined by counting over 650 erythrocytes from at least four fields in each thin 
smear.  Parasites from thin smears were sorted into classifications of dead, dormant, ring, 
trophozoite, or schizont.  At each time point, parasitemia was calculated as the number of 
total parasites counted/total number of erythrocytes counted.  Recrudescence was 
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expressed as the percentage of morphologically normal/total parasites and the percentage 
of dormant/total parasites.  Photomicrographs of W2 (clone D7) and W2.QHS200x2 were 
taken from thick smears at 0, 24, 48, 72, 96, and 120 hours post-exposure to drug. 
Initial D6 recovery assay.  D6 and D6.QHS340x2 (treated twice at 340 ng/ml 
QHS) were synchronized and split to 2% parasitemia in 5 ml volumes in 6-well microtiter 
plates.  QHS (1 mg/ml) was diluted 1:40 in complete media and added to final 
concentrations of 28.2 ng/ml (100 nM), 80 ng/ml (283 nM), 120 ng/ml (425 nM), 160 
ng/ml (567 nM), 200 ng/ml (709 nM), 240 ng/ml (850 nM), 280 ng/ml (992 nM), 300 
ng/ml (1.06 μM), 340 ng/ml (1.20 μM).  For D6, the concentration of QHS ranged from 
28.2-300 ng/ml, but 80.0-340 ng/ml was used for D6.QHS340x2 because prior 
experiments showed the parasite is not affected by 28.2 ng/ml QHS (data not shown).  
DMSO was diluted 1:40 and an equivalent volume as the highest drug dilution was added 
to parasites for a control well.  In this experiment, QHS was applied for 48 hours, similar 
to induction of resistance described above.  At 48 hours post-drug addition, cultures were 
transferred to conical tubes and centrifuged.  Parasites were washed three times with 
stock RPMI, resuspended in the original culture volume, and transferred to new 6-well 
plates.  Thick and thin smears were made before drug treatment and at every 24 hours 
after.  Culture media was changed every day.  Parasites were followed to a point beyond 
when normal growth and morphology had returned (over 300 hours post-drug).  In this 
experiment, recovery was monitored by inspecting thick smears.  Because dormant and 
dead parasites could not be separated in thick smears, they were scored together on each 
smear.  Parasites were counted from thick smears and classified as dead/dormant, ring, 
trophozoite, or schizont.  Most counts were based on 800 or more parasites, but it became 
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difficult to count that many parasites for some time points (at least 400 total parasites 
were counted in this case).  Recrudescence was expressed as a percentage of the number 
of morphologically normal/total parasites counted.  Stocks of D6 that grew out of 300 
ng/ml QHS and stocks of D6.QHS340x2 that grew out of 340 ng/ml QHS (named 
D6.QHS340x3) were cryopreserved.  Culture pellets were saved for these resistant levels 
for later genomic DNA extraction.   
Adapting D6 parasites beyond clinically relevant concentrations.  In a separate 
experiment, we aimed to determine the maximum concentration that both the D6 parent 
and resistant D6.QHS340x3 (produced from the above experiment) could tolerate.  
Concentration ranges were selected that included levels of drug that could typically be 
found in plasma of malaria patients treated with artemisinin drugs (and beyond) 
375
.  D6 
and D6.QHS340x3 were synchronized to rings/early trophozoites and split to 2% 
parasitemia in 1.5 ml volumes in 12-well microtiter plates.  QHS (1 mg/ml) was diluted 
as above and was added for a final concentration of 80 ng/ml, 160 ng/ml, 240 ng/ml, 500 
ng/ml (1.77 μM), 800 ng/ml (2.83 μM), 1000 ng/ml (3.54 μM), 1500 ng/ml (5.31 μM), 
2000 ng/ml (7.08 μM), and 2400 ng/ml (8.50 μM).  DMSO was diluted 1:40 and an 
equivalent volume as for the 2400 ng/ml drug addition was added to a control well 
parasite suspension.  After the drug was applied for 48 hours, cultures were transferred to 
conical tubes and centrifuged.  Parasites were washed as before and transferred to new 
12-well plates.  Thick and thin smears were made before drug treatment and at every 22-
24 (one gap of 43 hours) hours after.  Culture media was changed every day.  Parasites 
were followed to a point beyond when normal growth and morphology had returned 
(over 300 hours post-drug).The number of parasites present was calculated from thick 
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smears as described above.  D6.QHS2400 was treated three more times after this 
experiment to maintain the resistance level, and then D6.QHS2400x4 was cloned by 
limiting dilution.  One of these clones (D6.QHS2400x4 clone C9) was treated with 2400 
ng/ml QHS once more, referred to as D6.QHS2400x5 in this work.  Stocks of D6 that 
grew out of 300, 500, 800, 1000, and 1500 ng/ml QHS were cryopreserved.  Stocks of 
D6.QHS340x3 that grew out of 340, 500, 800, 1000, 1500, 2000, and 2400 ng/ml QHS 
were cryopreserved.  Culture pellets were saved for each resistant level and individual 
clones for later genomic DNA extraction.  Photomicrographs of D6 and D6.QHS340x3 
exposed to 1500 ng/ml were taken from thick smears at 0, 22, 48, 235, 264, and 360 
hours post-exposure to drug. 
Growth assay.  Parental and resistant parasites were synchronized to ring stage 
and split to 0.1% parasitemia in 5 ml volumes in 25 cm
2
 flasks.  These assays utilized D6 
(clone C11), D6.QHS2400x5, W2 (clone D7), W2.QHS200x2, TM91c235 and 
TM91.AL280x2.  Thick and thin smears were made twice a day and both parasitemia and 
percentage of stages were calculated every day for at least 97 hours.  Media was changed 
daily on each culture.  Photomicrographs reflecting the most representative stages were 
taken at each time point, and the number of merozoites in segmenting schizonts was 
counted.  Sixty segmenting schizonts (where individual merozoites could be 
distinguished) were counted in blood smears for each strain over the complete time 
course.  The mean, median, mode, and standard deviation for number of merozoites in 
segmenting schizonts was calculated, and an unpaired two-tailed student‟s t-test 
(Microsoft Excel, Microsoft, Redmond, WA.) was used for testing of statistical 
significance (α=0.05) 
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In vitro drug susceptibility testing. 
Antimalarial drugs.  A collection of antimalarial drugs (n=11) was used to test 
the susceptibility of P. falciparum strains in a 1:2 dilution scheme.  The collection 
included DHA, QHS, artesunate (AS), artemether (AM), artelinic acid (AL), chloroquine 
(CQ), MQ, and atovaquone (ATOV), Lumefantrine (LUM), Halofantrine (HAL), and 
Piperaquine (PIP).  The types of drugs tested per strain varied and the entire collection 
was not tested for certain strains.  More than one assay was performed for each parasite.  
Drugs were either dissolved in DMSO or 70% ethanol (CQ only), and stock solutions 
were made at concentrations of 1 mg/ml or 10 mg/ml (CQ only).  Stock concentrations 
were then diluted in complete media to either 625 ng/ml (all Artemisinin drugs [QHS-
2.21 µM, AL-1.50 µM, AM-2.09 µM, AS-1.63 µM, DHA-2.20 µM], ATOV [1.70 µM], 
HAL [1.16 µM]), 2500 ng/ml (MQ [6.03 µM], LF [4.73 µM], PIP [2.50 µM]), or 6250 
ng/ml (CQ, 12.1 µM) as starting concentration for the serial dilution of drugs.  The range 
of concentrations after serial dilution were: artemisinins, ATOV, HAL (625-0.610 ng/ml); 
CQ (6250-6.10 ng/ml); and MQ, LF, PIP (2500-2.4 ng/ml). A Biomek 3000 Laboratory 
Automation Workstation (Beckman Coulter, Brea, CA.) serially diluted drugs 1:2 in 
complete media in a 96 well assay “mother” plate, which could be frozen for later use.  
This plate contained multiple drugs (up to four per plate).  The robot then transferred 15 
µl of each drug dilution in duplicate to a new 96 well plate that contained parasite culture. 
In vitro SYBR green drug susceptibility assay.  The procedure utilized here was 
adopted from Bacon et al. (2007) 
376
.  P. falciparum strains were synchronized (≥70% 
rings) and grown until they reached parasitemias ranging from 4-10%.  The same parent 
and resistant pairs of D6, W2, and TM91c235 as described above were used for the 
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growth assay.  Using the Biomek robot, a parasite suspension was made that consisted of 
a final parasitemia of 0.5% and the hematocrit was adjusted to 1.5%.  A total of 135 μl of 
this suspension was distributed to 96-well drug assay plates in duplicate containing the 
aforementioned drugs using the Biomek robot.  Once the parasites were added to the 
assay plate, drugs were effectively diluted 1:10, giving final concentration ranges of: 
artemisinins, ATOV, HAL (62.5-0.0610 ng/ml), CQ (625-0.610 ng/ml), MQ, LUM, PIP 
(250-0.24 ng/ml).  Negative controls included 25 µg/ml of QHS and DHA (88.6 µM, 
87.9 µM, respectively) and cultures without drug were used as positive controls.  Drug 
susceptibility plates were incubated in a humidified modular incubator chamber (Billups-
Rothenberg, Del Mar, CA.) for 72 hours at 37°C under a mixture of gas (5% O2, 5% CO2, 
90% N) with re-gassing every 24 hours.  After the conclusion of incubations, the drug 
susceptibility assay was stored at -80°C until the SYBR green assay was performed.  
Drug susceptibility plates were thawed at room temperature for a minimum of 30 minutes.  
A total of 100 µl/well of the drug susceptibility plate was transferred by the Biomek robot 
into a new black 96-well plate, followed by the addition of 100 µl of SYBR green 
(Invitrogen) lysis buffer
376
.  The plates were covered and placed in the dark at room 
temperature for 1 hour.  Fluorescence intensity was measured with a Spectra Max-M2 
plate reader.  The mean concentration and standard deviation for inhibition of parasite 
growth by 50% and 90% (IC50 and IC90) was determined for each parasite line.  
IC50/IC90s were estimated based on linear and non-linear regression curves calculated 
by DataAspects Plate Manager software (DataAspects Corporation, Glencoe, CA.).  Data 
was exported and analyzed in Microsoft Excel.  The average IC50/IC90 and standard 
deviation was calculated from replicate values for each strain tested. 
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Ring stage viability in parental and resistant lines. 
In vitro drug testing using a radioisotope microdilution technique.  A procedure 
similar to Webster et al. (1985) 
377
 was employed for testing.  Synchronous ring-stage 
parasites of W2 (clone D7), W2.QHS200x2, D6 (clone C11), and D6.QHS2400x5 were 
treated with various artemisinin drugs to induce dormancy.  Parasite cultures were grown 
as described above, except they were cultured in complete media containing plasma 
without added adenosine (to avoid altered growth kinetics).  Cultures were synchronized 
to 2-8% rings in 25cm
2
 flasks.  After sorbitol treatment, cells were washed three times in 
stock RPMI.  A suspension consisting of 1% parasitemia/2% hematocrit was prepared for 
each parasite prior to testing.  The parent and resistant pair for each P. falciparum line 
was tested on the same 96 well plate (Fig. 2.1) and plates were made for 24 and 48 time 
points (post-drug exposure).  In these assays, DHA, QHS, AL, and CQ were tested with 
each parasite pair.  Drugs were serially diluted in a 1:2 scheme covering 11 
concentrations over a range from 8000 ng/ml- 7.8 ng/ml (DHA [28.1-0.0274 µM]), 1000 
ng/ml-0.98 ng/ml (DHA [3.52-0.00345 µM], QHS [3.54-0.00350 µM ] AL [2.39-0.00234 
µM]), or 6250 ng/ml-6.1 ng/ml (CQ [12.1 µM-0.0118 µM]) in a 96 well “mother” plate.  
A Biomek robot transferred 10μl of each drug to the test plate and the robot transferred 
90 μl parasite suspension to each well, diluting the drug 10-fold.  Each concentration of 
drug was run in triplicate per parasite tested.  An extra row of parasite and drug was 
included without hypoxanthine added for making smears.  Each plate included parasitized 
erythrocytes without drug and non-parasitized erythrocyte controls (NRBCs) (each was in 
duplicate per strain tested).  Immediately after parasites were added to drug,
3
[H] 
Hypoxanthine monohydrochloride (equivalent to 1 µCi/well) (Perkin Elmer, Waltham, 
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MA.) was added to each well of the test plate.  Plates were then incubated in a modular 
chamber at 37°C that contained a mixture of gas as above.  After six hours, thick smears 
were made for each concentration level for both parasite sets.  At 24 hours and 48 hours 
post-drug, thick smears were made from the respective plates, and plates from 24 and 48 
hours post-drug were stored at -80°C until harvesting.  Plates were washed and harvested 
in a FilterMate cell harvester (Perkin Elmer). Next, 50 µl/well of OptiPhase scintillation 
cocktail mix (Perkin Elmer) was added and plates were read in a TopCount NXT 
scintillation counter (Perkin Elmer).  Data (counts per minute [cpm]) from the 
scintillation counter were imported into Microsoft Excel.  For each parasite and time 
point, the average cpm for each drug concentration (triplicate) was calculated.  Data were 
imported into TableCurve 2D (Systat Software, San Jose, CA.) for curve fitting analysis 
and IC50 calculation.  The percent parasite growth was plotted as a function of log drug 
concentration and the logistic dose response was fitted using SigmaPlot (Systat Software). 
DNA sequencing. 
Genomic DNA extraction.  A procedure similar to that of Beck 
378
 was used for 
freeing parasites from erythrocytes.  Cultures were centrifuged at 4,000 rpm for 5 
minutes and the supernatant was aspirated.  The cell pellet was measured, and 5x pellet 
volume of 0.05% saponin was added.  The mixture was placed on ice for 10 minutes, 
centrifuged, and the supernatant was aspirated.  Parasite pellets were washed twice with 
1x PBS.  Genomic DNA was extracted from the parasite pellets using a QiAmp DNA 
Blood Mini Kit (Qiagen, Valencia, CA.).  Purified genomic DNA was quantitated using a 
NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham, MA.). 
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Sequencing for single nucleotide polymorphisms in candidate resistance genes 
identified by preliminary microarrays.  Genomic DNA was isolated as described above 
from W2 and W2.QHS200 for sequencing of pfmdr2, PFE1050w, and PF11_0466.  
Platinum Taq High-Fidelity DNA Polymerase (Invitrogen) was used in all PCR reactions 
described here.  The manufacturer‟s protocol was followed except for changing the 
annealing temperature from 53-57°C, and using an extra extension step of 68°C.  The 
amount of genomic DNA for each reaction ranged from 50-200 ng.  To sequence pfmdr2, 
a 3294 bp segment was amplified that encompassed the 3075 bp coding sequence (CDS) 
using pfmdr2 seqF-4 and pfmdr2 seqR-3 primers (Table 2.1).  This fragment was then 
subjected to PCR using seven different primer pairs (Table 2.1): pfmdr2 seqF-4/pfmdr2 
seqR-4; pfmdr2 Cd F-2/pfmdr2 seqR-5; pfmdr2 seq F5/pfmdr2 seq R-6; pfmdr2 CdF-
4/pfmdr2 seq R-7; pfmdr2 seq F-6/pfmdr2 CdR-5; pfmdr2 CdF-6/pfmdr2 seq R-8; and 
pfmdr2 Cd F-7/pfmdr2 seqR-3.  Primer names containing “Cd” denote primer sequences 
from Rosenberg et al. (2006) 
379
.  PCR using these primer sets yielded overlapping 
fragments ranging from 328-774 bp.  Using the primer sets PFE1050w seq2 F/PFE1050w 
seq2 R-1, the CDS of PFE1050w was amplified (1440 bp).  The primers PF11_0466seq 
F/PF11_0466 seq2 R-1 (Table 2.1), were designed to amplify polymorphic regions of 
PF11_0466 that encompassed 2075 of the 2772 bp genomic sequence.  Gene sequences 
from individual forward and reverse reactions were assembled into contigs and aligned 
using Vector NTI Advance 11.0 (Invitrogen).  Multiple sequence alignments were 
completed using an online version of ClustalW (located at http://align.genome.jp/).  
Single nucleotide polymorphisms (SNPs) were detected by viewing sequence alignments 
and verifying with sequence chromatograms. 
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Real-time quantitative polymerase chain reaction. 
Optimization of oligonucleotide sets for real-time quantitative polymerase chain 
reaction.  Sets of primers for pfmdr1 (PFE1150w), S-adenosyl-L-homocysteine 
hydrolase (PFE1050w), and the putative transporter PF11_0466 were tested against 3D7 
or D6 genomic DNA (isolated as described above) to determine optimal annealing 
temperature and concentration for use in real-time quantitative polymerase chain reaction 
(real time QPCR) assays.  All primer sequences are listed in Table 2.1. To determine 
optimal annealing temperature, 10-100 ng of genomic DNA was used as template for 
standard PCR using a temperature gradient ranging from 50-65°C in a Biorad Mycycler 
thermal cycler (Hercules, CA.).  All primer sets were found to amplify equally well from 
55-65°C.  It was empirically found that ldh and pfmdr1 primers performed the best at 
57°C (Peters, personal communication), so this annealing temperature was used for all 
real-time PCR assays.  A Stratagene (LaJolla, CA.) MX3000P real-time quantitative PCR 
system was used for all QPCR assays.  Optimal final primer concentration was 
determined by designing primer matrices where the final primer concentration per 
reaction (run in duplicate) ranged from 100-500 nM and genomic DNA template ranged 
from 10-50 ng.  Brilliant I/II QPCR SYBR Green 2x mastermix (Stratagene) and 30 nM 
final concentration ROX was used for all real-time QPCR assays, and all reactions were 
25 µl.  The thermal profile for all reactions was as follows: segment 1 (95°C 10 minutes), 
segment 2 (95°C 30sec, 57°C 1 minute, 72°C [repeat 40 cycles]), and segment 3 
(dissociation curve: 95°C 1 minute, 55°C 30 sec, 95°C 30 sec).  Fluorescent data were 
collected at the end of each annealing step three times and averaged.  The dissociation 
curve was performed after the amplification cycles to verify that the correct products 
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were produced.  Text reports containing threshold cycle (Ct) values were produced in 
Stratagene MXPro software and exported for further analyses in Microsoft Excel.  The 
concentration of primer that caused the lowest Ct value with high fluorescence intensity 
was selected for subsequent assays.  From this procedure, we found that the optimum 
concentration for pfmdr1 and ldh primer pairs was 400 nM F/400 nM R.  The optimum 
concentration of 200 nM F/200 nM was identified for PFE1050w and PF11_0466. 
Determination of gene copy number by real-time QPCR.  The relative copy 
numbers (CN) of pfmdr1, pfmdr2, PFE1050w, and PF11_0466 were determined for D6, 
W2, TM91c235 parental and resistant lines by using ldh as normalizer.  A variety of 
pressure levels were selected from the stepwise selection of D6 and TM91c235 resistant 
parasites, including intermediate pressure levels (D6 [80, 120, 200, 300, 340, 2400x2, 
2400x4, 2400x5 ng/ml QHS]; TM91c235 [80, 240, 280 ng/ml AL, but 80 ng/ml not 
included for chromosome 10 genes]).  For the W2 series, we included W2, W2 (clone 
D7), W2.QHS200, and W2.QHS200x2.  QPCR assays were designed where the Ct value 
was measured in triplicate for each template and primer set.  In some cases, outlier values 
were produced within a triplicate, which were disregarded.  Each primer set included a no 
template control (NTC) reaction so we could assess if primer dimers or other PCR 
technicalities occurred.  Copy number assays were run at least twice for each unknown 
sample.  In a given assay, the CN of a gene of interest was assessed for unknown 
templates against ldh.  A 96 well plate was used for each experiment that included a five-
point standard curve using serial diluted uncloned D6 genomic DNA for the gene of 
interest and for ldh (Fig 2.2).  It was empirically found that serially diluting DNA 
1:3/1:3/1:2/1:2 allowed us to achieve a standard curve where standards were only 
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separated by 1-1.5 cycles.  The amount of standard ranged from 20-0.036 ng of genomic 
DNA (overall, not in a single experiment) in the 5-point standard curve (this varied per 
experiment).For each standard curve dilution, it was necessary to determine the amount 
of genomic DNA for unknown samples to use.   It is imperative to have unknown Ct 
values between the standard Ct values in order to assure the proper concentration of DNA 
was used.  The concentration of genomic DNA that allows unknown Ct values to occur 
between standard was empirically determined.  Either DNA was diluted to an equivalent 
concentration, then diluted 1:100 before use in an assay, or each sample was diluted to 
0.1 ng/µl.  The components of each reaction mixture were the same as for primer 
optimization above, but accounting for changes in diluted primer and water volumes to 
make up a final volume of 25 µl reactions in each reaction.  A master mix for ldh and the 
gene of interest were made separately, then 23 µl was dispensed to wells in a 96 well 
plate.  The 96 well plate was split in half so that different DNA templates could be run 
for ldh and the gene of interest on the same plate (Fig. 2.2).  Two microliters of diluted 
genomic DNA was added to make a final reaction volume of 25 µl.  The thermal profile 
for all reactions was the same as above. 
After a QPCR run was completed, we verified that the gene of interest and ldh 
had Ct values between the respective standards (Fig. 2.3).  A standard curve equation 
method (DNA concentration [log2] vs. Ct) was used to extrapolate copy number of 
unknown samples relative to D6. Each unknown sample had a Ct value for the gene of 
interest and ldh, so that the difference in Ct value (Fig. 2.4) could be calculated.  Data 
from the MX3000P system were exported into Microsoft Excel where the standard curve 
equations were determined to calculate copy number of the gene of interest relative to ldh.  
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Briefly, the average Ct per triplicate vs. log2 concentration D6 DNA for each standard 
(ldh and target gene) was plotted and a slope and y-intercept for target gene and ldh were 
determined from a trend line (Fig 2.5).  The slope and y-intercept from the standard curve 
trend lines were used to convert Ct of the various unknown templates to a relative copy 
number with respect to the D6 standard ([Average Ct ldh-ldh y-intercept)/-(slope ldh)]-
[Average Ct target gene-target gene y-intercept)/-(slope target gene)]).  To calculate 
primer efficiencies, log ng input DNA was plotted vs. average Ct for D6 standards of 
target gene and ldh.  The slope from the fitted line was used in the equation E=10
(-1/slope)
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 to determine efficiency of each primer set.  The average CN and standard deviation 
were calculated from replicate assays for each parasite line and gene of interest and 95% 
confidence intervals for mean CN were constructed (Microsoft Excel).  
Results 
Discontinuous drug pressure generated P. falciparum lines resistant to increased 
levels of artelinic acid and artemisinin in vitro.  Resistance was induced in parasite 
lines by using two different methods.  In the first method, D6 and TM91c235 strains that 
already tolerated 80 ng/ml of QHS and AL, respectively 
276
, were exposed to increasing 
concentrations of drug in a stepwise manner (Figs 2.6, 2.7; Tables 2.2, 2.3).  Each round 
of drug pressure consisted of a 48 hour exposure, then drug was washed out and parasites 
were put back in culture.  Each time QHS or AL was applied to a culture, a majority of 
parasites had a morphology that was distinct from dead parasites beginning at 24 hours 
post drug-addition.  These dormant parasites were equivalent to what has been reported 
previously (Kyle et al., 2010 unpublished; 
362
; Tucker et al., 2010 unpublished).  They 
were significantly smaller than normal parasites and resembled merozoites.  Dormant 
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parasites are small with a regular round outline on a Giemsa stained blood smear and 
differ from the collapsed nuclei of pyknotic bodies in their retention of a small circle of 
blue staining material that is cytoplasm and condensed red chromatin.  These 
characteristics separate dormant parasites from dead parasites which appear smaller and 
globular with no distinct organization of chromatin and cytoplasm, appearing purplish-
pink when stained with Giemsa.  However, it is very difficult in some cases to discern 
dead parasites from dormant ones.  After a few days, morphologically normal parasites 
began to appear in cultures, which corresponded with the reduction of dormant forms.  A 
strain was considered recovered when the percentage of morphologically normal 
parasites was ≥1%.  After a parasite was treated with a specific concentration of drug, it 
tolerated successive doses at the same concentration level.  During the process of the 
stepwise induction of resistance, high-quality photomicrographs were not taken of 
parasites.  However, in the experiments below detailing selection of higher resistance, 
parasites enter dormancy and exhibit the same morphology after drug treatment and 
recrudesce after a period of time.  Therefore, you are referred to those photomicrographs 
that reflect morphological observations of the original induction experiments.  The 
stepwise induction of resistance method produced parasites resistant to higher levels of 
QHS and AL more rapidly than other experiments in our lab.  In less than year using this 
method, D6.QHS80 tolerated 340 ng/ml QHS (x2) (1205.7 nM) and TM91c235.AL80 
tolerated 280 ng/ml AL (669 nM) in approximately a year (Tables 2.2, 2.3).  We found 
that parasites sometimes recrudesced faster after successive treatments at the same drug 
level compared to recrudescence after the primary treatment.  However, this was not 
consistent during the procedure.  The reason for this inconsistency may depend on 
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differences in starting parasitemia or differences in parasite stages in the culture.  
W2.QHS200 was already produced 
276
, but throughout experiments described in this 
paper, it was treated with 200ng/ml QHS to maintain the resistance level.  After applying 
200 ng/ml of QHS for 48 hours, the parasite recrudesced to 4% parasitemia by 7 days 
(data not shown).  This parasite was cloned by limiting dilution and clone C5 was then 
treated with 200 ng/ml of QHS once more.  The parasite grew back to ≥2% parasitemia 
10 days after drug.   
Resistant progeny of D6 and W2 recover faster than parent strains after 
exposure to clinically relevant concentrations of artemisinin.  After parasites were 
adapted to certain levels of artemisinin drugs, we aimed to quantitatively dissect 
differences in recrudescence between parent and resistant pairs of parasites.  Recovery 
rates of W2 (clone D7) and W2.QHS200x2 were determined by exposing parasites to 
DHA for 6 hours and monitoring parasitemia over approximately a week.  Parasitemia 
was monitored for several days after drug exposure (Fig. 2.8-A).  In both W2 (clone D7) 
and W2.QHS200x2, the initial parasitemia decreased below 2% at 24 hours post drug 
exposure, and all parasites observed were classified as dormant or dead.  As noted before, 
there is a distinct morphology for dormant parasites noted by small size and evidence of 
chromatin and cytoplasm (Fig. 2.8-B).  The dormant forms persisted through the end of 
the assay for each parasite, but there was a greater percentage of dormant/total parasites 
in W2.QHS200 vs. W2 (clone D7) up to 72 hours (24 hours, 41.7% vs. 27.3%, 48 hours, 
31.3% vs. 23.1%, 72 hours, 20% vs. 25% ) (Fig. 2.8-C).  The percentage of dormant/total 
parasites in thin smears decreased more precipitously for the resistant parasite compared 
to the parent.  This decrease in dormant forms correlated with the appearance of 
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morphologically normal parasites at 72 hours post-drug for W2.QHS200x2 (6.7% of 
parasites counted) (Fig. 2.8-B, D).  Morphologically normal parasites were observed at 
96 hours for W2 (clone D7) (12.5% of parasites counted) (Figs. 2.8-B, D).  The 
percentage of normal parasites that appeared was initially greater for the resistant parasite 
(from the time normal parasites appeared), but this equilibrated at 144 hours post-drug 
(Fig. 2.8-D).  The assay was terminated at 165.5 hours post drug after parasitemia of 
normal parasites was ≥2.5%/   
The process of discontinuous QHS pressure in D6 produced D6.QHS340x2.  This 
parasite was compared with D6 for differences in recrudescence.  In this assay, both D6 
and D6.QHS340x2 were exposed to a range of QHS that included clinically relevant 
concentrations.  Drug was applied for 48 hours in this assay and parasites were viewed in 
Giemsa-stained thick smears 24-336 hours after drug pressure.  At each drug 
concentration, dormant parasites were observed in D6 and D6.QHS340x2 after 24 hours, 
but some morphologically normal parasites persisted as well.  At 48 hours post-drug, a 
greater number of normal parasites persisted for D6.QHS340x2 vs. D6 at each 
concentration (data not shown), but the majority of parasites observed were dormant or 
dead.  Figure 2.9-A shows a representative comparison of recovery rates (#normal 
parasites/total parasites) for D6 vs. D6.QHS340x2 after exposure to 200 and 300 ng/ml of 
QHS.  At 24 hours, the percentage of morphologically normal parasites was greater for 
D6.QHS340x2 vs. D6 (1.4% vs. 0.49%) after 200 ng/ml QHS.  With 300 ng/ml QHS, 
0.24% normal parasites were observed for D6 vs. 1.1% for D6.QHS340x2.  After 48 
hours with 200 ng/ml QHS, a higher percentage of normal parasites remained in 
D6.QHS340x2 vs. D6 (0.49% vs. 0.12%).  At the 300 ng/ml drug level, only dead or 
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dormant parasites were observed in thick smears.  After this time point with 200 ng/ml, 
we only observed dead or dormant parasites in D6 and D6.QHS340x2 until the 120 hour 
time point.  At 120 hours, morphologically normal parasites (rings, trophozoites) were 
observed for both strains, but a higher percentage of normal parasites were observed for 
D6.QHS340x2 vs. D6 (0.25% vs. 0.13%) (Fig. 2.9-A).  This trend continued up to the 
last point where parasites were followed at 200 ng/ml (312 hours post-drug).  Although 
we observed morphologically normal parasites at later time points for D6, the percentage 
of normal parasites did not reach high levels (only 10.2% normal parasites for D6 at 312 
hours vs. 66.5% for D6.QHS340x2).  With 300 ng/ml, normal parasites (rings, 
trophozoites, schizonts) were observed at 144 hours post-drug for D6.QHS340x2 (0.61% 
of total parasites counted), whereas morphologically normal parasites were not observed 
until 240 hours (rings, trophozoites, schizonts) for D6 (0.86% of total parasites counted).  
At the last point where parasites were followed for 300 ng/ml (336 hours post-drug), 
67.4% of normal parasites were counted for D6.QHS340x3 and 38.3% for D6 (Fig. 2.9-
A).  Therefore, it appeared that D6 recrudesced at a greater rate when compared to 
D6.QHS340x3.  However, a greater number of morphologically normal parasites existed 
at each time point for D6.QHS340x3.   
The assay described above produced D6.QHS340x3 (D6.QHS340x2 exposed to 
340 ng/ml QHS), and this parasite was tested vs. D6 in another recovery assay aimed at 
determining if the resistant parasite could tolerate levels of QHS that surpassed clinically 
relevant concentrations.  In a similar manner as reported above, D6 and D6.QHS340x3 
were treated with QHS for 48 hours.  This assay, also terminated at 360 hours, produced 
D6 that tolerated a range of 80.0-1500 ng/ml QHS and D6.QHS340x3 that tolerated a 
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range of QHS from 80.0-2400 ng/ml (Fig 2.9-B).  A general trend from this assay was 
that normal parasites either appeared in culture for D6.QHS340x3 before D6, or in cases 
where parasites appeared for both D6 and D6.QHS340x3, a greater number of normal 
parasites were observed in D6.QHS340x3.  Figure 2.9-B shows D6 vs. D6.QHS340x3 
exposed to 1500 ng/ml QHS, the maximum amount of drug D6 could tolerate.  Much like 
the first recovery assay, normal parasites persisted up to 48 hours for both D6 and 
D6.QHS340x3 in thick smears (0.48% resistant vs. 0.23% parent), but the vast majority 
of parasites observed were dead or dormant.  Both D6 and D6.QHS340x3 remained dead 
or dormant until 235 hours post drug, when normal parasites (rings, trophozoites, 
schizonts) were observed (0.94% resistant vs. 0.37% parent).  The number of dead and 
dormant parasites in thick smears decreased methodically after 235 hours (Fig. 2.9-B).  
At 235 hours and continuing to the last point where parasites were followed (360 hours 
post-drug), there was a greater percentage of normal parasites for D6.QHS340x3 than D6 
(68.2% D6.QHS340x3 vs. 58.4% D6).  Figure 2.9-C shows the morphological 
appearance of D6 and D6.QHS340x3 after treatment with 1500 ng/ml QHS at 0, 22, 48, 
235, 264, and 360 hours (DMSO at 24, 48 hours).  After 24 hours post-drug, 
morphologically normal parasites were not observed in thin smears for D6, yet some 
were observed for D6.QHS340x3.  By 48 hours post-drug, all parasites observed in thin 
smears were dead or dormant for each strain.  At 235 hours (time when parasites were 
observed in thick smears), normal parasites were observed in thin smears for both strains, 
but they were present in greater numbers for D6.QHS340x3 (Fig. 2.9-B).  Normal 
parasites continued to appear in thin smears for both strains through 360 hours.  At the 
end of this experiment, the most resistant D6 line on hand was D6.QHS2400x1.  This 
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parasite was treated three more times at the 2400 ng/ml level (see Fig. 2.6), and each 
time, parasites recovered to at least 2% parasitemia within 11 days.  The parasite was 
cloned after the fourth treatment of 2400 ng/ml QHS and one clone (D6.QHS2400x4 C9) 
was treated a final time at 2400 ng/ml, yielding D6.QHS2400x5. 
Analysis of growth rates and merozoite number reveals differences between 
parental and resistant parasites.  Data from experiments with D6 lines in our lab 
suggested that earlier drug-selected D6 parasites grew slower than the parent strain (data 
not shown).  Based on these observations, we investigated growth and merozoite number 
in parent and resistant parasites.  In order to determine a difference in growth, pairs of 
parent and the most resistant parasite for each line were synchronized, split to 0.1% 
parasitemia, and allowed to grow for 2-3 cycles.  Over a period of 105.5 hours (post-
sorbitol treatment), parasitemias of D6 (clone C11) and D6.QHS2400x5 were calculated 
twice a day.  At each time point beyond 25 hours post-sorbitol, parasitemia of 
D6.QHS2400x5 was lower than D6 (clone C11) (Fig. 2.10-A).  At 33 hours post-sorbitol, 
parasitemias were D6 (clone C11): 0.5%, D6.QHS2400x5: 0.3%.  This trend continued 
up to the final time point where parasitemias were D6 (clone C11):12.3%, 
D6.QHS2400x5: 10.9%.  Furthermore, the resistant parasite lagged behind in 
development during the erythrocytic life cycle.  Sorbitol treatment left 10-16 hour rings.  
At 51 hours post-sorbitol (equivalent to early-mid part of the 2
nd
 cycle [61-67 hours into 
life cycle]), there was a noticeable difference in the percentage of parasite stages.  For D6 
(clone C11), there were 42.9% rings, 57.1% trophozoites, but 90.9% rings, 9.1% 
trophozoites in D6.QHS2400x5.  The same experiment with W2 (clone D7) and 
W2.QHS200x2 found that W2 initially reached a higher parasitemia (0.9% vs. 0.6% at 44 
136 
 
hours) and this lasted until 92 hours, when the resistant parasite reached higher 
parasitemia (4.1% W2 [clone D7] vs. 5.4% W2.QHS200x2) (Fig. 2.10-B).  We did not 
notice a difference in parasite development during the life cycles for the W2 pair.  For the 
TM91c235 series, a slightly less noticeable difference in growth was observed.  Both the 
parent and resistant parasite had similar growth up to 96 hours post-sorbitol, when the 
parasitemia of TM91c235.AL280x2 spiked compared to TM91c235 (1.6% TM91c235 vs. 
3.1% TM91.AL280x2) (Fig. 2.10-C).  Based on parasite stages, it was not clear why the 
resistant parasite grew faster at this point in the assay.  The parasitemias of both strains 
eventually equilibrated around 119 hours. 
In order to determine if a variation in growth rates between the parent/resistant 
pairs was related to invasion, the number of merozoites in segmenting schizonts for 
parent vs. resistant strains were determined (Figs. 2.10-D).  Sixty segmenting schizonts 
were counted for each parasite, and we determined mean, minimum, and maximum 
number of merozoites per schizont (Fig. 2.10-E; Table A-1, Appendix A).  The mean 
merozoite number for D6 (clone C11) (19.3±2.58) was significantly greater than 
D6.QHS2400x5 (16.3 ±2.24) (P=3.8x10
-10
).  In the W2 series, the mean number of W2 
(clone D7) merozoites per schizont was significantly less (15.3±2.38) than that of 
W2.QHS200x2 (19.7±2.66) (P=1.3x10
-16
).  For the TM91c235 series, the parental strain 
had significantly greater number of schizonts (20.7±2.26) than the resistant parasite 
(19.7±2.16) (P=0.012).  It was not clear why a lesser number of merozoites was 
associated with reduced growth with D6.QHS2400x5 vs. D6 (clone C11), whereas 
significantly more merozoites in W2.QHS200x2 was not associated with an increased 
rate compared to W2 (clone D7).  Also, TM91c235 had significantly more merozoites 
137 
 
than TM91.AL280x2, but only a slight increase in growth compared to the resistant 
parasite.   
Resistant parasites exhibit reduced susceptibility to artemisinins and 
mefloquine, but increased susceptibility to chloroquine.  Standard measures of drug 
resistance in Plasmodium are reported from in vitro susceptibility assays.  Parent and 
resistant pairs of cloned D6, W2, and TM91c235 lines were tested against five 
artemisinin drugs and a group of six standard antimalarial drugs (Tables 2.4, 2.5).  Assays 
were repeated ≥2 times and the average IC50 and IC90 were calculated.  Compared to D6 
(clone C11), D6.QHS2400x5 showed a general decrease in susceptibility to all 
artemisinin drugs (QHS, DHA, AS, AM, AL).  D6.QHS2400x5 had the greatest tolerance 
for AL compared to the parent (IC50 ~9-fold, IC90~2-fold), followed by QHS (IC50 ~8-
fold, IC90 ~5-fold).  For the W2 parasites, there was a similar trend for reduction in 
susceptibility, but W2.QHS200x2 was almost equally susceptible to DHA as W2 (clone 
D7).  W2.QHS200x2 had a greatest tolerance for AL compared to the parent (IC50, IC90 
both ~6-fold), followed by QHS again (IC50, IC90 each ~3-fold).  When 
TM91c235.AL280x2 was compared to its parent, it showed a similar trend in 
susceptibility as W2 (clone D7) vs. W2.QHS200x2 except it displayed a four-fold greater 
IC50 for QHS, the degree of resistance to AM was greater, and the overall IC90 for AL 
was greater.  When comparing the parental lines to each other, the parental lines had 
similar susceptibilities to artemisinin drugs, but TM91c235 exhibited greater resistance 
compared to the other parental lines (especially with AL [IC90]).  Testing of parent vs. 
resistant parasites with CQ found there was only a remarkable reduction in susceptibility 
with TM91c235.AL280x2.  However, the resistant D6 and W2 lines showed a slight 
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increase in susceptibility to CQ compared to respective parent parasites (more evident in 
W2 series).  Resistant lines of D6 and W2 had a moderate decrease in susceptibility to 
MQ compared to respective parental parasites, except W2.QHS200x2 had a more 
dramatic increase in IC90 (over 4-fold).  The IC90 of the TM91c235 lines was greatly 
increased compared to other tested strains, but the IC50 of parent and resistant strains of 
TM91c235 were similar.  For LF, HAL, and PIP, only the W2 lines were tested.  We 
found elevated IC50 of resistant parasites compared to the parent W2 for LF, but the 
IC90s were similar.  W2.QHS200x2 was more susceptible to PIP, but slightly more 
resistant to HAL. For ATOV, all parent and resistant pairs for each line were equally 
susceptible.   
Ring-stage viability assay reveals that resistant parasites withstand greater 
levels of drug compared to parental parasites.  We postulated that potential reasons 
why artemisinin-resistant parasites eventually recrudesce before parental parasites may 
be that resistant parasites form a greater number of dormant forms after treatment with 
artemisinin drugs, or that a greater percentage of resistant parasites are unaffected by 
drug.  Short term in vitro susceptibility assays may not be sufficient to quantify these 
differences because of dormancy and the time of viability assessment.  To quantitatively 
assess these differences more accurately, we measured hypoxanthine incorporation in 
cloned parent and resistant parasites (D6 and W2 pairs) directly after treatment with 
drugs.  Parasites were added to dilutions of artemisinin drugs, hypoxanthine was 
immediately added, and the parasites were harvested at 24 and 48 hours post-drug to 
quantify viability.  The percent parasite growth as a function of log drug concentration 
was plotted and IC50 was determined from dose response curves.  A pilot experiment 
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covering a range of DHA from 800-0.78 ng/ml in the D6 series found the resistant 
parasite had higher percent growth than the parent at 24 and 48 hours (data not shown).  
The parental parasite did not appear to incorporate a significant amount of hypoxanthine 
compared to background levels at 24 and 48 hours.  The resistant parasite tolerated at 
least 6.25 ng/ml DHA at 24 hours, but at 48 hours, the resistant parasite tolerated at least 
12.5 ng/ml DHA.  Previous experiments in our lab showed that at higher levels of 
artemisinin, it is difficult to measure a difference in drug tolerance (IC50 assays) between 
parent and resistant parasites.  We also expected that there a distinct difference between 
parent and resistant parasites at lower levels of artemisinins based on in vitro 
susceptibility data (Tables 2.4, 2.5).  Therefore, this experiment did not include a low 
enough concentration of drug that the parent parasite could tolerate.  In subsequent 
experiments, lower levels of drug were used so it would be possible to detect a distinct 
difference in drug tolerance at lower levels.  We also included W2 parasites to investigate 
how parasites would respond that are different from D6 in terms of geographical location 
and drug susceptibility profile.  These experiments were similar to above, but the drugs 
used were DHA, QHS, and AL (concentration ranged from 100-0.10 ng/ml), and CQ 
(625-0.610 ng/ml) as a control drug.  After each treatment with an artemisinin drug, the 
resistant parasite in each pair tolerated more drug compared to parent strains at 24 and 48 
hours (Fig. 2.11-A-C; E-G; Table 2.6).  In addition, parental and resistant parasites both 
tolerated more drug at 48 hours compared to 24 hours.  Drug susceptibility data reported 
here is for 24 and 48 hours post-drug, but Fig. 2.11 only shows data for 48 hours post-
drug exposure.  After D6 was treated with DHA, the IC50 was 0.23 ng/ml (24 hours) and 
0.53 ng/ml (48 hours).  The IC50 for D6.QHS2400x5 after DHA treatment at 24 hours 
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was 1.39 ng/ml and at 48 hours it was 2.27 ng/ml (Fig. 2.11-A; Table 2.6).  There 
appeared to be a large separation between D6 and D6.QHS2400x5 after treatment with 
AL and QHS (Fig. 2.11-B, C; Table 2.6).  With AL treatment, the IC50 of D6 was 1.90 
ng/ml at 24 hours and 5.76 ng/ml at 48 hours.  The IC50 for D6.QHS2400x5 was 35.7 
ng/ml at 24 hours and 57.8 ng/ml at 48 hours.  For QHS, the IC50 for D6 was 2.05 ng/ml 
at 24 hours and 3.26 ng/ml at 48 hours.  The IC50 of D6.QHS2400x5 at 24 hours was 
17.1 ng/ml at 24 hours and 25.0 ng/ml at 48 hours.  After D6 strains were treated with 
CQ, D6 tolerated more drug (IC50 24 hours=9.95 ng/ml; IC50 48 hours=17.8 ng/ml) than 
D6.QHS2400x5 (IC50 24 hours=6.52 ng/ml; IC50 48 hours=8.35 ng/ml) (Fig. 2.11-D; 
Table 2.6).   
After the W2 strains were treated with DHA, the IC50 for W2 was 0.32 ng/ml at 
24 hours and 0.48 ng/ml at 48 hours.  The IC50 for W2.QHS200x2 was 0.53 ng/ml at 24 
hours and 1.27 ng/ml at 48 hours (Fig. 2.11-E; Table 2.6).  For AL (Fig. 2.11-F, Table 2.6) 
and QHS (Fig. 2.11-G), there was not as much of a dramatic shift between parent and 
resistant parasites as compared to the D6 pair. The AL IC50 for W2 was 1.17 ng/ml (24 
hours) and 2.85 ng/ml (48 hours).  The AL IC50 for W2.QHS200x2 was 4.81 ng/ml at 24 
hours and 12.4 ng/ml at 48 hours.  The QHS IC50 for W2 was 0.80 ng/ml at 24 hours and 
1.55 ng/ml at 48 hours.  The QHS IC50 for W2.QHS200x2 was 2.69 ng/ml at 24 hours 
and 3.21 ng/ml at 48 hours.  For CQ, problems arose during data analysis where 24 and 
48 hour time points could not be used from individual experiments (low r
2
 produced from 
logistic analyses).  Therefore, 24 and 48 hour data were derived from separate 
experiments (Fig. 2.11-H; Table 2.6).  The IC50 for W2 was 158.5 ng/ml at 24 hours and 
94.5 ng/ml at 48 hours.  For W2.QHS200x2, the IC50 was 143.2 ng/ml at 24 hours 147.7 
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ng/ml at 48 hours.  Although the 24 hour data reflects greater tolerance of W2 for CQ 
compared to W2.QHS200, the data from 48 hours (Fig. 2.11-H) probably more accurately 
reflect tolerance to CQ. Overall, the results of artemisinin drug treatment indicate that 
resistant parasites tolerate more drug than parent strains, possibly due to the increased 
ability to enter dormancy and recover at a higher rate, or a greater number of parasites are 
unaffected by drug.   
Sequencing and real-time QPCR of genes implicated in prior molecular 
studies.  In this work, we conducted sequencing and QPCR on the differentially 
expressed genes from the initial microarrays to investigate if these genes are involved in 
resistance.  The CN of pfmdr1 and other selected genes was also analyzed in higher-
selected parasites.  A possible reason for differential expression of genes in resistant vs. 
parent parasites could be that single nucleotide polymorphisms (SNPs) occur within these 
genes that contribute to a reduced signal due to reduced binding affinity.  Initially, genes 
of interest were sequenced using W2 and W2.QHS200, as W2.QHS200 was the most 
resistant parasite on hand at the time.  Although the primary goal was to determine 
differences between W2 vs. W2.QHS200, we also thought it would be interesting to 
compare sequences of pfmdr2 (PF14_0455), PFE1050w, and PF11_0466 against other 
strains with different drug sensitivities where SNPs have already been described 
(PlasmoDB).  We chose CQ and MQ-resistant Dd2 (also known as W2-mef) because it 
descended from W2 
369,381
, so we could use Dd2 as a reference to validate our sequencing 
and also to find any other differences.  We also chose CQ-sensitive D10 (Papua New 
Guinea) and included 3D7 as a reference strain.  No SNPs were described in PlasmoDB 
for PFE1050w.   
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For pfmdr2, we assembled the complete CDS sequence (3075 bp) for 
W2.QHS200 and W2 (only missing sequence for stop codon=TAA).  We found that the 
nucleotide sequences of W2 and W2.QHS200 were identical to each other (Fig. 2.12).  
We searched PlasmoDB for SNPs of 3D7 vs. Dd2 or D10, and four were identified (but 
all were of 3D7/D10 vs. Dd2 type).  These non-synonymous SNPs were at chromosome 
14 positions 1,956,996, changing codon AGT to AAT (Ser-Asn); 1,956,723, changing 
codon GGT to GAT (Gly-Asp); 1,956,351, changing codon TTT to TAT (Phe-Tyr), and 
1,956,168, changing codon ACA to ATA (Thr-Ile).  Sequences of pfmdr2 from W2 and 
W2.QHS200 were aligned against pfmdr2 sequences of 3D7 (NCBI Reference Sequence 
Accession Number XM_001348593.1), Dd2 (Broad Institute locus PFDG_00251.1), and 
D10 (NCBI GenBank Accession Number U04640.1).  All four of the Dd2-like SNPs 
were found in W2 and W2.QHS200.  For the most part, our W2 lines looked very similar 
to Dd2, with some exceptions.  Further analysis of the results found a deletion of an ATA 
codon in 3D7, Dd2, and W2 parasites just downstream from the SNP at position 
1,956,723.  When all strains were aligned, there was a single ATA codon deletion in 3D7, 
but a double ATA codon deletion in Dd2 and W2 parasites.  We also found a 
synonymous SNP for D10 vs. the other strains (position 1367 in CDS, changing codon 
GGT-GGA, Gly-Gly) that was not reported in PlasmoDB.  This was located in between 
the SNPs above at positions 1,956,351 and 1,956,168.  Other observations included the 
presence or absence of nucleotides in the Dd2 sequence from the Broad Institute that 
were different from the other strains that were aligned, and a synonymous SNP for 3D7 
vs. all other strains at position 2126 in CDS, changing codon ATA-ATC (Ile-Ile). 
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Sequencing of PFE1050w in W2 and W2.QHS200 returned 1393/1440 bp of the 
CDS sequence, just missing some nucleotides at the 3‟ end for both strains.  Sequences 
were aligned against the PFE1050w sequences of 3D7 (NCBI GenBank Accession 
Number XM_001351731) and Dd2 (Broad Institute locus PFHG_03949.1).  This analysis 
found that the nucleotide sequences were similar for W2 vs. W2.QHS200, and sequences 
were similar to all other strains (Fig. 2.13).  There were a few missing nucleotides within 
strings of adenosine (5‟end) or thymidine bases (3‟ end) in W2 and W2.QHS200 
compared to 3D7 and Dd2.  However, these were in areas of unreliable sequence and are 
not likely to constitute actual missing bases.  
For PF11_0466, we aimed to sequence the complete 2772 bp gene, but 
sequencing returned erratic results that made it impossible to compare complete 
sequences of W2 vs. W2.QHS200. We were able to align portions of sequences that 
encompassed polymorphic regions of the gene.  The obtained sequence from the strains 
was similar to each other and also 3D7 (Genbank XM_001348097) and Dd2 (Broad 
Institute locus PFDG_03578.1) in these regions (data not shown).  A Dd2-like SNP (vs. 
3D7) at chromosome 11 position 1,808,81, changing codon GTA to TTA (Val-Leu) was 
found in the W2 lines.  However, this only determined that sequence of W2 and 
W2.QHS200 was most likely of Dd2 type, which is a descendant of W2.   
QPCR was performed on a variety of parent and resistant strains of D6, W2, and 
TM91c235. Results of QPCR on PFE1050w, PF11_0466, and pfmdr2 found all strains 
had approximately one copy of each gene (Fig. 2.14 A-C; Table A-2, Appendix A).  
QPCR for CN of pfmdr1 (Fig. 2.14-D, Table A-2, Appendix A) found a similar trend as 
reported by Chavchich et al. (2010) 
276
.  The CN of pfmdr1 was approximately 1 in all D6 
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lines (ex. D6 CN, 1.01±0.015; 95% CI 1.00-1.01; D6.QHS2400x5 CN, 1.10±0.038; 95% 
CI 1.06-1.15) (Fig. 2.14-D), a departure from what we found in other strains.  W2 had 
approximately 1 copy of pfmdr1 (CN, 1.18±0.114; 95% CI, 1.11-1.24) as did W2 (clone 
D7) (CN, 1.21±0.101; 95% CI, 1.14-1.27).  However, there was a noticeable increase in 
pfmdr1 CN from 1 to >2 copies at 200 ng/ml QHS (W2.QHS200 CN, 2.24±0.166; 95% 
CI, 2.12-2.35).  There also was a slight increase after multiple treatments at 200 ng/ml 
QHS (W2.QHS200x2 CN, 2.55±0.0740; CI 2.49-2.62) (Fig 2.14-D).  The CN of pfmdr1 
increased from approximately 2 copies in the parent TM91c235 (CN, 2.20±0.167; 95% 
CI, 2.07-2.32) to almost 3 copies at 80 ng/ml (TM91c235.AL80 CN, 2.82±0.192; 95% CI, 
2.63-3.01).  As AL pressure increased to 240 ng/ml, the pfmdr1 CN increased beyond 3 
(TM91c235.AL240x2 CN, 3.60±0.325; 95% CI, 3.31-3.88).  The effect of increasing 
concentration with concomitant increase in pfmdr1 CN appeared to taper off after 
parasites tolerated 280 ng/ml (TM91c235.AL280x2 CN, 3.56±0.131; 95% CI, 3.41-
3.71).The CN of TM91c235 resistant parasites were greater than any other strains we 
measured.  All of these data are in agreement with that reported in Chavchich et al. (2010) 
in similar drug selected lines 
276
. 
Discussion 
Induction of resistance.  In the study presented here, we expanded on previous 
work from our lab that reported on the induction of resistance to artemisinin and its 
derivatives in several clones and lines of P. falciparum.  A stepwise procedure originally 
produced parasites that could tolerate up to 200 ng/ml QHS (W2), 80 ng/ml QHS (D6), 
and 80 ng/ml AL (TM91c235) 
276
.  The current study details the induction of higher 
resistance levels of these same parasites, but achieving resistance more rapidly.  In less 
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than a year, derivatives of D6 and TM91c235 were generated that tolerated 340 ng/ml 
QHS and 280 ng/ml AL, respectively.  The hallmark of the in vitro resistance for these 
parasites is the ability for parasites to recover after increasing concentrations of 
artemisinin derivatives over many generations.  The parasites recover after treatment with 
levels of drug which are equivalent to those found in plasma of patients taking 
artemisinin drugs for antimalarial therapy.  For certain artemisinin drugs, these parasites 
display a striking decrease in susceptibility.  Furthermore, when in vitro resistance to a 
certain artemisinin drug developed, there was a significant degree of resistance to other 
artemisinin derivatives not utilized in generation of resistance in a particular line.  An 
important note is that it is possible to select resistance in a sensitive background (D6) 
compared to other studies where it was thought that multiple resistance phenotypes must 
pre-exist 
301,332
.  Rathod et al. (1997) 
301
 were unable to induce resistance to ATOV and 5-
fluoroorotate in D6 and HB3, but could induce resistance in W2.  The authors of this 
study named the ability of certain P. falciparum clones to readily develop resistance to 
structurally and mechanistically unrelated compounds as the accelerated resistance to 
multiple drugs (ARMD) phenotype.  
Recovery assays.  Recovery assays using sets of parent and resistant parasites of 
W2 and D6 demonstrated that although parent and resistant parasites both enter 
dormancy, resistant parasites recrudesce either before parent parasites or with a greater 
number of parasites at the same time point.  Parasite recovery was dependent on dose of 
drug, where higher doses of QHS caused recovery at later times.  Results similar to these 
with other artemisinins were reported by Bwijo et al. (1997) 
382
 and Teuscher et al. (2010) 
362
 as well.  An assay measuring recovery between D6 and D6.QHS340x3 included QHS 
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concentrations beyond those considered clinically relevant.  At the end of the assay (360 
hours post-drug), D6.QHS340x3 tolerated the maximum concentration applied (2400 
ng/ml) and D6 tolerated 1500 ng/ml.  During recovery assays, the increase of normal 
parasites coincided with the decrease of dormant (W2 recovery study) or dead-dormant 
(D6 studies) parasites in resistant lines.  These data indicate that resistant parasites 
transitioned out of dormancy to normal growth before the parental parasite.  This may be 
because dormant resistant parasites have a higher survival rate from dormancy; if a 
greater number of dormant parasites existed in resistant cultures, recrudescence would 
occur earlier.  Also, since the parental parasite did not exhibit the same type of 
recrudescence, it may be possible that it is under more stress compared to the resistant 
parasite.   
Some variability was observed in recovery assays with sensitive and resistant 
parasites.  Although morphologically normal parasites sometimes were observed for 
resistant strains before the parental strain, there was not much separation in time.  In the 
W2 experiments with 200 ng/ml QHS, only 24 hours passed between the appearance of 
recrudescent parasites in W2.QHS200 and when they appeared for W2.  This may 
indicate that after 6 hours of drug exposure, the resistant parasite is capable of exiting 
dormancy at a greater rate than W2.  During the experiments with D6 and D6.QHS340x2, 
parasites appeared for each strain at the same time after 200 ng/ml QHS, but more 
parasites were present in D6.QHS340x2.  However, with 300 ng/ml QHS, normal 
parasites in D6.QHS340x2 appeared at 144 hours and D6 appeared at 240 hours.  
Apparently, higher concentrations of QHS are required to observe a phenotypic 
difference in recovery of resistant vs. susceptible parasites.  Perhaps even higher levels of 
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drug are required to surpass a critical threshold where differential recovery of D6 
resistant vs. sensitive parasites can be determined.   
The most interesting results were found from the high level recovery experiments 
using D6 lines.  D6 and D6.QHS340x3 tolerated 1500 ng/ml QHS and normal parasites 
were observed at 235 hours for each parasite.  However, there was a greater percentage of 
normal parasites for resistant D6.QHS340x3.  At subsequent time points, the number of 
parasites increased more in D6.QHS340x3.  To our knowledge, this study and Witkowski 
et al. (2010) 
360
 are the only studies where P. falciparum artemisinin susceptible and 
resistant lines generated in vitro survived levels of drug well beyond those typically 
found in patient sera.  Witkowski et al., 2010 
360
 showed that F32-Tanzania was induced 
to 9 µM QHS, then it could tolerate 70 µM QHS after an initial 48 QHS treatment.  The 
parent survived 9 and 18 µM QHS after 48 hours.  Although these levels are higher than 
what we show here (D6 tolerated 5.3 µM, D6.QHS340x3 tolerated 8.5µM after 48h 
QHS), drug levels greatly exceed the peak drug concentrations in treated patients.  Also 
intriguing is the ability of wild-type parasites, D6 (this study) and F32 
360
 to tolerate 5.3-
18 µM QHS without any prior selection pressure.  Both parasites are from Africa, which 
is interesting since most previous successful in vitro resistance studies were 
accomplished with Asian parasites (see Chapter One and below).  Recent work from our 
lab 
362
 reported on recovery rates of non-drug adapted W2, D6, S55, H3, and PH1 after 
treatment with 200 mg/ml DHA.  After a 6 hour exposure of DHA, parasites recovered at 
similar rates from 4-25 days after drug exposure.  D6, W2, and S55 had similar recovery 
rates and all strains had majority of parasite recovery by day 15 post-drug.  Another 
experiment treating W2 for 6 hours with 20 , 200, 500 DHA for 6 hours found 50% 
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recovery at day 9 at both 200 and 500 ng/ml, and day 5 for 20 ng/ml.  Our recovery assay 
that exposed W2 and W2.QHS200x2 to 200 ng/ml DHA for 6 hours showed that >40% 
of morphologically normal parasites were present 6 days post-drug.  It is difficult to 
compare our D6 recovery results because of differences in exposure to drug (hours, 
concentrations).  However, their study did show reduced recovery after repeated exposure 
up to 48 hours with DHA.  Interestingly, by using a magnetic column, it was found that 
parasite recovery was delayed.  This delay in recovery indicated that there was a small 
number of parasites that was either unaffected by the drug or had become dormant but 
recovered in the first 3 days and had been removed by the columns.  It would be 
interesting to see how resistant parasites perform in this recovery assay, with and without 
magnetic column.  Again, these findings may reflect an intrinsic tolerability of P. 
falciparum strains to artemisinin drugs.   
In vitro susceptibility testing. 
SYBR green assays.  Testing with artemisinin drugs found resistant progeny had 
reduced susceptibility compared to parental parasites as evidenced by IC50 and IC90.  Of 
the five artemisinin drugs tested, the resistant parasite in each pair showed the greatest 
tolerance for AL, but it also exhibited a moderate degree of resistance to QHS.  The 
initial drug pressure experiments for all strains involved treatment with AL (to 80 ng/ml), 
and D6 and W2 AL-resistant progeny were later switched to QHS pressure 
276
.  Therefore, 
we expected to find reduced susceptibility to drugs that were used in pressuring parasites 
during these studies.  Previous data from our lab also showed a degree of cross-resistance 
276
 to QHS, AL, and DHA with lower level drug selected parasites.  These data showed a 
marked reduction in sensitivity to AL and QHS for W2 resistant parasites when they 
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became adapted to 40 ng/ml AL, and this continued up to 80 ng/ml AL.  Susceptibility to 
AL in TM91C235 decreased significantly after exposure to 10 ng/ml AL, but after 
exposure to 30 ng/ml AL, there was no noticeable change at higher levels.  The 
susceptibility of D6 to AL decreased immediately after adaptation to 30 ng/ml of AL, and 
this peaked after adaptation to 50 ng/ml AL.  They did not report data for parasites 
switched to QHS pressure after the original AL pressure.  Although we did observe a 
general decrease in susceptibility of resistant lines to QHS and AL, only D6.QHS2400x5 
exhibited a substantial decrease in susceptibility to DHA (compared to D6).  We found 
that TM91.AL280x2 was equally susceptible to AL as reported for TM91.AL80 by 
Chavchich et al. 
276
.  Other reports on resistance selected with artemisinin drugs in 
Plasmodium and Toxoplasma spp. also detailed cross resistance to artemisinins as well 
332,368,383
.  Furthermore, Chavchich, 2010 
276
 also reported that resistant lines became 
more susceptible to CQ (except for higher selected TM91c235 parasites), but less 
susceptible to MQ.  Other studies found reduced susceptibility to artemisinin drugs 
coincides with reduced susceptibility to MQ and increased CQ susceptibility in P. 
falciparum 
205,260,262,322
.  The resistant D6 and W2 lines in our study showed increased 
susceptibility to CQ, but TM91c235.AL280x2 had a marked decrease in susceptibility to 
CQ.  Perhaps a threshold is passed in resistant TM91c235 parasites at some level where 
CQ resistance is no longer displayed.  We also found that TM91c235 parent/resistant 
parasites were equally susceptible to MQ (by IC50), and that W2.QHS200x2 and 
D6.QHS2400x5 showed a slight decrease in susceptibility to MQ compared to respective 
parental parasites. 
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Ring stage viability assays.  It is possible that SYBR Green assays do not capture 
true differences in parent vs. resistant parasites due to the formation of dormant parasites 
after artemisinin treatment (more below).  Therefore, a true measure of viability over the 
first part of the life cycle may be missed if assessment is conducted at 48-72 hours post-
drug.  Indeed, Teuscher et al. (2010) 
362
 showed that after DHA treatment, parasites exist 
for 3 days and can be removed by magnetic columns.  This showed that recrudescence 
before removal may be due to parasites that are unaffected, or those that go dormant and 
recrudesce before removal.  The addition of tritiated-hypoxanthine ([
3
H], Hx) as a 
method to assess antimalarial drug susceptibility was pioneered by Desjardins et al., 1979 
384
.  Much like SYBR Green assays, this method is based on measuring the rate of 
parasite growth via the incorporation of Hx into nucleic acid.  However, this assay is 
subject to variables such as starting parasitemia/hematocrit, isotope pulse time, and 
duration in culture.  Chulay et al. (1983) 
385
 examined the parameters influencing Hx 
measurements used for parasite proliferation.  This study found that Hx incorporation 
was directly proportional to the number of infected erythrocytes in culture.  It was found 
that a steady 1.5% hematocrit level and 18 hour Hx pulse could maintain a linear 
relationship between parasite numbers and Hx incorporation for initial parasitemia levels 
of 0.4% or lower and this worked at different pulsings.  If parasites are cultured for 
longer periods or at hematocrit level greater than 1.5%, then the initial parasitemia must 
be proportionally reduced to insure a linear relationship between the numbers of parasites 
and hypoxanthine incorporation.  There was a reduced rate of incorporation when 
parasites were at higher initial parasitemia.  This may be due to accumulation of acid 
metabolites, depletion of nutrients during log phase growth. 
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The outcome of an experiment using this method (IC50) is critical, and there can 
be problems depending on when the hypoxanthine is added.  Studies in the literature have 
usually reported that hypoxanthine is added 18-24 hours after drug is added to parasites 
384,386-388
.  Basco (2004) 
389
 found that the time point when Hx was added (0 versus 18 
hours) had no effect on the IC50 during a 42-hour incubation after CQ exposure.  An 
increase in Hx incorporation and CQ IC50 was observed when hematocrit increased from 
1.0% to 2.5%.  For the same isolates, CQ IC50 values were generally similar when the 
initial parasitemia was between 0.1% and 0.5% but increased at higher (>0.75%) 
parasitemias. Based on these results, it was recommended that assays should include a 
42-hour incubation period, addition of Hx at the beginning of incubation, a 1.5% 
hematocrit, and an initial parasitemia 0.1-0.5%.  
Our studies pointed toward the fact that artemisinin-resistant parasites treated with 
artemisinin drugs may produce a greater number of dormant parasites and/or exit 
dormancy faster than parent parasites.  Also, we knew that at high drug levels, it is 
difficult to determine accurate differences in susceptibility after artemisinin exposure.  At 
low levels, some parasites may be unaffected or recrudesce during the assay.  Therefore, 
we investigated parasite viability during the first 48 hours after artemisinin treatment.  
We chose to add Hx immediately after drug exposure because we theorized that IC50s 
may be underestimated (due to dormancy) if Hx was added later.  Also, we utilized 1% 
parasitemia/2% hematocrit, which is in agreement with the above studies.  We added a 
lower range of artemisinin drug concentrations (than what parasites tolerate) and assessed 
parasite viability at 24 and 48 hours.  Dose-response curves for resistant and parent 
parasites were produced and it was found that resistant parasites (D6, W2 lines) tolerate 
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higher levels of AL, DHA, and QHS compared to parental parasites.  Resistant parasites 
tolerated AL the most (followed by QHS), much like we observed in SYBR Green drug 
susceptibility assays.  There was a greater degree of resistance between D6 and 
D6.QHS2400x5 tolerance compared to W2 and W2.QHS200x2.  This was also observed 
in SYBR Green assays.  Also, D6.QHS2400x5 exhibited higher tolerance for artemisinin 
drugs compared to W2.QHS200x2. This is probably due to the fact that D6.QHS2400x5 
was made resistant to much higher levels of QHS.  Interestingly, it appeared that parental 
D6 tolerated more drug than parent W2 (which was not as easily observed in SYBR 
Green assays). The IC50 results from dose response curves were validated by blood 
smears that showed levels of drug that parasites could not tolerate, and resistant parasites 
were observed at higher drug doses than parent strains.  We also used CQ as a control 
drug and found CQ phenotypes of D6 (CQ-sensitive) and W2 (CQ resistant) were 
reflected in this assay.  We also observed that D6 was slightly more resistant to CQ 
compared to D6.QHS2400x5 (as found in SYBR Green testing), but W2.QHS200x2 was 
more resistant to CQ than W2 (at 48 hours post-drug exposure).  This result for W2 is the 
opposite of what we observed with SYBR Green testing (W2.QHS200x2 was more 
susceptible vs. W2).  This discrepancy in W2 results may be a factor of experimental 
variability in the SYBR Green assay, due to the time of assessment (72 hours vs. 24/48 
hours), or due to the fact that the CQ hypoxanthine results used different data for 24 and 
48 hour time points.  At 24 hours, W2 appeared to tolerate slightly more drug than 
W2.QHS200x2.  However, this result does not fit with other results we obtained where 
higher IC50 values were observed while progressing from 24 to 48 hours post-drug 
exposure.  Overall, the reason for the higher drug tolerance in resistant vs. parent strains 
153 
 
could be a greater number of dormant parasites incorporating Hx or unaffected parasites 
that go through the life cycle as normal (saw by smear at low concentrations).  Our 
results with 1% parasitemia and 2% hematocrit seem to validate the results found by 
Chulay et al. (1983) 
385
 and Basco (2004) 
389
.  We were also able to detect a clear 
separation of drug tolerance between susceptible and resistant parasites by using higher 
parasitemia and hematocrit levels.  Furthermore, a recent study showed a 48 hour Hx 
assay (where Hx was added at time drug was added [Personal Communication]) detected 
differences in AS, MQ, CQ, and QN susceptibility in western Cambodia vs. eastern 
Cambodia 
390
.  
We believe this assay is very useful for exploring artemisinin resistance (and 
resistance to other antimalarials).  This assay can utilize even lower hematocrit (1%) and 
parasitemia (0.5%) when hypoxanthine is added at time zero (Sparks et al., unpublished 
data).  This assay would be suitable for ring stages which primarily exist in the 
circulation of infected patients.  It would also allow low parasitemias to be tested, making 
it amenable to testing parasites grown for short periods in vitro after taken from patients.  
This assay would also detect a suitable ring-trophozoite maturation period, indicating 
parasites have reduced susceptibility to artemisinins and other drugs.  The majority of Hx 
incorporation occurs in the trophozoite stage and reflects the rapid increase in DNA 
replication and transcription 
151,384,385
.  Therefore, the assay may be useful for detecting 
exit of dormancy or parasites unaffected by drug.   
Our findings and those of others (Kyle et al., unpublished; 
276,360
) emphasize a 
potential problem of short term in vitro growth studies for detection of artemisinin 
resistance.  As noted by us and Chavchich et al. (2010) 
276
, IC50/90 values of AL and 
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QHS for resistant lines generated were lower than the concentrations the parasites could 
endure in vitro.  A potential problem with current artemisinin susceptibility methods is 
ring stage parasites enter dormancy and take an extended time to recover after exposure 
to artemisinins.  Standard 48-72 hour drug susceptibility assays may not be sufficient to 
assess artemisinin resistance phenotypes.  These tests assess viability based on the 
presence or production of nucleic acid, which is maximal in mature trophozoites 
31
.  As 
we observed with SYBR Green methodology, there does not appear to be a difference 
between the resistant and parental lines at 72 hours with some artemisinin drugs.  
Dormant parasites do not contain high amounts of nucleic acid, and they persist beyond 
the time that typical in vitro drug susceptibility assays assess viability (48-72 hours).  
Although it is possible to detect differences in IC50 after artemisinin treatment, it is 
essential to recognize that parasites will eventually recrudesce after an initial period of 
dormancy after artemisinin treatment, so that parasite viability should be measured at a 
later time.  Reliance on the current IC50 is based in part on the assumption that parasites 
cannot alter their developmental cycle period.  In these assays, drug treated parasites are 
compared to expected growth of untreated parasites given the same amount of time and 
presumably number of cycles to grow.  If a drug delays the developmental cycle then the 
comparison is not as valid.  However, we have shown that resistant parasites can tolerate 
more drug than parental parasites at 24-48 hours by hypoxanthine incorporation.  
Interestingly, a recent study showed that some CQ resistant parasites had identical IC50 
values, yet recrudesced some time after treatment.  This indicated that conventional in 
vitro susceptibility testing (Hx incorporation in this case) is insufficient to detect strains 
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that have low-level CQ resistance or manifest tolerance to CQ.  These parasites had 
elevated IC90 CQ values, a critical measure of CQ tolerance 
236
.   
Growth rates and merozoite number.  While inducing resistance in the various 
parasite lines, we noticed that growth rates of resistant D6 strains were reduced and the 
life cycle was shorter compared to the parental parasite.  This was noted after parasites 
recovered after drug treatment and subsequent recrudescence.  Chavchich et al. (2010) 
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noted that in the absence of drug pressure, the selected progeny progressed normally 
through the erythrocytic stages of the life cycle with no substantial growth differences 
from the parent lines.  During comparison of growth with synchronized parent and 
resistant parasites, the most resistant D6 parasite (D6.QHS2400x5) was delayed in the 
progression from rings to trophozoites.  There was also a significant decrease in the 
number of merozoites in segmenting schizonts compared to D6.  These findings are 
important because recent studies found that artemisinin-resistant parasites have prolonged 
clearance times 
280,286,320,321
.  It may be that the delayed parasite clearance times are due 
to a delay in the life cycle of resistant parasites that are circulating in malarious areas 
(White, Personal Communication).  For the W2 parent/resistant pair, there was not much 
separation in growth between parent and resistant parasite until later in the assay.   
TM91c235.AL280x2 spiked in growth before TM91c235 shortly after the 3
rd
 
cycle, but we did find convincing evidence of this growth difference being caused by 
parasite development.  We found that W2 had significantly less merozoites in segmenting 
schizonts compared to W2.QHS200, but TM91c235 had significantly more merozoites 
than TM91c235.AL280x2.  Therefore, the association between growth and merozoite 
development is less clear in these strains.  It was surprising that the W2 parent had 
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significantly less merozoites than the resistant parasite.  Reilly et al. (2007) 
391
 reported 
on the difference in proliferation rates, cycle time, merozoite number, and invasion rates 
between Dd2 (descendent of W2) and HB3 (drug sensitive, Honduras).  Compared to 
HB3, Dd2 had a shorter cycle time (faster growth), more merozoites per segmenting 
schizont (18 vs. 16), and a higher invasion rate.  Interestingly, they found that the faster 
growth of Dd2 was attributed to a decreased ring to trophozoite transition time.  When 
comparing these results to our studies, W2 had less merozoites (15.3) compared to Dd2, 
although W2.QHS200x2 had more merozoites than Dd2 (19.7).  These differences may 
be a result of a number of things, but it is possible that drug pressure over time may have 
caused genetic changes enabling a greater capacity to produce merozoites.  However, the 
increase in merozoites was not reflected in growth difference.  We noticed an increase in 
ring to trophozoite transition time for D6.QHS2400x5 which corresponded with reduced 
merozoite number and slower growth.  Perhaps long-term QHS pressure on this parasite 
selected for genetic changes that manifested in growth inhibition.  A recent study by Balu 
et al. (2009) 
392
 found reduced growth rates in transposon-generated P. falciparum 
mutants.  The most attenuated mutants had insertions into the coding sequences of 
MAL8p1.104 and PFF0770c, which encode a putative CAF1 family ribonuclease and a 
protein serine/threonine phosphatase 2C, respectively.  PP2Cs participate in many 
cellular functions in eukaryotes, including growth factor dependent signal transduction, 
transcription, pre-mRNA splicing, DNA replication and the DNA damage response.  
These phosphatases also contribute to cell cycle and developmental check points 
393
.  It is 
possible that the D6 artemisinin resistant parasites we have generated display impaired 
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growth due to genetic alterations in cell cycle checkpoints.  However, this does not 
appear to affect the ability of resistant parasites to exit dormancy. 
Importance of artemisinin resistance and dormancy to patient studies.  
Artemisinin resistance is a major concern given the fact that these drugs are still used as 
monotherapies and they are part of combination therapies utilized in areas where drug-
resistant malaria is already prevalent.  Recently, artemisinin resistance has emerged in 
southeast Asia.  Studies have reported on reduced susceptibility to both artemisinins and 
ACTs in western Cambodia and eastern Thailand, characterized by prolonged parasite 
clearance times (PCT), significant drug failure rates, and reduction of parasite 
susceptibility to drugs in vitro 
280,320-322,390,394,395
.  Importantly, resistance does not appear 
to be mediated by polymorphisms or amplification of pfmdr1 (as with MQ resistance) or 
selected pfatp6 or pfubp-1 polymorphisms 
320,321,329
.  Studies from our groups have found 
that these candidate genes for artemisinin resistance do not provide a reason for 
artemisinin resistance.  Therefore, another mechanism for extended PCT and changes in 
drug susceptibility is responsible.  Interestingly, the study by Dondorp et al. (2009) 
320
 
found that resistance is characterized by slow parasite clearance in vivo without 
corresponding reductions using conventional in vitro susceptibility testing.  Therefore, 
there is a discrepancy between in vitro and in vivo findings.  Most reports of emerging 
resistance to artemisinin report some elevation in IC50.  A caveat to this is the use of in 
vitro susceptibility tests for artemisinin.  The tests do not properly assess resistance due 
to the formation of dormant parasites, and it is possible that findings of similar 
susceptibility patterns are misleading.  An important conclusion that can be drawn from 
recent studies is that although data point toward artemisinin resistance, it is likely still 
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localized to the Thai/Cambodia border.  Therefore, existing ACTs in use remain effective 
in areas close to where artemisinin resistance is being reported.   
Artemisinins clear parasites rapidly, an effect that is attributed to their unique 
activity against young ring-stage parasites 
141
.  However, it is well known that patients 
experience recrudescence after treatment with a single artemisinin drug.  Therefore, it is 
recommended that artemisinin is avoided as a monotherapy, which may promote 
resistance to this class of drugs 
396
.  Studies with recrudescent parasites find that these 
parasites do not differ from artemisinin resistant parasites that have been isolated from 
similar locations or those from successfully treated infections (Looareesuwan et al., 1994 
151 /id; Looareesuwan et al., 1997 100 /id).  We report here and elsewhere (
362
; Kyle 
unpublished) that artemisinin induces dormancy in ring stage parasites in vitro and a 
proportion of these parasites recover to cause recrudescence.  .  We previously showed 
that artemisinin induces dormancy in ring stage parasites in vitro and a proportion of 
these parasites recover to cause recrudescence.  The period of dormancy is marked by 
shrunken parasites containing pyknotic nuclei and reduced cytoplasm. Our laboratory has 
found that parasites enter a quiescent or dormant state after treatment with artemisinin 
drugs 
362
 (Kyle et al., 2010 unpublished data) and these parasites are capable of resuming 
growth after drug pressure is removed.  Witkowski et al. (2010) 
360
 found that parasites 
enter a quiescent state after exposure to high levels of artemisinin, and suggested that the 
ability to enter the quiescent state was a hallmark of resistance.  However, they only 
observed that artemisinin resistant parasites enter dormancy.  Our laboratory found that 
dormancy occurs in artemisinin sensitive and resistant parasites 
362
 (Kyle et al., 2010 
unpublished data; Tucker et al. 2010 unpublished data).   
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We hypothesize that multiple rounds of exposure to artemisinin drugs and 
recovery from dormancy select for parasites with reduced susceptibility to artemisinin 
drugs.  This process could enhance recrudescence rates (i.e., treatment failure) and 
explain a resistance mechanism where an increased the proportion of parasites recover 
from dormancy following the removal of drug pressure, by decreasing the duration of 
dormancy, or both.  If dormancy and recrudescence are related, and resistant parasites are 
selected for, then these viable parasites could be responsible for increased PCT.  Perhaps 
in resistant parasites, higher dormancy and faster recovery allows recrudescence, then 
prolonged PCT could result from more dormants lasting and not being eliminated.  The 
resistant parasites we have generated here and previously 
276
 display a noticeable 
difference in vitro susceptibility.  However, without prior drug pressure, we found that 
dormant parasites that eventually recrudesce are equally sensitive to artemisinins as 
control parasites.  Therefore, repeated exposure to drug is key for accelerated exit from 
dormancy and recrudescence.  It may be too soon to make the correlation between what 
we have found and what occurs in the field.  An interesting study by Stepniewska et al. 
(2010) 
395
 identified an indicator that could be used to screen for artemisinin resistance in 
patients.  They found that counting parasitemia from blood smears 3 days after drug 
treatment is a useful predictor or therapeutic response.  This takes into consideration that 
most patients have cleared their peripheral parasitemia by day 3 (∼72 h) after the start of 
treatment.  However, some patients with hyperparasitemia have a proportion of parasites 
that are not cleared, which may explain recrudescence and extended PCT.  Another 
interpretation based on our studies of artemisinin-treated ring stages is that parasites 
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existing after day 3 may be dormant or recrudescent populations that came out of 
dormancy.  
There are several reasons why artemisinin induced dormancy has not been 
observed previously, especially in vivo. Artemisinin drugs are known to rapidly reduce 
peripheral parasitemia with the spleen playing a central role in removing artemisinin-
affected parasites 
141
.  We hypothesize that late rings and early trophozoites will be easily 
cleared by the spleen after therapy, whereas erythrocytes infected with early rings may 
produce dormant forms that are less likely to be recognized by the spleen.  The 
population of dormant parasites may be difficult to detect microscopically, making it 
appear that parasites have been cleared.  Sequestered trophozoites would be killed by 
drug action, whereas schizonts could produce additional dormant progeny.  The 
erythrocytes infected with dormant parasites could continue to circulate, or possibly even 
sequester, until the parasites recover and begin to grow.  Alternatively, artemisinin-
treated parasites may be cleared more effectively than other drugs.  Newton et al. (2001) 
reported that red blood cells that do not contain parasites (pitted RBCs) yet have ring-
infected erythrocyte surface antigen (RESA) exist more after treatment with artemisinins 
compared to quinine.  The faster rise in RESA-RBC count after treatment with 
artemisinins than after quinine reflects the greater efficacy of artemisinin derivatives in 
killing or damaging circulating ring-stage parasites, since quinine is more active against 
mature stages.  It may be that dormant parasites still synthesize proteins after artemisinin 
treatment and these parasites are pitted (removed from RBCs) by the spleen.  Perhaps 
peroxide damage induced by artemisinin to parasites help the spleen recognize dormant 
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parasites or older rings change the architecture of RBCs so that they get picked out easier 
compared to mature stages.  This remains to be proven.   
It was thought until recently that clinical resistance to artemisinin does not occur 
in the world.  Interestingly, data were ignored that showed frequent recrudescence of 
infection following treatment with less than 7 days of an artemisinin derivative, with or 
without a companion drug 
347,370
.  It is important to note that confirmation of clinical 
resistance to artemisinin will be difficult to discern from normal recrudescent infections.  
The difficulty is amplified by the short half-life of the drug, which complicates 
therapeutic drug monitoring confirmation of patient compliance with the proper regimen.  
Due to these technical issues, it is likely that artemisinin resistance could emerge and 
spread rapidly before its occurrence is detected.  Identification and development of 
molecular markers, or other methods of identifying and tracking artemisinin resistant 
parasites, is critically important.   
Our current understanding of the mechanism of action of artemisinin drugs is 
limited, although many mechanisms are postulated.  Similarly, little is known about 
possible mechanism(s) of artemisinin resistance in P. falciparum.  In order to study 
mechanisms of resistance, investigators have attempted to establish in vitro and in vivo 
resistance models for artemisinin drugs in apicomplexan parasites 
332,335,340,344,345,363-
368,397,398
.   
Studies based on previous microarray data.  The in vitro resistance to 
artemisinin drugs we and others 
276
 have reported on is different from resistance to other 
conventional antimalarial drugs, such as CQ and MQ, where drug resistance mechanisms 
are well-established 
161
.  Genes linked to artemisinin resistance have been described 
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previously (see above).  Also, we previously reported that ring-stage dormancy occurs 
only in parasites treated with artemisinin drugs (Kyle et al., 2010 unpublished).  
Therefore, it appears that artemisinin resistance is unique in that parasites do not 
continually grow under drug pressure.  Previous data from our lab found W2 parasites 
exposed to artemisinin display differential regulation of certain genes.  We investigated 
the most differentially regulated genes in hope to find SNPs or copy number differences 
that may be responsible for resistance.  Transporters PF11_0466 and pfmdr2 were under-
expressed in the early microarrays.  PF11_0466 is a member of the ATP binding cassette 
(ABC) transporter superfamily and it contains a multidrug resistance domain 
399
.  ABC 
transporters are localized to the parasite food vacuole membrane or plasma membrane, 
and they decrease intracellular drug accumulation by pumping out drugs, resulting in 
drug resistance.  Mu et al., 2003 
201
 investigated 49 known P. falciparum transporters and 
assayed drug susceptibility and sequence of these transporters in various drug 
resistant/susceptible strains (HB3, Dd2, D10, 7G8, and 3D7).  Based on this analysis, five 
non-synonymous SNPs were found in PF11_0466.  Because of the close relation to 
pfmdr1, PF11_0466 could be a candidate drug resistance gene 
400
.  In addition, the WHO-
TDR drug target database classifies PF11_0466 with a druggability index of 0.5/1.0 
401
.  
Our efforts to sequence PF11_0466 in W2 and W2.QHS200 did not produce reliable 
sequence where we could determine SNPs between strains.  We also did not find an 
association between down regulation of PF11_04446 and copy number change (all strains 
analyzed had approximately 1 copy).  Therefore, PF11_0466 does not appear to be 
important in artemisinin resistance at this point.  However, its relation to pfmdr1 and 
other transporters still makes it important to analyze in future assays.  Pfmdr2 is another 
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ABC transporter exhibiting similarities to Pfmdr1, and for some time it was thought to be 
involved with antimalarial resistance 
400
.  Over-expression of Pfmdr2 was purported to be 
involved in CQ resistance 
402
, but other studies found that pfmdr2 was unassociated with 
CQ resistance 
403,404
.  Furthermore, a single genetic cross between CQ-resistant and CQ-
sensitive P. falciparum parent found that pfmdr2 does not segregate with the CQ-
resistance phenotype 
208
.  This gene has recently been linked to heavy metal resistance in 
a FCR3 strain of P. falciparum made resistant to cadmium chloride 
379
.  The gene has a 
druggability index of 0.7/1.0, indicating it has moderate potential as drug target 
401
.  Like 
PF11_0466, we did not detect SNPs in W2 lines, and there was no change in copy 
number in all strains we tested.  Based on these data, we do not believe pfmdr2 plays a 
significant role in artemisinin resistance.  But, like PF11_0466, it still may be interesting 
to determine if this transporter plays any role in artemisinin resistance in future assays.   
A group of non-transporter genes was found whose values of genotype effects 
were also highly significant in the early microarrays, with PFE1050w (S-adenosyl 
homocysteine hydrolase, up-regulated) being the most significant.  This gene catalyzes 
reversible hydrolysis of S-adenosyl homocysteine (SAH) to adenosine and homocysteine, 
and it is necessary for active methylation of different biomolecules 
405
.  Recent studies on 
the inhibition of P. falciparum spermidine synthase (PfSpdSyn) with cyclohexylamine 
and S-adenosyl methionine decarboxylase/ornithine decarboxylase (PfAdoMetDC/ODC) 
with DL-α-difluoromethylornithine (DFMO)/MDL73811 found that genes of the 
polyamine biosynthetic pathway were down-regulated (including PFE1050w) and 
parasites were morphologically and transcriptionally arrested at early trophozoite stage 
406,407
.  A key finding of these studies was that there is significant transcriptional level 
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control after drug treatment and drug-treated parasites displayed compensatory 
mechanisms for the inhibition of certain pathways.  Makanga et al. (2005) 
408
 reported 
that late rings of P. falciparum (CQ-resistant strain K1, Thailand) treated with AE are 
affected for a number of important biochemical processes.  Genes encoding enzymes 
involved in protein synthesis, nucleic acid metabolism (including PFE1050w), and 
parasite respiration were down-regulated.  Kidgell et al. (2006) 
409
 identified regions of 
amplification in P. falciparum strains that included PFE1050w in strain FCR3 (CQ-
resistant, Gambia) and PFE1115c (S-adenosyl methionine-dependent methyltransferase) 
in strains FCB (CQ, QN resistant, Thailand), FCR3, and Dd2.  Ribacke et al. (2007) 
410
 
identified duplication in PFE1115c in patient isolates from Uganda.  Gunasekera et al. 
(2007) 
411
 identified PFE111c as a differentially regulated gene after 3D7 was treated 
with CQ.  Witkowski et al. (2010) 
360
 determined that PF10_0121, which encodes 
hypoxanthine phosphoribosyltransferase) was down-regulated in QHS-selected P. 
falciparum.  Natalang et al. (2008) 
412
 also found PF10_0121 was down-regulated in a 
study of AS-treated P. falciparum.  These studies seem to implicate nucleic acid 
metabolism in drug-resistant parasites.  Although PFE1050w was up-regulated in W2 
resistant parasites in early microarrays, we did not find any changes in CN or detect SNPs 
in drug selected parasites.  We find it interesting that PFE1050w was down-regulated in 
these studies, whereas we found it to be up-regulated in our microarrays.  It appears that 
different compounds can arrest P. falciparum development (our data with rings and 
trophozoites from the study above), yet PFE1050w is differentially regulated.  Perhaps 
nucleic acid metabolism can be affected in numerous ways by drugs, reflecting 
transcriptional changes the parasite employs.  At this point, we can state that PFE1050w 
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does not appear to be involved in artemisinin resistance, but its potential as a drug target 
should not be understated.  The TDR drug target database lists the druggability index of 
PFE1050w as 0.8/1.0, making it a high interest drug target.  Studies have shown that 
elevated levels of SAH are inhibitory for viruses and tumor lines 
413
, making SAHH an 
intriguing antimalarial drug target. Early studies with SAHH in Plasmodium spp. found 
that neplanocin A and 4„,5„-didehydro-5‟-fluoroadenosine inhibited parasite growth, but 
the effect could not be attributed to inhibition of the parasite enzyme 
405
.  A more recent 
study showed that (6‟R)-6‟-C-methylneplanocin A (RMNPA) inhibits P. falciparum in 
vitro, and P. berghei was inhibited in an in vivo assay 
414
.  Therefore, nucleic acid 
metabolism is an important drug target for ongoing antimalarial drug development. 
The early microarrays demonstrated a role for pfmdr1 in resistance, and further 
studies by our group have further implicated this gene in the resistance generated in vitro.  
Pfmdr1 appears to involved in the AL and QHS resistance phenotypes of TM91c235 and 
W2 
276
.  Exposure to increasing doses of drug resulted in the proportionate increase in the 
pfmdr1 copy number as well as in its mRNA and protein expression in the W2 and 
TM91c235 resistant lines.  Interestingly, the adaptation of parasites to 40 ng/ml of QHS 
was associated with a decrease in pfmdr1 copy number from three to two copies.  The 
copy number remained stable at two, as this parasite was adapted up to 200ng/ml 
QHS.Interestingly, D6 lines at all drug pressure levels only had one copy of pfmdr1.  Our 
results with higher drug-selected lines recapitulate these findings.  These data suggest 
that pfmdr1 amplification can be associated with resistance to artemisinin drugs in vitro, 
but clearly pfmdr1 amplification is not the only mechanism involved in conferring 
artemisinin resistance.  Based on these analyses, artemisinin resistance appears 
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multifactorial, but it can be enhanced by amplification of pfmdr1, which also confers 
resistance to MQ 
205,206,260-262,266,277
. It is well known that pfmdr1 is associated with drug 
resistance in Asia 
205,260,262,286,298,415-417
.  However, few studies have reported on 
amplification of pfmdr1 in Africa 
275,418-421
.  Perhaps there is significant copy number 
variation in Africa as we did not detect a pfmdr1 CN change in D6, which is from West 
Africa.  Also, there may be a unique mechanism for resistance in resistant lines we 
generated since parasites tolerating 2400 ng/ml QHS still retained one copy of pfmdr1.  
We are in the process of identifying genetic determinants of artemisinin resistance in D6 
drug selected lines.  As mentioned above, PFE1050w was up-regulated in W2 resistant 
parasites in early microarrays, but we did not find any changes in CN.  We hypothesized 
that the up-regulation of PFE1050w was due to its presence on an amplicon including 
pfmdr1 since these genes are near each other.  Therefore, it was unexpected that 
PFE1050w was up-regulated and there was not an increase in CN when pfmdr1 was up-
regulated and amplified.  Chen et al. (2010) 
337
 showed amplification of 19 genes 
(PFE1095 to PFE1180) that included pfmdr1 (PFE1150w) in W2.AL80 (three copies of 
pfmdr1).  When a decrease in CN of pfmdr1 occurred, so did the CN of other genes on 
the amplicon.  Perhaps PFE1050w is not part of a pfmdr1amplicon produced after 
artemisinin pressure, but its up-regulation is still interesting.   
Artemisinin resistance phenotype.  Based our investigations with parental and 
resistant pairs of parasites, we can begin to define an artemisinin resistance phenotype.  
This phenotype can be defined by elevated IC50 by in vitro susceptibility testing with 
artemisinins, marked by resistance to more than one artemisinin derivative.  By 
hypoxanthine incorporation, resistant parasites will show increased tolerance to lower 
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levels of artemisinins compared to susceptible parasites- 48 hours after drug exposure.  
Recovery assays document the level of drug parasites can tolerate without being selected.  
We showed D6 tolerated 1500 ng/ml QHS and a line already induced to tolerate 340 
ng/ml QHS could tolerate 2400 ng/ml QHS.  Also, growth can be delayed through the 
normal erythrocytic cycle with a noticeable extended transition from rings to trophozoites.  
Resistance is not explained by candidate gene amplifications or mutations as Chavchich 
et al. (2010) 
276
 reported that genes (pftctp, pfatp6, pfmdr1) with tentative associations to 
artemisinin resistance have no changes in the gene coding sequences  in resistant 
progenies of W2, D6, or TM91c235 lines.  Our molecular data fit with this assertion as 
well. 
Artemisinin drugs are essential tools for controlling the world‟s most important 
parasitic disease.  The recent WHO decision to introduce ACT combination therapy 
globally makes the discovery of artemisinin resistance markers more important than ever 
before.  Subjecting P. falciparum to increasing amounts of artemisinin drugs has 
produced resistant parasites that will serve as valuable reagents for molecular analyses 
and other studies.  Our data suggest that artemisinin resistance was selected for by 
multiple pulse exposures to drug over time.  Although long-term stability studies at these 
high levels of drug exposure have not been completed, resistance to artemisinin 
derivatives (as indicated by the ability to survive increasing concentrations of the drug) 
can be induced in P. falciparum in vitro.  An alarming fact is that parasites in the field 
that are continually exposed to suboptimal levels of artemisinin drugs may begin to 
tolerate high levels of these drugs, leading to a greater distribution of drug resistance.  
The artemisinin resistant parasites we have generated represent a unique resource for 
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molecular and cellular studies of artemisinin resistance mechanism(s) and markers, 
mechanism of action studies, determining the role of drug-induced dormancy as a 
mechanism of recrudescence, and optimizing ACT drug partners.  We have used these 
reagents to investigate dormancy and resistance and to define a resistance phenotype for 
D6 parasites, exhibited by resistant parasites tolerating ≥1.5 µg/ml drug for > 48 hr, cross 
resistance between artemisinin derivatives, and the fact that resistant parasites recover 
faster than parental strains at low drug levels.  Future research will focus on dissecting 
whole genome sequence, transcription, and proteomic data of parental and resistant 
parasites to further elucidate mechanisms of resistance to artemisinin drugs. 
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  1 2 3 4 5 6 7 8 9 10 11 12 
D6 A 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.20 0.10 no drug 
 
B 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.20 0.10 no drug 
 
C 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.20 0.10 NRBC 
  D 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.20 0.10 NRBC 
D6.QHS2400x5  E 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.20 0.10 no drug 
 
F 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.20 0.10 no drug 
 
G 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.20 0.10 NRBC 
 
H 100 50 25 12.5 6.25 3.13 1.56 0.78 0.39 0.20 0.10 NRBC 
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Fig. 2.1.  96 Well Plate Setup for a Typical Hypoxanthine Assay.  After a mother plate 
was made with drugs from 1000 ng/ml-1.0 ng/ml, 10 µl of serially diluted drug was 
transferred into wells containing 90 µl of parasite suspension.  This made a 1:10 drug 
dilution in the final plate (100 ng/ml-0.1 ng/ml).  Each test plate had 11 drug 
concentrations (representing 1:2 serial dilutions, left to right) in triplicate for each 
parasite tested (each half of a plate contained one parasite).  A fourth row of parasite and 
drug was included, but hypoxanthine was not added in order to take material from wells 
for smears.  The final column contained controls (no drug and non-parasitized RBCs 
[NRBCs]) for each parasite pair. The assay depicted here was for the initial DHA D6 and 
D6.QHS2400x5 assay starting at 800 ng/ml.  We also tested other drugs at lower 
concentrations in a 1:2 dilution scheme (see text) and W2, W2.QHS200 were tested in a 
similar manner as depicted here.   
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Figure 2.2.  96 Well Plate Setup for a Typical QPCR Assay for Assessment of Copy 
Number.  Each half of a plate was set up the same way for the gene of interest (in this 
example, PF10_0292) and the normalizer gene, ldh.  Every sample on the plate was run 
in triplicate. Each gene had the same serially diluted 5 point standard curve of D6 
(replicate numbers 1-5 for PF10_0292 and 14-18 for 1dh).  The unknown samples were 
replicates 6-13 for PF10_0292 and 19-26 for ldh.  Each primer set included a no template 
control (NTC) reaction. 
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Figure 2.3.  Amplification Plots of Standards and Unknowns in a Typical QPCR Assay.  
The y-axis indicates Fluorescence units and the x-axis indicates cycle number.  Here, the 
Ct value for each triplicate has been averaged and shown as a single plot for each 
standard and unknown sample of pfmdr1 and ldh.  There are separate thresholds 
generated for pfmdr1 and ldh.  The unknown Ct values (bulk of the amplification plots) 
occur between the standard Ct values.  Unknown Ct values in this experiment are very 
close for pfmdr1 and ldh, so that the plots almost overlap for each sample (this varied per 
experiment). 
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Figure 2.4.  Individual Amplification Plots of an Unknown Gene and Normalizer ldh.  In 
this pfmdr1 QPCR copy number assay, the average threshold cycle (Ct) for pfmdr1 and 
ldh is shown for an unknown sample.  The average Ct for ldh-pfmdr1 is calculated and 
used in the standard curve equations calculated for the overall difference of ldh-pfmdr1 
for the D6 standards (see text).  Standards are not shown in this figure for clarity. 
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Figure 2.5.  Standard Curve Generation for a QPCR Assay.  The Ct values (triplicate) of 
each serial-diluted D6 standard (five total) for pfmdr1 and ldh are averaged and the 
standard deviation is calculated.  The average Ct value of each standard is plotted vs. log2 
DNA concentration and a trendline is generated, giving a standard curve equation. The 
slope and y-intercept of each equation is used to calculate the relative copy number of the 
unknown samples (see text). 
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Figure 2.6.  Treatment of D6.QHS80 With Increments of Artemisinin Produced Parasites 
That Tolerated 2400 ng/ml of Artemisinin.  D6 adapted to 80 ng/ml artemisinin (QHS) 
was treated with QHS with increments of 20-40 ng/ml QHS in order to increase drug 
tolerance. After D6.QHS340 was treated one more time at 340 ng/ml QHS (x2), it was 
subjected to a range of QHS and tolerated the maximum dose, 340 ng/ml.  This parasite 
(D6.QHS340x3) was then subjected to a range of QHS in a second recovery assay (80-
2400 ng/ml), and it tolerated the maximum dose of 2400ng/ml.  This parasite was treated 
three more times with 2400 ng/ml QHS, and it was cloned by limiting dilution.  Selected 
clones were then treated one more time with 2400ng/ml QHS, yielding D6.QHS2400x5.   
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Figure 2.7.  Treatment of TM91c235.AL80 With Increments of Artelinic Acid Produced 
Parasites That Tolerated 280 ng/ml of Artelinic Acid.  TM91.AL80 was treated with 
artelinic acid (AL) increments of 20-40 ng/ml AL in order to increase drug tolerance.  
The parasite was first treated at 40 ng/ml, then 60 ng/ml before 80 ng/ml was applied, 
then moved up to 280 ng/ml (x2).  There is a long period of time between applications of 
280 ng/ml because TM91c235.AL280x1 was cryopreserved for a while, then thawed, and 
subjected to a second dose of 280 ng/ml AL. 
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Figure 2.8.  Recrudescence Assay With W2 and W2.QHS200 Clones Found the Resistant 
Parasite Recrudesced Before the Parent Strain After Dihydroartemisinin Treatment.  
Cloned parent W2 (clone D7) and resistant lineW2.QHS200x2 (clone C5) were exposed 
to 200ng/ml dihydroartemisinin (DHA) and the parasitemia (A), pictures of parasites 
during the time course (up to 120 hours post-drug exposure) (B), percentage 
dormant/total parasites (C), and percentage normal/total parasites (D) was calculated at 
each time point.   
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Figure 2.9.  Recovery Assays With D6 Parent and Resistant Lines Show Resistant 
Parasites Recrudesced Before the Parent Strain After Artemisinin Treatment.  Percentage 
of Normal/Total Parasites for D6 and D6.QHS340x2 after exposure of 28.2-340 ng/ml 
artemisinin (QHS) (showing 200 ng/ml and 300 ng/ml concentrations levels) (A.).  
Percentage of Normal/Total Parasites for D6 and D6.QHS340 (x3) after exposure of 80-
2400 QHS (showing representative example- D6+1500, D6.QHS340x3+1500) (B.).  
Pictures of D6 and D6.QHS340x3 during the time course at 0, 22, 48, 235, 264, and 360 
hours after treatment with 1500 ng/ml QHS (DMSO at 22 and 48 hours) (C.). 
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Figure 2.10.  Decreased Growth and Merozoite Number is Associated With D6 Resistant 
Progeny but not All Resistant Strains.  Growth curves of synchronized parental and 
resistant strains of D6 (A.) (clonal pairs), W2 (B.) (clonal pairs), and TM91c235 (C.).  In 
(D.), the mean merozoite number in segmenting schizonts of cloned parent D6 cloned 
resistant D6.QHS2400x5, cloned parent W2, cloned resistant W2.QHS200x2, cloned 
TM91c235, and TM91.AL280x2 is shown.  The number of merozoites was significantly 
less in the resistant D6 parasite (*p=3.8x10
-10
) compared to the parent.  The number of 
schizonts was significantly greater in the resistant W2 parasite compared to the parental 
W2 (**P=1.3x10
-16
).  For the TM91c235 series, the mean number of schizonts was 
greater in the parental strain compared to the resistant strain (***P=0.012).  Pictures (E.) 
of typical segmenting schizonts of D6, W2, and TM91c235 parasites, showing average, 
minimum, and maximum (left to right) for each strain.  D6 (clone C11): average-19.3, 
min-14, max-24 merozoites/schizont; D6.QHS2400x5 average-16.3, min-12, max-22 
merozoites/schizont;W2 (clone D7)-15.3, min-12, max-22 merozoites/schizont; 
W2.QHS200x2 average-19.7, min-14, max-26 merozoites/schizont; TM91c235 average-
20.7, min-16, max-26 merozoites/schizont; TM91c235280x2 average-19.7, min-16, max-
24 merozoites/schizont.
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Figure 2.11. Ring Stage Viability Assay Determined That Resistant Parasites Tolerate 
More Drug Than Parental Strains.  Clonal D6 and W2 parent and resistant lines were 
treated with drug and tritiated hypoxanthine was immediately added.  Percent parasite 
growth at 48 hours was compared to no drug controls for W2, D6 lines after exposure to 
artemisinin (QHS), dihydroartemisinin (DHA), artelinic acid (AL), and chloroquine (CQ).  
It is graphed as a function of drug concentration (ng/ml).  The graphs depict logarithmic 
dose response of parent (blue) and resistant (gray) parasites for each line after drug 
treatment  The graphs show D6/D6.QHS2400x5+DHA (A.), D6/D6.QHS2400x5+AL 
(B.), D6/D6.QHS2400x5+QHS (C.), D6/D6.QHS2400x5+CQ (D.); 
W2/W2.QHS200x2+DHA (E.), W2/W2.QHS200x2+AL (F.), W2/W2.QHS200x2+QHS 
(G.), W2/W2.QHS200x2+CQ (H.). 
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W2.QHS200       ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG 
Dd2             ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG 
W2              ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG 
3D7             ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG 
D10             ATGGATGTATCAAATTACGAGTATTTAAGATCCTATGGAATTAAGAACGAACTGAAAAGG 
                ************************************************************ 
 
W2.QHS200       AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA 
Dd2             AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA 
W2              AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA 
3D7             AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA 
D10             AAAAGAACGCACAAGAAGATAATAATATATCACTTATTAGATATTATAATATTTTTCTTA 
                ************************************************************ 
 
W2.QHS200       TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT 
Dd2             TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT 
W2              TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT 
3D7             TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT 
D10             TTATTTTTTAGTTGTTACAATTTTAATTTAGAATTATGTTATAAATATGAAAAGGCAATT 
                ************************************************************ 
 
W2.QHS200       TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA 
Dd2             TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA 
W2              TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA 
3D7             TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA 
D10             TTTTATAATTTTTTTAAATCATCAGTTGATTTATTTTTGTTGAATGTTATAAGAATAATA 
                ************************************************************ 
 
W2.QHS200       TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG 
Dd2             TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG 
W2              TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG 
3D7             TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG 
D10             TACACCGTAATTTTATTTAGATTACATAAAAAGTTAACAGAATTGAATACATTAGGAAAG 
                ************************************************************ 
 
W2.QHS200       GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG 
Dd2             GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG 
W2              GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG 
3D7             GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG 
D10             GTGTATGTATTATCCAGACATATAACCGGTATCTTAGTTATATTGAATGTAATAAAGATG 
                ************************************************************ 
 
W2.QHS200       ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA 
Dd2             ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA 
W2              ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA 
3D7             ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA 
D10             ATAAATTATAGTTATGTAATAAAATCAGAAAATCCTCTTTATAATACTAACATGTATTTA 
                ************************************************************ 
 
W2.QHS200       ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT 
Dd2             ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT 
W2              ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT 
3D7             ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT 
D10             ATAACACTCAAAGTTTTGTTTATGGTTTATAGTATGATTTCATCTATATATTATTATTTT 
                ************************************************************ 
 
W2.QHS200       ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA 
Dd2             ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA 
W2              ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA 
3D7             ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA 
D10             ATACAATTTAAATTATATAATATAAAGAAGAAATATATTATAGCTCGAGTTGAATTAGAA 
                ************************************************************ 
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W2.QHS200       AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATCTGATGAAAAT 
Dd2             AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATCTGATGAAAAT 
W2              AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATTTGATGAAAAT 
3D7             AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATCTGATGAAAAT 
D10             AAAATATTAATAAATGATATTAAATCAAAAAAATATAACATATATAAATCTGATGAAAAT 
                ************************************************* ********** 
 
W2.QHS200       AGTGGCTTATTAGGAACAGATAATAATAGTACCATAATGAATAATGAATATTTAAACCTT 
Dd2             AGTGGCTTATTAGGAACAGATAATAATAGTACCATAATGAATAATGAATATTTAAACCTT 
W2              AGTGGCTTATTAGGAACAGATAATAATAGTACCATAATGAATAATGAATATTTAAACCTT 
3D7             AGTGGCTTATTAGGAACAGATAGTAATAGTACCATAATGAATAATGAATATTTAAACCTT 
D10             AGTGGCTTATTAGGAACAGATAATAATAGTACCATAATGAATAATGAATATTTAAACCTT 
                ********************** ************************************* 
 
W2.QHS200       GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT 
Dd2             GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT 
W2              GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT 
3D7             GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT 
D10             GATTATAAAAATTTATTAGATATGAATATATCATATAACAAATTAAATGAAAAAATAAAT 
                ************************************************************ 
 
W2.QHS200       AATGATATTATAAATAATACTTCTGATGTTCAGGAGAAAAATATGGATTATAATGATATT 
Dd2             AATGATATTATAAATAATACTTCTGATGTTCAGGAGAAAAATATGGATTATAATGATATT 
W2              AATGATATTATAAATAATACTTTTGATGTTCAGGAGAAAAATATGGATTATAATGATATT 
3D7             AATGATATTATAAATAATACTTCTGATGTTCAGGAGAAAAATATGGATTATAATGATATT 
D10             AATGATATTATAAATAATACTTCTGATGTTCAGGAGAAAAATATGGATTATAATGATATT 
                ********************** ************************************* 
 
W2.QHS200       CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA 
Dd2             CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA 
W2              CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA 
3D7             CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA 
D10             CATAATTTTCAGAAAAAAAAAAAATCTTCTAATTTTGCTTATTTAAATTTTTTCCATAAA 
                ************************************************************ 
 
W2.QHS200       GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGATAGT 
Dd2             GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGATAGT 
W2              GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGATAGT 
3D7             GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGGTAGT 
D10             GAAAGTAAAGATAATAAAATTGATGTAAAAGAATCATTTTTAAATAAAAGATATGGTAGT 
                ******************************************************* **** 
 
W2.QHS200       AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATA------TA 
Dd2             AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATA------TA 
W2              AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATA------TA 
3D7             AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATAATA---TA 
D10             AATAAACGTAGTAGTAAAATATATGATAATAATAATAATAATAATAATAATAATAATATA 
                ****************************************************      ** 
 
W2.QHS200       AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT 
Dd2             AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT 
W2              AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT 
3D7             AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT 
D10             AACTCCAAAATTGATTATTTAGAAAATAATATAACATATACAGAATTCAAAAAAATACTT 
                ************************************************************ 
 
W2.QHS200       TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT 
Dd2             TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT 
W2              TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT 
3D7             TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT 
D10             TTACCATATTTGTGGCCAAGCAAAAGGATAGATATGAAAGGAAATAGCTCTATATTACGT 
                ************************************************************ 
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W2.QHS200       ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT 
Dd2             ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT 
W2              ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT 
3D7             ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT 
D10             ACATATATTGTTCTAATATTTTTATTTATATTAGTATCAAAAGTATTTAGTGTAATTTCT 
                ************************************************************ 
 
W2.QHS200       CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA 
Dd2             CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA 
W2              CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA 
3D7             CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA 
D10             CCGATATATTTAGGTTGGGCATCAAATGAAGTATTAAAAAAGAGTTTATCTAGTTCAGTA 
                ************************************************************ 
 
W2.QHS200       TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT 
Dd2             TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT 
W2              TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT 
3D7             TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT 
D10             TATTATTTAGGTTTATATGTAACATTTTTTTTTATATCTAAATTTTTAAAAGAGGTTTGT 
                ************************************************************ 
 
W2.QHS200       GGTGTATTATATTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT 
Dd2             GGTGTATTATATTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT 
W2              GGTGTATTATATTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT 
3D7             GGTGTATTATTTTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT 
D10             GGTGTATTATTTTCACAAGTACAACAATCAGCTTTTATAGAATTACAAGAATCTATATTT 
                ********** ************************************************* 
 
W2.QHS200       CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGTGGTATCATG 
Dd2             CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGTGGTATCATG 
W2              CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGTGGTATCATG 
3D7             CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGTGGTATCATG 
D10             CAAACATTTCATAATTTATCATATGAATGGTATTCTAGTAAAAATTCGGGAGGTATCATG 
                ************************************************** ********* 
 
W2.QHS200       AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT 
Dd2             AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT 
W2              AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT 
3D7             AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT 
D10             AGAATAGTTGATAGAGGTACCGAGAGTGCTAATAATTTGATGAGTTCTGTTTTAATGTAT 
                ************************************************************ 
 
W2.QHS200       ATTATTCCGGCAATAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG 
Dd2             ATTATTCCGGCAATAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG 
W2              ATTATTCCGGCAATAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG 
3D7             ATTATTCCGGCAACAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG 
D10             ATTATTCCGGCAACAATAGAAGGATTAATAACATGTATTATATTTATTTTTAAATATAAG 
                ************* ********************************************** 
 
W2.QHS200       AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA 
Dd2             AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA 
W2              AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA 
3D7             AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA 
D10             AATAGTTTATTAGGTAGTGTATTATTTATAGGTTTAACTTTATATATATATTCAACAATA 
                ************************************************************ 
 
W2.QHS200       AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT 
Dd2             AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT 
W2              AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT 
3D7             AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT 
D10             AAAATTACAAAGTGGAGAAAAAAAATTAGAACAAAAGCAAATGAGATGGATAATGTATAT 
                ************************************************************ 
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W2.QHS200       CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA 
Dd2             CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA 
W2              CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA 
3D7             CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA 
D10             CATGATATAGCTCATGATTCATTAACAAATTATGAAAATGTGAAATATTTTAGTAATGAA 
                ************************************************************ 
 
W2.QHS200       AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA 
Dd2             AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA 
W2              AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA 
3D7             AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA 
D10             AAATTTGAAATCAAAAAATTTTGTAATGCATTATCAAATTATCATAGATATAATTTAAAA 
                ************************************************************ 
 
W2.QHS200       ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA 
Dd2             ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA 
W2              ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA 
3D7             ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA 
D10             ATATTAAATAGTTTAGGTATATTAAATACTGTTCAACAATTTATATTGAATGGTACCTTA 
                ************************************************************ 
 
W2.QHS200       TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC 
Dd2             TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC 
W2              TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC 
3D7             TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC 
D10             TTCTTTACATTATTATGTGTAATATATATGATAGTTAAGGAAGGATCAGATCCAGGTACC 
                ************************************************************ 
 
W2.QHS200       TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA 
Dd2             TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA 
W2              TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA 
3D7             TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA 
D10             TTCATAAGTGTAGTTGTATATACATCTAATGTATTTGCTCCATTAAGTATATTAGGAACA 
                ************************************************************ 
 
W2.QHS200       TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA 
Dd2             TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA 
W2              TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA 
3D7             TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA 
D10             TTATATGCTACTATTATTAAATCATTTACTGATATTAGTGATTTGATAGATATTTTAAGA 
                ************************************************************ 
 
W2.QHS200       GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA 
Dd2             GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA 
W2              GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA 
3D7             GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA 
D10             GATAAAATTGATATATCAAATGATAAAAATTTGAAAAATTTTGATTTAACATCACAAGAA 
                ************************************************************ 
 
W2.QHS200       AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA 
Dd2             AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA 
W2              AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA 
3D7             AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA 
D10             AAAAAATTCGGTGTTAGTATTGAATTTAATAATGTACATTTTAATTACCCAACACAACCA 
                ************************************************************ 
 
W2.QHS200       TTACATACATCATTAAAAGATATTAATATCTACATAAAACCAGGTACAACATGTGCTCTT 
Dd2             TTACATACATCATTAAAAGATAT-AATATCTACATAAAACCAGGTACAACATGT------ 
W2              TTACATACATCATTAAAAGATATTAATATCTACATAAAACCAGGTACAACATGTGCTCTT 
3D7             TTACATACATCATTAAAAGATATTAATATATACATAAAACCAGGTACAACATGTGCTCTT 
D10             TTACATACATCATTAAAAGATATTAATATCTACATAAAACCAGGTACAACATGTGCTCTT 
                *********************** ***** ************************       
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W2.QHS200       GTAGGTCATACAGGTTCTGGAAAAACAACAATTTCGAAATTGTTA-TATCGATTCTATGA 
Dd2             ---------------------AAAACAACAATTTCGAAATTGTTAATATCGATTCTATGA 
W2              GTAGGTCATACAGGTTCTGGAAAAACAACAATTTCGAAATTGTTA-TATCGATTCTATGA 
3D7             GTAGGTCATACAGGTTCTGGAAAAACAACAATTTCGAAATTGTTA-TATCGATTCTATGA 
D10             GTAGGTCATACAGGTTCTGGAAAAACAACAATTTCGAAATTGTTA-TATCGATTCTATGA 
                                     ************************ ************** 
 
W2.QHS200       TTCAAAAGGAGAGATTAAAATTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT 
Dd2             TTCAAAAGGAGAGATTAAA-TTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT 
W2              TTCAAAAGGAGAGATTAAAATTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT 
3D7             TTCAAAAGGAGAGATTAAAATTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT 
D10             TTCAAAAGGAGAGATTAAAATTGGAGGACGTAATATAAATGAATATACCAGAAACTCCAT 
                ******************* **************************************** 
 
W2.QHS200       TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA 
Dd2             TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA 
W2              TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA 
3D7             TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA 
D10             TAGAAATATTATAGGTATAGTACCACAAGATACCATATTATTTAATGAATCTATAAAATA 
                ************************************************************ 
 
W2.QHS200       TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC 
Dd2             TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC 
W2              TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC 
3D7             TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC 
D10             TAATATTTTATACGGAAAATTAGATGCCACTGAAGAAGAATTAATACAAGCTGTTAAATC 
                ************************************************************ 
 
W2.QHS200       GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA 
Dd2             GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA 
W2              GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA 
3D7             GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA 
D10             GGCTCAGTTATATGATTTTATACAATCTCTTCCAAAAAAATGGGACACTTTAGTTGGTGA 
                ************************************************************ 
 
W2.QHS200       TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT 
Dd2             TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT 
W2              TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT 
3D7             TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT 
D10             TAAAGGAGTCAAATTATCAGGAGGAGAACGACAAAGAATATCTATAGCAAGATGTTTATT 
                ************************************************************ 
 
W2.QHS200       GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA 
Dd2             GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA 
W2              GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA 
3D7             GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA 
D10             GAAAGATCCTAAAATTGTTATATTTGATGAAGCAACCAGTTCATTAGATTCAAGAACCGA 
                ************************************************************ 
 
W2.QHS200       ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC 
Dd2             ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC 
W2              ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC 
3D7             ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC 
D10             ATATCTTTTCCAAAAAGCTGTAGAAGATTTAAGAAAAAATAGAACCATTATTATTATAGC 
                ************************************************************ 
 
W2.QHS200       ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT 
Dd2             ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT 
W2              ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT 
3D7             ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT 
D10             ACATAAACTATGTACTATCACAACCGCTGAATTAATTATCTTATTGAACAAAGGAAAAAT 
                ************************************************************ 
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W2.QHS200       TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG 
Dd2             TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG 
W2              TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG 
3D7             TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG 
D10             TATAGAAAGAGGAACACATCTAGATTTATTAAAATGTAATGGAGAATACACAGAAATGTG 
                ************************************************************ 
 
W2.QHS200       GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA 
Dd2             GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA 
W2              GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA 
3D7             GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA 
D10             GAATATGCAATCAAAATCAAATGAACCACATACTGAAACAAATTCATCAATTGATAAAGA 
                ************************************************************ 
 
W2.QHS200       CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA 
Dd2             CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA 
W2              CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA 
3D7             CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA 
D10             CGATGTAAATAAAAATAATAACAAAAATAATGATGTCATACTTAATACATGTAAAAATGA 
                ************************************************************ 
 
W2.QHS200       TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG 
Dd2             TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG 
W2              TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG 
3D7             TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG 
D10             TATCACCACAAGTTTTAGATCGAACAGTGAAAAAAGTAGTCAAGAATTTAGTGACGCAAG 
                ************************************************************ 
 
W2.QHS200       TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA 
Dd2             TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA 
W2              TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA 
3D7             TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA 
D10             TAATCATATTAAGCAATCGAAAACTTCTAATGACCATAATAATAATATTAACGTACACAA 
                ************************************************************ 
 
W2.QHS200       AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT 
Dd2             AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT 
W2              AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT 
3D7             AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT 
D10             AAAAAATGAACAAGAACAACTTTTTTTAACAAATGATAAAACAGATATGGATGATAATAT 
                ************************************************************ 
 
W2.QHS200       GAATAACAAAAAAAAATAG 
Dd2             GAATAACAAAAAAAAATAG 
W2              GAATAACAAAAAAAAA--- 
3D7             GAATAACAAAAAAAAATAG 
D10             GAATAACAAAAAAAAATAG 
                ****************    
 
Fig. 2.12.  Alignment of pfmdr2 Nucleotide Sequences in W2 Lines did not Identify 
Dissimilarities. ClustalW Alignment of pfmdr2 sequences from 3D7, D10, Dd2, W2, and 
W2.QHS200.  The CDS of pfmdr2 is 3075 bp.  Similar bases in the alignment are 
denoted by an asterisk in the last row of the alignment, whereas SNPs or missing bases 
can be detected by a gap in continuous asterisks.  There was a gap in the middle of the 
Dd2 sequence (highlighted) that caused missing asterisks, but in that part of sequence, 
there is similarity between W2 strains, 3D7, and D10.  
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3D7             ATGGTTGAAAATAAGAGTAAGGTCAAAGATATCAGTTTGGCCCCCTTTGGAAAAATGCAG 
Dd2             ATGGTTGAAAATAAGAGTAAGGTCAAAGATATCAGTTTGGCCCCCTTTGGAAAAATGCAG 
W2              ATGGTTGAAA-TAAGAGTAAGGTCAAAGATATCAGTTTGGCCCCCTTTGGAAAAATGCAG 
W2.QHS200       ATGGTTGAAA-TAAGAGTAAGGTCAAAGATATCAGTTTGGCCCCCTTTGGAAAAATGCAG 
                ********** ************************************************* 
 
3D7             ATGGAAATTTCTGAAAATGAAATGCCGGGATTAATGAGAATAAGAGAAGAATACGGAAAA 
Dd2             ATGGAAATTTCTGAAAATGAAATGCCGGGATTAATGAGAATAAGAGAAGAATACGGAAAA 
W2              ATGGAAATTTCTGAAAATGAAATGCCGGGATTAATGAGAATAAGAGAAGAATACGGAAAA 
W2.QHS200       ATGGAAATTTCTGAAAATGAAATGCCGGGATTAATGAGAATAAGAGAAGAATACGGAAAA 
                ************************************************************ 
 
3D7             GATCAACCATTAAAAAATGCTAAAATTACTGGTTGTTTACATATGACTGTTGAATGTGCT 
Dd2             GATCAACCATTAAAAAATGCTAAAATTACTGGTTGTTTACATATGACTGTTGAATGTGCT 
W2              GATCAACCATTAAAAAATGCTAAAATTACTGGTTGTTTACATATGACTGTTGAATGTGCT 
W2.QHS200       GATCAACCATTAAAAAATGCTAAAATTACTGGTTGTTTACATATGACTGTTGAATGTGCT 
                ************************************************************ 
 
3D7             TTATTAATTGAGACTTTACAAAAATTAGGAGCTCAGATTAGGTGGTGTTCATGTAATATT 
Dd2             TTATTAATTGAGACTTTACAAAAATTAGGAGCTCAGATTAGGTGGTGTTCATGTAATATT 
W2              TTATTAATTGAGACTTTACAAAAATTAGGAGCTCAGATTAGGTGGTGTTCATGTAATATT 
W2.QHS200       TTATTAATTGAGACTTTACAAAAATTAGGAGCTCAGATTAGGTGGTGTTCATGTAATATT 
                ************************************************************ 
 
3D7             TATTCAACAGCTGATTATGCTGCAGCAGCAGTAAGTACATTAGAAAATGTAACGGTTTTT 
Dd2             TATTCAACAGCTGATTATGCTGCAGCAGCAGTAAGTACATTAGAAAATGTAACGGTTTTT 
W2              TATTCAACAGCTGATTATGCTGCAGCAGCAGTAAGTACATTAGAAAATGTAACGGTTTTT 
W2.QHS200       TATTCAACAGCTGATTATGCTGCAGCAGCAGTAAGTACATTAGAAAATGTAACGGTTTTT 
                ************************************************************ 
 
3D7             GCTTGGAAAAATGAAACTTTAGAAGAATACTGGTGGTGTGTTGAAAGTGCCCTTACGTGG 
Dd2             GCTTGGAAAAATGAAACTTTAGAAGAATACTGGTGGTGTGTTGAAAGTGCCCTTACGTGG 
W2              GCTTGGAAAAATGAAACTTTAGAAGAATACTGGTGGTGTGTTGAAAGTGCCCTTACGTGG 
W2.QHS200       GCTTGGAAAAATGAAACTTTAGAAGAATACTGGTGGTGTGTTGAAAGTGCCCTTACGTGG 
                ************************************************************ 
 
3D7             GGTGATGGAGATGATAATGGTCCAGATATGATTGTAGATGATGGGGGTGATGCAACCTTA 
Dd2             GGTGATGGAGATGATAATGGTCCAGATATGATTGTAGATGATGGGGGTGATGCAACCTTA 
W2              GGTGATGGAGATGATAATGGTCCAGATATGATTGTAGATGATGGGGGTGATGCAACCTTA 
W2.QHS200       GGTGATGGAGATGATAATGGTCCAGATATGATTGTAGATGATGGGGGTGATGCAACCTTA 
                ************************************************************ 
 
3D7             TTAGTTCATAAAGGTGTTGAGTATGAAAAATTATATGAAGAGAAAAATATATTACCTGAT 
Dd2             TTAGTTCATAAAGGTGTTGAGTATGAAAAATTATATGAAGAGAAAAATATATTACCTGAT 
W2              TTAGTTCATAAAGGTGTTGAGTATGAAAAATTATATGAAGAGAAAAATATATTACCTGAT 
W2.QHS200       TTAGTTCATAAAGGTGTTGAGTATGAAAAATTATATGAAGAGAAAAATATATTACCTGAT 
                ************************************************************ 
 
3D7             CCAGAAAAAGCAAAAAA-TGAAGAAGAACGATGTTTTCTAACTTTATTAAAAAATTCCAT 
Dd2             CCAGAAAAAGCAAAAAA-TGAAGAAGAACGATGTTTTCTAACTTTATTAAAAAATTCCAT 
W2              CCAGAAAAAGCAAAAAAATGAAGAAGAACGATGTTTTCTAACTTTATTAAAAAATTCCAT 
W2.QHS200       CCAGAAAAAGCAAAAAAATGAAGAAGAACGATGTTTTCTAACTTTATTAAAAAATTCCAT 
                ***************** ****************************************** 
 
3D7             ATTAAAAAATCCAAAGAAATGGACAAATATTGCAAAGAAAATTATAGGTGTATCTGAAGA 
Dd2             ATTAAAAAATCCAAAGAAATGGACAAATATTGCAAAGAAAATTATAGGTGTATCTGAAGA 
W2              ATTAAAAAATCCAAAGAAATGGACAAATATTGCAAAGAAAATTATAGGTGTATCTGAAGA 
W2.QHS200       ATTAAAAAATCCAAAGAAATGGACAAATATTGCAAAGAAAATTATAGGTGTATCTGAAGA 
                ************************************************************ 
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3D7             AACTACTACAGGAGTATTAAGATTAAAAAAAATGGACAAACAAAATGAATTATTATTTAC 
Dd2             AACTACTACAGGAGTATTAAGATTAAAAAAAATGGACAAACAAAATGAATTATTATTTAC 
W2              AACTACTACAGGAGTATTAAGATTAAAAAAAATGGACAAACAAAATGAATTATTATTTAC 
W2.QHS200       AACTACTACAGGAGTATTAAGATTAAAAAAAATGGACAAACAAAATGAATTATTATTTAC 
                ************************************************************ 
 
3D7             TGCTATTAATGTAAATGATGCTGTCACTAAACAAAAATATGATAATGTGTATGGATGTAG 
Dd2             TGCTATTAATGTAAATGATGCTGTCACTAAACAAAAATATGATAATGTGTATGGATGTAG 
W2              TGCTATTAATGTAAATGATGCTGTCACTAAACAAAAATATGATAATGTGTATGGATGTAG 
W2.QHS200       TGCTATTAATGTAAATGATGCTGTCACTAAACAAAAATATGATAATGTGTATGGATGTAG 
                ************************************************************ 
 
3D7             ACATTCCTTACCTGACGGATTAATGAGAGCTACCGATTTTTTAATATCTGGAAAAATCGT 
Dd2             ACATTCCTTACCTGACGGATTAATGAGAGCTACCGATTTTTTAATATCTGGAAAAATCGT 
W2              ACATTCCTTACCTGACGGATTAATGAGAGCTACCGATTTTTTAATATCTGGAAAAATCGT 
W2.QHS200       ACATTCCTTACCTGACGGATTAATGAGAGCTACCGATTTTTTAATATCTGGAAAAATCGT 
                ************************************************************ 
 
3D7             TGTCATATGTGGATATGGTGACGTAGGTAAAGGATGTGCTTCTTCTATGAAAGGTTTAGG 
Dd2             TGTCATATGTGGATATGGTGACGTAGGTAAAGGATGTGCTTCTTCTATGAAAGGTTTAGG 
W2              TGTCATATGTGGATATGGTGACGTAGGTAAAGGATGTGCTTCTTCTATGAAAGGTTTAGG 
W2.QHS200       TGTCATATGTGGATATGGTGACGTAGGTAAAGGATGTGCTTCTTCTATGAAAGGTTTAGG 
                ************************************************************ 
 
3D7             TGCAAGAGTATATATAACAGAAATTGATCCCATATGTGCTATACAAGCTGTAATGGAAGG 
Dd2             TGCAAGAGTATATATAACAGAAATTGATCCCATATGTGCTATACAAGCTGTAATGGAAGG 
W2              TGCAAGAGTATATATAACAGAAATTGATCCCATATGTGCTATACAAGCTGTAATGGAAGG 
W2.QHS200       TGCAAGAGTATATATAACAGAAATTGATCCCATATGTGCTATACAAGCTGTAATGGAAGG 
                ************************************************************ 
 
3D7             ATTTAATGTTGTTACTTTAGATGAAATTGTAGATAAAGGAGATTTTTTTATTACTTGTAC 
Dd2             ATTTAATGTTGTTACTTTAGATGAAATTGTAGATAAAGGAGATTTTTTTATTACTTGTAC 
W2              ATTTAATGTTGTTACTTTAGATGAAATTGTAGATAAAGGAGATTTTTTTATTACTTGTAC 
W2.QHS200       ATTTAATGTTGTTACTTTAGATGAAATTGTAGATAAAGGAGATTTTTTTATTACTTGTAC 
                ************************************************************ 
 
3D7             AGGTAATGTTGATGTTATTAAATTAGAACACTTACTTAAAATGAAAAATAATGCTGTTGT 
Dd2             AGGTAATGTTGATGTTATTAAATTAGAACACTTACTTAAAATGAAAAATAATGCTGTTGT 
W2              AGGTAATGTTGATGTTATTAAATTAGAACACTTACTTAAAATGAAAAATAATGCTGTTGT 
W2.QHS200       AGGTAATGTTGATGTTATTAAATTAGAACACTTACTTAAAATGAAAAATAATGCTGTTGT 
                ************************************************************ 
 
3D7             TGGAAACATTGGTCATTTTGATGATGAAATACAAGTAAATGAACTTTTTAATTATAAAGG 
Dd2             TGGAAACATTGGTCATTTTGATGATGAAATACAAGTAAATGAACTTTTTAATTATAAAGG 
W2              TGGAAACATTGGTCATTTTGATGATGAAATACAAGTAAATGAACTTTTTAATTATAAAGG 
W2.QHS200       TGGAAACATTGGTCATTTTGATGATGAAATACAAGTAAATGAACTTTTTAATTATAAAGG 
                ************************************************************ 
 
3D7             AATACATATAGAAAATGTAAAACCACAGGTTGATAGAATTACTTTACCTAATGGAAATAA 
Dd2             AATACATATAGAAAATGTAAAACCACAGGTTGATAGAATTACTTTACCTAATGGAAATAA 
W2              AATACATATAGAAAATGTAAAACCACAGGTTGATAGAATTACTTTACCTAATGGAAATAA 
W2.QHS200       AATACATATAGAAAATGTAAAACCACAGGTTGATAGAATTACTTTACCTAATGGAAATAA 
                ************************************************************ 
 
3D7             AATTATTGTTTTAGCTAGAGGGAGATTATTAAATCTAGGATGTGCAACAGGACATCCAGC 
Dd2             AATTATTGTTTTAGCTAGAGGGAGATTATTAAATCTAGGATGTGCAACAGGACATCCAGC 
W2              AATTATTGTTTTAGCTAGAGGGAGATTATTAAATCTAGGATGTGCAACAGGACATCCAGC 
W2.QHS200       AATTATTGTTTTAGCTAGAGGGAGATTATTAAATCTAGGATGTGCAACAGGACATCCAGC 
                ************************************************************
 196 
 
3D7             ATTTGTTATGTCCTTTTCATTTTGTAATCAAACCTTTGCTCAATTAGATTTATGGCAAAA 
Dd2             ATTTGTTATGTCCTTTTCATTTTGTAATCAAACCTTTGCTCAATTAGATTTATGGCAAAA 
W2              ATTTGTTATGTCCTTTTCATTTTGTAATCAAACCTTTGCTCAATTAGATTTATGGCAAAA 
W2.QHS200       ATTTGTTATGTCCTTTTCATTTTGTAATCAAACCTTTGCTCAATTAGATTTATGGCAAAA 
                ************************************************************ 
 
3D7             CAAGGATACAAACAAATATGAAAATAAAGTTTATTTGTTACCTAAACATCTTGATGAAAA 
Dd2             CAAGGATACAAACAAATATGAAAATAAAGTTTATTTGTTACCTAAACATCTTGATGAAAA 
W2              CAAGGATACAAACAAATATGAAAATAAAGTTTATTTGTTACCTAAACATCTTGATGAAAA 
W2.QHS200       CAAGGATACAAACAAATATGAAAATAAAGTTTATTTGTTACCTAAACATCTTGATGAAAA 
                ************************************************************ 
 
3D7             GGTTGCTCTTTATCATTTGAAAAAATTGAACGCTTCCTTGACAGAATTGGATGACAATCA 
Dd2             GGTTGCTCTTTATCATTTGAAAAAATTGAACGCTTCCTTGACAGAATTGGATGACAATCA 
W2              GGTTGCTCTTTATCATTTGAAAAAATTGAACGCTTCCTTGACAGAATTGGATGACAATCA 
W2.QHS200       GGTTGCTCTTTATCATTTGAAAAAATTGAACGCTTCCTTGACAGAATTGGATGACAATCA 
                ************************************************************ 
 
3D7             ATGTCAATTTTTGGGAGTCAACAAAAGTGGTCCCTTTAAGAGTAACGAATACAGATATTA 
Dd2             ATGTCAATTTTTGGGAGTCAACAAAAGTGGTCCCTTTAAGAGTAACGAATACAGATATTA 
W2              ATGTCAATTTTTTG---------------------------------------------- 
W2.QHS200       ATGTCAATTTTTTG---------------------------------------------- 
                ************ *                                               
 
3D7             A 
Dd2             A 
W2              - 
W2.QHS200       - 
                  
 
Fig. 2.13.  Alignment of PFE1050w Nucleotide Sequences in W2 Lines did not Identify 
Dissimilarities. ClustalW Alignment of PFE1050w sequences from 3D7, Dd2, W2, and 
W2.QHS200.  The CDS of PFE1050w is 1440 bp.  Similar bases in the alignment are 
denoted by an asterisk in the last row of the alignment, whereas SNPs or missing bases 
can be detected by a gap in continuous asterisks.  Sequence from the 3‟ end of the gene 
for W2 and W2.QHS200 was not returned from sequencing efforts.  Sequences of W2 
and W2.QHS200 are identical to each other and 3D7 and Dd2 except for a few missing 
nucleotides within strings of adenosine (5‟end) or thymidine bases (3‟ end).  However, 
these were in areas of unreliable sequence and are not likely to constitute actual missing 
bases. 
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Figure 2.14.  Real-Time QPCR Assays for Copy Number Found PFE1050w, PF11_0466, 
and pfmdr2 Were not Amplified in Resistant Parasites, but pfmdr1 was Amplified in W2 
and TM91c235 Lines.  Average copy number of PFE1050w (A.), PF11_0466 (B.), 
pfmdr2 (C.), and pfmdr1 (D.) in parental and resistant strains (D6, W2, TM91c235) 
relative to D6 as determined by SYBR Green real-time QPCR. 
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Table 2.1.  Oligonucleotides Used in Analyses of PFE1050w, PF11_0466, pfmdr2, and 
pfmdr1 
 
Primer Name Sequence 5'-3' Source/Reference 
Sequencing 
  pfmdr2 seqF-4 TGAGACATTTATTCTATTCCGA This work 
pfmdr2 seqR-4 CATTCAATATAACTAAGATACCG This work 
   
pfmdr2 Cd F-2 GAATACATTAGGAAAGGTGT 
Rosenberg et al., 
2006 
379
 
pfmdr2 seq R-5 GCTATTTCCTTTCATATCTATC 
Rosenberg et al., 
2006 
379
 
   pfmdr2 seq F-5 GCAAAAGGATAGATATGAAAGG This work 
pfmdr2 seq R-6 GAACTCATCAAATTATTAGCACT This work 
   
pfmdr2 Cd F-4 TTTTAAAAGAGGTTTGTGGTGT 
Rosenberg et al., 
2006 
379
 
pfmdr2 seq R-7 CTTATGAAGGTACCTGGATCT This work 
   pfmdr2 seq F-6 GATCAGATCCAGGTACCTTCA This work 
pfmdr2 Cd R-5 GTATGACCTACAAGAGCACATG 
Rosenberg et al., 
2006 
379
 
   
pfmdr2 Cd F-6 CATAAAACCAGGTACAACATGT 
Rosenberg et al., 
2006 
379
 
pfmdr2 seq R-8 GAATCTAATGAACTGGTTGCT This work 
   
pfmdr2 Cd F-7 AAATGGGACACTTTAGTTGG  
Rosenberg et al., 
2006 
379
 
pfmdr2 seq R-3 CGAAGAATTTTGGATATGATTA This work 
   PFE1050w seq2 F GTATCATACCCATCGGCATATAA This work 
PFE1050w seq2 R-1 CGTTACTCTTAAAGGGACCAC This work 
   PF11_0466 seq F AACGATTGAGAATGGTACGTTTT This work 
PF11_0466 seq2 R-1 GCGTTTCATATCTCTTTCTTAATC This work 
   Real-Time QPCR 
  
LDH-T1F AGGACAATATGGACACTCCGAT 
Chavchich et al., 
2010 
276
 
LDH-T1R  TTTCAGCTATGGCTTCATCAAA 
Chavchich et al., 
2010 
276
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Table 2.1 Continued 
Primer Name Sequence 5'-3' Source/Reference 
Real-Time QPCR  
  
MDR-T1F TATGCATTTGTGGGAGAATCAG 
Chavchich et al., 
2010 
276
 
MDR-T1R CTCCTTCGGTTGGATCATAAAG 
Chavchich et al., 
2010 
276
 
   pfmdr2 rt F-3 ACAAGCTGTTAAATCGGCTCAG This work 
pfmdr2 rt R-3 TCTTTGTCGTTCTCCTCCTGA This work 
   PFE1050w RT-1 F GAAATGCCGGGATTAATGAG This work 
PFE1050w RT-1 R ATCTCCATCACCCCACGTAA This work 
   PF11_0466 RT-1 F GGATAAGCAATTTTTCGAATGG This work 
PF11_0466 RT-1 R CCACCACCACTTTTCCCTATT This work 
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Table 2.2.  Stepwise Induction of Artemisinin Resistance in D6 
Strain Date QHS Added 
Days Post 
Original Drug 
Addition 
QHS Concentration 
(ng/ml) 
QHS Concentration 
(nM) Notes 
D6.QHS80 8/27/2007 0 80 283.7 
 D6.QHS80x1 8/31/2007 4 80 283.7 
 D6.QHS80x2 9/6/2007 10 120 425.5 
 D6.QHS120x1 9/14/2007 18 120 425.5 
 D6.QHS120x2 10/2/2007 36 160 567.4 
 D6.QHS160x1 10/10/2007 44 160 567.4 
 D6.QHS160x2 10/16/2007 50 200 709.2 
 D6.QHS200x1 10/26/2007 60 200 709.2 
 D6.QHS200x2 11/9/2007 74 200 709.2 
 D6.QHS200x3 11/15/2007 80 240 851.1 
 D6.QHS240x1 11/19/2007 84 240 851.1 
 D6.QHS240x2 11/21/2007 86 280 992.9 
 D6.QHS280x1 12/3/2007 98 280 992.9 
 D6.QHS280x2 12/10/2007 105 300 1063.8 
 D6.QHS300x1 1/4/2008 130 300 1063.8 
 
D6.QHS300x2 3/7/2008 193 200 709.2 
D6.QHS300x2 was exposed to 200 ng/ml 
before a cloning attempt 
D6.QHS300x2, 
200x1 3/14/2008 200 300 1063.8 
 D6.QHS300x3 4/7/2008 224 300 1063.8 
 D6.QHS300x4 5/5/2008 252 340 1205.7 
 D6.QHS340x1 5/28/2008 275 340 1205.7 
 
D6.QHS340x2 7/24/2008 332 340 1205.7 
D6.QHS340x2 to recovery assay 80-340 
ng/ml QHS=D6.QHS340x3 
D6.QHS340x3 8/29/2008 368 2400 8510.6 
D6.QHS340x3 to recovery assay 80-2400 
ng/ml QHS=D6.QHS2400x1 
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Table 2.2 Continued 
Strain Date QHS Added 
Days Post 
Original Drug 
Addition 
QHS Concentration 
(ng/ml) 
QHS Concentration 
(nM) Notes 
D6.QHS2400x1 9/24/2008 394 2400 8510.6 
 D6.QHS2400x2 11/26/2008 457 2400 8510.6 
 D6.QHS2400x3 2/16/2009 539 2400 8510.6 D6.QHS2400x4 to cloning 
D6.QHS2400x4 
clone C9 10/28/2009 793 2400 8510.6 
D6.QHS2400x4 (clone C9) treated with 
2400 ng/ml for 5th time  
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Table 2.3.  Stepwise Induction of Artelinic Acid Resistance in TM91c235 
Strain 
Date AL 
Added 
Days Post 
Original AL 
Addition 
AL 
Concentration 
(ng/ml) 
AL 
Concentration 
(nM) Notes 
TM91c235.AL80  11/26/2007 0 40 95.6 40 ng/ml applied because it did not tolerate 80 ng/ml 
TM91c235.AL80 
(40x1) 1/14/2008 49 40 95.6 
 TM91c235.AL80 
(40x2) 1/23/2008 58 60 143.4 
 TM91c 235.AL80 
(40x2, 60x1) 1/28/2008 63 80 191.2 
 TM91c 235.AL80x1 3/5/2008 100 80 191.2 
 TM91c 235.AL80x2 3/25/2008 120 120 286.8 
 TM91c235.AL120x1 4/1/2008 127 120 286.8 
 TM91c235.AL120x2 4/15/2008 141 160 382.3 
 TM91c235.AL160x1 4/30/2008 155 160 382.3 
 TM91c235.AL160x2 5/28/2008 184 180 430.1 
 TM91c235.AL180x1 6/18/2008 205 180 430.1 
 TM91c235.AL180x2 6/23/2008 210 200 477.9 
 TM91c235.AL200x1 8/11/2008 259 200 477.9 
 TM91c235.AL200x2 9/1/2008 280 200 477.9 
 TM91c235.AL200x3 9/21/2008 300 240 573.5 
 TM91c235.AL240x1 10/6/2008 315 240 573.5 
 TM91c235.AL240x2 11/26/2008 366 280 669.1 thawed out to continue pressure much later- 280 for 2nd time 
TM91c235.AL280x1 10/23/2009 697 280 669.1   
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Table 2.4.  In Vitro Susceptibility Testing of Parental and Resistant Lines: Artemisinin Drugs 
 
DHA   QHS   AS   AM   AL   
Parasite line IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90 
W2  0.69±0.34 1.6±0.95 1.3±0.71 3.2±0.80 0.40±0.16 0.94±0.50 0.73±0.38 1.5±0.56 2.0±0.75 3.3±1.2 
W2.QHS200x2  0.89±0.33 2.3±0.70 4.2±2.0 9.6±4.1 1.2±0.36 2.2±0.58 1.6±0.42 3.4±1.4 12.3±3.35 18.4±5.93 
                      
D6  0.15±0.028 0.34±0.19 0.92±0.10 4.1±0.75 0.28±0.080 0.68±0.17 0.50±0.070 1.3±0.44 2.8±0.66 11.5±4.80 
D6.QHS2400x5  1.4±0.30 4.0±0.44 8.8±1.0 19.3±2.95 1.2±0.040 2.0±0.13 2.7±0.30 5.8±0.27 18.0±1.56 22.2±4.32 
                      
TM91c235  1.2±0.78 2.7±0.81 2.2±1.8 5.7±2.1 0.93±0.77 1.4±0.57 0.91±0.73 2.3±0.67 3.2±1.5 22.3±15.9 
TM91c235.AL280x2 1.7±1.2 3.7±1.2 8.7±5.4 16.5±6.2 1.7±0.82 4.0±2.1 3.5±2.1 6.0±2.1 16.0±12.0 37.6±19.7 
 
DHA=Dihydroartemisinin 
QHS=Artemisinin 
AS=Artesunate 
AM=Artemether 
AL=Artelinic Acid 
IC50=50% Inhibitory Concentration (in ng/ml) 
IC90=90% Inhibitory Concentration (ng/ml) 
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Table 2.5.  In Vitro Susceptibility Testing of Parental and Resistant Lines: Common Antimalarial Drugs 
 
 
CQ 
 
MQ   LF   
Parasite line IC50 IC90 IC50 IC90 IC50 IC90 
W2  140.1±43.68 193.3±46.99 2.7±0.94 5.7±1.7 26.0±12.7 169.1±89.44 
W2.QHS200x2  101±7.44 142.6±10.28 5.9±1.3 22.3±4.36 98.8±17.3 144.5±25.98 
              
D6  2.6±0.26 4.3±0.72 0.93±0.17 3.1±1.2     
D6.QHS2400x5  1.8±0.19 2.8±0.31 3.8±0.37 7.8±0.77     
              
TM91c235  23.2±5.54 51.3±10.6 8.0±3.0 91.3±37.9     
TM91c235.AL280x2 66.5±40.4 126.1±74.10 8.7±4.5 51.7±22.0     
 
  HAL   PIP   ATOV   
Parasite line IC50 IC90 IC50 IC90 IC50 IC90 
W2  0.28±0.10 0.84±0.39 115.6±12.66 158.6±56.90 0.21±0.0904 1.3±0.96 
W2.QHS200x2  1.1±0.68 2.0±0.95 94.2±5.45 123.5±15.56 0.21±0.067 0.75±0.31 
              
D6          0.022±0.0040 0.11±0.045 
D6.QHS2400x5          0.041±0.0050 0.25±0.044 
              
TM91c235          0.26±0.15 2.0±1.2 
TM91c235.AL280x2         0.29±0.19 1.9±0.88 
 
CQ=Chloroquine, MQ=Mefloquine, LF=Lumefantrine, HAL=Halofantrine, PIP=Piperaquine, ATOV=Atovaquone  
IC50=50% Inhibitory Concentration (in ng/ml) 
IC90=90% Inhibitory Concentration (ng/ml) 
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Table 2.6.  Ring Stage Viability Assay Utilizing D6 and W2 Parental and Resistant Strains at 24 and 48 Hours Post-Drug Exposure 
 
 
DHA 
 
AL 
 
QHS 
 
CQ 
 
Parasite line 24 hours 48 hours 24 hours 48 hours 24 hours 48 hours 24 hours 48 hours 
D6 0.23 0.53 1.9 5.76 2.05 3.26 9.95 17.8 
D6.QHS2400x5 1.39 2.27 35.7 57.8 17.1 25 6.52 8.35 
         
W2 0.32 0.48 1.17 2.85 0.8 1.55 158.5 94.5 
W2.QHS200x2 0.53 1.27 4.81 12.4 2.69 3.21 143.2 147.7 
 
DHA=Dihydroartemisinin, AL=Artelinic Acid, QHS=Artemisinin, CQ=Chloroquine 
Values in ng/ml
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Chapter Three: 
Proteomic, Whole Genome, and Transcriptional Approaches for Dissecting 
Artemisinin Resistance (Specific Aim 2) 
 
Rationale for Study 
Given the global adoption of ACTs, considerable research has been devoted to the 
artemisinin drugs; however, the mechanism of action of the class of drugs on 
Plasmodium spp. remains controversial.  Perhaps equally controversial is the debate on 
the emergence of artemisinin resistance and molecular determinants associated with the 
resistance phenotype.  Considering that recent studies have documented the emergence of 
clinical artemisinin resistance, it is imperative to discover the true mechanism of action 
and potential drug resistance mechanisms.  Prior molecular characterization of 
artemisinin resistant parasites in our lab focused on early drug-selected parasites for the 
most part.  The results from our initial microarrays (W2 vs. W2.AL80 and W2.QHS40) 
determined that a subset of genes was differentially expressed in low-level artemisinin-
selected W2 lines after exposure to DHA.  Further molecular studies that focused 
primarily on pfmdr1 used parasites that only tolerated a maximum of 80 ng/ml AL (W2, 
D6, TM91c235) or up to 200 ng/ml AL/QHS (W2) 
276,337
.  Chavchich et al. 
276
 reported 
on genes (tctp, pfatp6, pfmdr1) that have tentative associations with the site of action or 
reduced susceptibility to this class of drugs.  No changes in the putative resistance gene 
coding sequences were detected in resistant progenies of the W2, D6, or TM91c235 lines.  
This study found different results than others in regard to pfatp6 and tctp (see Chapter 
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One), but the pfmdr1 results were in agreement with many studies that showed this gene 
can be involved in modulating drug resistance to other drugs (mostly MQ), and possibly 
artemisinins.  Chen et al. found pfmdr1 can be deamplified in drug resistant W2 lines 
when grown off drug pressure.  Based on these analyses, artemisinin resistance appears 
multifactorial, but it can be enhanced by amplification of pfmdr1.   
Based on these results, we performed similar molecular analyses in the current 
study on parasites with higher tolerance to QHS and AL, and we went even further to 
investigate putative molecular markers for resistance.  The high-level QHS-resistant D6 
progeny we selected in vitro (up to 2400 ng/ml) represented parasites that, at the time of 
selection, had never been described before.  These parasites tolerate levels of artemisinin 
beyond those typically found in patients taking artemisinin therapy for malaria.  We 
hypothesized that genetic determinants of artemisinin resistance (SNPs, copy number 
variations) accumulated over the process of selecting these parasites.  By comparing 
parent vs. resistant strains, novel molecular markers of artemisinin resistance would be 
revealed, and possibly markers of dormancy.  Therefore, we utilized next-generation 
molecular technologies to dissect differences between parent and resistant lines that were 
pressured to artemisinin resistance levels beyond that which were originally obtained.  
We used a proteomic approach combined with whole-genome DNA sequencing and 
transcriptional analyses to dissect potential artemisinin resistance mechanisms in resistant 
parasites we generated in vitro.  If any interesting gene amplifications, SNPs, or 
differentially regulated genes were found, we planned to investigate low and intermediate 
level resistant parasites to see where these changes occurred.  We also aimed to verify 
transcriptional changed by reverse transcriptase (RT) real-time QPCR, conduct copy 
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number assays to verify amplifications from sequencing, and sequence individual genes 
that contained SNPs for confirmation.  In addition, we thought it would be interesting to 
correlate proteomic data with newer microarrays we would perform.  We also 
hypothesized that transcriptome analysis would allow us to characterize dormancy in ring 
stages of resistant and sensitive strains after treatment with artemisinin drugs.  We 
theorized it would be possible to identify genes that were over-expressed during 
dormancy that we could use as markers to allow identification of dormant parasites in 
future assays. 
Materials and Methods 
Parasites and in vitro culture.  Asexual stages of P. falciparum were maintained 
in routine culture by using previously described methods 
4
.  Parasites were cultured in 
complete media which consisted of RPMI 1640 medium (Invitrogen, Carlsbad, CA.) 
supplemented with 10% heat-inactivated A+ human plasma in anticoagulant/preservative 
Citrate Phosphate Dextrose Adenine (CPDA-1) (Interstate Blood Bank, Memphis, TN). 
CPDA-1 preservative), a final concentration of 25 mM HEPES (Invitrogen), and 0.24% 
v/v sodium bicarbonate (Invitrogen).  Routine cultures were maintained in a total volume 
of 5-60 ml in 25 cm
2
, 75 cm
2
, or 150 cm
2 
sealed culture flasks.  An inoculum of stock 
culture of each parasite was cultured in a 4% suspension of type A+ human erythrocytes 
in CPDA-1 (Interstate Blood Bank) (hematocrit changed for drug and hypoxanthine 
assays, below) at 1-15% parasitemia.  Cultures were synchronized using 5% (w/v) D-
sorbitol (Sigma-Aldrich Corp. St. Louis, MO.), following the method of Lambros and 
Vanderberg (1979) 
374
.  Synchronization of cultures was repeated 1-2 times before 
parasites were used for an experiment.  Media was changed every 48 hours or daily, 
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depending on parasitemia.  Cultures were incubated at 37°C under a gas mixture of 5% 
O2, 5%CO2, and 90% N2.  Pelleted cultures were saved for later genomic DNA extraction.  
When culture conditions required different modifications, these methods are listed in 
individual sections below. 
Proteomics. 
Parasites.  We used parent and resistant pairs of D6 and W2 for analysis of 
protein expression.  In the process of adapting D6 to high levels of resistance, it was 
treated with 2400 ng/ml multiple times (above). Once D6.QHS2400x2 was produced, it 
was treated with 2400 ng/ml QHS (a third total treatment) and allowed to recover until 
normal growth returned (parasitemia>6% 12 days after treatment).  This parasite was 
grown in culture for about 2 months to increase volume of culture and reach high 
parasitemia (proteomic analysis protocol called for microgram quantities of protein).  W2 
and W2.QHS200 were grown in tandem as well around this time, but W2.QHS200 was 
not placed under drug pressure.  D6/D6.QHS2400x3 and W2/W2.QHS200 were 
synchronized together during this process.  Parasites were grown to 60 ml in 150 cm
2 
flasks at 4% hematocrit.  The last sorbitol treatment before cultures were frozen for 
subsequent proteomic analysis synchronized them to late rings/early trophozoites. Final 
parasitemia counts were D6 (5.6%), D6.QHS2400x3 (6.4%), W2 (3.8%), W2.QHS200 
(7%).  Pelleted cells were treated with 0.05% (w/v) saponin to free parasites from RBCs 
and culture lysates were incubated on ice for 10 minutes.  The lysates were centrifuged 
and the resulting parasite pellets were washed three times with 1x PBS to remove RBC 
components.  Washed parasite pellets were frozen at -80°C until shipping for proteomic 
analysis. 
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Two dimensional fluorescence difference gel electrophoresis.  Two Dimensional 
Fluorescence Difference Gel Electrophoresis (2D-DIGE) and protein identification was 
performed by Applied Biomics, Inc (Hayward, CA).  Essentially, protein extracts of 
resistant/parent pairs are labeled with different dyes, mixed together, a SDS-PAGE gel is 
run with labeled extracts, differential excitation of resistant/parent proteins is performed 
enabling fold changes of identical proteins, and proteins are isolated and identified.  
Parasite pellets were washed with Washing Buffer (10 mM Tris-HCl, 5 mM magnesium 
acetate, pH 8.0) three times, then 150 µl of 2-D cell lysis buffer (30 mM Tris-HCl, pH 
8.8, containing 7 M urea, 2 M thiourea and 4% CHAPS) was added to each sample. The 
mixture was sonicated at 4
o
C followed by shaking for 30 minutes at room temperature. 
The samples were then centrifuged for 30 minutes at 14,000 rpm and the supernatant was 
collected. Protein concentration was measured using a Bio-Rad protein assay method.  
For each sample, 30 µg of protein was mixed with 1.0 µl of diluted CyDye, and 
kept in the dark on ice for 30 min. Cy2 and Cy5 have different excitation/emission 
wavelengths (Cy2 [489 nM/506 nM; Cy5 [625-650 nM/670 nM]), enabling differential 
analysis of labeled proteins.  Parental and resistant parasites from each pair were labeled 
with Cy2 (green) and Cy5 (red) dyes, respectively.  The labeling reaction was stopped by 
adding 1.0 µl of 10 mM Lysine to each sample, and incubating in the dark on ice for an 
additional 15 min. The labeled samples were then mixed together.  The 2X 2-D Sample 
buffer (8 M urea, 4% CHAPS, 20 mg/ml DTT, 2% pharmalytes and trace amount of 
bromophenol blue), 100 µl Destreak solution and Rehydration buffer (7 M urea, 2 M 
thiourea, 4% CHAPS, 20 mg/ml DTT, 1% pharmalytes and trace amount of bromophenol 
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blue) were added to the labeling mix to make the total volume 250 µl.  This solution was 
mixed well and centrifuged before loading the labeled samples into a strip holder. 
Isoelectric focusing and sodium dodecyl sulfate polyacrylamide gel 
electrophoresis.  After loading the labeled samples, Isoelectric focusing (IEF) was run 
following the protocol provided by Amersham BioSciences (Sweden).  Upon finishing 
the IEF, Immobilized pH Gradient (IPG) strips were incubated in freshly made 
equilibration buffer-1 (50 mM Tris-HCl, pH 8.8, containing 6 M urea, 30% glycerol, 2% 
SDS, trace amount of bromophenol blue and 10 mg/ml DTT) for 15 minutes with gentle 
shaking.  Then the strips were rinsed in freshly made equilibration buffer-2 (50 mM Tris-
HCl, pH 8.8, containing 6 M urea, 30% glycerol, 2% SDS, trace amount of bromophenol 
blue and 45 mg/ml DTT) for 10 minutes with gentle shaking.  Next, the IPG strips were 
rinsed in SDS-gel running buffer before transferring into 13.5% SDS-gels.  The SDS-gels 
were run at 15
o
C until the dye front running out of the gels.  
Image scan and data analysis.  Gel images of each resistant/parent parasite pair 
were scanned immediately following the SDS-PAGE procedure using Typhoon TRIO 
(Amersham BioSciences).  Since each dye produced different excitation, individual gel 
images could be made for each fluor, then merged.  The scanned images were then 
analyzed by Image Quant software (version 6.0, Amersham BioSciences), followed by 
in-gel analysis using DeCyder software version 6.0 (Amersham BioSciences). The fold 
change of the protein expression levels was obtained from in-gel DeCyder analysis.  
Protein identification by mass spectrometry.  The above analysis identified 29 
spots for D6/D6.QHS2400x3 and 33 for W2/W2.QHS200 comparisons based on 
positioning on gel images (Fig 3.1) and the degree of over-expression/under-expression.  
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We selected 13 spots for each D6/D6.QHS2400x3 or W2/W2.QHS200 comparison (over-
expressed and under-expressed) for further analysis.  The spots of interest were picked up 
by Ettan Spot Picker (Amersham BioSciences) based on the in-gel analysis and spot 
picking design by DeCyder software.  The gel spots were washed a few times then 
digested in-gel with modified porcine trypsin protease (Trypsin Gold, Promega). The 
digested tryptic peptides were desalted by Zip-tip C18 (Millipore, Billerica, MA.).  
Peptides were eluted from the Zip-tip with 0.5 µl of matrix solution (α-cyano-4-
hydroxycinnamic acid [5 mg/ml in 50% acetonitrile, 0.1% trifluoroacetic acid, 25 mM 
ammonium bicarbonate] and spotted on the Matrix-Assisted Laser Desorption/Ionization 
(MALDI) plate (model ABI 01-192-6-AB). 
MALDI-Time of Flight (TOF) MS and TOF/TOF tandem MS/MS were 
performed on an ABI 4700 mass spectrometer (Applied Biosystems, Framingham, MA).  
MALDI-TOF mass spectra were acquired in reflectron positive ion mode, averaging 4000 
laser shots per spectrum. TOF/TOF tandem MS fragmentation spectra were acquired for 
each sample, averaging 4000 laser shots per fragmentation spectrum on each of the 10 
most abundant ions present in each sample (excluding trypsin autolytic peptides and other 
known background ions). 
Database search.  The resulting peptide mass and the associated fragmentation 
spectra were  both submitted to a GPS Explorer workstation equipped with MASCOT 
search engine (Matrix Science, Boston, MA.) to search the National Center for 
Biotechnology Information non-redundant database (NCBInr).  Searches were performed 
without constraining protein molecular weight or isoelectric point, with variable 
carbamidomethylation of cysteine and oxidation of methionine residues, and with one 
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missed cleavage also allowed in the search parameters.  Candidates with either protein 
score C.I.% or Ion C.I.%  greater than 95 were considered significant. 
Whole genome sequencing. 
Parasites and DNA isolation.  Initially, we sequenced uncloned D6 and 
D6.QHS2400x2.  Cultures at 4% hematocrit were scaled up to 10 ml (D6) and 25 ml 
(D6.QHS2400x2).  Parasites were asynchronous, but consisted of majority trophozoites.  
Subsequent sequencing focused on W2 (clone D7), W2.QHS200x2, D6 (clone C11), and 
D6.QHS2400x5.  Parasites were grown to highly synchronous rings/early trophozoites in 
large volume cultures at 4% hematocrit and >3% parasitemia.  Cultures were centrifuged 
and pellets were saved for later DNA extraction.  A procedure similar to that of Beck 
378
 
was used for freeing parasites from erythrocytes.  Cultures were centrifuged at 4,000 rpm 
for 5 minutes and the supernatant was aspirated.  The cell pellet was measured, and 5x 
pellet volume of 0.05% saponin was added.  The mixture was placed on ice for 10 
minutes, centrifuged, and the supernatant was aspirated.  Parasite pellets were washed 
twice with 1x PBS.  Genomic DNA was extracted from the parasite pellets using a 
QiAmp DNA Blood Mini Kit (Qiagen, Valencia, CA.).  Purified genomic DNA was 
quantitated using a Nano Drop spectrophotometer (Thermo Fisher Scientific, Waltham, 
MA.). 
Paired end library preparation.  At least 1 µg of genomic DNA was used for 
Illumina Solexa sequencing.  Samples for sequencing of artemisinin sensitive (D6, D6 
[clone C11]; W2, W2 [clone D7]) and resistant strains (D6.QHS2400x2, D6.QHS2400x5; 
W2.QHS200x2) were prepared using the Illumina paired end sample kit (Illumina, Inc. 
San Diego, CA.).  The procedure called for the nebulizatoin of 2-5 µg of genomic DNA 
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at 32 psi for 6 minutes and purification of DNA using Zymo-Spin Columns (Zymo 
Research Corporation, Orange, CA.).  End repair, ligation of adapters, and PCR 
enrichment were performed as described in the Illumina Paired End Sample Kit protocol.  
Ligation products were purified on a 2% TAE agarose gel, extracting a range of 250-350 
bp fragments using an Invitrogen PureLink Gel Extraction Kit.  Validation of sequencing 
libraries was performed by TOPO cloning (Invitrogen) 4 µl of the PCR enriched library 
and sequencing of 30 clones.  A final library concentration of 8 pM was loaded into a V4 
flow cell and clusters were generated using the Illumina Cluster Generation Kit and 
sequenced on the Illumina Genome Analyzer GAII. 
Downstream analysis.  Base calling was run using the standard Illumina pipeline.  
Reads were then aligned to the P. falciparum genome (PlasmoDB version 6.3) using the 
Bowtie short read aligner.  Using MegaBLAST, reads were pre-filtered through the 
human genome to remove reads that result from culture growth conditions before 
aligning to the P. falciparum genome.  Since the published genome is based on the 3D7 
reference strain, we allowed for two read mismatches due to possible strain specific SNP 
differences with D6 and W2.  Any reads with more than 2 mismatches were not further 
analyzed.  We also required that reads were unique such that reads that mapped to 
multiple loci were not used.  We calculated coverage per base pair throughout the entire 
genome and created wiggle (WIG) files to view the sequenced genomes on the UCSC 
genome browser.  Binary alignment/map (BAM) files were also created using sequence 
alignment/map (SAM) tools to view the aligned reads on the Broad Institute‟s Integrative 
Genome Viewer. 
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Sequencing for verifying single nucleotide polymorphisms from whole 
genome sequence data.  Genomic DNA was isolated from D6, D6 (clone C11), 
D6.QHS2400x2, D6.QHS2400x4, D6.QHS2400x4 (clone C9), D6.QHS2400x5 (clone 
C9), W2, W2 (clone D7), W2.QHS200, W2.QHS200x2, and 3D7 for sequencing of 
PF13_0238 (kelch protein, putative) and PFF0275c (nucleoside diphosphate kinase, 
putative).  Not every gene was sequenced for each parasite sample.  The primer 
sequences used for these genes are listed in Table 3.1.  As in Chapter Two, the optimal 
annealing temperature was determined by temperature gradient PCR.  Promega (Madison, 
WI.) GoTaq was used in all PCR reactions described here.  The manufacturer‟s protocol 
was followed except for changing the annealing temperature from 53-62°C, changing the 
extension temperature to 68°C, and using an extra extension step of 72°C for 5 minutes.  
Each reaction used 15 ng of genomic DNA as template for standard PCR using a 
temperature gradient ranging from 53-62°C in a Biorad Mycycler thermal cycler.  All 
primer sets were found to amplify equally well from 56-60°C.  The optimum annealing 
temperature was determined to be 57°C and 200 nM F/200 nM R was the optimal primer 
pair concentration.  The PCR products of PF13_0238 1F new/1R new, PFF0275c 1F/1R, 
PFF0275c 3F/3R, and PFF0275c 4F/4R were 668 bp, 687 bp, 491 bp, and 400 bp, 
respectively.  Gene sequences from individual forward and reverse reactions were 
assembled into contigs and aligned using Vector NTI Advance 11.0 (Invitrogen).  
Assembled sequences were searched for presence of SNPs and verified in sequence 
chromatograms.   
 
 
  
220 
 
Real-time QPCR for copy number assessment of chromosome 10 genes. 
Optimization of oligonucleotide sets.  Sets of primers for PF10_0275 
(protoporphyrinogen oxidase), PF10_0277 (nucleolar rRNA processing protein EBP2, 
putative), PF10_0278 (nucleolar preribosomal assembly protein, putative), PF10_0279 
(conserved Plasmodium protein, unknown function), PF10_0285 (conserved Plasmodium 
protein, unknown function), PF10_0286 (conserved Plasmodium protein, unknown 
function), PF10_0292 (conserved Plasmodium protein, unknown function), PF10_0294 
(RNA helicase, putative), PF10_0295 (conserved Plasmodium protein, unknown 
function), PF10_0296 (conserved Plasmodium protein, unknown function), PF10_0299 
(glycoprotease, putative), and PF10_0300 (RNA methyltransferase, putative) were tested 
against 3D7 or D6 genomic DNA to determine optimal annealing temperature and 
concentration for use in assays.  All primer sequences are listed in Table 3.1.  The 
procedure for primer optimization was the same as that detailed in Chapter Two.  The 
concentration of primer that caused the lowest Ct value with high fluorescence intensity 
was selected for subsequent assays.  The optimum concentration of 200nM F/200nM R 
was identified for PF10_0277, PF10_0278, PF10_0279, PF10_0285, PF10_0294, 
PF10_0295, PF10_0296, and PF10_0300 primer sets.  The combination of 500 nM F/500 
nM R was identified as optimal for PF10_0286, PF10_0292, PF10_0299 primer sets.  
Determination of gene copy number by real-time QPCR.  The relative copy 
numbers (CN) of the chromosome 10 genes listed above were determined for D6, W2, 
TM91c235 parental and resistant lines by using ldh as normalizer.  The procedure was 
similar to that described in Chapter Two for QPCR of pfmdr1, pfmdr2, PFE1050w, and 
PF11_0466.  A variety of pressure levels were selected from the stepwise selection of D6 
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and TM91c235 resistant parasites, including intermediate pressure levels (D6 [80, 120, 
200, 300, 340, 2400x2, 2400x4, 2400x5 ng/ml QHS]; TM91c235 [80, 240, 280 ng/ml AL, 
but 80 ng/ml not included for chromosome 10 genes]).  For the W2 series, we included 
W2, W2 (clone D7), W2.QHS200, and W2.QHS200x2.  Patient isolates from Thailand 
(#3, 6) and Cambodia (#3, 5, 6, 8, 10, 18, 26, 32, 33) were also tested for a few genes 
within the amplification.  Each assay was performed more than once (except for Thai-
Cambodia isolates).  The amount of standard ranged from 3.3-0.036 ng of genomic DNA 
(overall, not in a single experiment) in the 5-point standard curve (this varied per 
experiment).  Mean copy number relative to D6, standard deviation, and 95% confidence 
intervals were calculated as in Chapter Two. 
Measurement of the rate of recovery from dormancy for D6 parasites.  To 
determine the rate of recovery from dormancy, D6 (clone C11) and D6.QHS2400x5 were 
synchronized to mid-late ring stages and split to 2.5±0.15 parasitemia/4% hematocrit in 
15 ml volumes in 75 cm
2
 culture flasks.  DHA (1 mg/ml) was diluted 1:40 in complete 
media and was added to each flask to a final concentration of 200 ng/ml (703.3 nM).  
This dose was chosen because previous experiments (data not shown) showed that this 
concentration of drug was high enough to induce dormancy in both parent and resistant 
parasites, yet low enough to allow parasites to recrudesce over a period of approximately 
a week after treatment.  Control flasks containing the same parasite suspensions also were 
made.  DMSO was diluted 1:40 in complete media and a volume equal to the 200 ng/ml 
drug amount was added to control flasks.  Six hours post-treatment, cultures were 
transferred to conical tubes and centrifuged.  Parasites were washed three times with 
stock RPMI, resuspended in the original volume, transferred to new flasks, and incubated 
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at 37°C.  Thick and thin smears were made before drug treatment (time zero), after drug 
was washed out (T6), and every 24 hours post-treatment up to 192 hours.  Culture media 
was changed every day and parasites were monitored until parasitemia of normal 
parasites in drug-treated cultures exceeded 4% (192 hours post-drug).  For each time 
point, parasitemia was determined by counting over 800 erythrocytes from five fields in 
each thin smear. Parasitemia was calculated as the number of total parasites /total number 
of erythrocytes.  The ratio of normal/total parasites and dormant/total were calculated at 
each time point. 
Microarrays. 
Culture for microarray experiments.  For the pilot studies with W2, synchronized 
parasites were exposed to 28.4 ng/ml (100 nM) DHA for six hours, washed with stock 
RPMI, and put back into culture. Samples representing parasites six hours post-treatment 
(T6) and 27 hours post-treatment (T27) were collected for microarray analysis.  
For the transcriptional studies with D6 parasites, D6 (clone C11) and 
D6.QHS2400x5 were divided into four groups: parent synchronized (PS), parent 
unsynchronized (mixed) (PM), resistant synchronized (RS), and resistant mixed (RM) 
(Fig. 3.2).  To obtain highly synchronized cultures, parasites were synchronized 7 times 
over a 192-hour period.  Approximately 26 hours following the seventh synchronization, 
cultures were monitored for maximum invasion (the time when the number of rings=the 
number of schizonts counted in Giemsa stained blood smears).  Two hours post-
maximum invasion, parasites were subjected to a final round of synchronization and 
cultures (mixed and synchronous) were split to 3.47±0.97% parasitemia and 4% 
hematocrit.  Eight hours post-invasion, time zero (T0, untreated samples) were collected 
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and 200 ng/ml DHA (703 nM) was added to selected cultures (making parent treated 
synchronized [PTS], parent treated mixed [PTM], resistant treated synchronized [RTS], 
and resistant treated mixed [RTM]).  An equivalent amount of diluted DMSO was added 
to control cultures (making parent untreated synchronized [PUS], parent untreated mixed 
[PUM], resistant untreated synchronized [RUS], and resistant untreated mixed [RUM]).  
Six hours post-treatment (T6), parasites were washed with fresh media and put back into 
culture as described in the previous section.  At this point, there were eight sample groups.  
Samples were collected from DHA-treated cultures over 189 hours post-drug (time points 
were 6, 12, 18, 24, 32, 40, 48, 57, 69, 81, 93, 105, 129, 141, 153, 165, 177, 189).  
Samples from PTM and RTM were collected from 6-153 hours post-drug, and samples 
from PTS and RTS were collected from 6-189 hours post-drug.  Samples from PUS, 
PUM, RUS, and RUM were collected for the first 48 hours of the time-course and then 
discontinued.  All samples were snap-frozen in liquid Nitrogen for later RNA extraction 
and subsequent transcriptional analysis.   
Microscopy and smear counts.  For parasitemia quantification, thin smears were 
taken at each time point (out to 189 hours for PTS, RTS) and were independently 
examined in a blinded fashion by three people.  Each person analyzed at least three fields 
per slide and counted between 300-900 total cells per slide.  Parasitemia was calculated 
as the number of parasites per total number of erythrocytes counted.  Average parasitemia 
(and standard deviation) for the independent counts for each time point and treatment 
group were plotted.  Parasites from thin smears were sorted into classifications of dead, 
dormant, ring, trophozoite, or schizont.  For DHA-treated cultures, only data from two of 
three microscopists was used because one of the labs in the joint project could not assess 
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time points beyond 48 hours.  Also, time points after 117 hours were only assessed by 
one microscopist.  Analysis of blood smears by microscopy allows the efficient 
quantification of normal morphological forms as compared to dormant parasites, but it is 
very difficult to discriminate between dead and dormant parasites.  Also, in some 
instances, discrimination of dormant vs. dead was not performed during counting of 
parasites.  Therefore, a separate category was developed that grouped dead and dormant 
parasites together (dead-dormant).  The ratios of dead-dormant parasites in relation to 
total parasites and normal/total parasites were calculated for each time point of the drug 
treated groups (PTM, PTS, RTM, and RTS).   
RNA extraction and amplification.  Total RNA used for microarray analysis was 
isolated from experimental samples using Trizol (Invitrogen), per the manufacturer‟s 
instructions.  Briefly, 10 ml Trizol (55°C) and 2 ml chloroform were added to frozen cell 
pellets (approximately 250 µL) on ice, mixed, and centrifuged to obtain the aqueous 
phase. The aqueous phase was isopropanol/sodium acetate precipitated overnight at -
80°C, centrifuged, washed with 70% ETOH, and the resulting RNA pellet was re-
suspended in RNAase-free water prior to amplification.  Next, 110 ng of total RNA was 
amplified and aminoallyl-labeled using the Amino Allyl MessageAmp II aRNA 
Amplification kit (one round, oligo dT priming, 14 hr IVT, Ambion, Austin, TX).  As 
much total RNA as possible was used for amplification when samples contained <110 ng 
total RNA.  An amplified 3D7 RNA pool representing transcripts expressed throughout 
the intraerythrocytic development cycle (IDC) was compiled as a reference. 
Cy dye labeling and microarray hybridization.  Aliquots of amplified and pooled 
reference RNA (2 µg) were coupled to Cy3 and 2 µg amplified experimental RNA was 
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coupled to Cy5 using Amersham post-labeling reactive dye packs (GE healthcare, 
Piscataway, NJ).  Prior to hybridization, microarrays were printed and post-processed as 
described in Bozdech et al (2003).  Cy3 reference pool and Cy5 samples were 
competitively hybridized at 65˚C on a spotted microarray containing 8159 70-mer oligos 
that map to 5338 ORFs as annotated in PlasmoDB release 6.3.  Samples were hybridized 
against the pooled reference instead of against each other, to avoid the confounding 
effects of differential growth rates noted by others 
412
.  In total, 89 arrays were used.  
Following an 18 hour hybridization, microarrays were washed in 65˚C 0.6x SSC, 0.03% 
SDS, and then washed in room temperature 0.06x SSC.  After spinning dry, arrays were 
scanned on an Axon 4000B scanner using Axon Genepix software, taking care to balance 
the intensities of the two dye channels (version 6.0 and 6.1, Molecular Devices, Union 
City, CA).  Several arrays have technical replicates.  For subsequent calculations the 
results of replicate arrays without large artifacts were averaged together. 
Array analysis.  Microarrays were manually gridded and Cy3 and Cy5 intensity 
of each spot was extracted using Genepix software. Arrays were uploaded to Nomad v2.0 
(http://ucsf-nomad.sourceforge.net/) where the data was normalized in bins of pixel 
intensity R
2, and then filtered to remove spots with “bad” or “missing” manual flags 
added during gridding, as well as spots with sum of median intensities less than 500.  The 
resulting ratio Cy5/Cy3 intensity tables were log2 transformed and re-centered about zero.  
Re-centered arrays were compared with all time points of the HB3 IDC by Pearson‟s 
correlation (after filtering out surface antigen genes that are very strain-specific, 
422
).  
The lists of genes up-regulated and down-regulated in the 48 hours after drug 
treatment in treated PTS and RTS groups were generated by averaging the log2 ratios for 
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the 6 through 48 hr time points and subtracting the time zero log2 ratios.  Those results 
were considered our measure of induction and the data were sorted for genes consistently 
up-regulated or down-regulated in both strains (114 genes). We also were interested in 
gene inductions that differed between the two strains.  Therefore, we sorted for oligos 
with measures of induction that had opposite signs in D6 (clone C11) versus 
D6.QHS2400x5 synchronized cultures with absolute distance between the two inductions 
greater than an arbitrary cutoff of 1.8.  To compare the transcriptomes of PTS and RTS at 
baseline, we calculated the residual between the time zero array signals of the 
synchronized resistant parasites and a linear regression of its relationship with 
synchronized resistant parasites. By this measure of differential baseline transcription 
after taking our variable antigen oligos, we arrived at the list of the 100 most different 
oligos (this is the top 1.2% of the data). 
Results 
 
Proteomics identified differentially expressed proteins in artemisinin 
resistant vs. parent parasites.  Proteomic analyses of D6 parasites focused on uncloned 
strains D6 vs. D6.QHS2400x3 and W2 vs. W2.QHS200.  D6.QHS2400x2 was treated 
with 2400 ng/ml QHS to produce D6.QHS2400x3, and this parasite was grown up to 
large volume to have enough material to send for proteomics.  However, this process took 
about two months after parasites recovered from the drug treatment.  W2.QHS200 was 
not treated with QHS before growing up for proteomics.  Pairs of D6 and W2 parasites 
were synchronized to ring/early trophozoite stages in parallel.  Comparison of 2D gels of 
D6 vs. D6.QHS2400x3 and W2 vs. W2.QHS200 found some protein spots that were 
under-expressed/over-expressed in resistant vs. parental parasites (Table 3.2).  We picked 
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13 spots from 2D-DIGE of D6 vs. D6.QHS2400x3 and W2 vs. W2.QHS200 for mass 
spectrophotometry and protein identification (in red, Table 3.2).  The ratio of proteins 
expressed in resistant/parental strains was determined for D6.QHS2400x3/D6 and 
W2.QHS200/W2.  Computer analysis measured protein peaks and ratios were calculated.  
An example of down-regulation and up-regulation in D62400x2/D6 is displayed in Fig 
3.3.  Spot 1594 had decreased ratio of 1.53 in the resistant vs. parent parasite, whereas 
spot 2300 had increased ratio of 2.05 in the resistant parasite.  We were confident the 
results were valid as surrounding protein peaks looked similar in the protein pairs.  For 
the W2 series (Fig. 3.4), examples of differential regulation are spot 439, which was 
decreased 2.75 fold in W2.QHS200 compared toW2, whereas spot 788 was increased 
1.88 fold in the resistant parasite.  For D6.QHS2400x3/D6, the highest scoring proteins 
that were differentially regulated included PF11_0098 (endoplasmic reticulum-resident 
calcium binding protein, down-regulated, ratio= -1.41), PFI0265c (RhopH3 rhoptry 
protein, up-regulated, ratio= +1.57), PF14_0425 (Fructose bisphosphate aldolase, down-
regulated, ratio= -1.53), and PFI1270w (conserved Plasmodium protein unknown 
function, up-regulated, ratio= +1.74) (Table 3.2).  For W2.QHS200/W2, the highest 
scoring proteins that were differentially regulated included PFI0875w (Heat shock 
protein 70 [HSP70] homologue, up-regulated, ratio= +1.62), PFI1475w (MSP-1 
precursor, up-regulated, ratio= +1.88), PFL2215w (actin I, up-regulated, ratio= +1.38), 
PF13_0197 (MSP-7 precursor, up-regulated, ratio= +1.54) (Table 3.3) 
Whole genome sequencing identified single nucleotide polymorphisms and 
copy number amplifications in artemisinin resistant parasites.  D6 and 
D6.QHS2400x2 were the first set of parent/resistant parasites for sequencing.  We aimed 
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to detect SNPs and/or amplifications in parent vs. resistant strains.  At the point 
D6.QHS2400x2 was submitted for sequencing, it had been grown for about 2 weeks 
since the last pulse of 2400 ng/ml.  A second set of sequencing was conducted with 
D6.QHS2400x5, W2, W2 (clone D7), and W2.QHS200x2.   
Single nucleotide polymorphisms identified in resistant D6 strains.  To search 
for high-likelihood SNPs in the first set of sequencing, a tool was developed to measure 
the percentage of reads for a particular base in the parent or resistant strain.  This analysis 
also took into account differences between parent and resistant parasites caused by 
antigenic variation genes between the strains.  We expected that a causative mutation for 
artemisinin resistance would likely be present in an exon at nearly 100% of the reads in 
D6.QHS2400x2, so SNPs that are heterogeneous (i.e. 40% have one base, 60% have 
another) are not likely to be very important.  This was a way to reduce noise while 
analyzing the data.  Another important factor was that SNPs could only be credible if 
there were sufficient reads for both the parent and the selected strain (more is better).  
Our initial analysis focused on at least three reads for a base either for D6 or 
D6.QHS2400x2.  As a result of the analysis, it was possible to find high likelihood SNPs 
based on the number of reads for a base/total number of reads (ex. 100 reads of A in 100 
total reads=100%).  This was done for a particular base in both D6 and D6.QHS2400x2 (% 
parent SNP or % resistant SNP).  After removing the antigenic variation genes, the actual 
number of SNPs affecting coding regions was fairly small (Table 3.4).  In this initial 
analysis, SNPs were divided into two groups where D6/3D7 were similar vs. 
D6.QHS2400x2, and where D6.QHS2400x2/3D7 were similar vs. D6.  The results of this 
analysis found an overall trend of a greater number of reads for D6 bases compared to 
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D6.QHS2400x2.  Based on a high number of reads for both D6 and D6.QHS2400x2 
while having a high percentage of a single base /total reads, PF13_0238, PFC0320w 
(encodes a conserved Plasmodium protein of unknown function), PFF0275c, PFE1155c 
(encodes a putative mitochondrial processing peptidase alpha subunit), MAL13P1.298 
(encodes a conserved Plasmodium membrane protein of unknown function) contained 
high-quality SNPs for D6/3D7 vs. D6.QHS2400x2.  A similar analysis of 
D6.QHS2400x2/3D7 vs. D6 found high quality SNPs in PF14_0419 (encodes a 
conserved Plasmodium protein of unknown function) and PFA0315w (encodes a 
conserved Plasmodium protein of unknown function).  More coverage was gained from 
additional rounds of sequencing, allowing us to define the most promising SNPs.  We 
further defined criteria for true SNPs where 80% of reads for a particular base 
corresponded to a nucleotide difference between D6 and D6.QHS2400x2 (Table 3.5).  
These SNPs all came from genes from the original D6/3D7 vs. D6.QHS2400x2 group, so 
all associated amino acid changes are in the resistant parasite.  Based on this analysis, a 
small list of high quality reads was produced for SNPs in D6 vs. D6.QHS2400x2.  As 
before, the highest quality SNPs were in PF13_0238, PFF0275c, MAL13P1.298, 
PFC0320w, and PFE1155c.  The SNPs caused non-synonymous amino acid changes in 
codons for PF13_0238: GAA-AAA (Glu-Lys) at position 1726407 in chromosome 13; 
PFF0275c: GAT-CAT (Asp-His) at position 230387 in chromosome 6; PFC0320w: 
AAT-ATT (Asn-Ile) at position 323233 in chromosome 3; PFE1155c: AGT-GGT (Ser-
Gly) at position 963839 in chromosome 5; and MAL13P1.298: GGT-GAT (Gly-Asp) at 
position 2394027 in chromosome 13. 
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A potential problem we noted with the initial sequencing with the uncloned 
parasites was heterogeneity of bases for a given number of reads.  Because of this, we 
attempted a second set of sequencing using D6 (clone C11), D6.QHS2400x5, W2 (clone 
D7), W2.QHS200x2, and another parental W2 strain from the MR4 depository.  The 
results of whole genome sequencing of the clonal parasites are currently being analyzed, 
and we are trying to assess the same high-probability non-synonymous SNPs reported 
above in D6.QHS2400x5 and W2.QHS200x2, and also non-synonymous SNPs in the 
same gene for these pairs of parasites. 
Single nucleotide polymorphisms verified in resistant D6 strains.  The initial 
sequencing of D6 vs. D6.QHS2400x2 found high probability SNPs between the strains, 
and these SNPs were located in PF13_0238, PFC0320w, PFE1155c, PFF0275c, and 
MAL13P1.298.  We sought to verify some of these SNPs by sequencing a few genes 
using genomic DNA we had for these parasites and parasites that had been exposed to 
additional rounds of 2400 ng/ml (D6.QHS2400x4, D6.QHS2400x4 [clone C9], and 
D6.QHS2500x5).  We used D6, D6 (clone C11), W2, W2 (clone D7), and 3D7 as control 
parasites. We chose two genes in an attempt to independently verify the SNPs separating 
D6 vs. QHS-selected D6 strains.  Sequencing of PF13_0238 and PFF0275c (using 
PFF0275c-1 primers) found that D6, D6 (clone C11), W2, W2 (clone D7), and 3D7 
possessed the wild-type nucleotide, but D6.QHS2400x2, D6.QHS2400x4, 
D6.QHS2400x4 (clone C9), and D6.QHS2400x5 (clone C9) had the nucleotide change 
(Table 3.6).  We noticed that for a few genes (PF13_0238, PFF0275c-1, MAL13P1.298), 
SNP data for D6 vs. 3D7 were deposited in PlasmoDB.  We were interested in verifying 
if all the D6 parasites we were using at the time all were the same genotypically and 
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different from W2 (which had same base as 3D7).  We had some concern at the time 
since multiple strains were being cultured as at the same time.  These SNPs were in 
regions of DNA that could be amplified using primers that we used for SNP detection of 
D6 vs. QHS-selected D6 parasites (for PF13_0238) or with new primers we designed 
(PFF0275c-3, PFF0275c-4).  The SNP separating D6 vs. 3D7/W2 in PF13_0238 was at 
position 1,726,463 in chromosome 13, changing codon AAA to ACA (Lys-Thr).  Primer 
set PFF0275c-3 amplified a region of DNA containing a SNP at position 229836 of 
chromosome 6, changing codon AAA to AAG (Lys-Lys).  Primer set PFF0275c-4 
amplified a region of DNA containing a SNP at position 229481 of chromosome 6, 
changing codon AAA-CAA (Lys-Gln).  For this round of sequencing, 3D7, D6, D6 
(clone C11), D6.QHS2400x2, D6.QHS2400x4, W2, W2 (clone D7), W2.QHS200, and 
W2.QHS200x2 were used as templates.  We did not have genomic DNA for 
D6.QHS2400x4 (clone C9) or D6.QHS2400x5 (clone C9) at the time these sequencing 
reactions were performed.  The results of the sequencing showed that 3D7 and W2 
parasites contained similar wild-type nucleotide, but D6 strains were different (Table 3.6).  
Also, all D6 strains contained the same nucleotide when compared to each other. 
Amplifications identified in chromosome 10 in artemisinin resistant D6 and W2 
lines.  We scanned for differences in readings between D6 and D6.QHS2400x2 by 
looking at output signals that changed between the two parasites.  There was a clear 
increase in signal for D6.QHS2400x2 in a region of chromosome 10.  An initial analysis 
confined the amplification region to PF10_0279 through PF10_0299.  It appeared that 
each gene within this amplification was amplified 2-fold compared to D6.  The genes 
interior of these boundaries included: PF10_0278 (nucleolar pre-ribosomal assembly 
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protein, putative), PF10_0279, PF10_0280 (both conserved Plasmodium proteins of 
unknown function), PF10_0281 (merozoite TRAP-like protein), PF10_0282, PF10_0283, 
PF10_0284, PF10_0285, PF10_0286, PF10_0287, PF10_0288 (all conserved 
Plasmodium proteins of unknown function), PF10_0289 (adenosine deaminase, putative), 
PF10_0290 (conserved Plasmodium protein, unknown function), PF10_0291 (RAP 
protein, putative), PF10_0292 (conserved Plasmodium protein, unknown function), 
PF10_0293 (transcription factor, putative), PF10_0294 (RNA helicase, putative), 
PF10_0295 (conserved Plasmodium protein, unknown function), PF10_0296 (conserved 
Plasmodium protein, unknown function), PF10_0297 (conserved Plasmodium protein, 
unknown function), PF10_0298 (26S proteasome subunit, putative), and PF10_0299 
(glycoprotease, putative).   
A second round of sequencing with D6 (clone C11), D6.QHS2400x5, W2 (clone 
D7), W2.QHS200x2, and W2 (MR4 reference strain) strains found that the chromosome 
10 amplification existed in D6.QHS2400x5 (PF10_0279-PF10_0299), similar to what we 
reported for D6.QHS2400x2 (data not shown).  Also, a subset of genes within the D6 
amplification was found in the clonal W2 parent and resistant strains (PF10_0288 
through PF10_0297).  In both W2 and W2.QHS200x2, it appeared that there were three 
copies of each gene within the amplification.  These results are interesting because they 
showed that two sets of geographically different parasites contain amplified genes in a 
similar region.  Interestingly, the amplification was not found in the MR4 reference W2 
strain.  Although the presence of the amplification in W2 (clone D7) makes the results for 
W2 lines less clear, we believe this is a technicality (see below). 
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Copy number amplification was verified in D6 and W2 artemisinin resistant 
strains by QPCR.  To verify the amplification on chromosome 10, primers were designed 
to assess copy number of genes within the amplicon (Table 3.1).  We chose a subset of 
genes within the amplicon for copy number assessment and a few outside of the amplicon.  
These genes were PF10_0275, PF10_0277, PF10_0278, PF10_0279, PF10_0282, 
PF10_0285, PF10_0286, PF10_0292, PF10_0293, PF10_0294, PF10_0295, PF10_0296, 
PF10_0299, and PF10_0300.  During primer optimization, it was determined that primers 
for PF10_0282 and PF10_0293 did not perform well in our assay, so these genes were 
discontinued from further analyses.  Based on the results, some general trends were noted.  
We determined the boundaries of the amplification in QHS-resistant D6 parasites to be 
PF10_0279 and PF10_0299.  It was found that all D6 parasites had approximately 1 copy 
of PF10_0275, PF10_0277, and PF10_0300 (Fig. 3.5-A, Table A-3, Appendix A).  For 
the resistant D6 parasites, CN of genes from PF10_0279 to PF10_0299 was 
approximately two across the amplification.  The minimum CN was for D6.QHS2400x5 
in PF10_0286 (CN, 1.82±0.0812, 95% CI 1.74-1.90) and the maximum CN was for 
D6.QHS80 (CN 2.49±0.060, 95% CI, 2.43-2.55) and D6.QHS2400x2 (CN, 2.50±0.20, 95% 
CI, 2.30-2.69), both in PF10_0292 (Fig. 3.5-A, Table A-3, Appendix A).  The overall 
mean of average CN for resistant parasites from PF10_0279-PF10_0279 was 2.09 ±0.112, 
95% CI 2.06-2.12.  In the W2 series, there was a smaller region of amplification within 
the large amplification detected in resistant D6 parasites (Fig. 3.5-B, Table A-3, 
Appendix A).  This region was from PF10_0292 to PF10_0296, and parts of this region 
were found in W2, W2 (clone D7), as well as resistant W2 progeny.  However, the 
amplification in W2 and W2 (clone D7) was only in PF10_0292 and PF10_0294.  We 
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also found that CN differed between W2 (CN, 3.46±0.52 95% CI, 3.34-3.59) and W2 
(clone D7) (CN, 2.18±0.069 95% CI, 2.12-2.24) for PF10_0292 and for PF10_0294 (W2 
CN, 3.05±0.302 95% CI, 2.75-3.34; W2 [clone D7], CN 2.17±0.085 95% CI, 2.08-2.27).  
The amplification in W2 and W2 (clone D7) was not found in any other gene we 
analyzed.  The resistant W2 parasites had amplification in PF10_0292 (W2.QHS200 CN, 
2.97±0.18, 95% CI 2.72-3.22; W2.QHS200x2 CN, 3.58±0.021 95% CI 3.55-3.60), 
PF10_0294 (W2.QHS200 CN, 2.87±0.150, 95% CI 2.70-3.03; W2.QHS200x2 CN, 
3.07±0.028 95% CI 3.03-3.11), PF10_0295 (W2.QHS200 CN, 2.96±0.35 95% CI, 2.66-
3.27; W2.QHS200x2 CN, 3.50±0.0071 95% CI, 3.49-3.50), and PF10_0296 
(W2.QHS200 CN, 3.07±0.21 95% CI 2.89-3.25; W2.QHS200x2 CN, 3.61±0.042 95% CI, 
3.55-3.67) (Fig. 3.5-B, Table A-3, Appendix A).  These data for W2.QHS200x2 validate 
the sequencing results reported above where the copy number of PF10_0292-PF10_0296 
inW2.QHS200x2 was increased over 3 copies.  Currently, it is not known why W2 and 
W2 (clone D7) contained amplification in PF10_0292 and PF10_0294 at all, or why only 
these genes were amplified (more in Discussion).  Also, sequencing determined that W2 
(clone D7) had amplification in PF10_0295 and PF10_0296, but we did not detect 
amplification in these genes.  Furthermore, sequencing found that there were 3 copies of 
amplified genes in W2 (clone D7), yet we found they were amplified only ~2-fold.  
In the TM91c235 series, copy number of chromosome 10 genes was 
approximately 1 for all strains that we analyzed (Fig. 3.5-C, Table A-3, Appendix A).  
The lowest value in the set was for TM91.AL280x2 in PF10_0286 (CN, 0.945±0.0071 95% 
CI, 0.935-0.955).  The highest copy numbers in chromosome 10 were for PF10_0279 in 
TM91c235 (CN, 1.36±0.035 95% CI 1.31-1.40) and TM91c235.AL240x2 (CN, 
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1.39±0.038 95% CI, 1.35-1.44).  We also observed CN ≥1.2 for other genes (PF10_278, 
PF10_0294).  We also examined patient isolates from Thailand and Cambodia for some 
of the genes within the amplification, but not all.  These isolates were from another study 
where our laboratory performed in vitro susceptibility testing on isolates from this region 
of Asia.  It was found that a few of these (including Cambodia 18) had reduced 
susceptibility to artemisinins.  All isolates that were assayed had approximately 1 copy of 
the particular gene tested within chromosome 10 (genes tested were PF10_0275, 
PF10_0279, PF10_0292, PF10_0294, PF10_0295, PF10_0296) (Fig 3.5-D, Table A-3, 
Appendix A).   
Dihydroartemisinin treatment is associated with the appearance of dormant 
forms prior to recrudescence.  Before microarrays were conducted on D6 resistant 
strains, we performed an experiment to determine the rate of recovery from dormancy 
after D6 (clone C11) and D6.QHS2400x5 were treated with 200 ng/ml DHA.  This dose 
was chosen because previous experiments (data not shown) showed that this 
concentration of drug was high enough to induce dormancy in both parent and resistant 
parasites, yet low enough to allow parasites to recrudesce over a period of approximately 
a week after treatment. Recovery rates of parent and resistant D6 parasites were 
determined by exposing parasites to DHA for 6 hours and monitoring parasitemia over 
eight days (Fig 3.6).  For the untreated parasites, parasitemias spiked at 48 hours, then 
decreased as parasites started becoming stressed and dying.  In both D6 and 
D6.QHS2400x5, the total parasitemia did not decrease below 2% after drug exposure 
(Fig. 3.6-A); however, the number of normal parasites decreased markedly after DHA 
was added (Fig  3.6-B).  At 24 hours, the majority of parasites observed in DHA-treated 
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D6 were classified as dormant or dead, with 4.2% of parasites identified as 
morphologically normal.  In contrast, a higher percentage of morphologically normal 
parasites were noted for the resistant parasite (21.1%) (Figs 3.6-B, C [for pictures at 24 
hours]).  At 48 hours post-drug, again the majority of parasites were classified as dead or 
dormant, but normal parasites were still detected in each strain (Figs 3.6-B, C).  The 
percentage of normal parasites observed was greater for the resistant parasite compared to 
the parent (8.0% vs. 3.8%).  At 72 hours post-drug, normal parasites were not counted for 
D6, although after thorough examination of the smear, very few normal parasites were 
observed (Fig. 3.6-C).  A greater number of normal parasites were observed in 
D6.QHS2400x5 (23.5% of total parasites counted).  The percentage of normal parasites 
was consistently greater after 72 hours in the resistant parasite compared to the parent 
until the end of the assay (Fig. 3.6-B).  At 96 hours, normal parasites were observed for 
the parent strain (Fig. 3.6-C), but the percentage was less than the resistant parasite (9.5% 
vs. 31.6%) (Fig. 3.6-B).  Overall, dormant forms persisted until 144 hours in thin smears 
for each strain (Fig. 3.6-C), but there was a greater number of dormant parasites in the 
resistant strain at every time point (after 24 hours) (Figs. 3.6-D).  The assay was 
terminated at 192 hours post drug after parasitemia of normal parasites was ≥4%.  The 
parasitemia of morphologically normal parasites was greater for the resistant parasite 
(6.3%) compared to the parent (3.9%) at the end of the assay.   
Transcriptional analysis of dihydroartemisinin treated parental and resistant 
parasites reveals transcriptional arrest and differences in gene expression. 
Dihydroartemisinin induces transcriptional arrest at ring stage in W2 parasites.  
In a pilot microarray experiment, synchronized rings of wild-type W2 parasites were 
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exposed to 100 nM DHA for 6 hours, and RNA was isolated at 6 (T6) and 27 (T27) hours 
post-drug treatment.  For untreated parasites, a 21 hour separation in the IDC would 
constitute a huge change in the transcriptome 
422-424
 and be expected to have a negative 
correlation of -0.69 (calculated from the HB3 dataset).  However, these studies revealed 
that following treatment with DHA, samples taken 21 hours apart had surprisingly similar 
transcriptomes with a Pearson correlation of 0.63 and correlated best with 12 and 13 hour 
post invasion (hpi) (Fig. 3.7) in transcriptome data from the normal IDC of HB3 
422
.  
These data suggest there is an arrest in ring-stage development following treatment with 
DHA.  Unfortunately, these data contained numerous gaps for expression of genes and it 
only involved DHA-treated parental W2 (without relative untreated controls) over a 
limited time.  Therefore, a study with a longer time course was conducted with QHS 
sensitive and resistant parasites to probe DHA-induced dormancy over a prolonged 
period of time.  The experimental design is illustrated in Fig. 3.2. 
Dihydroartemisinin induces arrest with a ring-like transcriptome in artemisinin 
sensitive and resistant D6 parasites.  Clones of D6 (artemisinin sensitive) and 
D6.QHS2400x5 (artemisinin resistant) were grown into highly synchronous cultures for 
microarray analysis.  Approximately 8 hours after merozoite invasion, one half of each 
strain was treated with 200 ng/ml DHA, while the other half was treated with DMSO as a 
negative control.  Drug or DMSO was washed out of cultures at six hours after treatment 
(T6).  Starting at the time of drug treatment (T0), samples were taken from both treated 
and untreated cultures every six hours for the first 24 hours, then every 8 hours until 48 
hours after drug treatment.  After T48, untreated control cultures were discontinued, but 
samples from treated cultures were taken at 57 hours and then every 12 hours thereafter 
  
238 
 
until the cultures recrudesced beyond measurable parasitemia (treated synchronized 
cultures were terminated after 189 hours, treated unsynchronous [mixed] cultures were 
terminated after 153 hours).  After RNA isolation and linear amplification in parallel, 
dye-labeled samples were hybridized to 89 P. falciparum expression arrays.  The array 
results were analyzed as described for the W2 pilot microarrays, comparing results from 
each array to every hour of the IDC from normally growing HB3 parasites (data from 
422
).  
In Figure 3.8, DMSO-treated control parasites present a drifting sine wave of correlation 
whose peak correlation (0.73±0.05 for D6 and 0.64±0.07 for D6.QHS2400x5) shifts 
across the IDC as expected (Fig 3.8-A, C).  In stark contrast, D6 and D6.QHS2400x5 
synchronized treated parasites failed to progress their transcriptome past a state most 
closely resembling a normal ring at 8-11 hours post invasion (hpi).  This period of 
transcriptional arrest lasted for 86 hours post-drug for DHA-treated D6 and 62 hours 
post-drug for DHA-treated D6.QHS2400x5 (Fig 3.8 B, D).  Peak correlations to the IDC 
stalled at 8-11 hpi (0.63±0.02) for D6 and stalled at 9-11 hpi (0.55±0.02) for 
D6.QHS2400x5.  These results confirm and significantly extend our observation of a 
DHA-induced dormancy and transcriptional arrest in the W2 pilot experiment (Fig. 3.7).  
Importantly, both parental and QHS resistant clones exhibited transcriptional arrest 
consistent with a 8-11 hpi ring stage parasite.  The data suggest the period of dormancy 
was shorter for the resistant clone compared to the drug sensitive parent and the 
correlation of the DHA treated to the normal IDC ring transcriptome did not appreciably 
diminish across the prolonged period of dormancy.  We believe this unique observation is 
consistent with the morphological observation of dormant rings at the same time points 
(below). 
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Recovery following exposure to dihydroartemisinin: artemisinin resistant 
parasites exit dormancy earlier than parental parasites.  The recovery of parasites from 
dormancy was evaluated by morphological and transcriptional analysis.  Parasitemia of 
the untreated groups was followed up to 48 hours and the treated groups were followed 
for up to 189 hours (Fig. 3.9-A, B).  Figure 3.9-A shows parasitemias of the untreated 
groups (PUM, PUS, RUM, RUS).  Figure 3.9-B shows parasitemias of the treated groups 
(PTM, PTS, RTM, RTS).  In the untreated cultures, the mixed groups reached greater 
parasitemias before the synchronized groups, with the PUM group eventually reaching 
highest parasitemia.  There fact that the different untreated groups grew to different 
parasitemias is a factor of starting parasitemia, which we attempted to standardize.  In the 
treated groups, parasitemias of all groups declined after drug treatment, but parasitemias 
of PTM, PTS, and RTM spiked at 57 hours before declining again.  This may indicate a 
greater number of dead and dormant parasites were counted at this time point for those 
groups.  The untreated groups also reached greater parasitemias compared to the treated 
groups over the time course.   
As noted previously (Kyle et al., 2010 unpublished; 
360,362
), there was a 
predominant shift in morphology from rings to dormant forms after synchronized cultures 
were treated with DHA (see Fig. 3.6-C for dormant morphology in D6 recrudescence 
assay).  As stated before, dormant parasites are small with a regular round outline on a 
Giemsa blood smear and they differ from the collapsed nuclei of pyknotic bodies in their 
retention of a small circle of blue staining material that is cytoplasm and condensed red 
chromatin.  These characteristics separate them from dead parasites which appear smaller 
and globular with no distinct organization of chromatin and cytoplasm, appearing 
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purplish-pink when stained with Giemsa.  By 24 hours after DHA exposure, most of the 
parasites observed had ring-stage dormant morphology.  Much like the D6 recrudescence 
assay before the microarrays, the period of dormancy after treatment preceded eventual 
recrudescence of morphologically normal parasites.  Although overall parasitemia in 
treated groups did not change significantly (Fig 3.9-B), the proportion of parasites with 
normal morphology (rings, trophozoites, schizonts) dropped dramatically, which 
corresponded with an increase in dead-dormant stages in all treated groups.  Figures 3.9-
C and 3.9-D show the percentage of dead and dormant/normal parasites for the treated 
groups (asynchronous and synchronous, respectively), which increased greatly 12 hours 
after drug pressure.  The majority of parasites observed were classified as dead rather 
than dormant at this point.  In the treated synchronized groups, the ratio of dead and 
dormant/total parasites was similar after 12 hours post-drug up to a point.  Analysis of 
parasite morphology in synchronous cultures revealed that morphologically normal 
parasites appeared earlier in resistant parasites.  There was a sharper decrease for the 
resistant parasite (starting at 57 hours post-drug) indicating an increasing prevalence of 
parasites with normal ring, trophozoite, or schizont morphology later in the time course 
(Fig. 3.9-E, which is inverse of Fig. 3.9-D).  In addition, a greater percentage of parasites 
with normal morphology were evident in the resistant strain at time points after parasites 
appeared in culture.  Although the synchronized treated parent culture reached higher 
overall parasitemia before the resistant treated parasite (Fig. 3.9-B), the percentage of 
normal/total parasites was lower for the parent strain during the majority of the time 
course (Fig. 3.9-E).  Like the D6 recrudescence assay above, the period of recrudescence 
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did not differ significantly between parent and resistant strains.  Normal parasites were 
observed in PTS at 69 hours post-drug. 
Dormant forms were observed from 12 hours to 141 hours post drug exposure in 
both PTS and RTS.  Generally, there were more dormant parasites observed in PTS 
compared to RTS (data not shown) throughout the time course.  This is different from the 
initial D6.QHS2400x5 recrudescence assay that showed more dormant parasites present 
in the resistant parasite throughout the experiment.  Perhaps experimental variability 
between the two assays played a factor.  Although there appeared to be a lower 
percentage of dormant parasites in the resistant strain in the arrays, those parasites 
recrudesced before the susceptible parent strain.  This may indicate that resistant parasites 
are more capable of emerging from dormancy compared to the parent strain. 
Interestingly, time points starting at 68 hpi revealed the resistant parasites resume 
a progressing transcriptome earlier that the parental parasites. Fig 3.8-D illustrates that 
the DHA-treated resistant parasites‟ transcriptome at 68 starts to shift away from the 
stalled transcriptome and at 80 hours is clearly shifted later in the IDC (peak Pearson 
correlation 0.61 with 23 hpi).  We noticed a strange effect of the progression of the 
transcriptome of the resistant parasite after leaving dormancy.  At 68 hours, it appeared 
that the transcriptome started to resemble that of late rings and early-trophozoites.  
Another 12 hours later (80 hours total), the transcriptome resembles mid-trophozoites.  
Strangely, at 92 hours, the transcriptome again resembles early ring stages.  We do not 
completely understand how rings could appear after drug at 68 hours, then appear again 
only 24 hours later (one would expect to observe late trophozoites and schizonts in a 
normal 48-hour P. falciparum life cycle).  Perhaps some parasites that released early 
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from dormancy died as they progressed at 80-92 hours.  Maybe some of the rings that 
originally exited dormancy were stalled in progression so that they still remained at 92 
hours.  Also, it may be that another population of rings emerged from dormancy at 92 
hours.  Taken together, there were unexpected effects on progression of the life cycle 
after leaving dormancy.  This will be followed up by more detailed studies.  In contrast, 
the parental lines‟ transcriptome remains stalled in the ring-like state through at least 92 
hpi (Fig 3.8-B).  The parental transcriptome at 104 hpi had progressed out of the ring-like 
state, around 24 hours or half a replicative cycle after the matched resistant parasite clone.  
The time points subsequent to the exit from dormancy have reduced peak correlations in 
the transcriptome probably due to the loss of synchrony as individual parasites exit 
dormancy at different times and create a combined asynchronous population.  This is 
consistent with observations on recovery from dormancy by Teuscher et al (2010) 
362
.  
Asynchronous cultures exposed to dihydroartemisinin become dominated by a 
ring-like transcriptome.  An alternative to the ring stage dormancy hypothesis is this 
transcriptional arrest in ring-treated parasites might simply reflect a pause relative to their 
stage of development at the time of drug treatment or that signal captured on the 
microarrays could represent residual RNA from dead or dying rings in the synchronized 
culture. Therefore, simultaneously with the synchronized culture experiment, we exposed 
asynchronous cultures of the same D6 and D6.QHS2400x5 parasites and harvested 
samples for microarray analysis.  If the transcriptional arrest was due to dead parasites or 
to the developmental stage of each parasite, then we would expect the asynchronicity of 
the cultures to be maintained over the time course following drug exposure.  In contrast, 
we found that DHA induced a similar arrest at ring stage in asynchronous cultures of 
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parental and resistant parasites.  Time points after drug treatment showed increased 
correlation to a normal ring in the IDC (0.40±0.10 for D6 and 0.37±0.07 for 
D6.QHS2400x5) (Figure 3.10-B, D).  DMSO treated controls produced low peak 
correlations (0.18±0.07 for parental and 0.16±0.02 for resistant) that reflected normal 
asynchronous growing cultures (Fig 3.10-A, C).  Importantly, the transcriptome of 
asynchronous DHA treated parasites converged and paused consistent with a dormant 
state in both resistant and parental clones (peak correlation at 15±1.3 hpi for D6 and 
11±2.3 hpi for D6.QHS2400x5, p=0.0017).  The slight difference between the hpi of peak 
correlation during stall might be due to differences in the mix of populations at time zero, 
with the parental asynchronous sample most closely resembling 21 hpi and the resistant 
sample most closely resembling 9 hpi.  The fact that the period of transcriptional arrest 
across time points is tight, but across cultures is more broad suggests that there is a 
window of time in the IDC in which parasites can go dormant.  The data demonstrate the 
ring stage is the only point in the IDC where DHA arrests transcription.  In addition, the 
pause in the transcriptome may indeed be relative to the parasites‟ current transcriptional 
state at the time DHA is added.  This might also explain why the peak correlations for the 
asynchronous transcriptome peak correlations are not as high as those of the originally 
synchronized dormant parasites (i.e. more developed stages are killed and not able to 
enter dormancy).  In the parental culture the 6 and 12 hpi time points exhibit lower peak 
correlations than subsequent time points suggesting a recruitment of more parasites into 
the dormant state.  Perhaps the resistant parasites are able to enter dormancy more 
quickly than sensitive parasites, yet this remains to be confirmed. 
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Dihydroartemisinin-induced dormancy is characterized by unique gene 
expression in parental and resistant strains.  Although the overall transcriptome of these 
dormant parasites most closely matches ring stage, the data provided an opportunity to 
identify those genes that were reproducibly up-regulated or down-regulated following 
drug exposure in both parasites.  For this purpose we used the expression data from the 
treated synchronized cultures of D6 and D6.QHS2400x5.  The time zero expression data 
was subtracted from the dormant state expression data averaged across all post-drug time 
points for each gene. This analysis provides a measure of gene induction (or down-
regulation) from baseline expression.  The data were filtered for spots with more than 17 
total data points that passed previous quality control filters, and spots with a measure of 
induction < -1.0 or > 1.0.  In Table 3.7, the top 113 oligo hits most different from time 
zero are displayed.  The most up-regulated gene in the data set was PFE0065w (skeleton 
binding protein, chromosome 5), expressed 15-fold (3.92 log2) in D6.QHS2400x5 and 
165-fold (7.37 log2) in D6.  Thioredoxin reductase (PFI1170c, chromosome 9) was up-
regulated 9-fold (3.16 log2) in D6.QHS2400x5 and 23-fold (3.16 log2) in D6 in the first 
48 hours after drug treatment.  P. falciparum thioredoxin reductase (PfTrxR) is a 
NADPH-dependent disulphide oxidoreductase which catalyses the reduction of 
thioredoxin (Trx) 
425
.  PF14_0017 (chromosome 14) was up-regulated 7.3-fold in both 
strains at 48 hours after DHA treatment (log2 D6:2.86, log2 D6.QHS2400x5: 2.87).  This 
gene encodes a lysophosopholipase, which belongs to a family of alpha/beta hydrolases.  
PF14_0183 (encodes a putative signal recognition particle RNP) was up-regulated 22-
fold in D6 (log2: 4.43) and 2.5-fold in D6.QHS2400x5 (log2: 1.31).  Also, PFF0510w 
(encodes a histone H3 protein) was up-regulated 5-fold in D6 (log2: 2.34) and 7.4-fold in 
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D6.QHS2400x5 (log2: 2.89).  PF14_0010 (encodes a glycophorin family binding protein) 
was up-regulated 19-fold in D6 (log2: 4.25) and 6.2-fold in D6.QHS2400x5 (log2: 2.63).  
Interestingly, up-regulation of a longevity-assurance (LAG1) domain gene (PFE0405c) 
was observed in both D6 and D6.QHS2400x5.  The gene was up-regulated to a higher 
degree in the resistant parasite, with large differences at baseline and in the first few time 
points after DHA was added (data not shown).  Conversely, PF10_0327 was down-
regulated 2.8-fold in both parasites (log2 D6:-1.53, log2 D6.QHS2400x5: -1.50), and 
PF13_0088 was down-regulated 2.1-fold in D6 (log2:-1.08) and 3.3-fold in 
D6.QHS2400x5 (log2:-1.73).  These genes both encode PfMyb domain proteins.  Two 
genes (MAL7P1.19 and PF08_0020) that encode a putative ubiquitin transferase and a 
ubiquitination mediated degradation component, respectively were also down-regulated 
in both PTS and RTS.  MAL7P1.10 was down-regulated 2.8-fold in PTS (log2: -1.50) and 
3.3-fold in RTS (log2: -1.71).  PF08_0020 was down-regulated 2.5-fold in PTS (log2: -
1.35) and 2.1-fold in RTS (log2: -1.09). 
Dihydroartemisinin induces differential expression of genes in artemisinin 
resistant and sensitive parasites.  Genes involved in DHA-induced dormancy or QHS 
resistance could potentially be up-regulated in resistant parasites during dormancy or 
only after drug treatment.  To explore this possibility, the microarray data were analyzed 
for genes that showed a different direction of regulation from baseline after drug 
treatment.  We sorted for oligos with measures of induction that had opposite effects in 
the D6 versus D6.QHS2400x5 synchronized cultures with absolute distance between the 
two inductions greater than an arbitrary cutoff of 1.8 (Table 3.8).  There appears to be 
differential regulation of cytochrome c complex genes after DHA treatment, as three 
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genes of this complex had various expression effects.  MAL13P1.55 was down-regulated 
1.7-fold (log2:-0.766) in D6, but up-regulated 2.8-fold in D6.QHS2400x5 (log2: 1.51).  
PF14_0038 was down-regulated 2.8-fold in D6 (log2:-1.47) and up-regulated 2.6-fold in 
D6.QHS2400x5 (log2: -1.38).  PF10_0252 was up-regulated 3.1-fold in D6 (log2:1.63), 
but down-regulated 3.3-fold in D6.QHS2400x5 (log2: -1.73).  The differential induction 
of two zinc finger proteins PF11_0357 and PFC0510w was also identified.  PF11_0357 
was down-regulated 3.3-fold in D6 (log2: -1.71) and up-regulated 3.7-fold in 
D6.QHS2400x5 (log2:1.87).  PFC0510w was up-regulated 1.6-fold in D6 (log2: 0.69) and 
down-regulated 2.2-fold in D6.QHS2400x5 (log2:-1.14).   
Constitutive transcription differences were identified between artemisinin 
resistant and sensitive strains.  The genetic determinant of dormancy or resistance might 
induce constitutive up-regulation or down-regulation of some transcripts in resistant 
parasites.  Therefore, we queried the data from time zero synchronized parasites, looking 
for differences in expression in the absence of drug.  To compare the transcriptomes of 
D6 and D6.QHS2400x5 at baseline, the residual between the time zero array signals of 
the synchronized resistant parasites and a linear regression of its relationship with 
synchronized resistant parasites was calculated.  By this measure of differential baseline 
transcription after removing variable antigen oligos, a list of almost 200 differentially 
expressed oligos was generated (Table 3.9, represents the top 1.2% of the data).  Notable 
in the genes that are higher expressed in the resistant strain are a few from a relatively 
tight physical location on chromosome 10.  PF10_0281 was down-regulated 2.6-fold in 
D6 (log2: -1.39) and up-regulated 2.8-fold in D6.QHS2400x5 (log2:1.47).  PF10_0282 
was down-regulated 2.3-fold in D6 (log2: -1.18) and up-regulated 2.8-fold in 
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D6.QHS2400x5 (log2:1.51).  PF10_0291 was down-regulated 2.3-fold in D6 (log2: -1.21) 
and up-regulated 2.7-fold in D6.QHS2400x5 (log2:1.45).  PF10_0296 was expressed at 
baseline for D6 (log2: -0.051), but up-regulated 4.5-fold in D6.QHS2400x5 (log2:2.17).  
The putative role of these genes in artemisinin resistance is described below.  PfMDR1 
(encoded by PFE1150w), known to be involved in resistance to some drugs and a 
possible compensatory protein for artemisinin resistance, had lower expression in 
D6.QHS2400x5 (7.2-fold, log2: -2.85), compared to D6 (1.4-fold, log2: -0.483). 
Discussion 
Studies in this specific aim have thoroughly examined artemisinin resistant 
parasites and identified putative molecular markers of resistance, while characterizing 
artemisinin-induced ring-stage dormancy.  We utilized next-generation sequencing 
technology and found high-probability polymorphisms between D6 and D6.QHS2400x2 
that also existed in parasites treated additional times with 2400 ng/ml QHS.  Sequencing 
also identified amplifications in chromosome 10 for resistant D6 and W2 QHS-selected 
parasites.  We believe the SNPs and amplifications we identified represent great promise 
for public health efforts, possibly representing markers that can be used to analyze field 
isolates in areas where artemisinin resistance is reported to be emerging.  An assay 
measuring recrudescence of D6 vs. D6.QHS2400x5 after DHA treatment found the 
resistant parasite produced more dormant parasites and recrudesced earlier than the 
parental strain.  Importantly, D6.QHS2400x5 represents the highest selected artemisinin-
resistant parasite we have, and it tolerates drug levels beyond those typically found in 
patients taking artemisinin therapy for malaria.  We also used transcriptional analysis to 
dissect molecular mechanisms of artemisinin-induced dormancy and identify genes 
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linked to artemisinin resistance in highly QHS-resistant D6 parasites.  As we expected, 
both D6 and D6.QHS2400x5 exposed to DHA entered a dormant state in ring stage.  
Interestingly, the dormant parasites continually expressed a ring like transcriptome for 
68-92 hours after drug treatment before recovering, growing normally, and reverting to a 
normal transcriptome as parasites progressed through development.  In addition, 
transcriptional analysis revealed 113 genes that were up- or down-regulated during 
dormancy.  Furthermore, genes were identified that were differentially expressed in 
artemisinin resistant versus susceptible parasites. These data provided new insight into 
artemisinin-induced developmental arrest in the IDC and revealed novel candidate genes 
associated with dormancy and resistance to the most important antimalarial drug. 
Proteomics.  The proteome of Plasmodium spp. changes as parasites progress 
through different stages of the life cycle.  Researchers have studied the proteome of 
various stages of P. falciparum, enabling a systematic cataloging of protein expression.  
Prior studies provided functional profiles of thousands of proteins encompassing protein 
expressed in gametocytes, asexual stages, and sporozoites 
426,427
.  Significant proteomic 
changes occur in the erythrocytic stage of the life cycle, where parasites express and 
display numerous, variable proteins on the surface of the red blood cell.  Although studies 
have thoroughly characterized functionality of proteins in relation to stage, there is a 
significant lack of studies regarding proteomic changes after treatment of parasites with 
antimalarial drugs.  Therefore, we attempted to use proteomic analysis to characterize 
molecular mechanisms of artemisinin resistance by focusing on comparisons of highly 
synchronous (ring/early trophozoite) parental/resistant parasites (D6 vs. D6.QHS2400x3 
and W2 vs. W2.QHS200).  An important fact to consider when analyzing the data is that 
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D6.QHS2400x3 was culture for months after the last pulse of 2400 ng/ml.  Also, 
W2.QHS200 was thawed from cryopreservation and grown for some time in culture 
before proteomic analysis.  The time since the last drug pulse in W2.QHS200 is unknown.  
Since these parasites were grown without drug pressure or off drug pressure for a period 
of time, it may be difficult to make valid comparisons to other studies.   
In the D6 series, the most significantly differentially regulated proteins were 
PF11_0098, PFI0265c, PF14_0425, and PFI1270w.  PF11_0098 encodes an endoplasmic 
reticulum-resident calcium binding protein (PfERC) 
428
.  It was down-regulated (1.4 fold) 
in D6.QH2400x2.  In a study comparing proteomes of P. falciparum strain FCR3 and 
progeny (ring stage) that were made resistant to a synthetic endoperoxide (N-89), it was 
found that PfERC was up-regulated 1.5-fold 
429
.  Makanga et al. (2005) 
408
 reported on 
protein expression of P. falciparum strain K1 (ring stage) after treatment with AE or 
LUM, and found PfERC was up-regulated in both drug treatments.  Also, Nirmalan et al. 
(2004) 
430
 characterized proteins expressed in strain Dd2 (rings) without drug pressure, 
and found PfERC was expressed (no data on levels).  The gene encoding this protein is 
minimally expressed in merozoites, but maximally expressed in gametocytes.  It is also 
up-regulated in later blood stages, but down-regulated in rings (PlasmoDB).  Perhaps in 
the absence of drug pressure, this gene is under-expressed in ring stages, and 
endoperoxide drugs including artemisinins cause the over-expression of the protein.  
D6.QHS2400x2 was grown for some time without drug pressure, so expression of PfERC 
may have returned to basal levels in ring-stages we assessed.  As stated previously, it is 
hypothesized that artemisinins target a sarco-endoplasmic reticulum ATPase and these 
drugs are reputed to alter calcium homeostasis 
323
.  Interestingly, the studies that detailed 
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protein expression after artemisinin drug treatment above did not find differential 
regulation of pfatp6 itself.  It may be that these drugs cause the expression of 
compensatory calcium-regulatory mechanisms when pfatp6 is inhibited.  Since the 
parasites we assessed were grown without drug pressure or off drug pressure for a period 
of time, this may be a reason we did not find up-regulation of calcium-related proteins.   
Fructose bisphosphate aldolase (FBA, encoded) was also down-regulated (1.5-
fold) in D6.QHS2400x2.  FBA is an enzyme of the glycolytic pathway. It is minimally 
expressed in gametocytes and maximally expressed in merozoites.  However, other 
studies found steady-state expression of FBA throughout the life cycle (PlasmoDB).  The 
study by Aly et al. (2007) 
429
 found FBA was up-regulated in resistant parasites, whereas 
Makanga et al. (2005) 
408
 reported that FBA (and a host of other glycolytic enzymes) 
were both down-regulated after AE treatment, but up-regulated after LUM treatment.  
Natalang et al. (2008) 
412
 described the transcriptional changes that occur in trophozoite 
parasites in response to AS.  This study described dying stages 3 and 10 hours after drug 
treatment. This study found PF14_0425 was down-regulated in AS-treated P. falciparum.  
It is not known how antimalarial treatment would affect enzymes of glycolysis, but it is 
theorized that enzymes of this pathway could be good antimalarial targets since malaria 
parasites rely on this pathway for energy production while inside the RBC 
431
.  Also, it is 
not known why this protein would be under-expressed in resistant D6.QHS2400x2, but 
not differentially expressed in W2.QHS200.   
RhopH3 rhoptry protein (encoded by PFI0265c) was up-regulated (~1.6 fold) in 
D6.QHS2400x2.  Also, MSP-1 precursor (PFI1475w) and MSP-7 precursor (PF13_0197) 
were up-regulated (~1.9 fold and 1.5 fold, respectively) in W2.QHS200x2 compared to 
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W2.  Other than being found on merozoites, these proteins are also associated with up-
regulation in trophozoite and schizont stages, as merozoites are being packaged for the 
next invasion cycle 
426,427
.  The study by Aly (2007) 
429
 found MSP-7 was up-regulated in 
endoperoxide-resistant parasites, but Makanga et al. (2006) 
408
 did not report any 
significant differences in regulation of MSPs in their study with AE or LUM-treated 
parasites.  Jiang et al. (2008) 
432
 found PFI0265 was up-regulated at the transcriptional 
level in both CQ-resistant (>4-fold) and CQ-sensitive (>11-fold) P. falciparum parasites 
(trophozoites) after exposure to CQ.  Gunsakera et al. (2003) also found CQ-treated 
parasites (trophozoites) over-expressed genes encoding RBC invasion proteins (including 
MSP-1).  It is unclear why a merozoite-associate protein would be up-regulated in 
artemisinin-resistant parasites and after CQ-treatment.  In the CQ studies, it may be that 
trophozoites already express a certain amount of merozoite proteins, and drug effects 
may cause even more expression or maybe not contribute that much (it would depend on 
basal expression of these proteins).  Perhaps merozoite proteins such as these have dual 
roles.  The proteins may be expressed maximally during invasion, then non-expressed in 
the erythrocytic cycle until artemisinin drug treatment caused up-regulation.  Another 
reason we may have found MSPs in W2 parasites is that perhaps the cultures contained a 
minority population of mature schizonts.  However, these proteins were not found in the 
D6 parasites, which were synchronized in the same fashion.   
Actin I (encoded by PFL2215w) was up-regulated (~1.4 fold) in W2.QHS200.  
Actin I is a motor protein that is associated with merozoite invasion and up-regulated in 
late trophozoites and schizonts (PlasmoDB, 
427
), but Actin II is found in sexual stages and 
ring stages (PlasmoDB, 
426
).  Actin I was down-regulated in endoperoxide resistant 
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parasites in the study by Aly et al. (2007) 
429
.  Makanga et al. (2005) 
408
 did found Actins 
I and II in their study, but did not state if they were significantly differentially regulated 
in AE or LUM treated parasites.  We cannot definitely state why Actin I was up-regulated 
in W2.QHS200.  Actin appears to be present in many proteome analyses of parasites, but 
its role in artemisinin resistance is not clear.  It may be that this protein is constitutively 
expressed in W2 parasites and artemisinin exposure caused the parasite to up-regulate the 
protein, where the effect was maintained even after long periods of culture.  Nirmalan et 
al. (2004) 
430
 identified Actin I and Actin II in their analysis of Dd2 ring-stage proteins.  
Since Dd2 is a descendant of W2, these results may fit with what we found.  Also, since 
Actin I is expressed in late stage asexual parasites, perhaps some contaminating late stage 
parasites remained after synchronization in our cultures, leading to the detection of this 
protein.   
The heat shock protein 70 (HSP70) homolog (encoded by PFI0875w) was up-
regulated in W2.QHS200 (1.6-fold).  PFI0875w is reported to be minimally expressed in 
gametocytes, but maximally expressed in schizonts (PlasmoDB).  HSPs are stress-related 
proteins that have been reported to be expressed during drug pressure.  However, the 
resistant W2 parasite was not grown in presence of drug.  Perhaps this protein is 
continually expressed after the original artemisinin pressure to induce resistance in W2.  
HSP70 was up-regulated in endoperoxide resistant parasites in the study by Aly et al. 
(2007) 
429
.  Witkowski et al. (2010) 
360
 determined that PF08_0054, which encodes 
HSP70 was down-regulated in QHS-selected P. falciparum.  Natalang et al. (2008) 
412
 
found a variety of genes encoding HSPs or related proteins that were differentially 
expressed after AS treatment of P. falciparum strain FCR3 (trophozoites).  Makanga et al. 
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(2005) 
408
 found HSPs were up-regulated in both AE and LUM treated parasites.  
PFI0875 was up-regulated in the study of CQ-resistant parasites by Gunasekera et al. 
(2003) 
433
.  The fact that HSPs are up-regulated in drug-treated parasites and in 
W2.QHS200 reveals that proteins of the general stress response in response to drugs are 
active.  Interestingly, these were found in W2.QHS200, which had not undergone QHS 
pressure for some time after thawing.  Nirmalan et al. (2004) 
430
 identified a variety of 
HSPs in their analysis of Dd2 ring-stage proteins, so perhaps these proteins are 
constitutively expressed by W2 parasites, and pressuring of QHS lead to up-regulation. 
The second-highest differentially regulated protein in our analysis was the conserved 
Plasmodium protein of unknown function, PFI1270w.  It was up-regulated almost 1.7-
fold in D6.QHS2400x2.  Unfortunately, little is known about this protein in the literature 
and it is not possible at this time to hypothesize why this protein would be up-regulated in 
artemisinin-resistant parasites.   
Interestingly, Prieto et al. (2008) 
434
 performed a large scale proteomic analysis of 
3D7 (trophozoites) exposed to either QHS or CQ, and they did not report differential 
regulation of any of the genes we present here.  Their study found subunits of vacuolar 
ATP synthase (encoded by PF13_0130) were down-regulated after QHS treatment.  This 
may go along with the reported effect of artemisinin on pfatp6.  Several processes also 
had slight up-regulation after QHS-treatment including proteins involved in nucleotide 
and nucleic acid metabolism, transport and secretion as well as the expected response to 
stimuli.  There were many hypothetical proteins or conserved, undescribed Plasmodium 
proteins that were significantly up-regulated or down-regulated as well.  It may be 
difficult to compare our results to those of Prieto et al. (2008) 
434
 because of different 
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stages of parasites used and the fact that we did not expose parasites to drug prior to 
proteomic analysis.  One of the most important observations of Prieto et al. (2008) 
434
 is 
that pfmdr1 was found to be up-regulated under CQ and QHS pressure, indicating that 
pfmdr1 indeed mediates resistance to a number of unrelated classes of agents.  Studies 
from our lab have shown the role of Pfmdr1 in artemisinin resistance in W2 lines 
276
 and 
it is well known that it factors into MQ resistance and modifies susceptibility to other 
drugs (see Chapter One). 
Whole genome sequencing. 
Single nucleotide polymorphisms.  The first attempt at whole genome sequencing 
focused on D6 and D6.QHS2400x2.  Results from initial analysis of sequencing data 
found a relatively small list of SNPs that could be potentially involved in artemisinin 
resistance.  After applying further SNP filters and criteria, there were five high-
probability SNPs identified in D6.QHS2400x2 vs. D6: MAL13P1.298, PF13_0238, 
PFC0320w, PFE1155c, and PFF0275c.  We conducted follow-up sequencing of various 
strains to verify these SNPs in D6-resistant lines (3D7, W2 as controls).  SNPs in 
PF13_0238 and PFF0275c that separated D6 vs. D6.QHS2400x2 were found in all D6-
QHS resistant lines we assayed.  Unfortunately, we did not assay earlier-selected D6 lines, 
any QHS-resistant W2 progeny, or any AL-resistant TM91c235 progeny.  It would be 
interesting to see at what QHS-selection level these SNPs became present in the genome 
of D6 lines, and also if these SNPs exist at all in W2 and TM91c235 artemisinin-resistant 
parasites.  If these SNPs are present in W2 and TM91c235 resistant parasites, it would 
also be interesting to find at what drug concentration level they appeared in the genome.  
Future studies will focus on these analyses.   
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MAL13P1.298 (CDS=6381 bp) encodes a conserved Plasmodium membrane 
protein of unknown function (PlasmoDB).  This gene is expressed in merozoites and 
shows steady state levels in other erythrocytic stages as well.  The SNP in MAL13P1.298 
is located 1720 bases downstream from the start codon, changing the codon GGT-GAT 
(Gly-Asp).  The protein contains an alpha/beta hydrolase domain toward the C-terminus, 
but the SNP we identified is not in the region of the gene encoding this portion of the 
protein.  PlasmoDB lists a variety of SNPs in the gene, found in isolates around the world 
(including D6), so it appears to exhibit a high degree of diversity.  The SNP found in our 
sequencing analysis is not listed in PlasmoDB, but it appears to exist between regions 
with polymorphisms.  The gene is not described in the literature, and we currently do not 
have a reason why this SNP may be involved in artemisinin resistance.   
PF13_0238 (CDS=2181 bp) encodes a putative kelch protein, which is a protein 
formed of multiple kelch sequence motifs, each corresponding to a 50-amino acid motif 
that forms a beta-sheet blade.  Several of these repeats can associate to form a super-
barrel structural fold (beta propeller) 
435
.  PF13_0238 is minimally expressed in 
gametocytes and maximally expressed in merozoite.  The protein also contains a motif 
that is related to voltage-gated potassium channel complexes, which are responsible for 
potassium ion transport.  The SNP we identified in D6.QHS2400x2 vs. D6 is located 621 
bp from the start codon, changing codon GAA to AAA (Glu-Lys).  The SNP we found is 
also upstream of regions with high polymorphic character.  PlasmoDB does not have a 
record of the SNP we detected, but this SNP is near (57 bases) another SNP that is found 
in D6/HB3 vs. 3D7/Dd2/D10 (AAA-ACA [Lys-Thr]).  However, these SNPs are located 
outside of any functional domains of the protein, including potassium transport.  It is 
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tempting to implicate SNPs in this gene with artemisinin resistance, possibly showing a 
link between a conformational change in the protein and potassium transport.  It is 
already theorized that artemisinin may affect calcium homeostasis, and SNPs in pfatp6 
may affect susceptibility to these drugs.   
PFC0320w is located on chromosome 3 (genomic sequence=2241 bp) and it 
encodes a conserved Plasmodium protein of unknown function.  The gene is minimally 
expressed in early ring stages and maximally expressed in gametocytes.  The SNP we 
identified occurred 636 bp from the 5‟ end of the gene, changing codon AAT to ATT 
(Asn-Ile).  PlasmoDB lists only a few SNPs for this gene.  Like MAL13P1.298, we 
cannot state a reason why this nucleotide change may exist in D6.QHS2400x2.   
PFE1155c (genomic sequence=1818 bp) is located on chromosome 5 and encodes 
a putative mitochondrial processing peptidase alpha subunit.  It a component of 
mitochondrial electron transport (Complex III / Ubiquinol-cytochrome c oxidoreductase / 
cytochrome bc1) 
436
.  The gene is minimally expressed in gametocytes and maximally 
expressed in early trophozoites.  The protein has domains that exhibit activities ascribed 
to metalloendopeptidases, proteolysis, metal ion binding, zinc ion binding, catalysis, and 
metallohydrolases.  The SNP we detected is located 1200 bp from the 5‟ end of the gene, 
in the codon AGT-GGT (Ser-Gly).  There are only four SNPs described in the gene in 
PlasmoDB, and they exist more upstream in the gene than the one we found.  Proteins of 
key mitochondrial processes (including PFE1155c) have been proposed as antimalarial 
drug targets 
436
.  Atovaquone is an antimalarial drug that is known to inhibit 
mitochondrial electron transport at the cytochrome bc1 complex and collapses 
mitochondrial membrane potential 
165,436
.  Mutations in this cytochrome complex are 
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responsible for ATOV resistance in P. falciparum 
309,313-315
.  Although ATOV and 
artemisinins are structurally unrelated, artemisinins have also been theorized to target 
mitochondria 
182,183
.  The molecular target in mitochondria has not been described for 
artemisinin, but perhaps mutations in mitochondrial genes could be responsible.  Further 
research into this possibility is necessary.  Interestingly, Jiang et al. (2008) 
437
 described 
copy number variations (CNVs) in different P. falciparum strains and found 
amplification of a region within chromosome 5 that contained a total of 20 genes.  These 
genes included PFE1065w-PFE1155c that were amplified ~2–3 copies in FCR3 and 14 
genes (PFE1095w-PFE1160w [including PFE1155c]) amplified ~4–5 copies in Dd2.  
Perhaps this gene may play a role in antimalarial drug resistance in both CNV and SNPs 
much like pfmdr1. 
PFF0275c (genomic sequence=6704 bp) encodes a putative nucleoside 
diphosphate kinase that is minimally expressed in gametocytes and maximally expressed 
in merozoites.  The protein appears to be steadily expressed throughout the IDC.  The 
protein contains domains with ATP binding activity and it is active in UTP, CTP, and 
GTP biosynthetic processes.  The SNP we detected is located 4445 bp from the 5‟ end of 
the gene and it is a codon GAT-CAT (Asp-His).  The SNP is not reported in PlasmoDB.  
The SNP exists in between regions of high polymorphic character, and it is located 16 bp 
from a SNP (GAA-GTA, Glu-Val) found in D6/3D7/D10/Dd2 vs. Senegal3404.  There 
are a number of other SNPs in this gene (including D6) in PlasmoDB.  There are not any 
reports in the literature about this gene, but nucleic acid metabolism is theorized to be an 
important antimalarial drug target 
438,439
  Makanga et al. (2005) 
408
 found nucleic acid 
metabolism genes in proteomic analysis under AE and LUM exposure, with up-
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regulation of one protein (PGC0250c).  Witkowski et al. (2010) 
360
 determined that 
PF10_0121, which encodes hypoxanthine phosphoribosyltransferase) was down-
regulated in QHS-selected P. falciparum.  Natalang et al. (2008) 
412
 also found this gene 
was down-regulated in AS-treated P. falciparum.  PF10_0121 encodes an enzyme 
involved in purine biosynthesis, which is essential for DNA synthesis.  We found that 
PFE1050w, involved in nucleic acid metabolism, was up-regulated in microarrays but we 
did not find SNPs in artemisinin-resistant W2.  Therefore, PFF0275c may be one of gene 
of many nucleic acid-related genes that could be implicated in drug resistance.   
A potential problem we noted with the initial sequencing that used uncloned 
parasites is heterogeneity of bases for a given number of reads.  The heterogeneity could 
be attributed to two sources: error rates in the sequencing and true heterogeneity at the 
base.  While both sources exist in our data, some bases have high coverage and clear 
heterogeneity (for example, 100 reads covering a base with only 60% showing the major 
base).  A clear argument could be made that the sample is heterogeneous at these 
positions.  Therefore, we aimed to repeat the sequencing with a sample from a clonal 
population of each parasite in order to eliminate these types of SNPs.  This second set of 
sequencing used D6 (clone C11), D6.QHS2400x5, W2 (clone D7), W2.QHS200x2, and 
another parental W2 strain from the MR4 depository.  SNP analysis is pending for this 
second round of sequencing.   
Chromosome 10 amplification.  The initial sequencing we performed with D6 
and D6.QHS2400x2 identified a clear region of amplification on chromosome 10 in 
D6.QHS2400x2.  The region of amplification was determined to be from PF10_0279 
through PF10_0299.  Each gene appeared to be amplified 2-fold compared to the parent 
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D6.  These data were substantiated by QPCR data that we accumulated on various D6 
resistant strains.  It was determined that each gene in the amplification had approximately 
two copies, and the amplification existed in D6 parasites that tolerated 80 ng/ml up to 
2400 ng/ml (treated five times).  It is interesting that the amplification occurred relatively 
early in the selection of QHS-resistant D6 parasites, indicating that this may represent a 
necessary resistance mechanism in D6 lines.  Further research will focus on D6 lines that 
were selected prior to the 80 ng/ml QHS level to determine when the amplification 
originally occurred.   
In the TM91c235 series, copy number of chromosome 10 genes was 
approximately 1 for all strains we analyzed.  There were instances where the CN 
exceeded 1.2 for some genes (PF10_0278, PF10_0279, PF10_0294).  But, in these cases, 
the parent and resistant progeny both had elevated CN, so we do not think these findings 
are significant for artemisinin resistance.   
We also discovered a region of amplification from PF10_0288-PF10_0297 in 
both W2 (clone D7) and QHS-resistant W2 (W2.QHS200x2) during a second round of 
whole genome sequencing.  Genes within this part of chromosome 10 have also been 
identified as amplified in other artemisinin resistant W2 progeny by our colleagues in 
Australia (Kyle, Personal Communication).  When we assessed copy number by QPCR, 
amplification of this region was verified in PF10_0292 to PF10_0296 in QHS-resistant 
W2 lines (≥ 3 copies).  Strangely, amplification also existed in W2 parent lines (W2, W2 
[clone D7]), but found only in PF10_0292 and PF10_0294.  Also, the magnitude of 
amplification differed in W2 parental lines in these genes (≥3 copies in W2, but 
approximately 2 copies of W2 [clone D7]).  These results are different than what was 
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determined from sequencing which found 3 copies of each gene in W2 (clone D7) from 
PF10_0288-PF10_0297.  Furthermore, sequencing of a reference MR4 W2 strain did not 
find amplification in chromosome 10 genes.  A key remaining issue to resolve in the W2 
series is why amplification of genes in chromosome 10 was also found in W2 parental 
lines.  It may be difficult to explain why parental W2 lines contained amplified genes, 
and how to relate this to resistant W2 lines.  The W2 parent line we routinely used for 
culture in our lab (and from what W2 [clone D7] was cloned from) was once thought to 
have originated from the first W2 clones isolated 
381
 that are now in the MR4 depository 
(Kyle, personal communication).  W2.QHS200 is believed to have descended from this 
W2 parent.  In regard to the amplification of chromosome 10 genes in parent W2 strains, 
we theorize that parent W2 was probably mixed with an AL or QHS-resistant W2 line, 
making it appear that the parental line has amplification in genes.  The W2 parent that 
was submitted to MR4 has no amplification and the W2 parent our colleagues in 
Australia work with (again from Dr. Kyle‟s collection) has no amplification (Kyle, 
Personal Communication).  Another interesting fact is that the W2 parent parasites that 
have amplification in chromosome 10 genes also have approximately one copy of pfmdr1.  
If the parent W2 was somehow mixed with an artemisinin-resistant W2 line, we should 
have found amplification of pfmdr1 (our QPCR results found ≥2 copies in W2.QHS200 
lines).  However, this logic is complicated by the fact that W2 lines resistant to artelinic-
acid lose copies of pfmdr1 when grown without drug pressure 
337
.  Also, we found that 
AL-resistant TM91c235 lines had increased pfmdr1 copy number, yet no amplification of 
chromosome 10 genes.  Therefore, the link between the genes is not very strong.  Perhaps 
W2 parasites are capable of de-amplifying genes other than pfmdr1, and the parasite that 
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resulted from a mixture of parent and resistant line lost a few genes of the amplification.  
Alternatively, it may be that earlier selected W2 lines do not contain all the genes of the 
amplification (and mixing with parent W2 made it seem that only a few were amplified).  
It is unclear why the parent W2 parasites only had amplification of two genes on 
chromosome 10 (by QPCR), whereas the resistant W2 parasites had a larger region of 
amplification.  If the parent W2 was mixed with resistant W2, then we should have found 
more amplified genes.  We will resolve this issue by targeting the earliest artemisinin-
selected W2 lines we have.  If it is determined that the original W2 line that started the 
artemisinin-selection process has only a single copy of the genes in the amplification, 
then this will conclusively show that amplification only exists in artemisinin-resistant W2.  
Also, we do not currently have a reason for the discrepancy between CN estimated by 
sequencing for W2 (clone D7 ~ 3 copies) and that determined by QPCR (~2 copies).  An 
important point to take away from amplifications in chromosome 10 (and pfmdr1) is that 
once the amplification appeared in parasites, it remained a stable CNV through multiple 
cycles in culture.  Therefore, we believe these amplifications are probable markers of 
resistant parasites.  
In addition to laboratory strains that were selected for resistance to artemisinin 
drugs assayed patient isolates from Cambodia and Thailand.  These regions represent 
areas where artemisinin is thought to currently be occurring.  We had some evidence that 
some strains had reduced artemisinin susceptibility, so these strains were included with 
others for chromosome 10 analysis.  Our results found that all isolates had approximately 
one copy of the genes we assayed.  It is interesting that strains D6 and W2 had 
amplifications, whereas other patient isolates (TM91c235 and Thai-Cambodia isolates) 
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did not have amplifications.  This may indicate that QHS-selected progeny of only certain 
backgrounds will amplify strains, or that laboratory lines are unique in some manner.  
Alternatively, it is possible that field isolates may only have one type of genetic 
amplification that affords artemisinin resistance, as with pfmdr1 amplification in 
TM91c235.  We did not examine pfmdr1 copy number in the isolates from Cambodia and 
Thailand, but it will be interesting to assay these in the future.  
The detection of amplification in chromosome 10 may be a unique resistance 
mechanism that possibly exists in two parasite strains from different parts of the world.  
In the field of malaria research, copy number amplifications have been linked to MQ 
resistance and artemisinin resistance (Chapter One) in P. falciparum.  However, 
amplification in chromosome 10 has only been described in a few studies, and never 
described in D6 parasites in relation to drug resistance.  Jiang et al. (2008) 
437
 reported on 
a number of CNVs and SNPs from Dd2 (CQ-resistant, Asia) 7G8 (CQ-resistant, Brazil), 
FCR3, and HB3 (CQ-sensitive, Honduras) strains of P. falciparum.  Within chromosome 
10, only a few a genes were amplified (HB3: PF10_0005-PF10_0008, PF10_0323; Dd2: 
PF10_342, PF10_0382, PF10_0382; PF10_0404, PF10_0405; 7G8: PF10_0014, 
PF10_0190, PF10_0374).  They did not detect any of the chromosome 10 gene 
amplifications that we observed.  Cheeseman et al., 2009 
5
 investigated CNVs in a variety 
of P. falciparum strains from Africa (including D6), South East Asia (including Dd2 and 
W2mef), Papua New Guinea (including D10), South America (7G8), Central America 
(HB3), and 3D7.  Genes that were deleted or amplified included PF10_0007, PF10_0008, 
PF10_0074, PF10_0353, PF10_0383, PF10_0388, PF10_0390, PF10_0394, PF10_0398, 
and PF10_0399.  Most significant to our study, PF10_0074 was amplified in D6 and W2-
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mef.  It is not known why genes were not found to be amplified in D6 and W2 that we 
identified in these strains.  The fact that D6 did not contain many amplifications seems to 
justify our results that amplifications were observed only in resistant parasites.  For W2-
mef, the same may be true for our findings in W2 resistant strains.  However, it is 
possible that MQ resistance may not induce the same type of chromosome 10 
amplifications as artemisinin does.  Some other studies 
409,410,440
 found amplifications in 
chromosome 10 in P. falciparum strains known to exhibit drug resistance (ex. CQ, QN, 
PYR).  Of these studies, the one by Mackinnon et al. (2009) 
440
 is most significant in 
relation to our work.  This study investigated genomic and transcriptional changes in P. 
falciparum patient isolates from Kenya vs. long-term adapted laboratory isolates.  CNVs 
were determined by comparing to 3D7 and other field strains (P<0.001, >1.5-fold 
difference from 3D7 in at least 2 field strains).  This study showed that much of the 
biological variation in transcription among field isolates and between field/lab strains is 
due to genes near CNVs.  Gene copy number in the CNVs associated strongly with 
expression level of these genes.  Many of the CNV genes encode proteins that are: 
exported to the RBC surface, transcriptional regulation factors, involved in nutrient 
biosynthesis, transmission, involved in colonization of pregnant women, and proteins 
involved in metabolic pathways in drug resistance.  One of the most up-regulated genes 
was PF10_0350, which is suppressed in pregnancy-associated malaria.  This study also 
identified other CNVs in chromosome 10, from PF10_0016 to PF10_0392.  Within the 
region of amplification we investigated, this study found PF10_0281 was down-regulated 
in at least 5 strains; PF10_0282 and PF10_0285 were down-regulated in at least 7 strains; 
PF10_0283, PF10_0286, PF10_0288, PF10_0291, PF10_0292, PF10_0294, PF10_0295, 
  
264 
 
and PF10_0296.  were down-regulated in at least 8 strains; PF10_0284 and PF10_0287 
were down-regulated in at least 6 strains; PF10_0293 was down-regulated in at least 3 
strains; and PF10_0290 was not differentially regulated.  It is unclear why these genes 
would be down-regulated in various parasite strains, when we found amplification of 
genes and constitutive over-expression of genes within the amplification in resistant D6 
(from Africa) (microarrays).   
Proteomic and transcriptome studies have also identified genes of chromosome 10.  
Nirmalan et al. (2004) 
430
 found proteins within chromosome 10 (PF10_0065 [conserved 
hypothetical protein], PF10_0155 [Enolase AE down, LUM up], and PF10_0289) were 
abundantly present in Dd2.  PF10_0289 is part of the amplification we identified in QHS-
resistant D6 and W2 lines.  Aly et al. (2007) 
429
 also identified PF10_0155 as a down-
regulated protein in their study. Makanga et al. (2005) 
408
 described proteins in P. 
falciparum strain K1 that were differentially regulated under AE or LUM treatment.  
PF10_0153 (HSP60 up AE, up LUM), PF10_0155 (not diff regulated), PF10_0345 
(MSP-3 not diff regulated), PF10_0344 (glutamate rich protein, down AE), PF10_0203 
(ADP ribosylation factor up AE, up LUM), and PF10_0141 (MO15 related protein kinase, 
not diff regulated) were identified on chromosome 10.  Witkowski et al. (2010) 
360
 
conducted transcriptome analysis of a Tanzanian P. falciparum isolate that was selected 
for QHS resistance in vitro.  They identified PF10_0121 (hypoxanthine phosphoribosyl 
transferase) as a down-regulated gene (compared to parent). Prieto et al. (2008) 
434
 found 
PF10_0043 (ribosomal protein L13), PF10_0111 (20S proteasome beta subunit), 
PF10_0031 (hypothetical protein), and PF10_0170 (hypothetical protein) were up-
regulated proteins in artemisinin-treated 3D7.  Natalang et al. (2008) 
412
 reported that 
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genes within chromosome 10 are differentially regulated after exposure of P. falciparum 
to AS.  Genes that were highly up-regulated included PF10_0026 (Tryptophan-rich 
antigen 3, putative), PF10_0378 (DNAJ protein), PF10_0186 and PF10_0046 
(hypothetical proteins that probably encode transcription factor), PF10_0374 (Pf11-1 
protein), PF10_0345 (MSP-3), and PF10_0046, PF10_0319 (hypothetical proteins).  
Those that were down-regulated included PF10_0121 (above), PF10_0016 (acyl CoA 
binding protein, putative), PF10_0097, PF10_0211 (hypothetical proteins), PF10_0019 
(early transcribed membrane protein 10.1 [ETRAMP 10.1]), and PF10_0285.  The down-
regulation of PF10_0285 is interesting, since we did not detect differential regulation of 
this gene in our microarrays.  Also, we found the gene was amplified in QHS-resistant 
D6 and W2, indicating the gene may be important for artemisinin resistance. 
Taking all this into consideration, it appears that genes within chromosome 10 are 
fairly variable in terms of copy number.  The studies above identified CNV in 
chromosome 10 from different strains around the world, but these reports did not focus 
on drug-selected lines.  However, some of these isolates may exist in areas where 
artemisinin pressure is constant, making it possible to compare with our studies.  
Interestingly, the study by Mackinnon et al. (2009) 
440
 found under-expressed genes in 
multiple parasites in Africa that are in the region we found in QHS-resistant D6.  Our 
arrays found constitutive up-regulation of PF10_0281, PF10_0282, PF10_0291, and 
PF10_0296 in D6.QHS2400x5 vs. D6 throughout the life cycle.  Therefore, these genes 
seem to be important for parasites even when drug pressure is not involved.  Our data are 
in opposition to Mackinnon et al. (2009) 
440
, indicating that these genes are differentially 
regulated in different strains from Africa.  Outside of Africa, amplification of these genes 
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as a marker of artemisinin resistance may not be clear either.  Although we found 
amplification in W2 lines, we did not find it in AL-resistant TM91c235 lines.  However, 
pfmdr1 is clearly linked to artemisinin resistance in these parasites.  Interestingly, a 
section that was down-regulated in at least 8 strains in Mackinnon et al. (2009) 
encompassed the region of amplification that overlaps between D6 and W2 QHS-
resistant strains.  Perhaps these genes are the most variable within the amplification and 
could be the most likely markers of artemisinin resistance in field isolates.  Therefore, we 
provide more evidence that artemisinin resistance may be multifactorial.   
Recrudescence assays with D6 vs. D6.QHS2400x5.  The goal of this experiment 
was to verify that a 6-hour exposure of 200 ng/ml DHA is high enough to induce 
dormancy in both D6 and D6.QHS2400x5, but low enough to allow recovery of both 
strains in less than 10 days.  Much like we found in experiments reported in Chapter Two, 
a greater number of morphologically normal parasites were observed in the resistant 
parasite compared to the parent.  Interestingly, we found that a greater number of 
dormant parasites were found in the resistant strain, and also that normal parasites were 
observed at some level throughout the entire assay for each strain (except 72 hours for 
D6).  This seems to contradict what we reported in Chapter Two for D6 vs. 
D6.QHS340x2 exposed to 200 ng/ml QHS.  In that experiment, both parent and resistant 
parasites entered dormancy and did not appear to recrudesce until 120 hours (more 
normal parasites in resistant strain).  Also, the resistant parasites were adapted to different 
levels of drug in the two assays and the more resistant parasite seemed to tolerate lower 
levels of drug better than D6.QHS340x2. However, this experiment involved a different 
drug than DHA and the drug was applied for 48 hours.  Therefore, this comparison may 
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be inappropriate.  We exposed W2 and W2.QHS200x2 to 200 ng/ml DHA for 6 hours 
and found that both strains entered dormancy.  The resistant parasite recrudesced 24 
hours before the parent strain, and there were a greater number of dormant parasites in 
the resistant strain during the first few time points of the assay.  Again, it may be 
inappropriate to compare this assay to the D6.QHS2400x5 assay due to strain differences 
and resistance levels.  A more appropriate comparison of this assay is the results from 
microarrays discussed below.  The same strains and drug dosage were used to induce 
dormancy and monitor recrudescence in the microarrays as the initial recrudescence 
assay.  However, the microarray experiment found both parent and resistant strains 
recrudesced later in time (57 hours resistant parasite, 69 hours parent) compared to the 
initial experiment where morphologically normal parasites remained even at early time 
points.  The reason for this is probably due to experimental variability and the fact that 
starting parasitemias for the different groups were different.  Importantly, resistant 
parasites recrudesced before the parent (or a greater percentage of normal/total parasites 
were present compared to the parent) in these assays.  
Transcriptional analyses of D6 and D6.QHS2400x5.  Here we have described 
in molecular detail a long-lasting developmental arrest in P. falciparum induced by DHA.  
The induction of dormancy at the ring stage was confirmed microscopically and by 
transcriptional analysis.  Both dormancy and transcriptional arrest were qualitatively 
similar for QHS sensitive and resistant clones, yet important differences were observed. 
As stated above, results of the recovery experiments showed that the parent and resistant 
D6 parasites both tolerated the drug as parasites recrudesced after a period of dormancy.  
However, D6.QHS2400x5 recrudesced 12 hours prior to the parent strain (57 hours vs. 69 
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hours).  Perhaps the most intriguing result was the transcriptional arrest at ring stage in 
DHA treated parasites (W2 and D6 strains).  The transcriptome of DHA-treated parasites 
was similar to early-mid rings and coincided with morphological observations of arrest at 
early ring stage.  This result is remarkably different from the effect of other antimalarial 
drugs that have no demonstrated effect on progression through the IDC.   
By using expression microarrays we compared the transcriptomes of DHA-treated 
cultures of an in vitro selected artemisinin resistant clone D6.QHS2400x5 and its 
artemisinin sensitive parent clone, D6.  By correlating each transcriptome snapshot to 
historical datasets of the transcriptome of normally growing parasites, we found that 
DMSO-treated parasites continue progressing through the IDC, whereas both artemisinin-
resistant and -sensitive parasites exposed to DHA arrest in a dormant, ring-like state for 
3-4 days.  The timing of this transcriptional pause correlates with the observance of 
dormant ring stage parasites, which we (Kyle et al., unpublished results; 
362
) and others 
360
 have previously observed after artemisinin treatment.  Witkowski et al. 2010 
360
 
suggested the ability to enter a quiescent state was a hallmark of resistance, yet they 
suggested only artemisinin resistant parasites enter dormancy.  Our studies have 
demonstrated that dormancy occurs in both QHS sensitive and resistant parasites, which 
our laboratory already had determined prior to this study (
362
; Kyle and Tucker, 
unpublished data).  Interestingly, previous work on expression profiling the response to 
AS in sensitive trophozoite stage parasites 
412
 also indirectly noted growth rate effects 
that complicated analysis of later time points under their experimental design.  
Although the transcriptional arrest we observed at ring stages is most likely due to 
effects of DHA, the phenomenon of transcriptional arrest could be due to other causes.  It 
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is unlikely that leftover mRNA from dead parasites could account for a paused ring-like 
transcriptome since previous studies have found that cidal antimalarials typically do not 
disturb the normal progression through the IDC 
441,442
.  These published data suggest 
parasites killed by other means do not exhibit a developmental arrest, either 
morphologically or transcriptionally when assayed by expression microarrays.  
Additionally, Shock et al. (2007) 
443
 demonstrated that P. falciparum mRNA decay rates 
are relatively rapid, with the average half-life of ring-stage transcripts being 9.5 minutes.  
Correlations such as those are illustrated in decay to noise data in the absence of active 
transcription.  Furthermore, if the transcriptional arrest observed only reflected the 
mRNA of dead parasites, then it would be difficult to explain the observed convergence 
upon a ring-like state in the originally asynchronous cultures. This is because dead 
parasites from several stages would contribute to the signal and therefore it should 
continue to have no correlation to any specific hour of the IDC.  Thus far the 
preponderance of the data suggests that DHA induces a cell cycle arrest at the ring stage 
characterized by dormant rings and a ring stage transcriptome. 
The possibility that artemisinins induces cell cycle arrest has precedence in 
studies with human carcinoma cell lines.  Morrisey et al. (2010) 
444
 concluded that 
artemisinin disrupts transcription at the promoter of CDK4 in prostate cancer.  In 
pancreatic cancer, T cells, and hepatoma cells, artemisinins have been shown to disrupt 
cyclin levels and induce G1 arrest 
445-447
.  Additionally, Efferth et al. (2001) 
448
 reported 
that a yeast strain with a defective mitosis spindle checkpoint gene showed increased AS 
sensitivity and another strain with a defective gene that encodes a cyclin (involved in the 
G1 to S phase transition) showed increased AS resistance over the wild-type strain.  
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These results suggested that cell-cycle checkpoints that regulate growth are important in 
mediating artemisinin sensitivity, as uncontrolled proliferation (no DNA replication 
checkpoint prior to S phase) leads to artemisinin resistance and functional mitosis 
regulation is necessary for tolerating artemisinin.  Although Plasmodium spp. are known 
to encode cell cycle regulatory genes, there has been doubt over the existence of any 
inducible checkpoint or arrest. 
The observation that the resistant parasites released from dormancy earlier than 
sensitive clones stimulates speculation about the nature of the dormant state as it relates 
to artemisinin resistance. Interestingly, morphological and correlogram analysis suggest 
resistant parasites exit dormancy before the parental parasites.  Perhaps the mechanism of 
resistance involves an increased ability to recover from dormancy following exposure to 
drug.  Also, a greater proportion of parasites might survive drug pressure long enough to 
enter dormancy.  We showed that a greater percentage of parasites enter dormancy and 
there were a greater ratio of normal/total parasites in resistant vs. parent strains.  Also, 
hypoxanthine assays (Chapter Two) showed that resistant parasites tolerate more drug in 
a 48 window than parent strain indicating resistant parasites have the ability to enter 
dormancy and recover at a higher rate, or a greater number of parasites are unaffected  by 
drug.  This suggests the intriguing possibility that dormancy is a natural phenomenon that 
enables parasites to cope with environmental stressors.  Regardless of the mechanisms 
involved, our data suggest dormancy and resistance are linked, yet may be separate 
phenotypic responses to drug.   
Differentially expressed genes in parental/resistant strains during dormancy.  A 
subset of genes (>100) were strongly induced or suppressed during artemisinin-induced 
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dormancy (Table 3.7).  A skeleton binding protein (encoded by PFE0065w) was highly 
up-regulated in both D6 and D6.QHS2400x5, but the magnitude of regulation was much 
greater in D6.  This protein is required for transport of PfEMP1 to the RBC surface.  It 
functions at the parasitophorous vacuole membrane to load PfEMP1 into Maurer clefts 
during formation of these structures 
449
.  This protein is unlikely to be involved in drug-
related effects, but perhaps it assists in the secretion of other proteins that assist in 
remodeling parasite structure during dormancy (more below).  A gene encoding P. 
falciparum thioredoxin reductase (PFI1170c) was induced in both D6 and 
D6.QHS2400x5, but the degree of up-regulation in the parent parasite was much greater.  
Thioredoxin reductase (PfTrxR) and thioredoxin (PfTrx) are components of an efficient 
antioxidant system for P. falciparum while in RBCs.  This system is involved in a variety 
of cellular functions including the reduction of deoxyribonucleotides (DNA synthesis), 
regulation of transcription by interacting with transcription factors, and reducing 
hydrogen peroxide 
425,450
.  It is possible that this enzyme plays a role in the detoxification 
of the oxidative stress induced by DHA.  PfTrx is involved in one of two functional redox 
systems in P. falciparum (the other involving glutathione).  Both are part of enzymatic 
redox cascades, which transfer electrons from NADPH to acceptor molecules such as 
hydrogen peroxide and alkyl hydroperoxides but also proteins like ribonucleotide 
reductase and a number of transcription factors 
450
.  Interestingly, PlasmoDB lists PfTrxR 
as minimally expressed in ring stages and maximally expressed in gametocytes.  The 
strong induction of PfTrxR in dormant rings implicates the gene in parasite defense 
against artemisinin induced oxidative stress.  Currently, we do not know the reason why 
PfTrxR was up-regulated much more in the parent strain.  Perhaps over multiple rounds 
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of artemisinin drug pressure, the resistant parasite developed other tolerance mechanisms 
so that its reliance on PfTrxR decreased over time.  This could involve a multitude of 
regulatory factors in the resistant parasite that enable it to up-regulate other proteins.  The 
fact that Plasmodium-infected erythrocytes are under enhanced oxidative stress together 
with their susceptibility to exogenous oxidative challenge (artemisinin treatment) is a 
reason to believe that the antioxidant systems of the parasite are important for the 
survival of the parasite during their erythrocytic life stages.  PfTrxR may be a potential 
target for the development of new antimalarials.  One study found PfTrxR is essential for 
survival of the erythrocytic stages of P. falciparum 
450
.  Because functional antioxidant 
and redox systems are necessary for parasite survival (normally and maybe in response to 
drugs), inhibitors that target this enzyme would be effective antimalarials.  Indeed, 
compounds that target this enzyme in have been described.  Andricopulo et al. 2006 
451
 
identified three nitrophenyl derivatives that inhibit PfTrxR, and they were active against 
P. falciparum strain K1 (CQ resistant).  Importantly, an inhibitor selective for PfTrxR 
might be an ideal partner drug for future ACTs in controlling malaria in regions of multi-
drug resistant P. falciparum.   
Other up-regulated genes that may have important roles during dormancy 
included PF14_0017 (lysophosopholipase), PF14_0183 (signal recognition particle, 
RNP), PFF0510w (Histone H3), and PF14_0010 (glycophorin binding protein), and 
PFE0405c (Longevity Assurance [LAG-1] domain-containing protein).  PF14_0017 
encodes a lysophospholipase that is a member of a 9 member family of genes encoded 
near the telomeres.  These enzymes and host encoded lysophospholipases catabolize 
phosphoatidylcholine.  PlasmoDB lists the gene as minimally expressed in early 
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schizonts and maximally expressed in late rings.  We noticed the magnitude of up-
regulation was equal for D6 and D6.QHS2400x5.  Perhaps this gene was ramping up to 
maximum expression in our studies before DHA treatment and subsequent over-
expression.  This up-regulation may reflect a need to differentially remodel the parasite 
niche in the dormant state or to prepare the parasite for eventual recovery.  Also among 
the strongly up-regulated genes was signal recognition particle (SRP, encoded by 
PF14_0183).  SRPs are responsible for targeting new translated proteins to the 
endoplasmic reticulum.  This protein also has ATP-dependent RNA helicase activity 
(PlasmoDB).  It may be that this protein is capable of shuttling between the nucleus and 
cytoplasm where it interacts with secreted proteins.  PF14_0183 exhibits minimum 
expression in schizonts and maximum expression in ring stages.  Therefore, this protein 
may be involved in exporting proteins to the RBC surface as the parasite matures.  In 
terms of artemisinin exposure, perhaps dormant rings non-specifically required the up-
regulation of all secretion or they require an increased capacity to secrete a specific 
cohort of remodeling proteins in order to divert into dormancy.  The observed up-
regulated lysophospholipase may play a role in this remodeling.  Natalang et al. (2008) 
412
 also noted that AS induced the expression of several secreted proteins, though this 
could be related to antigenic switching.  PFF0510w encodes a histone H3 protein, which 
is normally minimally expressed in early rings and maximally expressed in max early 
schizont.  This reflects the protein‟s function in packaging and assembly of DNA into 
merozoites before the next invasion cycle.  We found the magnitude of up-regulation was 
equal in parent and resistant D6 strains.  Perhaps dormant parasites up-regulate this 
protein to protect DNA while in survival mode, then when parasites emerging, there is 
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intact DNA to continue gene expression in mature stages.  We also identified up-
regulation of a glycophorin binding protein (PF14_0010), which is known to be 
minimally expressed in gametocytes and maximally expressed in merozoites.  This 
reflects the need for merozoites to express proteins that recognize glycophorin on the 
surface of RBCs during invasion.  This gene was up-regulated at a higher level in D6 
compared to D6.QHS2400x5.  Also, genes encoding a rhoptry protein (PFB0680) and a 
MSP-7-like protein (PF13_0193) were up-regulated in both strains.  We currently do not 
understand why merozoite/invasion-related proteins were up-regulated in both strains 
after artemisinin pressure.  Our transcriptional analysis also found MSP-1 was the highest 
ranked down-regulated gene in D6 and D6.QHS2400x5.  Our proteomic studies (above) 
found merozoite-related proteins were up-regulated in resistant D6 and W2 compared to 
parent strains.  Also, other studies found merozoite proteins or transcripts were up-
regulated in response to an endoperoxide 
429
 or CQ 
432,433
.  Interestingly the study by 
Jiang et al. (2008) 
432
 found a rhoptry protein was up-regulated at the transcriptional level 
in both CQ-resistant (>4-fold) and CQ-sensitive (>11-fold).  This study, along with our 
results, indicates that drug-susceptible parasites may have a greater need to induce 
invasion-related genes, yet some are down-regulated.  We also identified up-regulation of 
a LAG1-containing protein (encoded by PFE0405c) in D6 and D6.QHS2400x5 (greater 
magnitude in resistant parasite; data not shown).  LAG1 domain proteins are part of the 
LASS (longevity assurance) family of ceramide synthases 
452
.  Deletion of LAG1 in yeast 
resulted in increased replication 
453
, whereas over-expression of LAG1 in yeast had a 
bimodal effect on longevity, with moderate expression resulting in increased longevity 
and with higher expression curtailing life span 
454
.  Ceramide synthases are important for 
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sphingolipid metabolism (proteins that have roles in different eukaryotic cell functions).  
Ceramide accumulates in response to cytotoxic agents or stress responses in eukaryotic 
cells 
455
.  Recently, a study found that an increase in the intracellular ceramide content 
and an activation of parasite sphingomyelinase(s) in P. falciparum were associated with 
the parasite death induced by artemisinin and mefloquine 
456
.  Interestingly, PFE0405c is 
usually minimally expressed in rings (PlasmoDB), yet it was over-expressed in 
transcriptionally arrested dormant rings in our study.  Perhaps the observed increased 
ceramide content and expression associated with artemisinin treatment is a factor of the 
parasite creating a protective stress response.  Ceramide metabolism maybe important for 
parasite survival as it was found that certain ceramide analogs can inhibit P. falciparum 
in vitro 
455
. 
Although we were more interested in genes that were up-regulated in dormancy 
(which may be useful for molecular marker studies), down-regulated genes could indicate 
ring-stage metabolic pathways that are normally important for progression through the 
life cycle (but have been shut down after drug treatment).  Notable genes that were down-
regulated in our transcriptional analysis included PF10_0327 and PF13_0088.  These are 
genes that encode proteins containing PfMyb domains, which are linked to DNA binding 
and regulation of transcription 
457
.  These genes are thought to both be minimally 
expressed in late schizonts and maximally expressed in early rings (PlasmoDB).  
PF13_0088 has a reported involvement in the transition from trophozoites to schizonts in 
P. falciparum, with knockdown inducing mortality at the trophozoite stage 
458
.  This gene 
was down-regulated more in the resistant strain compared to the parental strain.  It may 
be that artemisinin treatment caused inhibition of these proteins, leading to a halt in 
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progression of the life cycle.  The effect of more down-regulation in D6.QHS2400x5 is 
unknown.  Interestingly, PF10_0327 is outside of the amplification region we identified 
in D6 and W2 QHS-resistant parasites.  Our analysis also found genes that encode 
proteins involved in nucleic acid binding (PF10_0232, Chromodomain-helicase-DNA-
binding protein 1 homolog; PF13_0035, U3_small_nucleolar_RNA-associated protein 6) 
were down-regulated.  PF10_0232 is normally minimally expressed in gametocytes and 
maximally expressed in merozoites, whereas PF13_0035 has minimal expression in 
gametocytes/maximal expression in early rings.  These genes were down-regulated more 
in D6 compared to D6.QHS2400x5.  These may be housekeeping genes that were down-
regulated in response to DHA.  We found two genes encoding ubiquitin-related proteins 
(PF08_0020, MAL7P1.19) were down-regulated in both PTS and RTS.  These proteins 
are involved in modifying proteins that are targeted for degradation in parasite 
proteasomes.  A recent study by Hunt et al. (2010) 
342
 found that mutations in pcubp-1 
(encodes a deubiquinating enzyme) are related to artemisinin resistance.  It is expected 
that mutations in this gene would lead to reduced de-ubiquitinating activity, having the 
effect of increasing ubiquinated proteins destined for degradation.  It is proposed that 
artemisinin-resistant parasites may increase protein turnover or trafficking (ex. Pfmdr1 or 
proteins damaged by oxidative stress) 
341,342
.  We did not find a difference in expression 
in parent vs. resistant parasites, and the fact that the genes were down-regulated points 
toward protein preservation rather than degradation.  Perhaps dormant parasites need to 
prevent essential proteins from being degraded during or to maintain a variety of proteins 
that are usually not needed if the normal life cycle proceeds.  However, a gene in the 
chromosome 10 amplification we identified (PF10_0298) in artemisinin resistant D6 
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encodes a 26S regulatory proteasome subunit and Prieto et al. (2008) 
434
 found a 20S 
proteasome beta subunit was up-regulated in artemisinin-treated 3D7.  This may indicate 
that increased protein degradation may be interesting to investigate as a potential 
artemisinin-resistance mechanism. 
PFF0450c (encodes a Zn
+2
or Fe
+2
 permease) was also down-regulated in our 
study.  This gene is normally minimally expressed in merozoites and maximally 
expressed in early rings.  The protein is responsible for heavy metal ion transport.  We 
found the degree of down-regulation of PFF0450c was greater in D6 compared to 
D6.QHS2400x5.  DHA may have shut down expression of this protein to basal levels for 
entrance into dormancy, but it is not clear why it would be much more down-regulated in 
D6.  Another protein that is involved in heavy metal transport is Pfmdr2, which was 
originally thought to be involved in CQ-resistance 
402
.  The initial microarrays we 
performed with AL and QHS-resistant W2 (Chapters One, Two) found pfmdr2 was 
down-regulated after DHA exposure.  The results of transcriptional analysis in D6 and 
D6.QHS2400x5 also found pfmdr2 was down-regulated in both parasites (data not 
shown).  Therefore, heavy metal transport may be a pathway that could be important for 
antimalarial drug discovery.   
Dihydroartemisinin induces differential expression of genes in artemisinin 
resistant and sensitive parasites.  In addition to the description of the dormant 
transcriptional state and induced/repressed genes associated with it, transcriptional 
analysis identified genes that were differentially expressed in D6 vs. D6.QHS2400x5 
(Table 3.8).  Genes involved in DHA-induced dormancy or QHS resistance could 
potentially be up-regulated in resistant parasites during dormancy or only after drug 
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treatment.  To explore this possibility, the microarray data were analyzed for genes that 
were regulated with opposite effects for induction or repression (Table 3.8) in D6 versus 
D6.QHS2400x5 synchronized cultures.  There was differential regulation of cytochrome 
c complex genes, as MAL13P1.55 (cytochrome c2 precursor, up-regulated in 
D6.QHS2400x5 vs. D6), PF14_0038 (cytochrome c, putative, up-regulated in 
D6.QHS2400x5 vs. D6) and PF10_0252 (cytochrome c oxidase copper chaperone, up-
regulated D6 vs. D6.QHS2400x5) were differentially regulated between the two strains 
after drug treatment.  Atovaquone is a known inhibitor of cytochrome bc1 complex of the 
electron transport chain in Plasmodium spp., and resistance is mediated by mutations in 
cytochrome genes.  Artemisinin is also theorized to target mitochondrial function in 
Plasmodium spp. 
182,183
.  Unlike ATOV, which creates a loss of membrane potential and 
reduction of electron transport chain (ETC) activity, artemisinin does not inhibit the ETC.  
Instead, it exerts it effect through mediation of reactive oxygen species (ROS) or ROS 
together with some other free radicals as a result of artemisinin reduction 
183
.  A potential 
resistance mechanism to artemisinin involving cytochrome genes or other elements of 
parasite mitochondria is not described.  The up-regulation of genes encoding cytochrome 
c complex components in D6.QHS2400x5 seems to implicate mitochondrial function in 
artemisinin mechanism of action and/or resistance.  Wang et al. (2010) 
183
 theorized that 
the mitochondrial ETC stimulates artemisinin's effect, most likely by activating it, then 
the locally generated free radicals disrupt the normal function of mitochondria.  Taking 
this into consideration, perhaps artemisinin-sensitive and resistant parasites actually 
induce artemisinin activity through up-regulation of cytochrome genes.  This may cause 
parasites to enter dormancy.  The fact that D6 only up-regulated one of three 
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mitochondria genes may reflect metabolic differences in the dormant states of the two 
strains.  Two genes that encode zinc finger proteins were differentially expressed after 
DHA treatment.  These proteins were encoded by PF11_0357 (down-regulated in D6, up-
regulated in D6.QHS2400x5) and PFC0510w (up-regulated in D6, down-regulated in 
D6 .QHS2400x5).  These proteins are involved in zinc ion and nucleic acid binding.  The 
differential expression exhibited in D6 strains may reflect different post-transcriptional 
regulatory regimes in the two strains. 
Constitutive transcription differences were identified between resistant and 
sensitive strains.  We also theorized that genetic determinant(s) of dormancy or 
resistance may be constitutively up-regulated or down-regulated in the absence of drug 
pressure.  Indeed, our proteomic and sequencing results using D6 and W2 parasites 
resistant to QHS identified putative resistance markers in the absence of drug pressure.  
We identified constitutive transcriptional differences in D6 vs. D6.QHS2400x5 (Table 
3.9).  An important finding of this analysis was the detection of genes within 
chromosome 10 that were expressed higher in the resistant strain compared to the parent 
strain.  These genes exist in the same reason of chromosome 10 that was amplified in 
QHS-resistant D6 parasites described above.  These genes included PF10_0281, 
PF10_0282, PF10_0291, and PF10_0296.  Not much is reported about these genes in the 
literature.  PF10_0281 encodes a merozoite TRAP (thrombospondin-related anonymous 
protein) protein that is normally minimally expressed in late rings and maximally 
expressed in late schizonts.  Therefore, the gene is expressed during merozoite packaging 
and down-regulated after invasion of a new RBC.  PF10_0282 encodes a conserved 
protein of unknown protein that has min expression at early rings and max expression in 
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gametocytes.  It exhibits similarity to a merozoite TRAP protein in P. chabaudi.  
PF10_0291 encodes a RAP protein (rhoptry associated-protein) that has min expression 
in gametocytes and max expression in early trophozoites.  As discussed above, we found 
merozoite proteins were up-regulated in W2.QHS200 vs. W2 and D6.QHS2400x2 vs. D6.  
Other studies found merozoite proteins were up-regulated as well with or without 
endoperoxide or CQ drug pressure.  We found genes encoding MSPs can be highly 
down-regulated or moderately up-regulated in both parent and resistant parasites during 
dormancy.  Perhaps there is a clear reason for merozoite genes to be involved in 
dormancy and resistance, or maybe there are redundant pathways involving proteins 
encoded by these genes that are necessary for response to artemisinins.  Once parasites 
have been exposed to artemisinins, these genes may be constitutively expressed for some 
time. Maybe this gene has a definitive function in rings exposed to drug, or the gene is 
unimportant and just amplified as part of the whole amplicon.  PF10_0296 is another 
conserved protein with unknown function, with min expression in late trophozoites and 
max expression in gametocytes.  It exhibits similarity to P. yoelii erythrocyte membrane 
protein-3.  This protein is unlikely to play a role in drug resistance as it may be related to 
PfEMP1 (which is a variable antigen).  We do not understand why all of the genes in the 
chromosome 10 amplification were not over-expressed in our transcriptional analysis.  
Perhaps parasites only up-regulate necessary genes in response to artemisinin as they 
enter dormancy.  Also, it would have been interesting to see how these genes are 
regulated after parasites exit dormancy.  Unfortunately, our data analysis has not 
progressed to this point.   
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Notably missing among our baseline transcriptional differences are other 
candidate genes of interest postulated as being associated with artemisinin resistance (e.g. 
pfatp6, tctp, pfubp-1), suggesting that if these genes are indeed causative for resistance 
they do not exert their effect at the transcript abundance level.  However, our analysis 
focused on genes regulated before drug addition, so these genes may be expected to be 
induced upon drug exposure (we did not find these genes as differentially expressed in 
D6 vs. D6.QHS2400x5).  Pfmdr1 is linked to MQ and QN resistance, and it is thought to 
be associated with artemisinin resistance.  Pfmdr1 was down-regulated in 
D6.QHS2400x5 compared to D6.  This reinforces other data from our lab that showed 
this gene is not essential for artemisinin resistance in various parasite lines (Chavchich et 
al., 2010; Chen et al, 2010; Tucker et al, unpublished results).  
The three data sets we developed may allow particular insight into the progression 
of events that occur during dormancy (and maybe resistance) in synchronized 
parent/resistant cultures (PTS/RTS).  If one focuses on particular genes/functions that we 
have described above, there are some that overlap.  Zinc finger proteins are involved in 
DNA, protein, and zinc ion binding.  A gene encoding a zinc finger protein (PF11_0357) 
was up-regulated in PTS but down-regulated in RTS before drug exposure.  This protein 
was also found to be differentially regulated after DHA treatment (down-regulated in 
PTS, up-regulated in RTS).  Other genes encoding zinc finger proteins were either highly 
down-regulated in RTS before drug exposure (PFD0765w, PF10_0273) or differentially 
expressed after DHA-treatment (PFC0510w, up-regulated in D6, down-regulated in 
D6.QHS2400x5).  A gene encoding a Zn
+2
/Fe
+2
 permease (PFF0450c) was down-
regulated in dormancy in PTS and RTS.  This may indicate that these types of proteins 
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are not required for entrance into dormancy, but are employed in different ways in 
response to drug pressure over time.  Perhaps resistant parasites have a greater capacity to 
up-regulate these proteins and survive.  Lysophosopholipases (catalyze hydrolysis of 2-
lysophosphatidylcholine to glycerophosphocholine and a carboxylate) also were found in 
the various data sets.  PFI1775w (which encodes a putative lysophospholipase) was up-
regulated in both PTS and RTS at baseline, but the magnitude of regulation in PTS was 
much greater.  This gene is maximally expressed in merozoites, normally.  A 
lysophospholipase (encoded by PF14_0017) was up-regulated in both PTS and RTS 
during dormancy (about equal magnitude).  This gene is maximally expressed in late 
rings, normally.  A gene encoding a putative alpha/beta hydrolase (PF10_0020) was also 
down-regulated during dormancy in both strains.  Interestingly, a lysophospholipase of P. 
falciparum was found to exhibit different sensitivities to antimalarial compounds 
459
.  
This study found the enzyme was insensitive to MQ and the artemisinin derivative 
arteether, it was weakly inhibited by CQ, and more inhibited by QN.  Sulphydryl agents 
p-hydroxymercuribenzoate (pHMB) and thimerosal were more potent than QN.  When 
the sulphhydryl compounds were present at 10 µM prior to invasion, they arrested growth 
and re-invasion capacity of P. falciparum in vitro. Application of 5 µM thimerosal to 
synchronized parasites dramatically decreased total parasitemia and after 4 days, the 
capacity of surviving parasites to re-invade new RBCs was abolished.  An important 
question to ask based on this study and our data is if inhibition of the enzyme leads to 
arrest after drug treatment, why are the genes up-regulated?  Perhaps lysophospholipases 
are necessary during invasion and in the early part of the life cycle.  These enzymes may 
also be necessary for entrance into dormancy.  It is not clear why the parental parasite up-
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regulated PFI1775w so much.  Like PfTrxR, plasmodial lysophospholipase may represent 
a new target for anti-malarial chemotherapy that should be explored further.  
A recurring theme in the data sets was the differential regulation of genes 
involved in DNA replication, transcription, splicing, and translation.  Genes encoding 
proteins involved in DNA replication (PF10_0232, PFF1225c, PFL0580w, PFD0470c) 
were down-regulated in PTS and RTS, yet some of these were up-regulated in RTS 
(PF10_0232, PFF1225c) before DHA exposure.  One of these (PF10_0232) was down-
regulated in PTS and RTS during dormancy.  A gene encoding a DNA helicase 
(PFI0480w) was down-regulated in dormancy in PTS and RTS.  A gene encoding a 
DNA-replication factor gene (PFA0545c) was down-regulated in D6 vs. D6.QHS2400x5 
after DHA treatment.  PFF0510w (encodes a histone protein) was up-regulated in PTS 
and RTS in dormancy.  Another histone-binding protein (encoded by PF14_0314) was 
up-regulated after DHA treatment (D6.QHS2400x5 vs. D6).  These data may indicate 
that proteins of DNA replication machinery are unnecessary in both PTS and RTS during 
dormancy, but histone proteins are still needed for accessing DNA.  A reason separating 
parent and resistant parasites in this regard is not clear.  For transcription related genes, 
PF11_0477 (encodes CCAAT-box DNA binding protein subunit B) was down-regulated 
in PTS and RTS at baseline.  During dormancy, PF14_0374 (encodes a putative CCAAT 
binding transcription factor) was down-regulated in both PTS and RTS.  Again, 
transcription may not be important for rings at baseline, and during dormancy, a majority 
of it is probably shut down.  However, PF14_0469, which encodes a putative 
transcription factor IIIb subunit was up-regulated in both PTS and RTS at baseline.  
PlasmoDB lists its maximum expression in early rings, so maybe this protein is 
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responsible for expressing early ring-stage proteins, and artemisinin drove this gene into 
maximum efficiency.   
A group of genes involved in RNA metabolism/processing was also present in the 
data sets.  Before drug pressure, PFF0100w (encodes a putative ATP-dependent RNA 
Helicase) was down-regulated in PTS, but up-regulated in RTS.  Also, PF13_0077 
(encodes a putative DEAD box helicase) was up-regulated in PTS, but down-regulated in 
RTS before DHA was added.  PF10_0214, which encodes a putative RNA binding 
protein, was up-regulated in both strains before DHA was added.  During dormancy, a 
few genes were down regulated in both D6 and D6.QHS2400x5.  These included genes 
encoding RNA binding proteins (PFI0820c, PF08_0086, PF13_0058), a u5 small nuclear 
ribonucleoprotein specific protein (PFD1060w), and a putative cleavage stimulation 
factor subunit 1-like protein (PFF1000w).  After DHA was added, PFF0100w was up-
regulated in PTS, but down-regulated in RTS.  PFL1200c, which encodes a putative 
splicing factor 3b subunit, was down-regulated in PTS and up-regulated in RTS after 
DHA was added.  These results imply that the two strains differentially regulate these 
proteins before and during DHA pressure.  Perhaps there is redundancy in these pathways, 
enabling selection of different proteins in strains.  Importantly, genes of this class were 
down-regulated in dormancy.  This again indicates that nucleic acid machinery is 
unnecessary during dormancy.  Interestingly, the expression profile of PFF0100w in the 
two strains changed from baseline to dormancy.  The up-regulation in PTS while in 
dormancy may indicate that particular helicase is important for artemisinin-sensitive 
parasites.  Another interesting point is that PF10_0294 (encodes a RNA helicase), which 
is part of the chromosome 10 amplification in QHS-resistant D6 and W2, did not appear 
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in our data analysis.  Perhaps this gene is not as important as other helicase genes for the 
resistant parasite or this gene is unimportant (just appears that way because of overall 
amplicon). 
The genes we found that encode translation-related proteins were mostly down-
regulated in both PTS and RTS in all our data sets.  At baseline, a region that is antisense 
to PF08_0018 (which encodes a translation initiation factor), was more down-regulated in 
RTS.  MAL8P1.27 (encodes a putative translation initiation factor IF-3) was also down-
regulated in both strains, but much more in PTS.  The same was true for PFF0205w, 
which encodes a putative mitochondrial ribosomal protein L41 precursor.  During 
dormancy, MAL7P1.93 (encodes a putative mitochondrial ribosomal protein S8 
precursor) and PFD0770c (encodes a putative 60S ribosomal protein L15) were down-
regulated in both strains.  After DHA treatment, PF07_0079 (encodes a putative 60S 
ribosomal protein L11a) was down-regulated in PTS, but up-regulated in RTS.  These 
data substantiate the repression of DNA replication and transcription described above, as 
protein machinery is probably unnecessary before drug and during dormancy.  The fact 
that protein machinery is active in RTS may indicate that resistant parasites are ramping 
up proteins for exit from dormancy to progress through the life cycle.  Interestingly, we 
found DHA not only affected cytosolic translation genes, but also those involved in 
mitochondrial translation.  Therefore, artemisinins appear to affect mitochondria in other 
ways then the proposed mechanism described above. 
Our results are significant because other than the study by Witkowski et al. (2010) 
360
, there is no previous molecular description of any growth arrest state in the cell cycle 
of the malaria parasite.  This remains true even despite multiple attempts to disturb the 
  
286 
 
IDC with a variety of drugs and perturbations 
441,442,460
.  This transcriptional arrest was 
induced by DHA in both W2 and D6 in this study and in numerous P. falciparum strains 
in previous studies (
362
; Kyle unpublished data), making it unlikely to be a strain-specific 
phenomenon.  We knew that parental and resistant parasites enter dormancy and we 
hypothesized that transcription would be arrested at the ring stage.  We found that ring-
stages of both D6 parasites enter dormancy with an arrested transcriptome, which refutes 
the suggestion of Witkowski et al. (2010) 
360
 that only resistant parasites enter a dormant 
state following exposure to artemisinin.  Furthermore, our data provide evidence that 
DHA-exposed parasites do not become dormant or arrest transcription at any other time 
in the erythrocytic cycle other than ring stage.  Again, we had already morphologically 
confirmed this (Chapter One) but we had not molecular data to substantiate it.  
Interestingly, expression of a select set of genes during dormancy provides unique insight 
into cell cycle regulation and may introduce new strategies for antimalarial combination 
therapy.  More investigation into the nature and mechanisms of entry and exit from into 
this dormancy state is merited, particularly in relation to our understanding of cell cycle 
control mechanisms and new strategies for ACTs. 
In the broader context our results describe the time course of induction of 
dormancy that may prove very clinically relevant for better dosing schedules of ACTs 
and provide some kinetic data for epidemiological predictions about the acquisition and 
geographic spread of resistance.  In addition, the differentially expressed genes in 
dormant parasites and in QHS resistant parasites may serve as novel molecular markers 
for monitoring drug efficacy and emergence of resistance in the field.  Given the recent 
emergence of clinically relevant resistance, confirmation of dormancy in vivo and 
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correlation of the dormant parasite transcriptome provide new avenues to understanding 
artemisinin resistance, which is the most pressing public health problem for malaria 
control and elimination efforts.  
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Figure 3.1.  2-D DIGE of D6.QHS2400x3/D6 and W2.QHS200/W2 Identified Potential 
Spots Representing Differentially Expressed Proteins.  Separate gels were run for parent 
and resistant parasites and different dyes labeled parent or resistant parasite proteins in 
each comparison.  The dyes have different excitation wavelengths (red vs. green for 
resistant vs. parent) enabling two excitation images to be produced, then merged to 
determine overlapping proteins of interest.  For the D6 series, 29 potential protein spots 
were identified, whereas 33 were identified for the W2 series.  Thirteen spots were picked 
from each gel for further analyses. 
  
D6.QHS2400x3/D6 W2.QHS200/W2 
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Figure 3.2.  Artemisinin Microarray Experimental Design.  D6 (clone C11) and 
D6.QHS2400x5 (clone C9) were expanded into both highly synchronous ring stage 
cultures as well as asynchronous (mixed) stage cultures.  When the synchronous cultures 
were approximately at 8 hours post-invasion, 200 ng/ml DHS was added to half of each 
culture (purple arrow).  Six hours later, DHA was washed out (orange arrows).  Untreated 
controls were treated with DMSO and it was washed out 6 hours later (grey arrows).  The 
tick marks for each culture indicate samples hybridized against pool RNA on the 
microarray.  The figure here only shows a limited amount of time points.  Untreated 
cultures were discontinued after 48 hours, but treated/mixed cultures were followed up to 
151 hours and treated/synchronized cultures were followed to 189 hours. 
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Figure 3.3.  Analysis of Spots From 2D-DIGE Reveals Differentially Regulated Proteins 
for D6.QHS2400x3 vs. D6.  The ratio of proteins expressed in resistant/parental strains 
was determined for D6.QHS2400x3/D6.  Computer analysis measured protein peaks and 
ratios were calculated.  An example of down-regulation (A.) and up-regulation in 
D62400x3/D6 (B.) is displayed.  Each panel shows a particular protein spot from the gel, 
with D6 on left and D6.QHS2400x3 on right.  Spot 1594 (A.) had decreased ratio of 1.53 
in the resistant vs. parent parasite, whereas spot 2300 (B.) had increased ratio of 2.05 in 
the resistant parasite.  Surrounding protein peaks looked similar in the protein pairs.   
  
A. B. 
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Figure 3.4.  Analysis of Spots From 2D-DIGE Reveals Differentially Regulated Proteins 
for W2.QHS200 vs. W2.  The ratio of proteins expressed in resistant/parental strains was 
determined for W2.QHS200/W2.  Computer analysis measured protein peaks and ratios 
were calculated.  An example of down-regulation (A.) and up-regulation in 
W2.QHS200/W2 (B.) is displayed.  Each panel shows a particular protein spot from the 
gel, with W2 on left and W2.QHS200 on right.  Examples of differential regulation are 
spot 439 (A.), which was decreased 2.75 fold in W2.QHS200 compared toW2, whereas 
spot 788 (B.) was increased 1.88 fold in the resistant parasite.  For the W2 series (Fig. 
3.3), examples of differential regulation are spot 439, which was decreased 2.75 fold in 
W2.QHS200 compared toW2, whereas spot 788 was increased 1.88 fold in the resistant 
parasite.   
A. B. 
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Figure 3.5.  Chromosome 10 Genes are Amplified in Artemisinin-Selected D6 and W2 
Strains.  Average copy number of chromosome 10 genes (for PF10_0275 to PF10_0300) 
in D6 lines (A.), W2 lines (B.), TM91c235 lines (C.), and Cambodia-Thai isolates (D.) 
relative to D6.  Each QPCR copy number assays was performed at least twice (except for 
Thai-Cambodia assays, only performed once).  Standard deviation is shown as error bars. 
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Figure 3.6.  D6.QHS2400x5 Recrudesces Before D6 After Exposure to 200 ng/ml 
Dihydroartemisinin.  D6 recovery assay prior to microarray study.  Highly synchronous 
clonal parental D6 (clone C11) and resistant D6.QHS2400x5 (clone C9) were exposed to 
200 ng/ml DHA for 6 hours, then drug was washed out with RPMI.  (A.) Parasitemia 
counted from thin smears including dead, dormant, and normal parasites for all strains.  
(B.) Percentage of normal/total parasites counted for all strains.  (C.) Representative 
photomicrographs of D6 and D6.QHS2400x5 parasites through 120 hours post-drug. (D.)  
Percentage of dormant/total parasites counted for all strains.   
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Figure 3.7.  Pilot Microarray Experiment With W2 Strains Shows Dihydroartemisinin 
Arrests Ring Stage Parasites.  W2 was treated with 100 nM DHA for 6 hours, then drug 
was washed out.  RNA was isolated from parasites after 6 and 27 hours post-drug 
exposure.  The heat map has a gradient of color correlation of W2 parasites compared to 
a reference intraerythrocytic development cycle (IDC) transcriptome of HB3 (see text).  
The color gradient ranges from yellow to blue, which corresponds to high to low 
correlation with the HB3 transcriptome (see below Figures).  The right side of the map 
indicates time points within the IDC (0-48 hours).  There is a majority of yellow shading 
in the areas corresponding to 12-13 hours post-invasion, indicating that at 6 and 27 hours 
post-drug, parasites had a transcriptome that resembled ring-stage.  
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Figure 3.8.  Dihydroartemisinin Arrests Ring Stages in D6 Parental and Resistant 
Parasites and D6.QHS2400x5 Exits Dormancy Before D6.  D6 (clone C11) and 
D6.QHS2400x5 (clone C9) were treated with 200 ng/ml DHA for 6 hours, then drug was 
washed out.  RNA was isolated from parasites at T0 and time points beyond 100 hours  
post-drug exposure.  Microarrays were performed with experimental and pooled 
reference RNA.  The heat map has a gradient of color correlation of D6 parasites 
compared to a reference intraerythrocytic development cycle (IDC) transcriptome of HB3 
(see text).  The top of each heat map has time points from the experimental time course.  
The right side of the map is divided into two 0-48 cycles that indicates time points within 
the IDC (0-48 hours).  The color gradient ranges from yellow to black (+0.8-0.0 
correlation) and black to light blue (0.0 to -0.8 correlation), which corresponds to high to 
low correlation with the HB3 transcriptome.  There is a majority of yellow shading in the 
areas corresponding to 12-13 hours post-invasion of experimental samples, indicating 
that at 6 and 27 hours post-drug, parasites had a transcriptome that resembled ring-stage.  
Panels A and B show Parent Untreated and Parent Treated cultures, respectively.  Panels 
C and D show Resistant Untreated and Resistant Treated cultures, respectively.  In panels 
A and C, there is progression from rings-schizonts through the 0-48 hour cycle indicated 
by high correlation (yellow) of experimental time points and corresponding time points 
within the HB3 IDC (and low correlation where time points do not correspond [i.e. 6 
hours yellow for rings, but also blue in later times]).   In panels B and D, there is high 
correlation for experimental samples at ring stage (8-11 hours post invasion), indicating 
arrest of the transcriptome after DHA treatment.  In panel D, there is evidence of the 
resistant parasite exiting dormancy before the parent (panel B) as the heat map changes at 
68 hours post invasion. 
  
303 
 
A. 
 
B. 
 
 
 
 
 
 
 
 
 
 
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
0 10 20 30 40 50 60
P
a
ra
si
te
m
ia
Hours post-drug
PUM
PUS
RUM
RUS
0.0%
1.0%
2.0%
3.0%
4.0%
5.0%
6.0%
7.0%
8.0%
9.0%
0 50 100 150 200
P
a
ra
si
te
m
ia
Hours post-drug
PTM
PTS
RTM
RTS
  
304 
 
C. 
 
 
 
D.  
 
 
 
 
 
 
 
 
 
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
0 50 100 150 200
P
er
ce
n
ta
g
e 
 o
f 
D
ea
d
-D
o
rm
a
n
t/
T
o
ta
l 
P
a
ra
si
te
s
Hours post-drug
PTM
RTM
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
0 50 100 150 200
P
er
ce
n
ta
g
e 
 o
f 
D
ea
d
-D
o
rm
a
n
t/
T
o
ta
l 
P
a
ra
si
te
s
Hours post-drug
PTS
RTS
  
305 
 
E.  
 
 
Figure 3.9.  During Transcriptome Analysis, D6.QHS2400x5 Recrudesced Before D6 and 
a Greater Percentage of Normal Parasites Were Present After Dormancy.  Parasitemia 
calculations from array experiment with clonal D6 parent and resistant strains.  (A.) 
Three independent counts for untreated groups for hours 0-48 post-drug.  PUM (Parent 
Untreated Mixed), PUS (Parent Untreated Synchronized), RUM (Resistant Untreated 
Mixed), RUS (Resistant Untreated Synchronized).  (B.) Three independent counts for 
treated groups for hours 0-48 post-drug, then two counts for hours 57-117, then one count 
for time points after 117 hours post-drug.  PTM (Parent Treated Mixed), PTS (Parent 
Treated Synchronized), RTM (Resistant Treated Mixed), RTS (Resistant Treated 
Synchronized).  PTM and RTM groups were terminated after 153 hours post-drug (over 6% 
parasitemia in each).  (C.) Percentage of dead-dormant/total parasites for parental and 
resistant mixed-treated groups.  (D.) Percentage of dead and dormant parasites/normal 
parasites for parental and resistant synchronized-treated groups.  (E.) Percentage of 
normal/total parasites for parental and resistant synchronized-treated groups. 
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Figure 3.10.  Dihydroartemisinin Causes a Convergence on a Ring-like Transcriptome in 
Asynchronous D6 Strains.  D6 (clone C11) and D6.QHS2400x5 (clone C9) were treated 
with 200 ng/ml DHA for 6 hours, then drug was washed out.  RNA was isolated from 
parasites at T0 and time points up to 48 hours post-drug exposure.  The heat map has a 
gradient of color correlation of D6 parasites compared to a reference intraerythrocytic 
development cycle (IDC) transcriptome of HB3 (see text).  The top of each heat map has 
time points from the experimental time course.  The right side of the map is divided into 
two 0-48 cycles that indicates time points within the IDC (0-48 hours).  The color 
gradient ranges from yellow to black (+0.8-0.0 correlation) and black to light blue (0.0 to 
-0.8 correlation), which corresponds to high to low correlation with the HB3 
transcriptome.  There is a majority of yellow shading in the areas corresponding to 12-13 
hours post-invasion, indicating that at 6 and 27 hours post-drug, parasites had a 
transcriptome that resembled ring-stage.  Panels A and B show Parent Untreated and 
Parent Treated cultures, respectively.  Panels C and D show Resistant Untreated and 
Resistant Treated cultures, respectively.  In panels A and C, there is progression from 
rings-schizonts through the 0-48 hour cycle indicated by high correlation (yellow) of 
experimental time points and corresponding time points within the HB3 IDC (and low 
correlation where time points do not correspond [i.e. 6 hours yellow for rings, but also 
blue in later times]).   In panels B and D, there is high correlation for experimental 
samples at ring stage, indicating arrest of the transcriptome after DHA treatment.  It 
appears that the arrest occurred later in the parent (22 hours post-invasion) compared to 
the resistant parasite (9 hours post-invasion).   
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Table 3.1.  Oligonucleotides Used for Sequencing and Real-Time QPCR 
Primer Name Sequence 5'-3' Source/Reference 
Sequencing 
  PF13_0238 seq1-F 
new GGAAGTAGTAGCGAGAATGATTC This work 
PF13_0238 seq1-R 
new CGTACTCTTTCCATTTCTAGTTCT This work 
   PFF0275c seq1-F TGATAAGATACTAGAGGCCATTG This work 
PFF0275c seq1-R TCATCCTCAACCATTAATATAGC This work 
   PFF0275c seq3-F GGTTGAGGATGATTCTTATATGA This work 
PFF0275c seq3-R CATCTAAATCATACTCATCTCCA This work 
   PFF0275c seq4-F CATTTGGTAAGTTACGATGATGT This work 
PFF0275c seq4-R CATTCATAACATCGGAACATATC This work 
Real-Time QPCR 
  
LDH-T1F AGGACAATATGGACACTCCGAT 
Chavchich et al., 
2010 
276
 
LDH-T1R  TTTCAGCTATGGCTTCATCAAA 
Chavchich et al., 
2010 
276
 
   PF10_0275 rt-2F CAAATGGAAAGACGCAATACC This work 
PF10_0275 rt-2R CGTTCCAGTTATCCATCCAGA  This work 
   PF10_0277F TTTTTGAGGAAGCCTTTCTTTT This work 
PF10_0277R GCTGGAAAAATAACCGCAAA This work 
   PF10_0278F TTTCACTGAAGACGCCATGA This work 
PF10_0278R TTCTTGTAGCTTGGGAGGTTG This work 
   PF10_0279F ATCCGGCAAATTCTCACATC This work 
PF10_0279R GGAAGCGAAAAACCATAACG This work 
   PF10_0285F TGAACAAACCGAAAAAGGAA This work 
PF10_0285R AGGGAGATATGTCCAGAAGGTG This work 
   PF10_0286F GCCATTTCATCCATTTCGTT This work 
PF10_0286R CAACTTGAAGGATTTTCGTTCC This work 
   PF10_0292F CTACATTGGAAGATATGGTTAATCT This work 
PF10_0292R TATAATTTAATAGAGCCGAAACATT This work 
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Table 3.1 Continued 
Primer Name Sequence 5'-3' Source/Reference 
Real-Time QPCR 
  PF10_0294 rt-2F CGTCCTGAATATCCACCTGAA  This work 
PF10_0294 rt-2R TCACACTCTGCATTTCTGACG This work 
   PF10_0295 rt2-F GTAGAGACTTGGACACAACGA This work 
PF10_0295 rt2-R AAGCTTCAGGACATACAGATG This work 
   PF10_0296F AACATTTTCACGCGACTTCC This work 
PF10_0296R TGTGCGTTTTGCTCCAATAA This work 
   PF10_0299F TTCATTGCATCCTTGATTGG This work 
PF10_0299R AATGCACCCTCACCAGGATA This work 
   PF10_0300 rt-1F CACAATATGGGAAAGGTACTGCT This work 
PF10_0300 rt-1R TCATAATTTGCCCACACAGC This work 
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Table 3.2.  Spots Identified in Proteomic Analyses in D6 and W2 Strains with Indicated 
Differential Expression 
Protein 
ID Spot No. 
Ratio: 
D6.QHS2400x3/D6   
Protein 
ID Spot No. 
Ratio: 
W2.QHS200x2/W2 
1 107 -1.51 
 
1 95 1.43 
2 129 -1.52 
 
2 206 2.00 
3 54 -2.14 
 
3 281 1.51 
4 140 -1.52 
 
4 424 1.68 
5 780 -1.56 
 
5 439 -2.75 
6 788 -1.53 
 
6 571 1.51 
7 795 -1.55 
 
7 712 1.57 
8 913 -1.51 
 
8 719 1.57 
9 1108 -1.53 
 
9 721 1.50 
10 1276 1.63 
 
10 724 1.52 
11 1233 -1.18 
 
11 849 1.62 
12 1197 1.02 
 
12 788 1.88 
13 1209 1.02 
 
13 1221 -1.24 
14 1224 1.02 
 
14 1230 -2.14 
15 1310 -1.32 
 
15 1234 -1.62 
16 1656 -1.41 
 
16 1236 -1.95 
17 1781 1.56 
 
17 1185 -1.38 
18 1730 1.57 
 
18 1365 1.38 
19 1648 1.54 
 
19 1349 -1.57 
20 1594 -1.53 
 
20 1717 -1.00 
21 2300 2.05 
 
21 1939 -1.51 
22 2310 2.00 
 
22 1960 -1.51 
23 2237 1.53 
 
23 2210 -1.55 
24 2343 1.24 
 
24 2213 -1.72 
25 2384 1.70 
 
25 2214 -1.66 
26 2414 1.56 
 
26 2360 -1.56 
27 2428 1.74 
 
27 2254 -1.46 
28 2477 1.76 
 
28 2306 1.34 
29 2831 -1.13 
 
29 2417 -1.58 
    
30 2413 -1.87 
    
31 2602 1.54 
    
32 2776 1.32 
        33 2822 1.28 
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Table 3.3. Differentially Expressed Proteins in D6.QHS2400x3/D6 and W2.QHS200/W2 
D6.QHS2400x3/D6 
 
 
     
 PlasmoDB ID   PlasmoDB Name   Protein MW   Protein PI  
 Peptide 
Count  
 Expression 
Ratio   Protein Score C.I.%  
PF11_0098 
Endoplasmic reticulum-
resident calcium binding 
protein 39396.6 4.45 20 -1.41 100 
PFI0265c RhopH3 104789.2 6.25 20 1.57 100 
PF14_0425 Fructose-bisphosphate aldolase 40079.9 8.33 14 -1.53 100 
PFI1270w 
Conserved Plasmodium 
protein, unknown function 24682.6 5.49 4 1.74 100 
       W2.QHS200/W2 
      
PlasmoDB ID PlasmoDB Name Protein MW Protein PI 
Peptide 
Count Expression Ratio Protein Score C.I.% 
PFI0875w 
Heat shock protein 70 (HSP70) 
homologue 72343 5.18 21 1.62 100 
PFI1475w 
Merozoite surface protein 1 
precursor (MSP-1) 87991.8 8.13 16 1.88 100 
PFL2215w Actin I 41828.1 5.27 18 1.38 100 
PF13_0197 
Merozoite Surface Protein 7 
precursor (MSP-7) 41298.1 4.71 8 1.54 100 
  
 
 
3
1
2 
Table 3.4.  Whole Genome Sequencing Produced a Preliminary Set of Single Nucleotide Polymorphisms in D6 and D6.QHS2400x2 
 
Chrom 
3D7 
Base D6 Base 
D6.QHS
2400x2 
Base 
# D6 
Reads 
#D6.QHS
2400x2 
Reads D6 % SNP 
D6.QHS
2400x2 
% SNP Plasmo DB ID Description D6 AA change 
D6.QHS2400x2 
AA change 
13 C C T 59 31 100.0% 100.0% PF13_0238 kelch protein, putative 
 
Glu->Lys 
3 A A T 86 30 98.8% 100.0% PFC0320w 
conserved Plasmodium protein, 
unknown function 
 
Asn->Ile 
4 A A G 86 3 98.8% 100.0% PFD0900w 
conserved Plasmodium protein, 
unknown function 
 
Arg->Gly 
6 C C G 74 18 98.6% 94.4% PFF0275c  
nucleoside diphosphate kinase, 
putative 
 
Asp->His 
5 T T C 68 15 98.5% 100.0% PFE1155c 
mitochondrial processing 
peptidase alpha subunit, putative 
 
Ser->Gly 
13 G G A 56 16 98.2% 100.0% MAL13P1.298 
conserved Plasmodium 
membrane protein, unknown 
function 
 
Gly->Asp 
1 A A G 12 13 66.7% 84.6% PFA0675w 
RESA-like protein with DnaJ 
domain, putative 
 
Lys->Glu 
13 C C G 15 3 66.7% 100.0% MAL13P1.316 
conserved Plasmodium protein, 
unknown function 
 
Thr->Arg 
3 G G T 4 10 50.0% 100.0% PFC0770c kinesin-like protein, putative 
 
Asp->Glu 
9 G G A 10 10 50.0% 90.0% PFI0495w 
conserved Plasmodium protein, 
unknown function   Asp->Asn 
14 T C T 12 7 58.3% 100.0% PF14_0031 
conserved Plasmodium protein, 
unknown function Asn->Asp 
 14 T G T 3 11 66.7% 100.0% PF14_0404 TRAP-related protein Ile->Ser 
 
13 A T A 4 5 75.0% 100.0% PF13_0254 
conserved Plasmodium 
membrane protein, unknown 
function Ile->Lys 
 
3 A T A 17 9 70.6% 100.0% PFC1125w 
hypothetical protein, conserved 
in P. falciparum Met->Leu 
 14 T G T 72 84 58.3% 98.8% PF14_0081 DNA repair helicase, putative Asp->Ala 
 
1 T C T 61 28 80.3% 96.4% PFA0315w 
conserved Plasmodium protein, 
unknown function Cys->Arg 
 
14 C T C 58 11 98.3% 90.9% PF14_0419 
conserved Plasmodium protein, 
unknown function Val->Met 
 
7 C T C 11 8 63.6% 87.5% MAL7P1.102 
conserved Plasmodium protein, 
unknown function Gly->Asp 
 
8 A C A 45 58 53.3% 86.2% MAL8P1.335 
hypothetical protein, conserved 
in P. falciparum Ser->Arg 
 
7 A G A 8 6 62.5% 83.3% MAL7P1.170 
Plasmodium exported protein, 
unknown function Asn->Asp 
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Table 3.4 Continued 
Chrom 
3D7 
Base D6 Base 
D6.QHS
2400x2 
Base 
# D6 
Reads 
#D6.QHS
2400x2 
Reads D6 % SNP 
D6.QHS
2400x2 
% SNP Plasmo DB ID Description D6 AA change 
D6.QHS2400x2 
AA change 
8 G A G 10 16 60.0% 81.3% MAL8P1.335 
hypothetical protein, conserved 
in P. falciparum Val->Ile 
 
7 T C T 22 21 54.5% 81.0% MAL7P1.30 
conserved Plasmodium protein, 
unknown function Asn->Ser 
 
6 C T C 10 15 70.0% 80.0% PFF0770c 
conserved Plasmodium protein, 
unknown function Asp->Asn 
 
12 G A G 4 10 75.0% 80.0% PFL1370w 
NIMA-related protein kinase, 
Pfnek-1 Trp->Stop 
 3 A T A 3 5 66.7% 80.0% PFC0485w protein kinase,putative Asn->Ile 
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Table 3.5.  Reduced List of Single Nucleotide Polymorphisms in D6 vs. D6.QHS2400x2. 
 
3D7 Base  D6 Base  
D6.QHS2400(x2) 
Base  D6 Coverage  
D6.QHS2400(x2) 
Coverage  
D6 % 
SNP 
D6.QHS2400(x2) % 
SNP PlasmoDB_ID  
D6.QHS2400x2 
AA-change 
G  G  A  68 22 97 100 MAL13P1.298  Gly->Asp 
C  C  T  76 36 100 100 PF13_0238  Glu->Lys 
A  A  T  98 41 99 100 PFC0320w  Asn->Ile 
T  T  C  83 27 98 100 PFE1155c  Ser->Gly 
C  C  G  82 24 97 95 PFF0275c  Asp->His 
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Table 3.6.  Confirmation of Single Nucleotide Polymorphisms for D6 vs. D6 QHS-
Resistant Progeny and 3D7/D6 vs.D6 QHS-Resistant Progeny. 
 
Strain Nucleotide 
 
PF13_0238 
D6 vs. 3D7 AAA-ACA (Lys-Thr) 
at 1726463 
D6 vs. D6.QHS2400 GAA-AAA 
(Glu-Lys) at 1726407 
3D7 A G 
D6 C G 
D6 (clone C11) C G 
D6.QHS2400x2 C A 
D6.QHS2400x4 C A 
D6.QHS2400x4 C9 
 
A 
D6.QHS2400x5 C9 
 
A 
W2 A G 
W2 (clone D7) A 
 W2.QHS200 A 
 W2.QHS200x2 clone C5 A 
 
   
PFF0275c-3 
D6 vs. 3D7 AAA-AAG (Lys-Lys) 
at 229836 
 3D7 A 
 D6 G 
 D6 (clone C11) G 
 D6.QHS2400x2 G 
 D6.QHS2400x4 G 
 W2 A 
 
   
   
PFF0275c-4 
D6 vs. 3D7 AAA-CAA (Lys-Gln) 
at 229481 
 3D7 A 
 D6 C 
 D6 (clone C11) C 
 D6.QHS2400x2 C 
 D6.QHS2400x4 C 
 W2 A 
 
   PFF0275c-1 D6 vs. D6.QHS2400 GAT-CAT (Asp-His) at 230387 
3D7 G 
 D6 G 
 D6 (clone C11) G 
 D6.QHS2400x2 C 
 D6.QHS2400x4 C 
 D6.QHS2400x4 C9 C 
 D6.QHS2400x5 C9 C 
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Table 3.7.  List of Genes That are Either Up-Regulated or Down-Regulated in Both D6 and D6.QHS2400x5 During Dormancy 
 
PlasmoDB ID Description 
PTS 
induction  
RTS 
induction 
PFI1475w merozoite_surface_protein_1_precursor -4.0122758 -3.3474765 
PF13_0276 membrane-associated_histidine_rich_protein_2__(MARHP2) -3.7714916 -1.1615676 
PFF0450c Zn2+_or_Fe2+_permease -3.1865042 -1.6664611 
PFI0820c RNA_binding_protein__putative -2.9411938 -1.7712682 
PF13_0161 conserved_Plasmodium_protein__unknown_function -1.9201665 -2.75545 
PF13_0198 reticulocyte_binding_protein_2_homolog_A -2.0618474 -2.5750461 
PF11_0115 conserved_Plasmodium_protein__unknown_function -3.2893106 -1.2928555 
PFD0110w reticulocyte-binding_protein_homologue_1 -2.6834671 -1.6734861 
PFE1400c beta_adaptin_protein__putative -2.8350515 -1.4857174 
PF11_0291 conserved_Plasmodium_protein__unknown_function -2.7022322 -1.6080137 
PF08_0086 RNA_binding_protein__putative -3.0253363 -1.2537849 
PF11_0267 kelch_protein__putative -2.1881948 -2.0906963 
PFB0305c-b PFB0305c-a -1.1988956 -3.0547098 
PF14_0252 conserved_Plasmodium_protein__unknown_function -3.1564417 -1.0424037 
PF08_0127 conserved_Plasmodium_protein__unknown_function -2.4889283 -1.6180217 
PF10_0242 conserved_Plasmodium_protein__unknown_function -2.7487976 -1.3016852 
PFI1470c conserved_Plasmodium_protein__unknown_function -2.0585974 -1.9859202 
PFL1090w glideosome-associated_protein_45 -2.5617122 -1.4119216 
MAL7P1.141 conserved_Plasmodium_protein__unknown_function -1.9417168 -2.0233553 
PFD0100c surface-associated_interspersed_gene_4.1__(SURFIN4.1) -2.4074047 -1.5015648 
PFL2235w conserved_Plasmodium_protein__unknown_function -2.6613861 -1.2286429 
PF10_0232 
Chromodomain-helicase-DNA-
binding_protein_1_homolog__putative -2.4074828 -1.4622105 
MAL13P1.268 conserved_Plasmodium_protein__unknown_function -2.3809854 -1.4654799 
PF13_0035 U3_small_nucleolar_RNA-associated_protein_6__putative -2.2029116 -1.6331854 
PFE1270c WD_domain__G-beta_repeat-containing_protein -1.772013 -2.0598109 
PF11_0252 neutral-sphingomyelinase_activation_factor_protein__putative -2.234824 -1.5588927 
PF10_0179 conserved_Plasmodium_protein__unknown_function -2.2681419 -1.5091625 
PFF1295w conserved_Plasmodium_protein__unknown_function -2.2753111 -1.4903569 
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Table 3.7 Continued 
PlasmoDB ID Description 
PTS 
induction  
RTS 
induction 
PF13_0091 conserved_Plasmodium_protein__unknown_function -2.4429398 -1.313989 
PF08_0107 erythrocyte_membrane_protein_1__PfEMP1 -2.6416198 -1.0811586 
PFF1000w cleavage_stimulation_factor_subunit_1-like_protein__putative -2.5973208 -1.0891824 
PF13_0233 myosin_A -1.7689914 -1.9009532 
PFE0280c conserved_Plasmodium_membrane_protein__unknown_function -2.4344461 -1.2145255 
PFD1060w u5_small_nuclear_ribonucleoprotein-specific_protein__putative -2.5395158 -1.1089365 
PF13_0058 RNA_binding_protein__putative -2.3498467 -1.2967036 
PFL1235c conserved_Plasmodium_protein__unknown_function -2.6150319 -1.0292664 
PFI1480w conserved_Plasmodium_protein__unknown_function -1.7485015 -1.8639976 
PF10_0022 Plasmodium_exported_protein_(PHISTc)__unknown_function -2.3255101 -1.2869174 
PF10_0180 conserved_Plasmodium_protein__unknown_function -2.3178622 -1.251799 
PF14_0753 Plasmodium_exported_protein_(hyp13)__unknown_function -2.1774114 -1.3547956 
PF14_0201 surface_protein__Pf113 -1.9919416 -1.5215274 
PFL2225w myosin_A_tail_domain_interacting_protein -1.9138166 -1.5688659 
PF14_0374 CCAAT-binding_transcription_factor__putative -1.9621271 -1.5079823 
PFE1250w acyl-CoA_synthetase__PfACS10 -2.0509691 -1.4040629 
PF11_0218 conserved_Plasmodium_protein__unknown_function -1.450218 -2.003737 
PFE0320w conserved_Plasmodium_protein__unknown_function -1.919224 -1.5266028 
PF14_0308 conserved_Plasmodium_protein__unknown_function -2.2109622 -1.2212551 
PFB0145c Kid_domain_containg_protein -1.6270989 -1.7895704 
PF08_0003 tryptophan/threonine-rich_antigen -1.824834 -1.5731558 
MAL8P1.132 kinesin-like_protein__putative -2.1945282 -1.1771417 
PF14_0578 conserved_Plasmodium_protein__unknown_function -2.0242004 -1.3260126 
PF10_0021 Plasmodium_exported_protein_(PHISTc)__unknown_function -1.7513504 -1.5687649 
MAL7P1.19 ubiquitin_transferase__putative -2.0289881 -1.2388211 
PF13_0278 ran-binding_protein__putative -2.0315616 -1.2259204 
PFF0505c conserved_Plasmodium_protein__unknown_function -1.5631063 -1.6522202 
MAL7P1.19 ubiquitin_transferase__putative -1.5027399 -1.7102344 
PFI1725w Plasmodium_exported_protein__unknown_function -1.0496104 -2.1457842 
PFI1180w patatin-like_phospholipase__putative -1.4538159 -1.7365574 
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Table 3.7 Continued 
PlasmoDB ID Description 
PTS 
induction  
RTS 
induction 
PF08_0137 Plasmodium_exported_protein_(PHISTc)__unknown_function -1.65873 -1.5218798 
PFD0385w conserved_Plasmodium_protein__unknown_function -1.7089599 -1.4128193 
PF10_0244 formin_2__putative -2.0759703 -1.0308301 
PF10_0233 conserved_Plasmodium_protein__unknown_function -1.9969651 -1.0961442 
PFL0290w conserved_Plasmodium_protein__unknown_function -1.8251526 -1.2248395 
PFI0685w pseudouridylate_synthase__putative -1.839536 -1.2002081 
PF10_0327 Myb2_protein -1.5376157 -1.5017474 
PFI0095c Serine/Threonine_protein_kinase__FIKK_family -1.6836756 -1.2985878 
PF11_0111 asparagine-rich_antigen -1.5844931 -1.3962718 
PFC0700c conserved_Plasmodium_protein__unknown_function -1.3806204 -1.5249683 
PF14_0223 cyclophilin__putative -1.5090967 -1.3956387 
PFD0835c LETM1-like_protein__putative -1.6133704 -1.2512641 
PFL0380c tRNA_delta(2)-isopentenylpyrophosphate_transferase__putative -1.5937552 -1.2358461 
MAL13P1.26 conserved_Plasmodium_protein__unknown_function -1.3559142 -1.46311 
PF13_0088 Myb1_protein -1.0794496 -1.7325195 
PFI0700c met-10+_like_protein__putative -1.1615767 -1.6284459 
PFE1160w conserved_Plasmodium_protein__unknown_function -1.7797424 -1.0057264 
PFF1005w conserved_Plasmodium_protein__unknown_function -1.7195485 -1.0444659 
PF13_0215 conserved_Plasmodium_protein__unknown_function -1.6799098 -1.080074 
PF10_0078 histone_deacetylase__putative -1.4841942 -1.2667114 
PFD1145c reticulocyte-binding_protein_homologue_5 -1.1785154 -1.5710186 
MAL7P1.150 cysteine_desulfurase__putative -1.335683 -1.3941081 
PFI1480w conserved_Plasmodium_protein__unknown_function -1.1419108 -1.5050727 
PFI0480w helicase_with_Zn-finger_motif__putative -1.4058756 -1.2216186 
PFB0735c conserved_Plasmodium_protein__unknown_function -1.2763977 -1.2850339 
PFD0770c 60S_ribosomal_protein_L15__putative -1.2456682 -1.2713336 
PF08_0020 Ubiquitination-mediated_degradation_component__putative -1.3515606 -1.0947258 
PFD0290w conserved_Plasmodium_protein__unknown_function 1.11542411 1.4730496 
PFE1525w conserved_Plasmodium_membrane_protein__unknown_function 1.20835854 1.45335541 
PFD0830w bifunctional_dihydrofolate_reductase-thymidylate_synthase 1.13848086 1.42145005 
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Table 3.7 Continued 
PlasmoDB ID Description 
PTS 
induction  
RTS 
induction 
PFB0680w rhoptry_neck_protein_6 1.47303785 1.19186476 
PF11_0128 coq4_homolog__putative 1.09236079 1.10857838 
PF13_0193 MSP7-like protein 1.34046932 1.32447335 
PF14_0073 conserved_Plasmodium_protein__unknown_function 1.43318706 1.72749487 
PFA0395w conserved_Plasmodium_protein__unknown_function 1.0216813 1.82159222 
PFA0045c rifin 1.82509264 1.14030954 
PFI0385c P1_nuclease__putative 1.18473999 1.74250712 
PFA0650w 
surface-
associated_interspersed_gene_pseudogene__(SURFIN)_pseudogene 1.43675223 1.2129938 
PFA0130c Serine/Threonine_protein_kinase__FIKK_family__putative 1.63592879 1.04883918 
MAL7P1.144 Serine/Threonine_protein_kinase__FIKK_family 1.495712 1.62882184 
PF10_0020 alpha/beta_hydrolase__putative 1.17075642 1.9159615 
MAL7P1.93 mitochondrial_ribosomal_protein_S8_precursor__putative 2.21703878 1.05482928 
MAL13P1.470 Plasmodium_exported_protein_(PHISTa)__unknown_function 1.22671687 1.9985018 
PF11_0178 conserved_Plasmodium_protein__unknown_function 1.01390863 2.54695928 
PF08_0001 Plasmodium_exported_protein__unknown_function 1.87317625 2.18749991 
PF14_0014 Plasmodium_exported_protein__unknown_function 2.27287928 1.89517329 
PF14_0017 lysophospholipase__putative 2.85952559 2.87223754 
PFC0360w Activator_of_Hsp90_ATPase_homolog_1-like_protein__putative 2.65478733 2.85218388 
PF14_0438 conserved_Plasmodium_protein__unknown_function 3.66638406 3.09545633 
PF14_0010 glycophorin_binding_protein_family__Gbph 4.25363192 2.63414777 
PF14_0180 conserved_Plasmodium_protein__unknown_function 3.25933916 1.99953729 
PFF0510w histone_H3 2.34188341 2.88776901 
PF14_0183 signal_recognition_particle__RNP__putative 4.42940995 1.30698912 
PFI1170c thioredoxin_reductase 4.52840343 3.16225001 
PFE0065w skeleton binding protein 7.36566368 3.92378486 
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Table 3.8.  List of Genes That are Differentially Expressed in D6 vs. D6.QHS2400x5 During Dihydroartemisinin Treatment 
 
PlasmoDB ID Description 
PTS 
induction 
RTS 
induction 
PF10_0252 cytochrome_C_oxidase_copper_chaperone__putative 1.63394168 -1.7293658 
PFD1150c reticulocyte_binding_protein_homolog_4__Rh4 1.9377158 -1.4167447 
PF14_0735 probable_protein__unknown_function 1.70526971 -1.6320825 
PFI0975c conserved_Plasmodium_protein__unknown_function 1.72431216 -1.3863866 
PFA0545c replication_factor_c_protein__putative 1.94485287 -1.0753358 
PF11_0277 conserved_Plasmodium_protein__unknown_function 1.9377158 -1.0548411 
PFL2520w reticulocyte-binding_protein_3_homologue 0.65468142 -2.323381 
No_ORFs 
Control oligonucleotide to bifunctional dihydrofolate reductase-
thymidylate synthase(PFD0830w) 0.67189034 -2.1428645 
PFF1365c HECT-domain_(ubiquitin-transferase)__putative 1.57410936 -1.0059598 
PF14_0223 cyclophilin__putative 1.3192684 -1.2303327 
MAL8P1.92 ATPase__putative 1.50061036 -1.0117397 
PF07_0104 kinesin-like_protein__putative 0.62914432 -1.8820465 
MAL13P1.7 stevor 1.30543002 -1.1642392 
PF14_0748 Plasmodium_exported_protein_(PHISTa)__unknown_function 1.17385331 -1.2542606 
MAL7P1.17 conserved_Plasmodium_membrane_protein__unknown_function 1.13018205 -1.0386957 
PFF0100w ATP-dependent_RNA_Helicase__putative 0.80114659 -1.2366027 
Multiple_ORFs pseudogene, P. falciparum-specific conserved gene family 0.61496969 -1.313552 
MAL7P1.171 Plasmodium_exported_protein__unknown_function 0.26711822 -1.5967097 
PFC0510w RING_zinc_finger_protein__putative 0.6922195 -1.1445609 
MAL13P1.309 14-3-3_protein__putative 0.72930869 -1.0252043 
PFB0320c iron-sulfur_assembly_protein__putative 0.68211151 -1.0227192 
PFL0170w transporter__putative 0.23021723 -1.1489961 
MAL8P1.88 conserved_Plasmodium_protein__unknown_function -0.6801625 1.21307621 
PFI1210w conserved Plasmodium protein, unknown function -0.7885322 1.1218441 
MAL13P1.347 conserved_Plasmodium_protein__unknown_function -0.4784996 1.43249509 
PFL2425w Adaptor related_protein_complex3__sigma_2_subunit__putative -0.7182482 1.24491283 
PFD0400w conserved_Plasmodium_protein__unknown_function -0.9010357 1.06660293 
PFF0445w conserved_Plasmodium_protein__unknown_function -0.9945471 1.04164774 
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Table 3.8 Continued 
PlasmoDB ID Description 
PTS 
induction 
RTS 
induction 
PFE1110w conserved_Plasmodium_protein__unknown_function -0.9369856 1.1071453 
PFL1200c splicing_factor_3b_subunit__putative -0.9027705 1.21178864 
PF14_0540 conserved_Plasmodium_protein__unknown_function -0.8054582 1.34564343 
PFL0430w tim10_homologue__putative -0.7165572 1.45290844 
PF14_0314 chromatin_assembly_factor_1_P55_subunit__putative -0.90478 1.27814226 
MAL13P1.182 conserved_Plasmodium_protein__unknown_function -1.1691074 1.01649465 
MAL13P1.55 cytochrome_c2_precursor_putative -0.7657609 1.50796717 
PFF0175c conserved_Plasmodium_protein__unknown_function -0.677744 1.60759531 
PFA0475c conserved_Plasmodium_protein__unknown_function -0.7498068 1.55514139 
PFE0175c unconventional_myosin_pfm-b -1.2942585 1.02248954 
PF14_0100 cytidine_triphosphate_synthetase -1.2958324 1.13885037 
PFB0095c erythrocyte_membrane_protein_3 -0.5538473 1.94036823 
MAL13P1.68 peptidyl-prolyl_cis-trans_isomerase__putative -1.2144687 1.28329682 
MAL13P1.184 endopeptidase__putative -0.8838423 1.62952572 
PF13_0136 conserved_Plasmodium_protein__unknown_function -1.467772 1.06456325 
PF11_0035 Plasmodium_exported_protein__unknown_function -0.8038536 1.8773292 
PFF0375c conserved_Plasmodium_protein__unknown_function -1.1385198 1.56913753 
PFD0545w conserved_Plasmodium_protein__unknown_function -0.6997264 2.09387722 
PF14_0038 cytochrome_c__putative -1.4735048 1.37974371 
PF11_0506 Antigen_332__DBL-like_protein -1.8903742 1.01385261 
PF08_0044 protein_kinase_1 -1.840588 1.08346417 
PFC0695w conserved_Plasmodium_protein__unknown_function -0.8798918 2.09127396 
PF07_0079 60S_ribosomal_protein_L11a__putative -1.1331181 1.94007221 
PF10_0373a conserved_Plasmodium_protein__unknown_function -2.0389976 1.11186685 
PFF1260c conserved_Plasmodium_protein__unknown_function -1.7398095 1.54249857 
PF11_0357 zinc_finger_protein__putative -1.7087687 1.86705495 
PF11_0273 DNAJ_protein__putative -1.6011369 2.72544016 
PF14_0121 conserved_Plasmodium_protein__unknown_function -1.8520665 2.62650345 
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Table 3.9.  List of Genes That Were Differentially Expressed Before D6 and D6.QHS2400x5 Were Exposed to Dihydroartemisinin 
 
PlasmoDB ID Description 
mean PTS0 
& PUS0 
mean RTS0 
& RUS0 
Residual Resistant-
0.7478Parental-
0.2228 
PFI0900w conserved_Plasmodium_protein__unknown_function -0.0646314 -5.7004397 -5.4293083 
MAL7P1.29 conserved_Plasmodium_membrane_protein__unknown_function -0.3215103 -5.7004397 -5.2372143 
PFC1016w conserved_Plasmodium_protein__unknown_function -0.5151719 -5.7004397 -5.0923941 
PFF1260c conserved_Plasmodium_protein__unknown_function 3E-09 -5.0874629 -4.8646629 
No_ORFs antisense to PF08_0018 UTR Translation initiation factor -0.2947815 -4.7004397 -4.2572021 
PFD0765w RING_zinc_finger_protein__putative -0.3461112 -4.7004397 -4.2188178 
PF14_0751 acyl-CoA_synthetase__PfACS1b -0.1443899 -4.0874629 -3.7566881 
PFC0820w conserved_Plasmodium_protein__unknown_function -0.5173232 -4.10147 -3.4918158 
PFD0820w conserved_Plasmodium_protein__unknown_function -0.7258251 -4.2329872 -3.4674153 
No_ORFs conserved Plasmodium protein, unknown function 1.86835596 -2.2329872 -3.4073438 
No_ORFs yeast control oligonucleotide -0.2853273 -3.7004397 -3.2642719 
PF14_0224 serine/threonine_protein_phosphatase -0.3362127 -3.7004397 -3.2262198 
No_ORFs antisense to PF10_0195 kinesin, putative intron 0.06635125 -3.3939513 -3.2207688 
No_ORFs between mal7p1.82 and 83 conserved proteins -0.3931467 -3.7004397 -3.1836446 
PF10_0337 ADP-ribosylation_factor-like_protein 2.15116404 -1.7935491 -3.1793896 
No_ORFs near Pfmc-2TM family pseudogene -0.7331872 -3.8939513 -3.1228739 
PFC0911c conserved_Plasmodium_protein__unknown_function 0.04864858 -3.3089888 -3.1225682 
PFD0470c replication_factor_a_protein__putative -0.2168114 -3.5025004 -3.1175688 
PFE1300w conserved_Plasmodium_membrane_protein__unknown_function -1.0024005 -4.0874629 -3.1150678 
PF10_0184 conserved_Plasmodium_protein__unknown_function -0.2168114 -3.440506 -3.0555744 
PF11_0357 zinc_finger_protein__putative 1.29373122 -2.280108 -3.0247602 
PFI1390w conserved_Plasmodium_protein__unknown_function -0.2780029 -3.440506 -3.0098154 
PF10_0273 DHHC-type_zinc_finger_protein__putative -0.2025324 -3.3785116 -3.0042579 
PFI1465w procollagen_lysine_5-dioxygenase__putative -0.2561681 -3.3785116 -2.9641491 
PFE0680w conserved_Plasmodium_protein__unknown_function -0.4772346 -3.5437314 -2.9640554 
PF11_0481 tubulin-tyrosine_ligase__putative 0.36991925 -2.8930848 -2.9469104 
No_ORFs hypothetical protein -2.6196428 -5.1164005 -2.9346316 
MAL13P1.178 conserved_Plasmodium_protein__unknown_function -0.4618822 -3.4902738 -2.9220783 
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Table 3.9 Continued 
PlasmoDB ID Description 
mean PTS0 
& PUS0 
mean RTS0 
& RUS0 
Residual Resistant-
0.7478Parental-
0.2228 
MAL7P1.92 cysteine_repeat_modular_protein_2__putative -0.3505549 -3.3939513 -2.9090064 
PF11_0186 conserved_Plasmodium_protein__unknown_function 0.23341 -2.940506 -2.89225 
PFC0820w conserved_Plasmodium_protein__unknown_function -0.4558458 -3.440506 -2.8768245 
PF11_0480 sporozoite_asparagine-rich_protein -0.0687128 -3.1154772 -2.8412938 
No_ORFs outside PF14_0013 DNAJ protein -0.9109185 -3.7407754 -2.8367906 
PFD0462w DNAJ_protein -0.0687128 -3.0874629 -2.8132795 
PF07_0096 conserved_Plasmodium_protein__unknown_function -0.1111962 -3.1154772 -2.8095247 
No_ORFs hypothetical, plastid encoded -0.2473205 -3.1977926 -2.7900463 
PF11_0359 coatomer_delta_subunit__putative -0.1524273 -3.1154772 -2.778692 
No_ORFs antisense to PF14_0363 metacaspase-like protein -0.5184184 -3.3785116 -2.7680383 
PF13_0233 myosin_A 1.94005742 -1.5305147 -2.7584896 
No_ORFs antisense to PF14_0392 serine/threonine protein kinase, putative  1.9574395 -1.5025004 -2.7434736 
PF10_0139 conserved_Plasmodium_protein__unknown_function -0.4854268 -3.3089888 -2.7231866 
PFB0423c conserved_protein__unknown_function -1.0171739 -3.6821591 -2.6987165 
PFE0635c conserved_Plasmodium_protein__unknown_function -0.6549277 -3.4092341 -2.6966792 
MAL13P1.114 conserved_Plasmodium_protein__unknown_function -0.2969818 -3.0874629 -2.6425799 
No_ORFs intron of PFL0115 dynein heavy chain, putative  -0.2969818 -3.0874629 -2.6425799 
PF14_0384 allantoicase__putative -0.3318821 -3.0874629 -2.6164815 
No_ORFs 
between PFD0560w and PFD0565c conserved and DEAD box ATP-
dependent RNA helicase, putative  1.58496247 -1.6280313 -2.5904662 
PFE1060c conserved_Plasmodium_protein__unknown_function -1.083601 -3.60147 -2.5683532 
MAL13P1.301 guanylyl_cyclase -0.2223924 -2.940506 -2.5514009 
PF14_0506 conserved_Plasmodium_protein__unknown_function -0.5368742 -3.1642355 -2.539961 
PFL1575w conserved_Plasmodium_protein__unknown_function -0.4730434 -3.1154772 -2.5389354 
PFC0415c conserved_Plasmodium_protein__unknown_function -0.4427537 -3.0899234 -2.5360321 
PF13_0077 DEAD_box_helicase__putative 0.48906271 -2.3827674 -2.5256885 
No_ORFs no orfs Chr 7 0.03316683 -2.7004397 -2.5024418 
PF13_0204 nuclear_movement_protein__putative 3E-09 -2.7004397 -2.4776397 
MAL7P1.162 dynein_heavy_chain__putative -0.4850652 -3.0437314 -2.4581997 
PFC0525c glycogen_synthase_kinase_3 -0.7483934 -3.2329872 -2.4505387 
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Table 3.9 Continued 
PlasmoDB ID Description 
mean PTS0 
& PUS0 
mean RTS0 
& RUS0 
Residual Resistant-
0.7478Parental-
0.2228 
PF14_0121 conserved_Plasmodium_protein__unknown_function 1.58496245 -1.4775063 -2.4399412 
PFC0910w conserved_Plasmodium_protein__unknown_function -0.579436 -3.0945348 -2.4384326 
No_ORFs succinyl-CoA synthetase alpha subunit, putative -0.6198218 -3.1154625 -2.4291597 
MAL7P1.100 protein_kinase -0.5849625 -3.0874629 -2.4272279 
No_ORFs near PFD0310w sexual stage-specific protein precursor -0.6064969 -3.10147 -2.4251317 
PF14_0155 serine_C-palmitoyltransferase__putative -0.6300807 -3.1154772 -2.4215028 
MAL7P1.29 conserved_Plasmodium_membrane_protein__unknown_function -0.2433511 -2.8089888 -2.4042109 
PF14_0458 conserved_Plasmodium_protein__unknown_function -0.2223924 -2.7655348 -2.3764297 
PFD0520c conserved_Plasmodium_protein__unknown_function -0.6713773 -3.0874629 -2.362607 
PF10_0254 conserved_Plasmodium_protein__unknown_function -0.4668244 -2.9266355 -2.3547442 
PF14_0529 gamma-adaptin__putative 0.41083136 -2.2699875 -2.3544072 
PFD0260c sequestrin -0.4852214 -2.9378391 -2.3521906 
PF14_0298 conserved_Plasmodium_membrane_protein__unknown_function -0.3459389 -2.8318325 -2.3503394 
No_ORFs antisense near PFD1105w asparagine-rich protein -0.5946128 -3.0165075 -2.3490561 
PF11_0477 CCAAT-box_DNA_binding_protein_subunit_B -2.0703893 -4.1154772 -2.3444401 
PFI0130c Plasmodium_exported_protein_(PHISTb)__unknown_function -0.2355217 -2.7406511 -2.341728 
PFI1100w para-aminobenzoic_acid_synthetase -0.3030627 -2.7699875 -2.3205573 
PF11_0506 Antigen_332__DBL-like_protein -0.1744104 -2.6645618 -2.3113377 
PFD0872w conserved_Plasmodium_protein__unknown_function -0.5589514 -2.940506 -2.2997222 
PFA0685c Plasmodium_exported_protein_(hyp4)__unknown_function -0.5318474 -2.8930848 -2.2725693 
PFE1150w multidrug_resistance_protein -0.4829498 -2.8502199 -2.26627 
PFD0595w conserved_Apicomplexan_protein__unknown_function -1.2660624 -3.4351722 -2.2656108 
PFC0950c peptidase__putative -0.7948818 -3.0720232 -2.2548106 
PFI0490c ran-binding_protein__putative -0.0339474 -2.5025004 -2.2543145 
PFL1135c conserved_Plasmodium_protein__unknown_function -0.1074898 -2.5305147 -2.2273338 
PFI1775w lysophospholipase__putative 4.06263989 0.59633267 -2.2189094 
PF14_0180 conserved_Plasmodium_protein__unknown_function -0.4954719 -2.8089888 -2.2156749 
PF10_0390 Pfmc-2TM_Maurer's_cleft_two_transmembrane_protein -0.3629125 -2.7004397 -2.2062537 
PF14_0706 conserved_Plasmodium_protein__unknown_function 0.19264508 -2.280108 -2.201368 
PFB0615c conserved_Plasmodium_protein__unknown_function 0.17441797 -2.280108 -2.1877377 
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Table 3.9 Continued 
PlasmoDB ID Description 
mean PTS0 
& PUS0 
mean RTS0 
& RUS0 
Residual Resistant-
0.7478Parental-
0.2228 
PF11_0178 conserved_Plasmodium_protein__unknown_function -1.1265426 -3.2329872 -2.1677587 
MAL13P1.301 guanylyl_cyclase -0.140845 -2.4902738 -2.1621499 
PFL0045c Plasmodium_exported_protein_(PHISTc)__unknown_function -0.4641745 -2.7276535 -2.1577438 
PFF0470w conserved_Plasmodium_protein__unknown_function -0.5212085 -2.7512502 -2.1386905 
PF13_0068 mitochondrial_ribosomal_protein_S35_precursor__putative -0.260833 -2.5437314 -2.1258805 
PF11_0342 conserved_Plasmodium_protein__unknown_function -0.6933999 -2.8646437 -2.1233192 
PFE0540w WD-repeat_protein__putative 0.06196615 -2.2795419 -2.1030802 
MAL7P1.162 dynein_heavy_chain__putative 0.52793152 -1.9175379 -2.0895251 
PFL1645w conserved_Plasmodium_protein__unknown_function 2.36815108 -0.5274436 -2.075547 
PFD0380c conserved Plasmodium protein, unknown function -0.7495042 -2.8502199 -2.0669406 
MAL8P1.201 conserved_Plasmodium_protein__unknown_function 0.05781447 -2.2329872 -2.0534209 
No_ORFs hypothetical protein -1.0699652 -3.0720232 -2.0491033 
MAL8P1.56 conserved_Plasmodium_membrane_protein__unknown_function -0.5260842 -2.6480247 -2.031819 
PF14_0406 conserved_Plasmodium_protein__unknown_function 0.2175914 -2.0874629 -2.0273777 
PF08_0077 GDP-mannose_4_6-dehydratase__putative 0.17186854 -2.10147 -2.0071933 
No_ORFs utr PFEMP1 pseudogene PFD1025w 0.24616055 -2.0437314 -2.0050103 
PFI1145w MAC/Perforin__putative 0.55101513 -1.7935491 -1.9827982 
PFL0580w DNA_replication_licensing_factor_MCM5__putative -0.2468585 -2.3827674 -1.9753666 
PFF1120c conserved_Apicomplexan_protein__unknown_function -2.7655348 -0.2620813 2.0287856 
PFF0100w ATP-dependent_RNA_Helicase__putative -0.5620567 1.3867653 2.02987128 
PF14_0469 transcription_factor_IIIb_subunit__putative 1.52558879 2.94888774 2.03085245 
PFI1725w Plasmodium_exported_protein__unknown_function 2.53908099 3.71492819 2.03900342 
PFL0205w conserved_Plasmodium_protein__unknown_function -0.3250665 1.57634713 2.04223187 
PFI1330c conserved_Plasmodium_protein__unknown_function 0.16046462 1.94260428 2.04540883 
PFB0150c protein_kinase__putative -1.774903 0.50325664 2.05332914 
PFD0505c protein_phosphatase__putative 1.78722095 3.17168764 2.05800381 
PFI1180w patatin-like_phospholipase__putative 0.4681265 2.19288728 2.06562228 
PFL1260w hydrolase_/_phosphatase__putative -0.6713773 1.34635626 2.0712122 
PFB0161c conserved_Plasmodium_protein__unknown_function -2.1523262 0.25835824 2.0906678 
PFE1245w conserved_Plasmodium_protein__unknown_function -2.2911138 0.16066936 2.09676425 
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Table 3.9 Continued 
PlasmoDB ID Description 
mean PTS0 
& PUS0 
mean RTS0 
& RUS0 
Residual Resistant-
0.7478Parental-
0.2228 
MAL8P1.27 translation_initiation_factor_IF-3__putative -3.0874629 -0.431807 2.09979771 
PF11_0375 conserved_Plasmodium_protein__unknown_function 0.65977888 2.37223713 2.10165448 
PFF1225c DNA_polymerase_1__putative -0.3048546 1.65260255 2.1033728 
MAL13P1.106 probable_protein__unknown_function 0.11119619 1.97187102 2.11151851 
PFL0795c male_development_gene_1 0.35418088 2.15506387 2.11300741 
PF11_0114a conserved_Plasmodium_protein__unknown_function -0.3997411 1.59531044 2.11703682 
MAL13P1.184 endopeptidase__putative 0.92500801 2.6029861 2.13406511 
PFE0570w RNA_pseudouridylate_synthase__putative -0.1961587 1.79057292 2.16006042 
PFD0320c conserved_Plasmodium_protein__unknown_function 0.36512953 2.22380075 2.17355688 
PF13_0161 conserved_Plasmodium_protein__unknown_function -0.3992687 1.65526603 2.17663918 
MAL13P1.333 conserved_Plasmodium_protein__unknown_function 0.16046462 2.07448523 2.17728978 
PFC0110w Cytoadherence_linked_asexual_protein_3.2 -0.426399 1.63661517 2.17827631 
PF11_0291 conserved_Plasmodium_protein__unknown_function -0.2613391 1.77324487 2.19147427 
PFF0575c conserved_Plasmodium_protein__unknown_function -0.0937293 1.91020047 2.20309127 
PFB0790c conserved_Plasmodium_membrane_protein__unknown_function 3E-09 1.98606084 2.20886083 
PF14_0589 valine-tRNA_ligase__putative -0.8596559 1.38212096 2.24777164 
PF14_0588 conserved_Plasmodium_protein__unknown_function -0.9668332 1.30542056 2.2512184 
PFD0310w sexual_stage-specific_protein_precursor 3.24522699 4.45602015 2.25203941 
PF14_0457 conserved_Plasmodium_protein__unknown_function -1.5318474 0.9090856 2.27740105 
PFF0205w mitochondrial_ribosomal_protein_L41_precursor__putative -2.5025004 0.1836988 2.27786859 
PF14_0034 translocation_associated_membrane_protein__putative -0.2969818 1.86056505 2.30544802 
PF10_0214 RNA_binding_protein__putative 2.02023711 3.60081118 2.31287788 
PFL1530w asparagine-rich_protein__putative 1.48390977 3.20428487 2.31741714 
PFA0110w DNAJ_protein__putative 0.91753989 2.78735698 2.32402065 
PFB0105c Plasmodium_exported_protein_(PHISTc)__unknown_function 1.04402155 2.88255829 2.32463897 
PFE1595c Plasmodium_exported_protein_(PHISTc)__unknown_function -0.6385167 1.63153651 2.33181927 
PF13_0209 conserved_Plasmodium_protein__unknown_function -3.8413023 -0.7547266 2.34059929 
PFL1055c conserved_Plasmodium_membrane_protein__unknown_function 1.09543797 2.94944632 2.35307781 
PFD0310w sexual_stage-specific_protein_precursor 3.27537595 4.58399656 2.35747043 
PF13_0173 conserved_Plasmodium_protein__unknown_function -2.0730295 0.59634593 2.36935736 
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Table 3.9 Continued 
PlasmoDB ID Description 
mean PTS0 
& PUS0 
mean RTS0 
& RUS0 
Residual Resistant-
0.7478Parental-
0.2228 
PF10_0344 glutamate-rich_protein -2.6301497 0.18786174 2.37748771 
PFB0080c Plasmodium_exported_protein_(PHISTb)__unknown_function -2.2160956 0.52498734 2.40498362 
PFI1610c calcyclin_binding_protein__putative -2.5025004 0.31414296 2.40831275 
PF10_0296 conserved_Plasmodium_protein__unknown_function -0.0512849 2.17247954 2.43363038 
PF13_0044 carbamoyl_phosphate_synthetase 0.48261727 2.5895819 2.4514807 
MAL13P1.294 GTP_binding_protein__putative -1.8413023 0.86941592 2.46914177 
MAL13P1.179 conserved_Plasmodium_protein__unknown_function -0.0104704 2.252071 2.4827008 
PF10_0232 Chromodomain-helicase-DNA-binding_protein_1_homolog__putative -0.774903 1.70300298 2.50527547 
PF10_0291 RAP_protein__putative -1.2065225 1.44892203 2.57395953 
MAL7P1.171 Plasmodium_exported_protein__unknown_function 0.86853691 3.01221909 2.58552719 
PF13_0011 plasmodium_falciparum_gamete_antigen_27/25 4.69099559 5.88897695 2.60385044 
PF10_0282 conserved_Plasmodium_protein__unknown_function -1.1805723 1.50648246 2.61211442 
PFF0640w conserved_Plasmodium_protein__unknown_function -4.0874629 -0.6185779 2.66082685 
PFD0750w nuclear_cap-binding_protein__putative -0.7258251 1.96541455 2.73098653 
PF10_0281 merozoite_TRAP-like_protein__MTRAP -1.3870232 1.4713164 2.73133233 
MAL7P1.162 dynein_heavy_chain__putative -3.4262648 0.04277077 2.82773158 
PF10_0258 conserved_Plasmodium_protein__unknown_function 0.33688586 2.90870579 2.87958254 
PF14_0748 Plasmodium_exported_protein_(PHISTa)__unknown_function -0.5330144 2.27748852 2.89887668 
PF14_0745 probable_protein__unknown_function 2.41338379 4.57243739 2.99050899 
PFL1750c conserved_Plasmodium_protein__unknown_function 2.54916173 4.80953225 3.12606911 
PFD1035w steroid_dehydrogenase__putative 0.18285487 3.05921348 3.1452746 
PF14_0631 conserved_Plasmodium_protein__unknown_function -0.4022042 2.70996978 3.23353812 
PFB0090c RESA-like_protein_with_PHIST_and_DnaJ_domains -2.0515725 1.86236541 3.61933132 
PF14_0744 Plasmodium_exported_protein__unknown_function -0.0703893 3.73427736 4.0097145 
PF11_0512 RESA-like_protein_with_PHIST_and_DnaJ_domains 0.59242089 4.35894658 4.13873424 
PF14_0748 Plasmodium_exported_protein_(PHISTa)__unknown_function 1.51244995 5.17173284 4.26352277 
PFE1600w Plasmodium_exported_protein_(PHISTb)__unknown_function -5.5208296 1.28308453 5.6343609 
PFB0085c DNAJ_protein__putative -4.4926061 2.41346422 5.99583505 
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Chapter Four:  
Summary 
During the past three decades, Plasmodium falciparum, the most lethal malaria 
parasite infecting humans, has developed resistance to almost every commonly available 
antimalarial drug.  The emergence and spread of resistance to most antimalarial drugs has 
made the effective treatment of malaria difficult, and there is an urgent need for new 
antimalarial drugs and drug combinations.  The ineffectiveness of drugs such as 
chloroquine (CQ), sulfadoxine-pyrimethamine (SP), and mefloquine (MQ) has ushered in 
the usage of artemisinin combination therapies (ACTs) as front line therapy where P. 
falciparum exists.  Although ACTs are very promising tools for treating and controlling 
drug-resistant malaria, factors still exist that may serve to continue transmission of drug-
resistant parasites in endemic countries.  These include affordability of drugs, availability 
of sub-optimal/counterfeit drug regimens, sociocultural and behavioral barriers, and non-
compliance to ACT recommendations.  As a consequence of the decreased number of 
effective antimalarials and proven vaccine candidates, the WHO has instituted a policy of 
disease control rather than eradication.  The lack of development of new drugs and 
vaccines puts a burden on malaria prevention and control programs in endemic areas, 
focusing on bed net distribution, case management, and proper drug regimens.   
The development of new antimalarials has been slowed by the lack of financial 
incentive and the high cost of effective drugs that must be administered in multi-drug 
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resistant areas.  Researchers still have a limited view of what occurs at the molecular 
level in resistant parasites and these parasites are rapidly becoming the predominant 
strains in malaria-endemic areas.  Multi-drug therapies have been shown to be effective, 
but due to the high cost and the complexity of combining drugs with the correct 
pharmacodynamics, many poor countries will continue to use ineffective drug such as 
CQ and MQ even in high areas of drug resistance.  
Artemisinin (QHS) drugs have been used for the treatment of malaria for 
centuries and these drugs are effective against all stages of Plasmodium spp.  These drugs 
provide rapid clearance of parasitemia and kill gametocytes, making them valuable drugs 
for preventing transmission of malaria.  ACTs take advantage of artemisinin‟s ability to 
rapidly reduce parasite densities to low levels.  The two components of an ACT seem to 
have a synergistic effect as the artemisinin component reduces the chance that parasites 
will be exposed to sub-optimal levels of the longer acting antimalarial, and the longer 
acting antimalarial protects artemisinins from selection of a resistant mutant if adherence 
is good.  Importantly, the partner drug of choice must be one that still is highly 
efficacious in a given area.  Therefore, combination strategies must be tailored to each 
malarious location/drug resistance profile, taking into account if combination drug effects 
are potentiating for the area of administration (one of the drugs must be extremely 
effective) 
163
.   
Current Reports of Artemisinin Resistance 
The use of artemisinins in ACTs has brought about concern that resistance may 
potentially occur to this class of crucial antimalarials.  Also, despite the implementation 
of active malaria-control programs that include ACTs, a very high percentage of 
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artemisinin monotherapies are still provided through the private sector (as in Cambodia) 
320
.  Until recently, clinical resistance to these drugs was not described.  Historically, the 
area of Southeast Asia and specifically the Thailand-Cambodian border has been a focus 
of malaria drug resistance 
280,461
.  Noedl et al. 2008 
321
 reported on a clinical study in the 
western Cambodian province Battambang, which is located on the Thai-Cambodia border.  
This study involved the administration of high-dose AS therapy (60 patients) or 
quinine+tetracycline (QN+Tet) (34 patients) to patients with uncomplicated P. 
falciparum malaria.  Artemisinin resistance in patients was defined as: persistence of 
parasites 7 days after the start of treatment or reemergence of parasites within 28 days 
after the start of treatment; sufficient plasma concentrations of dihydroartemisinin (DHA); 
prolonged time to parasite clearance; and reduced in vitro susceptibility to DHA.  Two 
patients who received AS were classified as having artemisinin-resistant infections, 
according to the defined criteria.  These patients had parasite-clearance times (PCTs) that 
were prolonged (133 and 95 hours vs. 52.2 hours for patients who were cured), and 
sufficient plasma drug concentrations after a first dose of drug.  For these subjects, the 
IC50s of DHA were up to 4 times the geometric mean for cured patients and almost 10 
times that for the reference clone W2.  The authors suggested that clinical and in vitro 
data that allude to artemisinin resistance may not be the result of a sudden change in drug 
sensitivity.  Importantly, resistance did not appear to be mediated by the number of 
copies of pfmdr1 or selected pfatp6 polymorphisms tested in this study.  Dondorp et al. 
(2009) 
320
 conducted a clinical trial where efficacies of AS and AS+MQ were determined 
for uncomplicated malaria in Pailin, western Cambodia, and Wang Pha, northwestern 
Thailand.  An important finding was that an overall slower PCT was reported in Pailin for 
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both AS monotherapy and AS+MQ (median 84 and 72 hours) compared to Wang Pha 
(median 54 and 48 hours).  Also, recrudescence occurred in more patients receiving AS 
monotherapy in Pailin compared to Wang Pha.  The different parasitologic responses 
were not explained by differences in drug susceptibility; and again, no mutations, 
amplifications, or deletions in pfmdr1 or pfatp6 were present in long clearance time 
isolates.  The extended period of often-suboptimal use and high use of monotherapy, and 
the genetic background of parasites from this region, might contribute to the emergence 
and subsequent spread of these new artemisinin-resistant parasites in western Cambodia.  
In contrast, artemisinin derivatives have been used almost exclusively in combination 
with MQ on the Thai-Burmese border, where parasitologic responses to artemisinins 
remain good, even after 15 years of intensive use.  Noedl et al., 2009 reported on the use 
of a histidine-rich protein assay to assess artemisinin susceptibility in Thailand, 
Cambodia, and Bangladesh.  Blood samples were obtained from approximately 250 
patients who presented with uncomplicated P. falciparum malaria from 2004-2006.  
Compared to the reference W2 clone, samples from Eastern Thailand and Cambodia 
displayed elevated susceptibility to DHA (as evidenced by IC50).  Importantly, the 
authors concluded that although these results point to artemisinin resistance, it is unlikely 
that artemisinin resistance has spread across Thailand or into Bangladesh.  Lim et al. 
(2010) 
390
 also observed a trend of slightly elevated IC50s for QHS, MQ, CQ, and QN in 
P. falciparum isolates from western Cambodia (vs. eastern Cambodia).  Also, IC50s for 
isolates from participants who failed AS+MQ therapy were significantly higher than 
those for patients who were cured.  In addition, Carrara et al (2009) 
286
 showed a 
longitudinal increase in PCTs from 1995-2007 in northwestern Thailand (AS+MQ was 
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introduced at the Thai-Burmese border in 1995).  The study also found AS and MQ 
susceptibility increased from 1995-2001, but from 2002-2006, this trend reversed for AS.  
However, as of 2007, it appears that AS efficacy has returned to levels before 1995.  MQ 
IC50s also rose between 2001-2004, but fell again in 2006–2007.  In addition, the study 
also found an increase in gametocyte carriage of treated patients from 1995-1997.  These 
data are important because the failing efficacy of AS could not be related to amplification 
of pfmdr1 (which is usually associated with MQ resistance).  Importantly, the increases in 
PCT and concomitant gametocyte carriage may indicate a general failure of artemisinin 
for malaria transmission control in this area. 
Artemisinin Resistance in This Work 
In our studies, we have attempted to characterize potential artemisinin 
mechanisms of resistance.  Our efforts have resulted in a set of drug resistant parasites 
(from different parts of the world) that represent reagents that can be used for studies on 
molecular markers of resistance, drug discovery, and cell function/metabolism.  We 
produced parasites that tolerate clinically relevant levels of artemisinin drugs and a strain 
of D6 that tolerated concentrations of QHS that are beyond clinically relevant.  By using 
different recrudescence assays, we showed resistant D6 and W2 parasites recover faster 
than respective parent strains.  In vitro susceptibility testing (SYBR Green and 
hypoxanthine) showed some separation between artemisinin sensitivity between parent 
and resistant strains for some drugs (QHS, AL), but these results still may underestimate 
the magnitude of resistance between strains.  Other methods of characterization found 
growth differences were related to merozoite number in some strains (D6), but not in all.  
Through these methods of characterization, we defined an artemisinin resistant phenotype 
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which will be useful for future resistance studies. Molecular analyses were performed on 
a variety of resistant parasites to investigate putative molecular markers for resistance.  
We identified potential molecular markers in D6 and W2 QHS-resistant parasites by 
whole genome sequencing (SNPs in D6, chromosome 10 amplification in D6, W2).  
Gene amplification was validated in both strains by QPCR, and it was found that the 
amplification in D6 resistant strains occurred as early as 80 ng/ml.  Interestingly, we did 
not find amplifications in chromosome 10 genes in a set of isolates from Cambodia and 
Thailand.  Future experiments will focus on mining W2 resistant/parental cloned line 
sequence data for SNPs (with comparison to D6 data) and determining at what resistance 
level SNPs and gene amplifications occurred in both D6 and W2 resistant lines.  
Transcriptional analysis also identified some genes that may be important in D6 parent 
and resistant strains.  The large data set produced from these microarrays justifies further 
examination where we will attempt to find particular genes that are important for 
resistance during the entire time course we designed.  It will be interesting to analyze 
artemisinin-induced transcriptional changes in other strains (W2, etc.) in a similar manner 
as we did with D6.  Also, we will correlate transcriptional changes with earlier 
microarrays (low level QHS, AL-resistant W2 lines) and validate transcriptional changes 
by RT-QPCR.  Finally, we have different sets of field isolates from Thailand and 
Cambodia (where artemisinin resistance is thought to be occurring) that are verified as 
having reduced susceptibility to artemisinins.  It will be interesting to analyze these 
isolates for the molecular markers of artemisinin resistance we have identified.   
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Dormancy and Resistance 
Artemisinins are known to be associated with high rates of recrudescence when 
used without a partner drug.  We previously showed that ring-stage parasites enter a state 
of dormancy after treatment with artemisinin drugs.  A hypothesis we proposed is that 
artemisinin-induced dormancy may lead to the frequent recrudescence observed in 
patients.  Dormancy is similar to the post-antibiotic effect where there is a delayed 
growth of bacteria after complete removal of an antibiotic 
462
.  Bacteria can remain 
susceptible to an antibiotic over multiple exposures, but a degree of tolerance seems to 
develop over time.  During induction of resistance in the strains we describe, parasites 
always entered a dormant state before recovery.  We were able to adapt parasites to 
increasing amounts of drug by discontinuously applying drug pressure.  This indicated 
that multiple rounds of parasite exposure to an artemisinin drug, followed by dormancy, 
recovery, and growth, selects for parasites with reduced susceptibility to this class of 
antimalarial drugs.  Based on observations of dormancy and in vitro selection of 
artemisinin resistance, it may be possible to implicate dormancy as an artemisinin-
resistance mechanism.   
It is tempting to speculate about the nature of artemisinin-induced dormancy as it 
relates to an artemisinin resistance mechanism, as some lines of evidence point in this 
direction.  In the recovery assays we performed, QHS-resistant D6 and W2 strains both 
recrudesced before respective parent strains.  There was also an associated greater 
percentage of dormant/total or dead-dormant/total parasites observed during the time 
when most parasites were dormant or dead.  Also, the increase in percentage of 
normal/total parasites in resistant strains corresponded with the decrease of dormant/total 
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or dead-dormant/total parasites.  We believe these data given an indication that resistant 
parasites are capable of exiting dormancy at a greater rate than parent strains.  This may 
be because dormant resistant parasites have a higher survival rate from dormancy; if a 
greater number of dormant parasites existed in resistant cultures, recrudescence would 
occur earlier.   
Because artemisinin-exposed parasites enter dormancy and recrudesce over time, 
this may not be a true resistance mechanism where parasites would survive levels of drug 
without a significant decrease in parasitemia.  During induction of resistance in the 
strains we describe, parasites always entered a dormant state before recovery.  Another 
detractor to stating that dormancy is a resistance mechanism is that in vitro susceptibility 
testing does not show a dramatic difference for parent vs. resistance strains.  Although we 
did find differences we believe are significant in resistant parasites for some drugs (QHS, 
AL), this was not true for all artemisinin drugs.  The reason for this may be that the 
SYBR green assay we used is not appropriate for assessing resistance phenotypes.  Ring 
stage parasites enter dormancy and take an extended time to recover after exposure to 
artemisinins, so by assessing viability at 72 hours after drug was added, we did not 
capture parasites that recrudesce later.  This point is echoed in patient studies that find 
prolonged parasite clearance times of parasites but no reduction in IC50, making it 
difficult to characterize these parasites as resistant (below).  Our laboratory showed that 
some population of parasites can withstand greater levels of drug early after drug 
treatment, indicating they are unaffected by the drug, or become dormant only to 
recrudesce 
362
.  Based on these data, we investigated what may occur during the first 48 
hours of artemisinin treatment in both parent and resistant strains (D6 and W2).  From 
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these hypoxanthine incorporation assays, our studies found that at high levels of DHA, 
we were unable to determine a significant difference in recrudescence.  However, at 
lower levels of artemisinin drugs, resistant parasites tolerate more drug compared to 
parental parasites.  The greater incorporation of hypoxanthine we observed in resistant 
parasites may indicate that a greater number of parasites were unaffected by drug.  
Therefore, a greater number of resistant parasites progressed through the life cycle as 
normal.  The IC50 results indicating this were verified by blood smears.  Also, it may be 
that a greater percentage of dormant parasites were present after drug exposure.  If this is 
true, then resistant parasites have the ability to produce a greater number of dormant 
parasites and/or exit dormancy faster than parent parasites.  Therefore, this may be the 
reason that in longer susceptibility assays and recovery assays that artemisinin-resistant 
parasites recover at a higher rate than parent strains.   
Although our laboratory has characterized dormancy in terms of recovery rates, 
morphological observations, and flow cytometry, molecular characterization has not been 
performed.  Furthermore, studies have not focused on in vitro artemisinin-selected 
parasites we generated in the laboratory.  Based on the above results, we knew sensitive 
and resistant parasites enter dormancy, yet we did not know what may occur at the 
transcriptional level in terms of differential gene expression between parasites after drug 
exposure.  The microarray experiment we performed again found that QHS-resistant D6 
recrudesced before the susceptible parent strain, possibly indicating that resistant 
parasites are more capable of emerging from dormancy compared to the parent strain. 
This was confirmed by morphological and correlogram analysis that showed resistant 
parasites exited dormancy before the parental parasites.  Perhaps the mechanism of 
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resistance involves an increased ability to recover from dormancy following exposure to 
drug.  During the data analysis of microarray results, we searched for genes up-regulated 
in resistant and/or susceptible parasites that might be important during dormancy.  A 
group of genes were up-regulated in both parent and resistant strains, with PFI1170c 
(encoding thioredoxin reductase) being the most interesting gene.  This indicated that 
both sensitive and resistant parasites may employ similar mechanisms while dormant.  
We also searched for differentially regulated genes after drug treatment, and found some 
cytochrome genes were up-regulated in resistant vs. parent strains.  Unfortunately, this 
analysis did not produce obvious mechanisms of resistance that the QHS-resistant D6 
parasite might employ.  What was more interesting is that of a group of genes expressed 
at baseline, a few on chromosome 10 were up-regulated in the resistant parasite compared 
to D6.  The genes coincided with genes within the amplification we found in D6 and W2 
QHS-resistant parasites.  Taking these data into consideration, it may be that the drug 
selection pressure method we used caused genetic changes in the genome that exist to 
resist effects of artemisinin.  A key finding from this experiment is that parent and 
resistant strains were both arrested after drug exposure, suggesting that dormancy may be 
a hallmark of artemisinin treatment, rather than artemisinin resistance as has been 
suggested by others 
360
.   
If dormancy is not a true artemisinin-resistance mechanism, it may still play a 
critical role in the malaria transmission because parasites may remain in patients for an 
increased amount of time.  In fact, increased PCTs in patients treated with artemisinin 
drugs constitute the bulk of evidence for emerging resistance to artemisinins in the field.  
In a study of almost 20,000 patients from different locations in the world with different 
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malaria transmission intensities, Stepniewska et al., 2010 
395
 found that the main factor 
affecting PCT in was parasite density on admission.  Clearance rates were faster in high-
transmission settings and with more effective partner drugs in artemisinin-based 
combination treatments (ACTs).  This is probably a factor of a greater number of 
parasites carried by non-immunes in low-transmission settings 
191,463
.  Perhaps with 
increased parasitemia (and a higher dormant parasitemia), PCT becomes greatly 
increased in these areas.  Noedl et al. (2008) 
322
 found prolonged PCTs in the two cases 
meeting their definition of AS resistance.  Dondorp et al. (2009) 
320
 found resistance in 
western Cambodia was characterized by slow PCT in vivo without corresponding 
reductions on conventional in vitro susceptibility testing.  Wongsrichanalai and Meshnick 
(2008) 
280
 reviewed studies of AS+MQ treatment in Cambodia and Thailand and stated 
that clinical and molecular evidence (amplification of pfmdr1) indicate AS+MQ failures 
are occurring on the Cambodia–Thailand border.  There was an associated extended PCT 
in one of these studies from Pailin in 2004 
298
 where there was reduced efficacy of 
AS+MQ.  A study by Carrara et al. (2009) 
286
 found a reduction of PCT in northwestern 
Thailand parasite clearance associated with increase in treatment failure rates.  Although 
they reported higher IC50s for AS from 2002-2006, AS appears to be re-gaining 
effectiveness.  Therefore, there is dissociation between in vitro susceptibility findings of 
AS efficacy and PCT.  As stated above, conventional in vitro testing may not be 
appropriate for testing tolerance to artemisinins such as AS.  Prolonged PCT in endemic 
areas may be a result of dormant parasites causing recrudescence of malaria.  If 
dormancy and recrudescence are related, and parasites with reduced susceptibility to 
artemisinin drugs are selected for, then these viable parasites could be responsible for 
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increased PCT.  Perhaps in resistant parasites, higher numbers of dormant parasites and 
faster recovery allows recrudescence, then prolonged PCT could result from more 
dormant parasites lasting and not being eliminated.   
Utility of Molecular Markers for Field Studies 
The use of molecular markers for parasite identification has been a major windfall 
for the diagnosis of malaria, and these markers have enabled the detection of drug-
resistant infections.  Some of the major molecular markers identified for antimalarial 
resistance include polymorphisms in pfcrt for CQ resistance, polymorphisms in pfmdr1 
that modulate resistance to CQ, artemisinins, QN, and MQ, polymorphisms in dhfr/dhps 
responsible for pyrimethamine/sulfa drug resistance, and amplification of pfmdr1 
responsible for reduced MQ efficacy.  Molecular markers have been validated as tools for 
surveillance of resistance and they have great value to for public health policy in terms of 
controlling epidemics, guiding national malaria treatment policies, and the monitoring of 
changes in parasite drug susceptibility (which is integral for making changes in malaria 
drug treatment policy) 
464
.  Still, the global P. falciparum drug resistance situation is such 
that these molecular markers cannot do anything to preserve drugs that have lost efficacy 
such as CQ and SP.  As stated above, the ineffectiveness of these drugs, described by 
emergence and spread of resistance, has led to recommendations that they be replaced 
with ACTs.  If the artemisinin resistance reported by the studies above were to spread 
from the defined area it is in now, the results would be devastating for malaria control.  
An alarming fact is that with the failure of artemisinin drugs, gametocyte carriage would 
increase and transmission of resistant parasite would occur before the phenomenon could 
be detected.   This occurred with SP resistance in Southern Africa, even before any 
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discernable effect on cure rates was noticed 
465
.  Several public health strategies to 
interrupt the spread and prevent further emergence of artemisinin resistance are under 
consideration, and recently a containment program designed to stop the emergence of 
artemisinin resistance in western Cambodia and eastern Thailand was formed 
466
.  The 
proposed program involves a comprehensive approach, including early diagnosis and 
appropriate treatment of malaria, decreasing the drug pressure, optimizing insect vector 
control, targeting the mobile population, strengthening disease management and 
surveillance systems, and operations research 
463
.  Unfortunately, most countries that 
conduct drug resistance surveillance rely only on therapeutic efficacy testing.  Although 
this is applicable for most national malaria control programs and can identify areas where 
intensive drug resistance studies are needed, these tests have limited usefulness as an 
early warning system for artemisinin resistance 
189
.  Importantly, at the genetic level, 
artemisinin resistance may be multifactorial where an accumulation of genetic changes 
leads to resistance (like SP resistance).  Therefore, if resistance develops gradually 
through sequential mutations and/or gene amplifications, treatment failure may not 
manifest until late in this process.  Unfortunately, because of the lack of molecular 
markers for artemisinin resistance, clinical monitoring may be the most important facet of 
the artemisinin resistance containment program.  To ensure that the utility of ACTs is not 
compromised, the above approach could greatly benefit from reliable markers for 
artemisinin resistance.  The recent establishment of the World Antimalarial Resistance 
Network (WARN) will help integrate molecular markers for resistance with drug efficacy 
trials and in vitro susceptibility testing 
464
.  This can help monitor and deter resistance and 
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to guide malaria treatment and prevention policies.  If markers for ACT or artemisinin are 
identified, WARN will include these to help control resistance in real-time. 
Because markers linked to artemisinin resistance (pfmdr1, pfatp6, tctp, pfubp-1, 
pfcrt) are reported to be unassociated with clinical resistance 
320,321,329
, there is a dire need 
to develop and validate new markers.  We believe genes that are amplified on 
chromosome 10 may be strong indicators of resistance in certain strains, but not all.  We 
showed that in vitro QHS-selected parasites from Africa (D6) and Asia (W2) contained 
amplified genes, yet resistant progeny of an isolate from Asia (TM91c235) did not have 
these amplifications.  Also, field isolates from Thailand and Cambodia did not have 
genes amplified in chromosome 10 (particularly regions that overlapped with W2, 
another parasite from Asia).  It remains to be seen if the high-probability SNPs we 
detected in D6.QHS2400x2 are found in W2-QHS resistant strains, TM91c235-AL 
resistant strains, and any isolates from Thailand and Cambodia.  Also, it may be 
interesting to see if these putative markers of artemisinin resistance are found in any other 
African parasites, as there may be tremendous selection pressure with high ACT use.   
The spread of artemisinin resistance could have a devastating effect on global 
malaria control efforts.  The studies above suggest artemisinin resistance has emerged 
and they avoid long-standing arguments over whether potential ACT resistance may 
occur as a result of inefficacy of ACT partner drugs.  This is demonstrated by longer 
PCTs for both ACTs and AS administered as a monotherapy.  It is possible that 
artemisinin-induced dormancy and re-emergence is responsible for extended parasite 
clearance times in patients.  Ring-stage parasites of parent and resistant lines seem to 
enter dormancy, so perhaps dormancy is not a sole mechanism of artemisinin resistance. 
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We hypothesize that induction and selection of artemisinin resistant parasites could 
enhance recrudescence rates (i.e., treatment failure) and explain a mechanism where an 
increased the proportion of parasites recover from dormancy following the removal of 
drug pressure, by decreasing the duration of dormancy, or both.  A better understanding 
of dormant parasites and their susceptibility to combination drug partners may allow the 
design of optimal dosage regimens and help prevent the emergence of resistance to 
artemisinins and other new antimalarial drugs in the future.  Our studies on molecular 
markers for artemisinin resistance may provide an important advance in public health, but 
future work is necessary to validate these markers in a variety of isolates to determine 
their worth.   
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Appendix A: Extra Tables 
 
Table A-1.  Summary of Merozoite Characterization for Parental and Resistant Strains 
 
Strain Mean 
Standard 
Deviation Min Max Median  Mode 
95% 
Confidence 
Interval 
D6  19.3 2.58 14 24 20 18 18.6-20.0 
D6.QHS2400x5  16.3 2.24 12 22 16 16 15.7-16.9 
        W2  15.3 2.38 12 22 15 14 14.7-15.9 
W2.QHS200x2 19.7 2.66 14 26 20 20 19.1-20.4 
        TM91c235  20.7 2.26 16 26 20 20 20.1-21.3 
TM91c235.AL280x2 19.7 2.16 16 24 20 18 19.1-20.2 
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Table A-2.  Real Time QPCR Copy Number Results for PFE1050w, PF11_0466, pfmdr2, 
and pfmdr1 
 
Strain 
Mean   
CN 
Standard 
Deviation 
Number 
of Assays 
95% confidence 
interval 
PFE1050w 
     3D7 1.09 0.12 5 0.99 1.19 
D6 1.00 0.01 6 1.00 1.01 
D6.QHS80 0.98 0.06 2 0.89 1.06 
D6.QHS120 1.05 0.01 2 1.04 1.05 
D6.QHS200 1.05 0.01 2 1.03 1.07 
D6.QHS300x2 1.05 0.05 3 1.00 1.11 
D6.QHS340x3 0.96 0.04 2 0.91 1.00 
D6.QHS2400x2 1.05 0.05 2 0.98 1.11 
D6.QHS2400x4 1.13 0.03 2 1.09 1.17 
D6.QHS2400x5  0.98 0.07 3 0.91 1.05 
W2 1.07 0.16 5 0.93 1.20 
W2 (clone D7) 1.15 0.09 6 1.08 1.22 
W2.QHS200  1.10 0.08 5 1.03 1.16 
W2.QHS200x2  1.12 0.09 4 1.04 1.21 
TM91c235 1.08 0.02 3 1.06 1.09 
TM91c235.AL80 1.01 0.13 2 0.83 1.19 
TM91c235.AL240x2 1.12 0.03 2 1.08 1.16 
TM91c235.AL280x2 1.12 0.01 2 1.10 1.14 
PF11_0466 
     
3D7 1.08 0.12 5 0.98 1.19 
D6 1.00 0.01 6 0.99 1.01 
D6.QHS80 0.96 0.15 2 0.75 1.16 
D6.QHS120 1.21 0.06 2 1.12 1.29 
D6.QHS200 1.10 0.12 2 0.93 1.26 
D6.QHS300x2 1.05 0.05 3 0.99 1.10 
D6.QHS340x3 1.08 0.07 2 0.98 1.18 
D6.QHS2400x2 1.20 0.04 2 1.14 1.26 
D6.QHS2400x4  1.02 0.19 2 0.75 1.28 
D6.QHS2400x5 0.90 0.02 3 0.88 0.92 
W2 1.10 0.17 4 0.93 1.27 
W2 (clone D7) 1.32 0.08 3 1.24 1.41 
W2.QHS200  1.01 0.10 3 0.90 1.13 
W2.QHS200x2 1.11 0.01 2 1.10 1.11 
TM91c235  1.16 0.17 5 1.01 1.31 
TM91c235.AL80 1.21 0.16 3 1.03 1.39 
TM91c2325.AL240x2 1.00 0.08 2 0.89 1.10 
TM91c235.AL280x2 1.08 0.13 3 0.94 1.23 
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Table A-2 Continued 
Strain 
Mean   
CN 
Standard 
Deviation 
Number 
of Assays 
95% confidence 
interval 
pfmdr2 
     
3D7 1.05 0.10 4 0.95 1.15 
D6 1.00 0.00 7 1.00 1.01 
D6.QHS80 1.06 0.10 3 0.95 1.17 
D6.QHS120 1.06 0.02 3 1.04 1.08 
D6.QHS200 1.11 0.14 3 0.95 1.27 
D6.QHS300x2 1.06 0.15 3 0.89 1.24 
D6.QHS340x3 1.14 0.13 3 1.00 1.28 
D6.QHS2400x2  1.04 0.03 3 1.01 1.07 
D6.QHS2400x4 1.22 0.07 3 1.14 1.30 
D6.QHS2400x5  1.12 0.05 3 1.07 1.17 
W2 0.99 0.08 3 0.90 1.08 
W2 (clone D7) 1.20 0.11 4 1.09 1.30 
W2.QHS200  1.14 0.03 5 1.11 1.17 
W2.QHS200x2  1.20 0.08 3 1.11 1.29 
TM91c235  1.00 0.08 4 0.92 1.08 
TM91c235.AL80 1.00 0.10 3 0.89 1.12 
TM91c235.AL240x2 1.03 0.16 3 0.85 1.22 
TM91c235.AL280x2 1.16 0.16 3 0.98 1.34 
pfmdr1 
     
3D7 1.14 0.08 14 1.10 1.18 
D6 1.01 0.01 15 1.00 1.01 
D6.QHS80 0.99 0.09 3 0.89 1.09 
D6.QHS120 1.03 0.10 3 0.92 1.15 
D6.QHS200 1.16 0.09 2 1.03 1.28 
D6.QHS300x2  0.96 0.00 2 
  
D6.QHS340x3 1.16 0.11 3 1.03 1.29 
D6.QHS2400x2 1.02 0.07 3 0.94 1.10 
D6.QHS2400x4 1.03 0.09 3 0.93 1.14 
D6.QHS2400x5  1.10 0.04 3 1.06 1.15 
W2 1.18 0.11 13 1.11 1.24 
W2 (clone D7) 1.21 0.10 9 1.14 1.27 
W2.QHS200  2.24 0.17 8 2.12 2.35 
W2.QHS200x2  2.55 0.07 5 2.49 2.61 
TM91c235 2.20 0.17 7 2.07 2.32 
TM91c235.AL80  2.82 0.19 4 2.63 3.01 
TM91c235.AL240x2 3.60 0.33 5 3.31 3.88 
TM91c235.AL280x2 3.56 0.13 3 3.41 3.71 
  
 Appendix A (Continued) 
393 
 
Table A-3.  Real Time QPCR Copy Number Results for Chromosome 10 Genes 
Strain 
Mean 
CN 
Standard 
deviation 
Number 
of 
Assays 
95% confidence 
interval 
PF10_0275      
3D7 0.983 0.128 4 0.857 1.108 
D6 1.002 0.004 5 0.998 1.006 
D6.QHS80 1.070 0.113 2 0.913 1.227 
D6.QHS120 1.015 0.049 2 0.946 1.084 
D6.QHS200 1.100 0.085 2 0.982 1.218 
D6.QHS300x2 1.105 0.191 2 0.840 1.370 
D6.QHS340x3 1.070 0.089 3 0.969 1.171 
D6.QHS2400x2 1.000 0.090 3 0.898 1.102 
D6.QHS2400x4 1.087 0.047 3 1.033 1.140 
D6.QHS2400x5  1.070 0.101 3 0.955 1.185 
W2 1.115 0.106 4 1.011 1.219 
W2 (clone D7) 1.015 0.120 4 0.897 1.133 
W2.QHS200  1.110 0.057 4 1.055 1.165 
W2.QHS200x2  1.203 0.184 4 1.023 1.384 
TM91c235 1.090 0.014 2 1.070 1.110 
TM91c235.AL240x2 1.100 0.071 2 1.002 1.198 
TM91c235.AL280x2 1.040 0.028 2 1.001 1.079 
Cambodia 18 0.92 
 
1 
   
PF10_0277 
     3D7 0.965 0.035 2 0.916 1.014 
D6 0.998 0.004 5 0.994 1.002 
D6.QHS80 1.015 0.007 2 1.005 1.025 
D6.QHS120 0.977 0.042 3 0.930 1.024 
D6.QHS200 1.055 0.035 2 1.006 1.104 
D6.QHS300x2 1.113 0.122 3 0.975 1.252 
D6.QHS340x3 1.145 0.035 2 1.096 1.194 
D6.QHS2400x2 1.040 0.014 2 1.020 1.060 
D6.QHS2400x4 1.028 0.150 4 0.881 1.174 
D6.QHS2400x5  1.065 0.064 2 0.977 1.153 
W2 1.080 0.014 2 1.060 1.100 
W2 (clone D7) 1.170 0.028 2 1.131 1.209 
W2.QHS200  1.215 0.127 2 1.040 1.390 
W2.QHS200x2  1.120 0.014 2 1.100 1.140 
TM91c235 1.205 0.110 4 1.097 1.313 
TM91c235.AL240x2 1.055 0.007 2 1.045 1.065 
TM91c235.AL280x2 1.150 0.053 3 1.090 1.210 
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Table A-3 Continued 
Strain 
Mean 
CN 
Standard 
deviation 
Number 
of 
Assays 
95% confidence 
interval 
PF10_0278 
     3D7 1.020 0.105 3 0.901 1.139 
D6 0.988 0.027 5 0.964 1.012 
D6.QHS80 1.027 0.127 3 0.883 1.170 
D6.QHS120 1.063 0.090 3 0.962 1.165 
D6.QHS200 1.107 0.118 3 0.973 1.241 
D6.QHS300x2 1.170 0.113 4 1.059 1.281 
D6.QHS340x3 1.035 0.035 2 0.986 1.084 
D6.QHS2400x2 1.160 0.042 2 1.101 1.219 
D6.QHS2400x4 0.990 0.099 2 0.853 1.127 
D6.QHS2400x5  0.947 0.084 3 0.852 1.042 
W2 1.225 0.007 3 1.217 1.233 
W2 (clone D7) 1.155 0.134 3 1.003 1.307 
W2.QHS200  1.125 0.106 3 1.005 1.245 
W2.QHS200x2  1.190 0.069 3 1.112 1.268 
TM91c235 1.295 0.078 2 1.187 1.403 
TM91c235.AL240x2 1.240 0.040 3 1.195 1.285 
TM91c235.AL280x2 1.100 0.070 3 1.021 1.179 
 
PF10_0279 
     3D7 1.086 0.121 5 0.980 1.192 
D6 1.000 0.000 7 
  D6.QHS80 2.105 0.338 4 1.773 2.437 
D6.QHS120 2.165 0.281 4 1.890 2.440 
D6.QHS200 2.090 0.200 3 1.864 2.316 
D6.QHS300x2 2.123 0.155 3 1.948 2.299 
D6.QHS340x3 2.120 0.135 3 1.967 2.273 
D6.QHS2400x2 2.203 0.222 3 1.952 2.454 
D6.QHS2400x4 2.110 0.190 3 1.895 2.325 
D6.QHS2400x5  2.020 0.058 4 1.963 2.077 
W2 1.333 0.062 5 1.278 1.387 
W2 (clone D7) 1.278 0.073 5 1.214 1.342 
W2.QHS200  1.233 0.096 5 1.149 1.318 
W2.QHS200x2  1.360 0.036 5 1.328 1.392 
TM91c235 1.355 0.035 2 1.306 1.404 
TM91c235.AL240x2 1.393 0.038 3 1.350 1.436 
TM91c235.AL280x2 1.227 0.032 3 1.190 1.263 
Cambodia 3 1.18 
 
1 
  Cambodia 5 1.27 
 
1 
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Table A-3 Continued 
Strain 
Mean 
CN 
Standard 
deviation 
Number 
of 
Assays 
95% confidence 
interval 
PF10_0279 
     Cambodia 8 1.32 
 
1 
  Cambodia 10 1.03 
 
1 
  Cambodia 26 1.26 
 
1 
  Cambodia 32 1.28 
 
1 
  Cambodia 33 1.25 
 
1 
   
PF10_0285 
     3D7 1.045 0.104 4 0.943 1.147 
D6 0.993 0.016 6 0.980 1.006 
D6.QHS80 1.987 0.246 3 1.708 2.265 
D6.QHS120 2.217 0.158 3 2.038 2.396 
D6.QHS200 1.980 0.159 3 1.800 2.160 
D6.QHS300x2 2.197 0.214 3 1.955 2.438 
D6.QHS340x3 2.295 0.205 2 2.011 2.579 
D6.QHS2400x2 1.980 0.014 2 1.960 2.000 
D6.QHS2400x4 2.010 0.042 2 1.951 2.069 
D6.QHS2400x5  1.995 0.191 2 1.730 2.260 
W2 1.175 0.148 2 0.969 1.381 
W2 (clone D7) 1.020 0.085 2 0.902 1.138 
W2.QHS200  1.165 0.021 2 1.136 1.194 
W2.QHS200x2  1.145 0.049 2 1.076 1.214 
TM91c235 1.077 0.210 3 0.839 1.315 
TM91c235.AL240x2 1.060 0.226 3 0.804 1.316 
TM91c235.AL280x2 0.995 0.205 2 0.711 1.279 
 
PF10_0286 
     3D7 0.985 0.110 4 0.877 1.093 
D6 1.003 0.005 2 0.996 1.009 
D6.QHS80 1.935 0.078 2 1.827 2.043 
D6.QHS120 2.110 0.057 2 2.032 2.188 
D6.QHS200 2.060 0.141 2 1.864 2.256 
D6.QHS300x2 2.100 0.071 2 2.002 2.198 
D6.QHS340x3 2.070 0.283 2 1.678 2.462 
D6.QHS2400x2 2.170 0.297 2 1.758 2.582 
D6.QHS2400x4 2.070 0.134 3 1.918 2.222 
D6.QHS2400x5  1.820 0.081 4 1.740 1.900 
W2 1.160 0.085 2 1.042 1.278 
W2 (clone D7) 1.185 0.064 2 1.097 1.273 
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Table A-3 Continued 
Strain 
Mean 
CN 
Standard 
deviation 
Number 
of 
Assays 
95% confidence 
interval 
PF10_0286 
     W2.QHS200  1.010 0.042 2 0.951 1.069 
W2.QHS200x2  1.143 0.096 3 1.035 1.252 
TM91c235 1.060 0.014 2 1.040 1.080 
TM91c235.AL240x2 1.120 0.014 2 1.100 1.140 
TM91c235.AL280x2 0.945 0.007 2 0.935 0.955 
 
PF10_0292 
     3D7 0.994 0.062 5 0.940 1.048 
D6 1.018 0.031 8 0.996 1.039 
D6.QHS80 2.493 0.060 4 2.434 2.551 
D6.QHS120 1.985 0.136 4 1.851 2.119 
D6.QHS200 1.860 0.127 2 1.684 2.036 
D6.QHS300x2 2.175 0.149 4 2.029 2.321 
D6.QHS340x3 2.175 0.150 4 2.028 2.322 
D6.QHS2400x2 2.495 0.197 4 2.302 2.688 
D6.QHS2400x4 2.090 0.070 2 1.993 2.187 
D6.QHS2400x5  1.930 0.136 4 1.797 2.063 
W2 3.463 0.152 6 3.341 3.585 
W2 (clone D7) 2.176 0.069 5 2.115 2.237 
W2.QHS200  2.970 0.184 2 2.715 3.225 
W2.QHS200x2  3.575 0.021 2 3.546 3.604 
TM91c235 1.207 0.075 3 1.122 1.292 
TM91c235.AL240x2 1.133 0.131 3 0.986 1.281 
TM91c235.AL280x2 1.130 0.113 2 0.973 1.287 
Cambodia 3 1.04 
 
1 
  Cambodia 5 1.13 
 
1 
  Cambodia 6 1.05 
 
1 
  Cambodia 8 1.06 
 
1 
  Cambodia 10 1.16 
 
1 
  Cambodia 26 1.02 
 
1 
  Cambodia 32 1.03 
 
1 
  Cambodia 33 1.07 
 
1 
  Thai 3 1.07 
 
1 
  Thai 6 1.14 
 
1 
   
PF10_0294 
     3D7 1.102 0.108 5 1.008 1.196 
D6 1.002 0.004 6 0.998 1.005 
 Appendix A (Continued) 
397 
 
Table A-3 Continued 
Strain 
Mean 
CN 
Standard 
deviation 
Number 
of 
Assays 
95% confidence 
interval 
PF10_0294 
     D6.QHS80 2.035 0.049 2 1.966 2.104 
D6.QHS120 1.975 0.064 2 1.887 2.063 
D6.QHS200 1.975 0.106 2 1.828 2.122 
D6.QHS300x2 2.090 0.042 2 2.031 2.149 
D6.QHS340x3 2.020 0.125 3 1.879 2.161 
D6.QHS2400x2 1.977 0.040 3 1.931 2.022 
D6.QHS2400x4 2.063 0.153 3 1.890 2.237 
D6.QHS2400x5  1.967 0.085 3 1.870 2.063 
W2 3.045 0.302 4 2.749 3.341 
W2 (clone D7) 2.173 0.085 3 2.077 2.270 
W2.QHS200  2.867 0.146 3 2.701 3.032 
W2.QHS200x2  3.070 0.028 2 3.031 3.109 
TM91c235 1.260 0.014 2 1.240 1.280 
TM91c235.AL240x2 1.195 0.191 2 0.930 1.460 
TM91c235.AL280x2 1.140 0.185 3 0.930 1.350 
Cambodia 5 1.32 
 
1 
  Cambodia 33 1.03 
 
1 
   
PF10_0295 
     3D7 0.970 0.042 2 0.911 1.029 
D6 1.004 0.009 5 0.996 1.012 
D6.QHS80 2.000 0.174 3 1.803 2.197 
D6.QHS120 2.143 0.280 3 1.826 2.460 
D6.QHS200 1.937 0.137 3 1.782 2.091 
D6.QHS300x2 2.040 0.141 3 1.880 2.200 
D6.QHS340x3 1.983 0.162 3 1.800 2.166 
D6.QHS2400x2 2.230 0.279 3 1.915 2.545 
D6.QHS2400x4 2.220 0.184 2 1.965 2.475 
D6.QHS2400x5  2.025 0.035 2 1.976 2.074 
W2 1.135 0.021 2 1.106 1.164 
W2 (clone D7) 1.147 0.032 3 1.110 1.183 
W2.QHS200  2.964 0.352 5 2.656 3.272 
W2.QHS200x2  3.495 0.007 2 3.485 3.505 
TM91c235 1.065 0.064 2 0.977 1.153 
TM91c235.AL240x2 1.123 0.146 4 0.979 1.266 
TM91c235.AL280x2 1.103 0.121 4 0.984 1.221 
Cambodia 3 1.01 
 
1 
  Cambodia 5 1.11 
 
1 
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Table A-3 Continued 
     
Strain 
Mean 
CN 
Standard 
deviation 
Number 
of 
Assays 
95% confidence 
interval 
PF10_0295 
     Cambodia 8 1.05 
 
1 
  Cambodia 10 1.09 
 
1 
  Cambodia 26 1.05 
 
1 
  Cambodia 32 0.91 
 
1 
  Cambodia 33 0.89 
 
1 
   
PF10_0296 
     3D7 0.985 0.090 6 0.913 1.057 
D6 1.000 0.000 7 
  D6.QHS80 2.175 0.106 2 2.028 2.322 
D6.QHS120 2.270 0.127 2 2.094 2.446 
D6.QHS200 2.005 0.092 2 1.878 2.132 
D6.QHS300x2 2.115 0.120 2 1.948 2.282 
D6.QHS340x3 2.165 0.092 2 2.038 2.292 
D6.QHS2400x2 2.173 0.137 3 2.019 2.328 
D6.QHS2400x4 2.113 0.116 4 1.999 2.226 
D6.QHS2400x5  1.967 0.093 3 1.862 2.072 
W2 1.163 0.167 4 0.999 1.326 
W2 (clone D7) 1.073 0.085 3 0.977 1.170 
W2.QHS200  3.068 0.205 5 2.888 3.247 
W2.QHS200x2  3.610 0.042 2 3.551 3.669 
TM91c235 1.173 0.131 4 1.044 1.301 
TM91c235.AL240x2 1.200 0.075 3 1.115 1.285 
TM91c235.AL280x2 1.180 0.157 3 1.002 1.358 
Cambodia 3 1.32 
 
1 
  Cambodia 8 1.29 
 
1 
  Cambodia 10 1.04 
 
1 
  Cambodia 26 0.97 
 
1 
  Cambodia 32 1.08 
 
1 
   
PF10_0299 
     3D7 0.975 0.068 4 0.909 1.041 
D6 1.002 0.004 5 0.998 1.006 
D6.QHS80 2.285 0.134 2 2.099 2.471 
D6.QHS120 2.115 0.007 2 2.105 2.125 
D6.QHS200 2.210 0.127 2 2.034 2.386 
D6.QHS300x2 2.135 0.134 2 1.949 2.321 
D6.QHS340x3 2.095 0.049 2 2.026 2.164 
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Table A-3 Continued 
Strain 
Mean 
CN 
Standard 
deviation 
Number 
of 
Assays 
95% confidence 
interval 
PF10_0299 
     D6.QHS2400x2 2.260 0.028 2 2.221 2.299 
D6.QHS2400x4 2.045 0.219 2 1.741 2.349 
D6.QHS2400x5  1.970 0.028 2 1.931 2.009 
W2 1.250 0.042 2 1.191 1.309 
W2 (clone D7) 1.205 0.092 2 1.078 1.332 
W2.QHS200  1.210 0.127 2 1.034 1.386 
W2.QHS200x2  1.150 0.014 2 1.130 1.170 
TM91c235 1.160 0.028 2 1.121 1.199 
TM91c235.AL240x2 1.243 0.090 3 1.141 1.345 
TM91c235.AL280x2 1.125 0.035 2 1.076 1.174 
 
PF10_0300 
     3D7 1.000 0.057 2 0.922 1.078 
D6 1.000 0.000 4 
  D6.QHS80 1.025 0.092 2 0.898 1.152 
D6.QHS120 1.040 0.099 2 0.903 1.177 
D6.QHS200 1.050 0.071 2 0.952 1.148 
D6.QHS300x2 1.120 0.099 2 0.983 1.257 
D6.QHS340x3 1.015 0.035 2 0.966 1.064 
D6.QHS2400x2 1.060 0.000 2 
  D6.QHS2400x4 1.025 0.035 2 0.976 1.074 
D6.QHS2400x5  0.990 0.071 2 0.892 1.088 
W2 1.025 0.007 2 1.015 1.035 
W2 (clone D7) 1.050 0.042 2 0.991 1.109 
W2.QHS200  1.145 0.007 2 1.135 1.155 
W2.QHS200x2  1.035 0.021 2 1.006 1.064 
TM91c235 1.040 0.099 2 0.903 1.177 
TM91c235.AL240x2 1.075 0.021 2 1.046 1.104 
TM91c235.AL280x2 1.040 0.014 2 1.020 1.060 
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